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Stroke	   represents	   the	   second	   leading	   cause	   of	   global	  mortality.	   	   Despite	   improvements	   in	  
acute	  stroke	  management	  in	  recent	  years,	  many	  patients	  suffer	  a	  poor	  outcome	  and	  stroke	  
represents	  a	  leading	  cause	  of	  adult	  disability.	  	  Beyond	  the	  human	  impact	  of	  disease,	  societal	  
costs	  are	  huge.	  	  Stroke	  is	  principally	  a	  disease	  of	  the	  elderly	  population,	  which	  is	  increasing	  in	  
size.	   	   Incidence	   is	   increasing	   in	   the	   younger	   population	   and	   the	   developing	   world.	  	  
Accordingly,	  the	  global	  burden	  of	  stroke	  is	  anticipated	  to	  increase	  substantially	  in	  the	  coming	  
decades.	  	  	  
Fatal	  and	  disabling	  strokes	  are	  frequently	  preceded	  by	  either	  a	  milder,	  non-­‐disabling	  stroke	  
or	   a	   transient	   ischaemic	   attack	   (TIA).	   	   The	   optimised	   implementation	   of	   effective	  
preventative	   strategies	   and	   the	   evaluation	   of	   potentially	   novel	   therapeutic	   agents,	   both	  
represent	   crucial	   strategies	   in	   reducing	   the	  burden	  of	   cerebrovascular	  disease.	   	   This	   thesis	  
addresses	  two	  aspects	  of	  secondary	  prevention	  following	  ischaemic	  stroke:	  Firstly,	  improved	  
identification	   and	   optimised	   use	   of	   anticoagulant	   based	   secondary	   prevention	   for	   an	  
established	  but	  frequently	  occult	  risk	  factor	  for	  recurrent	  stroke;	  paroxysmal	  atrial	  fibrillation	  
(PAF).	   	   Secondly,	   the	   evaluation	   of	   xanthine	   oxidase	   inhibition	   (XOI),	   as	   a	   potential	  
therapeutic	  strategy	  for	  the	  prevention	  of	  stroke	  and	  cardiovascular	  disease.	  	  
Chapter	   1	   highlights	   the	   importance	   of	   optimising	   secondary	   preventative	   strategies	  
following	   ischaemic	   stroke	   and	   TIA.	   	   The	   anticipated	   increase	   in	   the	   global	   burden	   of	  
cerebrovascular	  disease	  is	  described,	  together	  with	  review	  of	  stroke	  outcomes	  in	  the	  context	  
of	   contemporary	   acute	   stroke	   management.	   	   The	   risk	   of	   stroke	   recurrence	   following	  
ischaemic	   stroke	   and	   TIA	   is	   reviewed,	   followed	   by	   discussion	   of	   available	   secondary	  
preventative	  strategies.	  	  
In	  Chapter	  2,	   the	  role	  of	  AF	   in	  the	  aetiology	  of	  stroke	  disease	   is	   reviewed	   in	  greater	  detail.	  	  
The	   early	   and	   subsequent	   risk	   of	   stroke	   recurrence	   in	   patients	   with	   AF	   is	   considered,	  
together	  with	  review	  of	  the	  evidence	  for	  antithrombotic	  therapy.	  	  The	  potential	  for	  increased	  
detection	   of	   paroxysmal	   AF	   in	   the	   ischaemic	   stroke	   and	   TIA	   population	   is	   discussed,	   with	  




In	  Chapter	  3,	  details	  of	  a	  randomised,	  open-­‐label	  trial	  with	  objective	  outcome	  assessment,	  in	  
patients	  with	  recent	  (<	  7	  days)	  ischaemic	  stroke	  or	  TIA,	  are	  presented.	  	  This	  study	  evaluated	  
the	   use	   of	   non-­‐invasive	   cardiac	   event	  monitoring	   to	   detect	   AF,	   in	   patients	  with	   ischaemic	  
stroke	   or	   TIA	   presenting	   with	   sinus	   rhythm,	   an	   area	   of	   management	   for	   which	   a	   robust	  
evidence	  base	  is	  lacking.	  	  The	  primary	  endpoint	  was	  the	  difference	  in	  AF	  detection	  at	  14	  days,	  
between	  patients	   randomised	   to	   receive	   supplemental	   cardiac	   event	  monitoring	   of	   7	   days	  
duration,	   compared	   to	   those	   receiving	   standard	   guideline	   based	   investigation	   alone.	  	  
Detection	   of	   AF	   was	   defined	   as	   evidence	   of	   “sustained”	   PAF	   and	   “any	   duration”	   PAF	  
episodes.	   	   Secondary	   endpoints	   were	   the	   difference	   in	   AF	   detection	   at	   90	   days	   and	   the	  
difference	  in	  AF-­‐thromboembolic	  prophylaxis-­‐related	  anticoagulation	  (e.g.	  warfarin)	  at	  14	  &	  
90	  days.	  	  100	  patients	  were	  enrolled	  and	  completed	  90	  day	  follow	  up.	  	  	  “Sustained”	  and	  “any	  
duration”	  PAF	  episodes	  were	  detected,	  respectively,	   in	  16%	  (95%	  CI,	  7.2	  –	  29.1%)	  and	  42%	  
(95%	   CI,	   28.2	   –	   56.8%)	   of	   patients	   through	   7	   days	   non-­‐invasive	   cardiac	   event	  monitoring.	  	  	  
Supplementation	   of	   standard	   guideline	   based	   investigation	   with	   7	   days’	   cardiac	   event	  
monitoring	   resulted	   in	   detection	   of	   “sustained”	   and	   “any	   duration”	   PAF	   episodes	   in	   an	  
additional	   16%	   (4.7	   –	   27.3%)	   and	   40%	   (25.2	   –	   54.8%)	   of	   patients,	   respectively,	   at	   14	   days	  
follow	  up.	   	  These	  differences	  persisted	  at	  90	  days.	   	  Anticoagulant	  therapy	  was	  commenced	  
within	  14	  days	  in	  16%	  of	  the	  group	  randomised	  to	  receive	  supplemental	  monitoring,	  versus	  
none	   randomised	   to	   standard	   investigation	  alone	   (p<0.01).	   	   This	  difference	  persisted	   to	  90	  
days	  (22%	  versus	  6%,	  p<0.05).	  	  This	  study	  provided	  the	  first	  randomised	  controlled	  evidence	  
for	  a	  specific	  investigation	  strategy	  for	  the	  detection	  of	  occult	  PAF	  in	  unselected	  patients	  with	  
ischaemic	  stroke	  and	  TIA.	  	  These	  data	  should	  support	  guidelines	  regarding	  the	  management	  
of	  this	  patient	  group.	  	  In	  addition,	  the	  study	  provided	  evidence	  that	  this	  strategy	  is	  not	  reliant	  
on	  specialist	  electrocardiological	  service	  support,	  with	  very	  good	  agreement	   [(96%;	  95%	  CI,	  
86.3	   –	   99.5%),	   Fleiss’	   Kappa	   0.86,	   p	   <	   0.00001]	   observed	   between	   non-­‐cardiology	   trained	  
stroke	  clinicians	  and	  the	  independent	  reporting	  electrocardiology	  laboratory	  for	  “sustained”	  
PAF	  detection.	  	  	  
In	   a	   related	   observational	   study,	   the	   predictive	   value	   of	   detection	   of	   AF	   in	   the	   period	  
immediately	  following	  ischaemic	  stroke	  or	  TIA	  was	  examined,	  relative	  to	  interval	  evaluation	  
for	   AF	   by	   non-­‐invasive	   cardiac	   event	   monitoring,	   performed	   90	   days	   following	   the	   index	  
event.	  	  This	  study	  demonstrated	  that	  identification	  of	  AF	  immediately	  following	  stroke	  holds	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strong	   positive	   predictive	   value	   for	   subsequent	   AF	   detection	   following	   a	   90	   day	   interval,	  
supporting	   treatment	  decisions	  being	  based	  on	   the	   findings	  of	   early	  monitoring.	   	  Negative	  
predictive	   value	   of	   failure	   to	   identify	   AF	   through	   early	   monitoring	   was	   only	   modest,	  
suggesting	  that	  repeated	  investigation	  may	  be	  of	  value.	  
In	   Chapter	   4,	   the	   hypothetical	   role	   of	   uric	   acid	   (UA)	   in	   the	   pathogenesis	   of	   cardiovascular	  
disease	   is	   reviewed.	   	   Conflicting	   data	   are	   discussed,	   including	   those	   which	   support	   the	  
hypothesis	   that	   serum	   UA	   represents	   a	   surrogate	   marker	   of	   elevated	   cardiovascular	   risk	  
attributable	   to	   either	   its	   association	   with	   established	   cardiovascular	   risk	   factors	   or,	  
alternatively,	   as	   a	   surrogate	   marker	   for	   a	   novel	   mechanism	   of	   vascular	   injury:	   harmful	  
oxidative	  stress	  produced	  by	  the	  xanthine	  oxidase	  enzymatic	  system.	   	  XOI	   is	  discussed	  as	  a	  
potential	   novel	   therapeutic	   strategy	   in	   the	   prevention	   and	  management	   of	   cardiovascular	  
disease.	  	  	  
In	  chapter	  5	  a	  systematic	  review	  and	  meta-­‐analysis	  of	  studies	  evaluating	  the	  effect	  of	  XOI	  on	  
cardiovascular	   health	   in	   humans	   are	   presented.	   	   This	   study	   identified	   a	   body	   of	  
heterogeneous	  studies,	  reporting	  largely	  positive	  results.	   	   In	  meta-­‐analysis,	   improvement	   in	  
brachial	  artery	  flow	  mediated	  dilatation,	  [2.50%	  increase	  (95%	  CI,	  0.15	  –	  4.84%)]	  and	  venous	  
occlusion	   plethysmography	   derived	   forearm	   blood	   flow	   response	   to	   acetylcholine,	   [69%	  
increase	  relative	  to	  control	  arm	  (95%	  CI,	  18	  –	  119%)],	  indicated	  that	  XOI	  improves	  endothelial	  
function	  amongst	  patients	  with,	  or	  at	  risk	  of,	  cardiovascular	  disease.	  	  In	  addition,	  XOI	  reduces	  
vascular	   oxidative	   stress,	  Malondialdehyde	   reducing	   by	   0.56	   nmol/ml	   (95%	   CI	   0.26	   –	   0.87	  
nmol/ml).	  	  Several	  studies	  indicated	  that	  the	  benefits	  of	  treatment	  may	  be	  limited	  to	  patients	  
with	  hyperuricaemia.	  	  Definitive	  clinical	  endpoint	  studies	  were	  lacking.	  	  The	  study	  confirmed	  
that	   XOI	   has	   beneficial	   effects	   within	   the	   cardiovascular	   system,	   providing	   supportive	  
evidence	  for	  further	  study	  in	  the	  stroke	  patient	  population	  and	  in	  relation	  to	  more	  definitive	  
clinical	  endpoints.	  
In	  Chapter	  6,	  three	  surrogate	  measures	  of	  cardiovascular	  risk:	  Carotid	  intima	  media	  thickness	  
(CIMT);	  blood	  pressure	  pulse	  wave	  analysis	  (BP-­‐PWA);	  and	  endothelial	  function	  are	  reviewed.	  	  
Each	   is	   considered	   with	   respect	   to	   their	   independent	   predictive	   value	   for	   risk	   of	  
cardiovascular	  disease,	  and	  utility	  as	  surrogate	  outcome	  measures	  in	  clinical	  trials.	  	  Together	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with	   chapter	   4	   and	   the	   systematic	   review	   reported	   in	   chapter	   5,	   this	   chapter	   provides	  
additional	  background	  to	  the	  randomised	  controlled	  trial	  reported	  in	  chapter	  7.	  
In	  Chapter	  7,	   the	  details	  of	   a	  double	  blind,	   randomised	  placebo-­‐controlled	   trial,	   evaluating	  
XOI	  (with	  Allopurinol	  300	  mg	  once	  daily)	  in	  a	  population	  with	  recent	  (<	  12	  months)	  ischaemic	  
stroke	  or	  TIA,	  are	  presented.	  	  Patients	  were	  followed	  up	  at	  1,	  3,	  6	  &	  12	  months	  in	  relation	  to	  
several	  prognostically	  important	  surrogate	  measures	  of	  cardiovascular	  function.	   	  End	  points	  
included	  differences	  in	  CIMT	  progression,	  change	  in	  central	  blood	  pressure	  (BP)	  and	  change	  
in	   arterial	   stiffness	   at	   one	   year	   and	   change	   in	   endothelial	   function	   at	   6	   months.	   	   Data	  
regarding	   safety	   and	   tolerability	   were	   also	   collected.	   	   Eighty	   participants	   were	   recruited,	  
mean	  age	  67.8	   (SD	  9.4)	  years.	   	  Progression	   in	  mean	  common	  CIMT	  at	  one	  year	  was	   less	   in	  
allopurinol	   treated	   patients	   compared	  with	   placebo	   [between	   group	   difference,	   -­‐0.097mm	  
(95%	  CI,	  -­‐0.175,	  -­‐0.019),	  p=0.015].	  	  Mean	  maximum	  CIMT	  progression	  did	  not	  differ	  between	  
treatment	  groups	  at	  one	  year	  [between	  group	  difference,	  -­‐0.060mm	  (95%	  CI,	  -­‐0.146,	  0.027),	  
p=0.17].	   	   Central	   aortic	   systolic	   BP	   [-­‐6.6	   mmHg	   (95%	   CI	   -­‐13.0	   to	   -­‐0.3),	   p=0.042]	   and	  
augmentation	   index	   [-­‐4.4%	   (95%	   CI	   -­‐7.9,	   -­‐1.0),	   p=0.013],	   were	   each	   reduced	   following	  
allopurinol	   treatment	   compared	  with	  placebo	  at	  12	  months.	   	  No	   significant	  difference	  was	  
observed	  for	  measures	  of	  endothelial	  function.	  	  This	  study	  extends	  the	  evidence	  of	  sustained	  
beneficial	  effects	  of	  allopurinol	  on	  the	  vasculature	  to	  the	  stroke	  population	  and	  to	  endpoints	  
including	  CIMT	  progression	  and	  central	  BP.	  	  The	  study	  confirmed	  that	  a	  previously	  reported	  
benefit	   of	   reduced	   arterial	   stiffness	   represents	   a	   sustained	   treatment	   effect.	   	   These	   data	  
provide	  evidence	   in	  support	  of	   the	  hypothesis	   that	   the	   therapeutic	   strategy	  of	  XOI	  has	   the	  
potential	  to	  reduce	  the	  risk	  of	  cardiovascular	  events.	  
The	   studies	   presented	   in	   this	   thesis	   provide	   a	   combination	   of	   clinically	   relevant	   and	   novel	  
scientific	   findings.	   	   The	   two	   randomised	   controlled	   clinical	   trials	   were	   robustly	   conducted	  
studies,	  adhering	  to	  vigorous	  regulatory	  standards	  and	  provide	  prospective	  data	  obtained	  in	  
clinical	   patient	  populations.	   	   The	  evidence	   from	   the	  non-­‐invasive	   cardiac	   event	  monitoring	  
study	  should	  immediately	  support	  the	  optimisation	  of	  care	  of	  patients	  with	  acute	  ischaemic	  
stroke	   or	   TIA	   for	   the	   detection	   of	   occult	   paroxysmal	   AF,	   thereby	   optimising	   use	   of	  
anticoagulant	   therapy.	   	   The	   systematic	   review	   and	   clinical	   trial	   evaluation	   of	   XOI,	  
respectively,	  provide	  confirmatory	  evidence	  of	  beneficial	  effects	  within	  the	  vasculature	  and	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extend	   this	   to	   the	   stroke	   patient	   population,	   including	   to	   the	   surrogate	   markers	   of	   CIMT	  
progression	  and	  central	  BP.	   	  Together	  they	  provide	  supportive	  evidence	  for	  more	  definitive	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  converting	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  Investigation	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  transaminase	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  monitoring	  
AMP:	  Adenosine	  monophosphate	  	  
ANCOVA:	  Analysis	  of	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AOI:	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  of	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AOPP:	  Advanced	  oxidation	  protein	  products	  
ARB:	  Angiotensin	  receptor	  blocker	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  Atheroscleosis	  Risk	  in	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  Apixaban	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ATP:	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  The	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  Stroke	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  registry	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  Apixaban	  Versus	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  Prevent	  Stroke	  in	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  Are	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  Antagonist	  Treatment	  study	  
Ba-­‐PWV:	  Brachial	  artery	  pulse	  wave	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BAFTA:	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  Treatment	  of	  the	  Aged	  study	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BMI:	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CEA:	  Carotid	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  Continuous	  electrocardiological	  monitoring	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  High	  Atherothrombotic	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  Management,	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  Confidence	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  intima	  media	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CLOTS:	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  Or	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  after	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  2	  
1.1. The	  burden	  of	  cerebrovascular	  disease	  
Stroke	   is	   defined	   by	   the	   World	   Health	   Organisation	   as	   a	   clinical	   syndrome	   of	   “rapidly	  
developing	  clinical	  signs	  of	  focal	  and	  at	  times	  global,	  loss	  of	  cerebral	  function,	  with	  symptoms	  
lasting	  more	  than	  24	  hours	  or	   leading	  to	  death,	  with	  no	  apparent	  cause	  other	  than	  that	  of	  
vascular	   origin”	   1	   	   Approximately	   80%	   of	   cases	   are	   accounted	   for	   by	   ischaemic	   pathology.	  	  
Haemorrhagic	   pathology,	   either	   intracerebral	   haemorrhage	   (10%)	   or	   subarachnoid	  
haemorrhage	  (5%),	  accounts	  for	  the	  majority	  of	  the	  remainder	  of	  cases	  2.	  	  Stroke	  has	  risen	  to	  
hold	  status	  as	  the	  2nd	  leading	  single	  cause	  of	  adult	  mortality	  globally	  3	  and	  is	  a	  leading	  cause	  
of	  disability	  in	  the	  adult	  population	  4, 5.	  
	  
1.1.1. Incidence	  
Stroke	   is	  principally	  a	  disease	  of	   the	  elderly	  population,	  with	   incidence	   rising	  exponentially	  
with	  age	   6.	   	   Recent	  decades	  have	  witnessed	  a	  42%	  decline	   in	   the	  age-­‐specific	   incidence	  of	  
stroke	  in	  developed	  countries	  7.	  	  General	  Practice	  Research	  Database	  data	  suggests	  that	  the	  
incidence	   is	   continuing	   to	   fall	   in	   the	  United	   Kingdom	   (UK),	  with	   a	   30%	   reduction	   reported	  
between	   1999	   and	   2008	   8.	   	   These	   findings	   have	   been	   attributed	   in	   large	   part	   to	   the	  
emergence	  of	   robustly	   implemented	  blood	  pressure	   (BP)	   screening	   and	   cardiovascular	   risk	  
factor	  (CVRF)	  management	  programmes	  8, 9.	  	  
Whilst	  age-­‐specific	  incidence	  of	  stroke	  may	  have	  fallen,	  the	  elderly	  population	  has	  increased	  
in	  size	  in	  recent	  years	  and	  is	  anticipated	  to	  continue	  to	  do	  so	  10.	  	  As	  the	  incidence	  of	  stroke	  is	  
highest	   in	   the	   elderly	   population,	   the	   absolute	   number	   of	   stroke	   hospital	   admissions	   has	  
increased	  in	  recent	  years	  11-­‐13.	  	  	  
Recent	   years	   have	   also	   witnessed	   a	   rise	   in	   stroke	   incidence	   in	   younger	   age	   groups.	   	   In	   a	  
combined	  analysis	  of	  the	  Greater	  Cincinnati	  &	  Northern	  Kentucky	  populations,	  the	  age	  at	  first	  
stroke	  fell	  by	  two	  years	  between	  1993-­‐94	  and	  1999	  –	  2005	  and	  events	  in	  the	  population	  aged	  
under	  55	  years	  comprised	  almost	  one	  fifth	  of	  all	  cases	  in	  the	  latter	  time	  period	  14.	  	  	  	  
	  3	  
Geographical	   variation	   in	   stroke	   incidence	  was	   observed	   20	   years	   ago	   15,	  with	   the	   highest	  
rates	  observed	  in	  the	  developed	  world.	  	  Subsequently,	  the	  effects	  of	  globalisation	  have	  given	  
rise	  to	  increased	  age-­‐specific	   incidence	  of	  stroke	  in	  developing	  countries	   in	  recent	  decades,	  
with	  approximately	  70%	  of	  global	  stroke	  deaths	  now	  occuring	  in	  developing	  countries	  7, 16.	  
The	  incidence	  of	  stroke	  remains	  high	  in	  the	  UK	  13.	  	  In	  England,	  stroke	  incidence	  was	  reported	  
as	  178	  and	  139,	  for	  males	  and	  females	  respectively,	  per	  100,000	  in	  2007	  17.	  	  There	  is	  regional	  
variation	   within	   the	   UK,	   with	   higher	   incidence	   in	   Scotland	   at	   208	   and	   159	   cases	   per	  	  	  	  	  	  
100,000	  18.	  	  
Based	  on	  the	  incidence	  reported	  in	  the	  Oxford	  Vascular	  Study	  (OXVASC),	  the	  number	  of	  first	  
instances	  of	  ischaemic	  stroke	  in	  the	  UK	  was	  estimated	  at	  98,000	  annually,	  with	  an	  additional	  
46,000	   incident	   cases	   of	   TIA	   12, 17	   8,500	   haemorrhagic	   strokes	   and	   5000	   subarachnoid	  
haemorrhages	   were	   also	   expected.	   	   These	   estimates	   were	   considered	   likely	   to	   be	  
conservative,	   based	   on	   the	   affluent	   status	   of	   the	   OXVASC	   population	   and	   higher	   regional	  
incidence	   elsewhere.	   	   Based	   on	   the	   combined	   regional	   stroke	   incidence,	   an	   estimated	  
150,000	  incident	  strokes	  occur	  annually	  in	  the	  UK	  13.	  	  In	  addition	  to	  incident	  cerebrovascular	  
events,	   a	   large	  number	  of	  patients	   experience	   recurrent	   events	   each	   year,	   comprising	  one	  
quarter	  of	  all	  annual	  stokes	  18, 19.	  	  
Due	  to	  the	  simultaneous	  expansion	  of	  the	  elderly	  population,	  increasing	  incidence	  in	  younger	  
age	  groups	  and	  in	  the	  developing	  world,	  the	  global	  burden	  of	  stroke	  is	  anticipated	  to	  rise	  in	  
the	  coming	  decades.	  	  By	  2030,	  7.8	  million	  stroke-­‐attributable	  deaths	  are	  anticipated	  globally	  
compared	  with	   5.7	  million	   in	   2005	   and	   the	   number	   of	   disability-­‐adjusted	   life	   years	   lost	   to	  
stroke	  is	  expected	  increase	  from	  50.8	  million	  to	  60.9	  million	  16.	  	  	  
	  
1.1.2. Mortality	  
Stroke	  has	   risen	   to	  hold	   status	  as	   the	  2nd	   leading	   single	   cause	  of	  adult	  mortality	  globally	   3,	  
reflecting	   high	   incidence	   in	   the	   developed	   world,	   increasing	   incidence	   in	   the	   developing	  
world	  and	  a	  persistently	  high	  case	  fatality	  rate	  7.	  
	  4	  
Despite	  improved	  availability	  of	  stroke	  unit	  care	  and	  development	  of	  services	  implementing	  
treatment	  with	  thrombolysis,	  case	  fatality	  rates	  (recorded	  at	  60	  days)	  remain	  high,	  at	  18.7%	  
and	  25.2%	  of	  males	  and	  females,	  respectively	  in	  Scotland	  13.	  	  In	  the	  Oxford	  community	  stroke	  
project	  (OCSP)	  population,	  1-­‐year	  case	  fatality	  was	  60%	  in	  the	  most	  severe	  clinical	  category	  
of	  stroke	  and	  varied	  between	  11	  –	  19%	  for	  other	  clinical	  categories	  20.	  
Thus,	  stroke	  related	  mortality	  remains	  high,	  with	  age-­‐standardised	  death	  rates	  of	  51	  males	  
and	   48	   for	   females,	   respectively,	   per	   100,000	   in	   the	   UK	   in	   2007	   12.	   	   Stroke	   accounts	   for	  
around	   50,000	   deaths	   in	   the	   UK	   annually	   12, 13,	   accounting	   for	   9%	   of	   adult	   deaths	   and	  
representing	  the	  second	  leading	  single	  cause	  of	  adult	  death	  in	  the	  UK	  12.	  	  	  	  
Mortality	  varies	  widely	  with	  geographical	  region.	   	  Rates	   in	  Scotland	  are	  higher	  than	  for	  the	  
UK	  average,	  at	  65	  (males)	  and	  58	  (females)	  deaths	  per	  100,000	  population	  12.	  	  Mortality	  rates	  
are	   broadly	   similar	   between	   most	   European	   Union	   nations	   but	   are	   markedly	   higher	   in	  
eastern	   European	  and	  non-­‐European	  developing	   countries	   21.	   	  Up	   to	   10-­‐fold	  differences	   in	  
mortality	  have	  been	  observed	  between	  developed	  and	  developing	  countries	  22.	  	  Death	  rates	  
appear	  related	  to	  socioeconomic	  status,	  including	  within	  developed	  countries	  such	  as	  the	  UK,	  
where	  manual	   occupation	   class	  mortality	   is	   approximately	   twice	   that	   observed	  within	   the	  
non-­‐manual	  classes	  12.	  	  
	  
1.1.3. Morbidity	  &	  societal	  burden	  
Approximately	  2	  –	  3%	  of	  the	  UK	  population	  is	  affected	  by	  stroke	  12, 13.	  	  Prevalence	  increases	  
with	  age.	   	   In	  2006,	  13%	  of	  males	  and	  9%	  of	   females	  over	  75	  years	  had	  suffered	  a	  previous	  
stroke	  12.	  	  With	  improved	  survival	  rates	  and	  an	  expanding	  elderly	  population,	  the	  prevalence	  
of	  stroke	  survivors	  is	  anticipated	  to	  rise.	  	  	  
Approximately	   half	   of	   stroke	   survivors	   become	   dependent	   on	   others	   to	   some	   degree	   4.	  	  
Likelihood	   of	   a	   good	   functional	   recovery	   is	   related	   to	   the	   clinical	   severity	   at	   the	   time	   of	  
presentation	  with	  stroke.	  	  In	  the	  OCSP,	  depending	  on	  the	  clinical	  nature	  of	  the	  stroke	  deficit,	  
19	   –	   36%	   of	   patients	   surviving	   at	   1-­‐year	   did	   so	   with	   severe	   levels	   of	   disability	   and	  
dependency	  20.	  	  UK	  data,	  from	  the	  era	  of	  modern	  management,	  suggest	  that	  approximately	  
	  5	  
one	   fifth	   of	   patients	   suffer	   severe	   residual	   disability	   associated	   with	   high	   levels	   of	  
dependency	   23.	   	   	   Consequently,	   stroke	   represents	   a	   leading	   cause	  of	   disability	   in	   the	   adult	  
population	  4, 5	  and	  requirement	  for	  institutional	  care	  24.	  	  
Beyond	  the	  human	  cost	  of	  stroke	  to	  patients	  and	  their	  families,	  stroke	  carries	  a	  huge	  societal	  
financial	  burden.	   	   In	   the	  UK,	  stroke	  accounts	   for	  1	  –	  2%	  of	  all	  hospital	  admissions	  13.	   	  With	  
lengthy	   admission	   durations	   (mean	   20	   days)	   23,	   healthcare	   related	   costs	   are	  
disproportionately	  high	   for	   stroke	  patients,	  accounting	   for	  an	  estimated	  1%	  -­‐	  5%	  of	  annual	  
healthcare	  budgets	  13, 25.	  
Most	   patients	   who	   suffer	   stroke	   survive	   their	   first	   episode	   13.	   	   Many	   do	   so	   with	   residual	  
disability	  4, 23	  and	  all	  remain	  at	  risk	  of	  recurrent	  stroke.	  	  Accordingly,	  the	  financial	  burden	  of	  
stroke	  comprises	  not	  only	  the	  healthcare	  costs	  during	  hospital	  based	  acute	  and	  rehabilitation	  
management	  but	  also	  the	  subsequent	  cost	  of	  institutional	  and	  community	  based	  social	  care	  
for	   patients	   with	   residual	   disability.	   Consequently,	   the	   financial	   cost	   of	   stroke	   is	   huge,	  
estimated	  at	  between	  £4	  -­‐	  7	  billion	  per	  year	  in	  the	  UK	  alone	  13, 24, 26.	  	  	  
	  
1.2. Management	  of	  acute	  stroke	  
1.2.1. Management	  principles	  
Patients	   presenting	  with	   acute	   ischaemic	   stroke	   are	   at	   risk	   of	   sustaining	   fatal	   or	   disabling	  
neurological	  injury.	  	  All	  patients	  remain	  at	  risk	  of	  a	  recurrent	  and	  often	  more	  severe	  stroke.	  	  
Survivors	  are	  also	  at	  risk	  of	  early	  stroke-­‐related	  medical	  complications,	  particularly	  infection,	  
venous	  thromboembolism	  and	  cardiac	  complications	  27, 28.	  	  	  
Accordingly,	  management	  of	  patients	  with	  acute	  stroke	   is	  based	  on	  attempting	  to	   limit	   the	  
extent	   of	   initial	   neurological	   injury	   and	   providing	   supportive	   physiological	   monitoring	   and	  
therapy	   to	   reduce	   the	   risk	   of	   complications	   28.	   	   Management	   seamlessly	   proceeds	   to	  
assessment	  for	  underlying	  aetiological	  mechanisms	  and	  initiation	  of	  secondary	  preventative	  
measures	  29.	  	  Rehabilitation	  is	  commenced	  at	  the	  earliest	  opportunity	  to	  optimise	  functional	  
recovery	  30.	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1.2.2. The	  ischaemic	  penumbra	  
Following	  arterial	  occlusion,	  cerebral	  blood	  flow	  and	  perfusion	  pressure	  each	  fall	  within	  the	  
territory	  supplied	  by	  the	  affected	  vessel	  31.	  	  Metabolic	  demand	  remains	  constant	  and	  cellular	  
ischaemia	  ensues,	  progressing	  over	  time	  to	  irreversible	  infarction	  32.	  	  Typically,	  a	  central	  core	  
of	  tissue	  infarction	  develops	  at	  the	  site	  of	  arterial	  occlusion,	  which	  subsequently	  expands	  to	  
encompass	  the	  surrounding	  volume	  of	  ischaemic	  but	  potentially	  viable	  tissue,	  referred	  to	  as	  
the	  penumbra	  33.	   	  However,	  avoidance	  of	  progression	  to	  infarction	  is	  dependent	  on	  arterial	  
recanalisation	   and	   restoration	  of	   perfusion	   34.	   	   Penumbral	   tissue	  may	  be	   salvageable	   for	   a	  
period	   of	   several	   hours,	   providing	   a	   window	   of	   opportunity	   for	   either	   spontaneous	   or	  
therapeutic	  recanalisation	  35.	  	  
Therapeutic	   interventions	   to	   improve	   outcome	   in	   acute	   stroke	   have	   been	   focused	   on	  
attempts	  to	  achieve	  recanalisation	  of	  the	  occluded	  artery	  and	  in	  turn	  restoration	  of	  cerebral	  
perfusion.	   	   In	   addition,	   studies	   have	   examined	   supportive	   manipulation	   of	   deranged	  
physiological	   variables	   which	   appear	   to	   influence	   clinical	   outcome	   and	   putative	  
neuroprotectant	  strategies	  which	  may	  delay	  or	  prevent	  tissue	  infarction	  28.	  
	  
1.2.3. Reperfusion	  strategies	  
1.2.3.1. Intra-­‐venous	  thrombolytic	  therapy	  
Three	   large	   randomised	   controlled	   trials	   (RCTs)	   have	   each	   demonstrated	   benefit	   of	  
intravenous	  (IV)	  thrombolytic	  therapy	  in	  reducing	  death	  and	  significant	  disability.	  	  The	  NINDS	  
study	   demonstrated	   benefit	   of	   treatment	   with	   Alteplase,	   initiated	   within	   three	   hours	   of	  
symptom	  onset,	  with	  an	  odds	  ratio	  (OR)	  of	  a	  favourable	  3-­‐month	  outcome	  of	  1.7	  (95%	  CI,	  1.2	  
–	  2.6)	  compared	  with	  placebo	  36.	  	  The	  ECASS-­‐3	  study	  demonstrated	  benefit	  of	  Alteplase	  in	  an	  
extended	   time	   window,	   between	   3	   to	   4.5	   hours	   from	   symptom	   onset,	   with	   an	   OR	   for	   a	  
favourable	  3-­‐month	  outcome	  of	  1.34	  (95%	  CI,	  1.02	  –	  1.76),	  compared	  with	  placebo	  37.	  	  Meta-­‐
analysis	  of	  studies	  examining	  intravenous	  thrombolysis	  concluded	  significant	  benefit	  existed	  
with	   treatment	  commenced	  up	  to	  4.5	  hours	   from	  symptom	  onset	   38.	   	  Benefit	  of	   treatment	  
declines	  with	  time	  from	  symptom	  onset;	  compared	  with	  placebo,	  the	  OR	  for	  a	  favourable	  3-­‐
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month	  outcome	  for	  those	  treated	  with	  90	  minutes	  of	  symptom	  onset	  is	  2.55	  but	  falls	  to	  1.34	  
(95%	  CI,	  1.06	  –	  1.68)	  for	  those	  treated	  between	  180	  and	  270	  minutes.	  	  Phase	  IV	  studies	  have	  
confirmed	  similar	  benefit	  in	  routine	  clinical	  practice	  to	  that	  reported	  in	  the	  RCTs	  39, 40.	  	  Such	  
studies	  have	  also	  indicated	  significant	  benefit	  amongst	  groups	  who	  were	  excluded	  from	  the	  
clinical	  trial	  populations,	  including	  more	  elderly	  patients	  41,	  diabetics	  and	  those	  with	  history	  
of	  prior	  stroke	  42.	  	  The	  results	  of	  the	  IST-­‐3	  study,	  an	  open	  label	  RCT	  comparing	  recombinant	  
tissue	   plasminogen	   activator	   (rt-­‐PA)	   with	   no	   treatment	   were	   published	   in	   2012.	   	   These	  
results	   confirmed	   the	   benefit	   observed	   in	   observational	   data	   amongst	   more	   elderly	  	  	  	  
patients	   43.	   	   Clinical	   guidelines	   recommend	   treatment	   with	   (IV)	   rt-­‐PA	   for	   all	   eligible	  	  	  	  	  	  
patients	  28.	  	  	  
Current	  research	  regarding	  use	  of	  IV	  thrombolysis	  is	  focused	  on	  identifying	  patients	  in	  whom	  
treatment	  may	  potentially	  be	  advantageous	  but	  who	  present	  either	  with	  an	  unclear	  time	  of	  
symptom	  onset	  or	  beyond	  the	  conventional	  4.5	  hour	  treatment	  window.	  	  These	  efforts	  have	  
been	  focussed	  on	   identification	  of	   ischaemic	  core	  and	  viable	  penumbra,	  through	  computed	  
tomography	   (CT)	   perfusion	   or	   magnetic	   resonance	   imaging	   (MRI)	   diffusion	   and	   perfusion	  
weighted	  mismatch	  imaging	  techniques	  34.	  	  Clear	  benefit	  of	  this	  approach	  in	  patient	  selection	  
is	  yet	  to	  be	  shown	  44.	  	  
1.2.3.2. Intra-­‐arterial	  neuroradiological	  procedures	  
Whilst	   IV	   thrombolytic	   therapy	   services	   may	   be	   readily	   implemented	   in	   most	   hospital	  
settings,	   many	   patients	   are	   ineligible	   for	   treatment,	   having	   either	   a	   contra-­‐indication	   to	  
systemic	   thrombolytic	   therapy,	   or	   presenting	   outwith	   the	   treatment	   time	  window.	   	  Many	  
patients	  receiving	   IV	  treatment	  still	  experience	  an	  unfavourable	  outcome,	   in	  part	  reflecting	  
vessel	  recanalisation	  being	  achieved	  in	  only	  30	  –	  40%	  of	  treated	  patients	  and	  fewer	  in	  large	  
artery	   occlusions	   45.	   	   For	   these	   reasons,	   establishing	   reperfusion	   through	   interventional	  
neuro-­‐radiological	  procedures	  has	  been	  explored.	  
Intra-­‐arterial	   (IA)	   thrombolysis	   up	   to	   six	   hours	   after	   symptom	   onset	   has	   been	   studied	   in	  
relation	  to	  middle	  cerebral	  artery	  occlusion	   in	  several	  small	  studies	  46.	   	   In	  meta-­‐analysis,	   IA	  
thrombolysis	  was	  associated	  with	  favourable	  odds	  of	  a	  good	  clinical	  outcome	  compared	  with	  
non-­‐active	  control	  (OR	  2.05;	  95%CI,	  1.33	  –	  3.14).	  	  Trial	  numbers	  are	  small	  however	  and	  such	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treatment	  is	  less	  readily	  available	  than	  intravenous	  therapy.	  	  In	  addition,	  there	  are	  concerns	  
regarding	   the	   risk	  of	   intracerebral	  haemorrhage	  as	  a	   complication	  of	   intra-­‐arterial	   therapy.	  	  
In	  the	  PROACT	  II	  study,	  symptomatic	  haemorrhagic	  transformation	  was	  observed	   in	  10%	  of	  
treated	   patients	   47.	   	   In	   patients	   with	   basilar	   occlusion,	   randomised	   controlled	   studies	   are	  
lacking	   but	   the	   available	   observational	   data	   identified	   no	   difference	   in	   outcomes	   between	  
intravenous	  and	  intra-­‐arterial	  thrombolysis	  48.	  	  	  
Mechanical	   thrombectomy	   has	   been	   examined	   in	   numerous	   retrospective	   &	   prospective	  
observational	   studies	   and	   case	   series	   reports.	   	   Arterial	   recanalisation	   rates	   with	   various	  
thrombectomy	  techniques	  and	  devices	  vary,	  are	   typically	  higher	   than	  those	  quoted	  with	   IV	  
therapy	  but	  are	  also	  associated	  with	  higher	  rates	  of	  symptomatic	   intracranial	  haemorrhage	  
(ICH)	   49.	   	   Randomised	   data	   have	   until	   recently	   been	   lacking.	   	   Results	   from	   the	   Synthesis	  
Expansion	  study,	  which	  compared	  endovascular	  treatment	  with	  IV	  rt-­‐PA,	  found	  no	  difference	  
in	   rates	  of	  disability	  between	  the	  two	  treatment	  groups	  3	  months	   (OR	  0.71	   (95%	  CI,	  0.44	   -­‐	  
1.14)	  50.	  	  However,	  only	  around	  one	  third	  of	  patients	  underwent	  mechanical	  thrombectomy,	  
with	   the	   remainder	   receiving	   IA	   rt-­‐PA	   alone.	   	   The	   IMS	   III	   study	   which	   evaluated	   the	  
combination	  of	  IV	  and	  IA	  (including	  mechanical	  thrombectomy)	  treatment,	  compared	  with	  IV	  
treatment	  alone,	  reported	  discontinuation	  of	  enrolment	  after	  crossing	  a	  futility	  boundary	  51.	  	  
The	  MR-­‐RESCUE	  study	  compared	  IV	  rt-­‐PA	  with	  mechanical	  thrombectomy	  and	  also	  reported	  
no	   difference	   in	   3	  month	   outcomes	   between	   treatment	   groups	   52.	   	   At	   present	   the	   use	   of	  
endovascular	  therapy	  is	  recommended	  in	  the	  context	  of	  clinical	  trials.	  
	  
1.2.4. Antiplatelet	  therapy	  
In	  the	  first	  International	  Stroke	  Trial	  (IST),	  amongst	  patients	  with	  suspected	  ischaemic	  stroke,	  
early	  institution	  (within	  48	  hours	  of	  ictus)	  of	  Aspirin	  (ASA)	  300mg	  once	  daily	  for	  14	  days	  was	  
found	  to	  reduce	  death	  or	  dependency	  at	  6	  month	  follow	  up	  compared	  with	  control,	  with	  14	  
fewer	  dead	  or	  dependent	  patients	  per	  1000	  treated	  (2p	  <	  0.05,	  after	  adjustment	  for	  baseline	  
prognosis).	   	   It	   appears	   likely	   that	   the	   observed	   treatment	   effect	   was	   attributable	   to	   a	  
reduction	   in	   early	   ischaemic	   stroke	   recurrence	   28, 53.	   	   The	   placebo	   controlled	   CAST	   study	  
reported	  similar	  benefits	  of	  early	  ASA	  therapy,	  with	  a	  14%	  reduction	  in	  odds	  of	  death	  at	  28	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days	   (2p	   =	   0.04),	   again	   driven	   by	   a	   significant	   reduction	   in	   recurrent	   ischaemic	   stroke	  	  	  	  
events	   54.	   	  The	  benefit	  of	  ASA	   in	   ischaemic	  stroke	  may	  have	  been	  underestimated	   in	   these	  
studies,	  which	  randomised	  one	  third	  of	  patients	  prior	  to	  CT	  imaging	  to	  exclude	  haemorrhagic	  
pathology.	   	   Guidelines	   recommend	   institution	   of	   antiplatelet	   therapy	   within	   24	   hours	   in	  
ischaemic	   stroke	   patients,	   following	   exclusion	   of	   haemorrhage	   with	   brain	   imaging.	  	  
Treatment	  with	  Aspirin	  is	  recommended	  in	  the	  initial	  14	  days	  on	  the	  basis	  that	  this	  agent	  was	  
studied	  in	  the	  IST	  and	  until	  recently,	  Clopidgrel	  lacked	  an	  evidence	  base	  supporting	  use	  in	  the	  
days	   immediately	   following	   symptom	   onset.	   	   A	   recent	   study,	   conducted	   in	   a	   Chinese	  
population,	   identified	   reduced	   stroke	   recurrence	  with	   combination	   therapy	   of	   Aspirin	   and	  
Clopidogrel	  compared	  with	  Aspirin	  monotherapy (HR	  0.68,	  95%	  CI;	  0.57	  to	  0.81)	  55.	  	  
	  
1.2.5. Anticoagulant	  therapy	  
Anticoagulants	  may	  putatively	  hold	  benefit	  through	  prevention	  of	  neurological	  deterioration	  
or	   enhanced	   neurological	   recovery.	   	   Prevention	   of	   early	   recurrent	   embolisation	   may	   also	  
improve	  patient	  outcomes,	  particularly	  in	  patient	  subgroups	  at	  increased	  risk	  for	  this.	  
The	   largest	   trial	   to	   examine	   the	   role	   of	   early	   anticoagulant	   therapy	   was	   the	   IST	   53,	   which	  
randomised	   19,435	   patients	   with	   suspected	   ischaemic	   stroke	   to	   receive	   fixed	   dose	  
subcutaneous	   unfractionated	   heparin	   (UFH)	   or	   not,	   within	   48	   hours	   of	   symptom	   onset.	  	  
Despite	   a	   significant	   reduction	   in	   ischaemic	   stroke	   events	   in	   the	   UFH	   group	   (2.9%	   versus	  
3.8%,	  2p<0.01),	  the	  study	  failed	  to	  demonstrate	  overall	  benefit	  due	  to	  an	  excess	  in	  ICH	  and	  
extracranial	  bleeding	  with	  (UFH)	  treatment.	  	  Similar	  findings	  were	  observed	  in	  a	  subgroup	  of	  
patients	  with	  atrial	   fibrillation	  (AF)	  56.	   	   Interpretation	  of	   these	  results	   is	  problematic	  due	  to	  
methodological	   flaws	   in	   the	   IST,	   including	   lack	  of	  exclusion	  of	   ICH	  with	  CT	   imaging	  prior	   to	  
administration	  of	  randomised	  therapy,	  concomitant	  administration	  of	  high	  dose	  ASA	  in	  50%	  
of	  the	  UFH	  group	  (the	  authors	  reported	  no	  significant	  interaction	  but	  without	  presentation	  of	  
subgroup	  analysis),	   lack	  of	  therapeutic	  monitoring	  and	  lack	  of	  subgroup	  reporting	  based	  on	  
stratification	  according	  to	  size	  of	  cerebral	  infarction	  on	  CT	  imaging.	  	  	  
Several	  smaller	  studies	  have	  also	  examined	  early	  treatment	  with	  a	  variety	  of	  anticoagulants,	  
including	   UFH,	   low	  molecular	  weight	   heparin	   (LMWH)	   and	   other	   heparinoids.	   	   The	   TOAST	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study	  was	  a	  placebo	  controlled	  trial	  of	  the	  heparinoid	  Danaparoid	  (Org10172),	  commenced	  
intravenously	  within	  24	  hours	  of	  ischaemic	  stroke	  onset	  and	  continued	  for	  7	  days	  57.	  	  In	  this	  
relatively	  mild	   stroke	  population,	   odds	  of	   a	   favourable	   3-­‐month	  outcome	  with	  Danaparoid	  
were	   similar	   to	   with	   placebo	   (OR	   1.13,	   95%	   CI	   0.57	   –	   2.24).	   	   Recurrent	   ischaemic	   stroke	  
events	   were	   similar	   between	   groups	   at	   7	   days	   but	   patients	   treated	   with	   Danaparoid	  
experienced	  higher	  rates	  of	  ICH	  and	  extra-­‐cranial	  bleeding.	  	  	  
The	  HAEST	  study	  compared	  subcutaneous	  Dalteparin	  with	  ASA,	  commenced	  within	  30	  hours	  
of	  acute	  ischaemic	  stroke,	  in	  patients	  with	  AF	  58.	  	  The	  study	  population	  had	  relatively	  severe	  
stroke,	  with	  65.5%	  of	  patients	  experiencing	  an	  outcome	  of	  either	  death	  or	  dependency	  at	  90-­‐
day	  follow	  up.	  	  Additionally,	  baseline	  systolic	  BP	  was	  significantly	  higher	  in	  the	  LMWH	  group.	  	  
No	   difference	   in	   functional	   outcome	  was	   observed	   between	   treatment	   groups	   at	   90-­‐days.	  	  
Odds	  of	  recurrent	  ischaemic	  stroke	  were	  similar	  between	  treatment	  groups	  (OR	  1.13,	  95%	  CI	  
0.57	   –	   2.24),	  while	  Dalteparin	  was	   associated	  with	   an	   increase	   in	   a	   composite	  measure	   of	  
early	   recurrent	   ischaemic	  stroke,	   stroke	  progression,	   symptomatic	   ICH	  and	  death	   (OR	  1.60,	  
95%	  CI	  1.01	  –	  2.54).	  	  	  	  
Meta-­‐analysis	   of	   trial	   data	   examining	   treatment	   with	   anticoagulants	   in	   acute	   stroke	   of	  
cardioembolic	   cause	   suggests	   that	   early	   ischaemic	   stroke	   recurrence	   may	   be	   reduced	  
compared	   with	   non-­‐anticoagulant	   treatment	   strategies	   (OR	   0.69,	   95%	   CI	   0.44	   –	   1.06).	  	  
However,	   symptomatic	   ICH	   is	   increased	   (OR	  2.89,	  95%	  CI	  1.19	  –	  7.01)	  and	  no	  difference	   is	  
observed	   in	  relation	  to	  death	  or	  disability	  at	  subsequent	  follow	  up	  (OR	  1.01,	  95%	  CI	  0.82	  –	  
1.24)	  59.	  	  Accordingly,	  guidelines	  do	  not	  routinely	  recommend	  use	  of	  anticoagulation	  in	  acute	  
ischaemic	  stroke	  of	  either	  presumed	  arterial	  or	  cardioembolic	  aetiology	  28,	  though	  limitations	  
of	   trial	   design	  mean	   that	   potential	   benefit	   in	   particular	   subgroups	   has	   not	   been	   excluded.	  	  
Evidence	  regarding	  early	  anticoagulation	  in	  TIA	  patients	  is	  lacking.	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1.2.6. Control	  of	  physiological	  variables	  
1.2.6.1. Blood	  pressure	  
Elevated	  BP	   in	   acute	   ischaemic	   stroke	  patients	   is	   associated	  with	   both	   increased	  mortality	  
and	  poor	  functional	  outcome	  60.	  	  However,	  the	  relationship	  between	  systemic	  BP	  and	  stroke	  
outcome	  appears	  to	  be	  complex.	  	  A	  non-­‐linear	  relationship,	  following	  a	  U-­‐shaped	  curve,	  with	  
poorer	  outcomes	  reported	  amongst	  patients	  with	  both	  the	  highest	  and	  lowest	  admission	  BPs	  
was	  observed	  in	  the	  IST	  61.	  	  Conversely,	  a	  more	  linear	  relationship	  between	  clinical	  outcome	  
and	  average	  BP	  over	  the	  days	  following	  stroke	  has	  been	  reported	  in	  other	  study	  populations,	  
with	   a	   less	   apparent	   relationship	   reported	  with	   admission	   BP	   62.	   	   Elevated	   BP	  may	   confer	  
poorer	   outcome	   through	   predisposing	   to	   haemorrhagic	   transformation,	   (including	   in	   the	  
context	   of	   thrombolytic	   therapy),	   increased	   cerebral	   oedema	   and	   other	   end	   organ	  	  	  	  	  	  
damage	   28.	   	   Conversely,	   elevated	   systemic	   BP	  may	   preserve	   cerebral	   blood	   flow,	   which	   is	  
linearly	   related	   to	   systemic	   BP	   in	   the	   context	   of	   impaired	   cerebral	   autoregulation	   during	  
acute	  stroke	  63.	  	  The	  optimal	  systemic	  BP	  remains	  undetermined	  and	  may	  vary	  according	  to	  
stroke	  subtype	  and	  individual	  patient	  factors.	  
Several	   studies	   have	   examined	   the	   role	   of	   acute	   BP	   reduction	   in	   the	   setting	   of	   acute	  
ischaemic	  stroke.	   	  None	  have	  demonstrated	  definite	  benefit	  with	  treatment,	  though	  lack	  of	  
statistical	  power	  has	  limited	  interpretation.	  	  The	  results	  of	  the	  large	  ENOS	  study,	  examining	  
early	  BP	   lowering	  with	  nitrate	  based	  treatment	  are	  anticipated	   in	  the	  near	   future.	   	  Current	  
guidelines	  make	  only	  limited	  recommendations	  regarding	  manipulation	  of	  BP	  in	  acute	  stroke,	  
reflecting	  the	  underpowered	  and	  equivocal	  nature	  of	  the	  available	  data	  28.	  
1.2.6.2. Serum	  glucose	  
Hyperglycaemia	  is	  highly	  prevalent	  amongst	  patients	  presenting	  with	  acute	  stroke,	  including	  
amongst	  non-­‐diabetic	  patients	   64.	   	   This	   in	  part	   reflects	   a	   group	  with	  hitherto	  undiagnosed,	  
occult	   diabetes	   mellitus	   (DM)	   65.	   	   However,	   hyperglycaemia	   also	   appears	   to	   represent	   a	  
component	  of	  the	  stress	  response	  to	  the	  acute	  physiological	  insult	  66.	  	  Larger	  infarct	  burden	  
on	   brain	   imaging	   is	   associated	   with	   hyperglycaemia	   67.	   	   The	   level	   of	   admission	   and	  
subsequent	  in-­‐patient	  hyperglycaemia	  is	  associated	  with	  clinical	  outcome,	  with	  higher	  blood	  
glucose	   levels	  predicting	  adverse	  prognosis	  66, 68.	   	   In	  addition,	  patients	  with	  hyperglycaemia	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treated	   with	   thrombolytic	   therapy	   are	   more	   likely	   to	   experience	   haemorrhagic	  
transformation	  69.	  
Randomised	  evidence	  assessing	  the	  treatment	  of	  hyperglycaemia	   in	  acute	  stroke	   is	   limited.	  	  
The	   largest	   study	   was	   the	   GIST-­‐UK	   study	   70,	   which	   terminated	   prematurely	   due	   to	   slow	  
patient	   enrolment.	   	   No	   significant	   clinical	   effect	   of	   treatment	   with	   a	   GKI	   regime	   was	  
observed,	   although	   the	   reduction	   in	   serum	   glucose	  was	  modest	   and	   active	   treatment	  was	  
associated	   with	   a	   moderate	   reduction	   in	   BP.	   	   Variable	   rate	   insulin	   infusions	   71, 72	   achieve	  
lower	  blood	   sugar	   levels	  but	  at	   the	  expense	  of	   increased	  hypoglycaemic	  episodes.	   	  Clinical	  
outcomes	  in	  relation	  to	  treatment	  have	  not	  been	  assessed.	  	  
1.2.6.3. Body	  temperature	  
Elevated	  body	  temperature	  in	  patients	  with	  acute	  stroke	  is	  associated	  with	  adverse	  outcome.	  	  
Whilst	  potentially	  attributable	  to	  central	  mechanisms,	  pyrexia	  may	  also	  indicate	  infection	  or	  
thrombotic	   phenomena	   complicating	   the	   post	   stroke	   period.	   	   Raised	   temperature	   is	  
conducive	   to	   increased	   metabolism,	   which	   in	   the	   context	   of	   cerebral	   ischaemia	   may	  
accelerate	   tissue	   infarction.	   	   Several	   small	   studies	   have	   examined	   the	   potential	   benefit	   of	  
modest	  induced	  hypothermia	  as	  a	  neuroprotective	  strategy	  during	  acute	  ischaemic	  stroke	  73.	  	  
Results	  have	  been	  inconclusive	  but	  larger	  studies	  are	  now	  enrolling	  patients.	  
	  
1.2.7. Neuroprotection	  
In	   the	   context	   of	   cerebral	   ischaemia,	   a	   number	   of	   cellular	  metabolic	   pathways	   have	   been	  
considered	   potential	   therapeutic	   targets	   for	   manipulation,	   with	   a	   view	   to	   delaying	   the	  
progression	   to	   cellular	   death,	   until	   tissue	   reperfusion,	   by	   whatever	   means,	   may	   occur.	  	  
Potential	  targets	  have	  included	  glutamate,	  calcium	  flux,	  cellular	  proteases,	  apoptosis,	  oxygen	  
free	   radicals	   and	   inflammatory	   pathways	   28.	   	   A	   large	   number	   of	   clinical	   trials	   have	   been	  
conducted	   in	   acute	   stroke	   which	   have	   examined	   the	   therapeutic	   manipulation	   of	   these	  
mechanisms	   of	   injury	   74.	   	   To	   date	   none	   has	   demonstrated	   efficacy	   in	   improving	   clinical	  
outcome	  following	  stroke	  and	  the	  use	  of	  neuroprotective	  agents	  is	  not	  recommended.	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1.2.8. Surgical	  strategies	  
Malignant	  middle	  cerebral	  artery	  syndrome	  is	  a	  complication	  of	  proximal	  middle	  cerebral	  or	  
terminal	   internal	   carotid	   artery	   occlusion,	   which	   may	   develop	   approximately	   48	   hours	  
following	   occlusion.	   	   Extensive	   infarction-­‐related	   cerebral	   oedema	   results	   in	   raised	  
intracranial	  pressure,	  mass	  effect	  and	  tentorial	  herniation	  28.	  	  Mortality	  is	  high	  and	  survivors	  
are	   invariably	   severely	  disabled.	   	  The	  data	   from	  the	  HAMLET,	  DESTINY	  and	  DECIMAL	   trials,	  
which	  each	  compared	  emergent	  decompressive	  hemicraniectomy	  with	  medical	  management	  
alone,	  were	  combined	  in	  a	  meta-­‐analysis	  which	  demonstrated	  a	  highly	  significant	  reduction	  
in	  mortality	   75, 76.	   	   The	  number	  of	  patients	  needed	   to	   treat	   to	  prevent	  one	  death	  was	  only	  
two,	   though	   survivors	  were	   frequently	   severely	  disabled	  at	   follow	  up.	   	   These	   studies	  were	  
conducted	   in	  patients	  below	  65	  years	   in	  age.	   	  A	  recent	  trial	  has	  demonstrated	  a	  significant	  
reduction	   in	  mortality	   in	  patients	  up	   to	  75	  years	   in	  age,	   though	  again	  with	   the	  majority	  of	  
survivors	  experiencing	  severe	  levels	  of	  residual	  disability	  77.	  
	  
1.2.9. Systems	  of	  care	  
Prompt	   admission	   to	   a	   specialist	   acute	   stroke	   unit,	   with	   access	   to	   medical,	   nursing,	  
physiotherapy,	   occupational	   therapy,	   speech	   and	   language	   therapy	   staff	   with	   specialist	  
experience	   in	   the	   management	   of	   stroke	   patients,	   has	   been	   shown	   to	   improve	   patient	  
outcomes.	   	  These	  include	  improved	  functional	  recovery	  and	  fewer	  patients	  experiencing	  an	  
outcome	   of	   either	   institutionalisation	   or	   death	   78.	   	   The	   contribution	   of	   the	   individual	  
components	  of	  stroke	  unit	  care	  to	  the	  observed	  treatment	  benefit	  has	  not	  been	  elucidated	  
further;	  a	  “black	  box”	  treatment	  effect	  of	  stroke	  unit	  care	  has	  consequently	  been	  described.	  	  
Irrespective	   of	   the	   mechanism	   of	   benefit,	   prompt	   admission	   to	   a	   specialist	   stroke	   unit	   is	  
recommended	  for	  all	  stroke	  patients	  27-­‐29, 79.	  	  
	  
1.2.10. Prophylaxis	  of	  post-­‐stroke	  venous	  thromboembolic	  disease	  
Venous	   thromboembolic	   (VTE)	   disease	   is	   a	   common	   complication	   following	   stroke,	  
particularly	  amongst	  more	  severely	  affected	  patients	  who	  are	  rendered	  immobile.	  	  Low	  dose	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anticoagulation,	  with	  either	  UFH	  or	  LMWH,	  reduces	  the	  frequency	  of	  deep	  vein	  thrombosis	  
(DVT)	  following	  stroke.	   	  However,	  routine	  use	  has	  not	  been	  recommended	  due	  to	  concerns	  
over	  treatment	  predisposing	  to	  haemorrhagic	  transformation	  of	  acute	  infarct	  80.	  
The	  CLOTS	  and	  CLOTS-­‐2	  trial	  investigators	  concluded	  no	  overall	  benefit	  to	  support	  the	  use	  of	  
either	  below	  or	  above	  knee	  length	  graduated	  compression	  TED	  stockings.	  	  Despite	  a	  reduced	  
incidence	   of	   DVT,	   a	   small	   excess	   in	   skin	   ulceration	   associated	   with	   stocking	   use	   was	  	  	  
observed	  80.	   	   In	  the	  CLOTS-­‐3	  trial,	  use	  of	   intermittent	  pneumatic	  compression	  was	  found	  to	  
reduce	  the	  incidence	  of	  proximal	  DVT	  in	  patients	  following	  stroke,	  with	  a	  number	  needed	  to	  
treat	  (NNT)	  to	  prevent	  one	  DVT	  of	  28	  patients	  81.	   	  Proximal	  DVT	  was	  evident	  on	  ultrasound	  
imaging	   in	   12.1%	   of	   control	   patients	   but	   symptomatically	   so	   in	   only	   one	   third,	   suggesting	  
there	  may	  be	  a	  role	  for	  routine	  DVT	  screening	  following	  stroke.	  	  
	  
1.2.11. Clinical	  outcomes	  following	  stroke	  
Admission	   to	   a	   specialist	   acute	   stroke	   unit	   is	   universally	   applicable	   to	   all	   stroke	   patients.	  	  
Despite	  efforts	  to	  establish	  healthcare	  models	  by	  which	  to	  deliver	  reperfusion	  treatment,	  this	  
is	  rarely	  achieved	  in	  more	  than	  10%	  of	  ischaemic	  stroke	  patients	  23, 82, 83,	  primarily	  reflecting	  
the	  constraint	  of	  time	  from	  ictus	  to	  the	  delivery	  of	  both	  safe	  and	  effective	  treatment.	   	  The	  
NNT	   for	   early	   initiation	   of	   ASA	   therapy	   is	   relatively	   high.	   	  Other	   therapeutic	   strategies	   are	  
either	   limited	   to	   relatively	   small	   subgroups	   of	   patients	   or	   lack	   a	   robust	   evidence	   base.	  	  
Despite	  improved	  outcomes	  with	  treatment	  with	  rt-­‐PA	  and	  management	  in	  specialist	  stroke	  
centres,	   approximately	   half	   of	   patients	   in	   the	   placebo	   arm	   of	   contemporary	   studies	   still	  
experienced	  an	  unfavourable	  outcome	  (death	  or	  dependency)	  at	  90	  days	  38.	  	  	  
Thus,	   a	   reduction	   in	   the	   burden	   of	   stroke	   disease	   is	   dependent	   on	   the	   identification	   and	  
implementation	  of	  effective	  preventative	  strategies.	  	  This	  is	  a	  particularly	  important	  aspect	  of	  
management	  given	  the	  high	  risk	  of	  recurrent	  stroke	  following	  index	  stroke	  or	  TIA.	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1.3. The	  risk	  of	  stroke	  recurrence	  following	  ischaemic	  stroke	  &	  TIA	  
1.3.1. Clinical	  and	  aetiological	  classification	  systems	  for	  ischaemic	  stroke	  
The	   Oxford	   classification	   system	   categorises	   patients	   according	   to	   their	   clinical	   pattern	   of	  
presentation	  as	  having	  experienced	  one	  of	  four	  stroke	  syndromes	  (table	  1-­‐1)	  20.	  	  This	  system	  
provides	   useful	   prognostic	   information	   regarding	   likelihood	   of	   functional	   recovery	   and	   in	  
relation	   to	   risk	   of	   stroke	   recurrence.	   	   The	   TOAST	   classification	   system	   considers	   the	  
combination	  of	  the	  clinical	  stroke	  syndrome,	  infarct	  topography	  on	  brain	  imaging,	  vascular	  &	  
cardiac	   imaging,	   electrocardiological	   studies	   and	   laboratory	   investigations	   in	   defining	  
ischaemic	  stroke	  according	  to	  one	  of	  five	  aetiological	  categories:	  large	  artery	  atherosclerosis	  
(LAA);	   small	   vessel	   disease	   (SVD);	   cardioembolism	   (CE);	   other	   determined	   pathology;	  
undetermined	  pathology	  84.	  	  	  
	  
Table	  1-­‐1:	  	  The	  Oxford	  clinical	  stroke	  classification	  system	  	  
(reproduced	  from	  Bamford	  et	  al,	  Lancet	  1991)	  
Prognosis	  at	  1	  year	  	   TACS	   PACS	   LACS	   POCS	  
Dead	   60	  %	   16	  %	   11	  %	   19	  %	  
Dependant	   36	  %	   29	  %	   28	  %	   19	  %	  
Independent	   4	  %	   55	  %	   60	  %	   62	  %	  
TACS,	  total	  anterior	  circulation	  stroke;	  PACS,	  partial	  anterior	  circulation	  stroke;	  LACS,	  lacunar	  anterior	  
circulation	  stroke;	  POCS,	  posterior	  circulation	  stroke.	  
	  
The	   relationship	  with	   outcome	   reflects	   the	   link	   between	   the	   clinical	   syndrome	   and	   infarct	  
topography	  on	  brain	  imaging,	  which	  in	  turn	  is	  indicative	  of	  potential	  aetiological	  mechanisms:	  
lacunar	  syndrome	  (LACS)	  events	  are	  associated	  with	   lacunar	   infarcts,	   indicating	  SVD,	  whilst	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partial	  and	  total	  anterior	  circulation	  events	  (PACS	  &	  TACS,	  respectively)	  are	  associated	  with	  
embolic	   pattern	   infarcts,	   indicative	   of	   either	   a	   LAA	   or	   CE	   aetiological	   mechanism	   85.	   	   The	  
latter	   categories	   appear	   to	   be	   associated	   with	   higher	   risk	   of	   recurrence,	   as	   discussed	   in	  
further	   detail	   below.	   	   In	   a	   small	   minority	   of	   cases,	   other	   causes	   including	   cervical	   artery	  
dissection,	   arterial	   vasculitis,	   underling	   thrombophilia	   and	   venous	   thrombotic	   disease	  may	  
each	  give	  rise	  to	  cerebral	  ischaemia	  32.	  	  
Historical	  studies	  examining	  the	  natural	  history	  of	  stroke	  have	  utilised	  diverse	  classification	  
systems,	   limiting	   direct	   comparisons	   between	   populations	   and	   time	   periods.	   	   The	   wider	  
adoption	  of	  TOAST	  provides	  a	  basis	  for	  direct	  comparability	  between	  study	  populations	  and	  
assessment	  of	  prognosis	   and	   treatment	  effects	  within	  aetiological	   subgroups	   86.	   	  However,	  
patients	  with	  undetermined	  pathology	   represent	  a	  heterogeneous	  cohort,	   comprising	  both	  
those	   in	  whom	  either	  no	  aetiological	   factor	   is	   identifiable	  but	  also	   those	  patients	   in	  whom	  
more	   than	   one	   aetiological	   factor	   is	   identified	   through	   investigation	   (following	   either	  
comprehensive	   or	   incomplete	   investigation).	   	   I.e.	   the	   presence	   of	   both	   LAA	   and	   AF	  would	  
result	   in	   an	   undetermined	   aetiological	   classification.	   Consequently,	   assignment	   of	   risk	   and	  
optimal	  treatment	  may	  be	  more	  problematic	  in	  this	  group.	  
	  
1.3.2. Prevalence	  of	  co-­‐existent	  aetiological	  mechanisms	  
Conventionally,	  LAA,	  SVD	  and	  CE	  have	  been	  considered	  the	  main	  causes	  of	  ischaemic	  stroke,	  
accounting	   for	   13.4	   –	   16.7%,	   15.9	   –	   22.6%	   and	   18.6	   –	   29.1%	   of	   cases	   respectively	   87.	  	  
However,	   as	   each	   of	   these	   aetiological	   categories	   share	   similar	   underlying	   risk	   factors,	  
combinations	   (or	   all)	   of	   these	   potential	   culprit	   pathologies	   are	   identified	   to	   coexist	   in	   a	  
substantial	   proportion	   of	   patients	   with	   ischaemic	   stroke	   &	   TIA.	   	   This	   is	   supported	   by	   the	  
largest	  aetiological	  category	  being	  “undetermined”,	  accounting	  for	  34.7	  –	  42.2%	  of	  cases	  87.	  
In	  patients	  with	  AF,	  the	  CHA2DS2-­‐VASC	  score	  predicts	  the	  presence	  of	  concomitant	  cerebral	  
artery	  atherosclerosis	  88.	  	  Approximately	  25%	  -­‐	  30%	  of	  patients	  found	  to	  have	  AF	  at	  the	  time	  
of	   ischaemic	   stroke	  will	   also	  have	  demonstrable	  evidence	  of	   LAA	   88, 89.	   	   In	  one	  consecutive	  
series	  of	  patients	  with	  acute	  brain	  ischaemia,	  188	  of	  300	  patients	  were	  identified	  as	  having	  a	  
potential	   cardiac	   source	   of	   embolism	   90.	   	   84.6%	   of	   these	   had	   competitive	   aetiologies,	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predominantly	  LAA.	  	  In	  one	  third	  of	  patients	  with	  a	  stroke	  and	  AF,	  the	  cerebral	  event	  may	  be	  
causally	  related	  to	  a	  co-­‐existent	  arterial	  lesion,	  rather	  than	  AF-­‐related	  cardioembolism	  91, 92.	  	  	  
Conversely,	   in	   patients	  with	   severe	   carotid	   stenosis,	   AF	  was	   noted	   in	   13.7%	   in	   one	   recent	  
case	  series	  93	  and	  in	  the	  NASCET	  clinical	  trial	  population,	  which	  included	  ischaemic	  stroke	  &	  
TIA	   patients	   with	   evidence	   of	   extracranial	   internal	   carotid	   artery	   (ICA)	   atherosclerosis	   of	  
varying	  degree,	  during	  5-­‐year	  average	  follow	  up,	  20%	  of	  recurrent	  strokes	  in	  the	  territory	  of	  
the	  originally	  symptomatic	  artery	  were	  considered	  to	  be	  unrelated	  to	  the	  carotid	  stenosis	  94.	  	  
Thus,	   the	   conventional	   proportional	   assignment	   of	   stroke	   aetiology	   may	   represent	   an	  
oversimplification.	  	  	  
	  
1.3.3. Risk	  of	  recurrence	  following	  ischaemic	  stroke	  
Approximately	  152,000	  strokes	  occur	  in	  the	  UK	  each	  year.	   	  Approximately	  129,000	  of	  these	  
are	   ischaemic	   stroke	   and	   in	   addition,	   46,000	  patients	   also	   suffer	   a	   first	   TIA	   9, 12.	   	   All	   these	  
patients	   remain	   at	   risk	   of	   a	   further,	   potentially	   disabling	   stroke.	   	   Indeed,	   incident	   strokes	  
represent	   only	   around	   three	   quarters	   of	   all	   annual	   stroke	   events,	   with	   the	   remainder	  
comprising	  recurrent	  events	  18, 19.	  	  In	  patients	  who	  experience	  mild	  ischaemic	  stroke	  or	  TIA,	  
subsequent	   events	   are	   major	   &	   disabling	   in	   approximately	   two	   thirds	   of	   cases	   32, 95.	   	   In	  
addition,	   these	   patients	   are	   at	   high	   risk	   of	   subsequent	   cardiac	   events	   and	   cardiovascular	  
death	   32.	   	   Thus,	   incident	   stroke,	   particularly	   mild,	   non-­‐disabling	   stroke	   events	   and	   TIA,	  
identifies	   a	   group	   of	   patients	   at	   risk	   of	   future	   disabling	   or	   fatal	   stroke	   and	   other	  
cardiovascular	  events.	  	  	  
Stroke	   recurrence	   rates	   reported	   in	   studies	   vary	   according	   to	   the	   characteristics	   of	   the	  
population	   studied,	   including	   concomitant	   risk	   factors	   for	   stroke,	   age	   and	   secondary	  
preventative	  measures	  contemporary	  to	  the	  period	  of	  study.	  	  Definition	  of	  stroke	  recurrence	  
and	  duration	  of	   follow	  up	  also	   influence	  reported	  rates	   32.	   	  There	   is	  some	  heterogeneity	   in	  
subsequent	   risk	   between	   patients	   with	   completed	   stroke	   and	   those	   with	   TIA	   (or	   minor	  
stroke).	   	   In	   addition,	   the	   risk	   of	   subsequent	   events	  may	   be	   stratified	   further	   according	   to	  
concomitant	  risk	  factors	  and	  the	  underlying	  stroke	  mechanism.	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Population	   studies	   indicate	   a	   high	   long	   term	   risk	   of	   recurrence	   following	   stroke	   96.	   	   A	  
systematic	   review	   &	   meta-­‐analysis	   of	   published	   hospital	   and	   community	   based	   stroke	  
registries,	  estimated	  the	  5-­‐	  and	  10-­‐year	  cumulative	  risk	  of	  recurrence	  to	  be	  26.4%	  (95%	  CI,	  
20.1	  –	  32.8%)	  and	  39%	  (95%	  CI	  27.2	  –	  51.2%),	  respectively	  97.	  	  Although	  long	  term	  cumulative	  
risk	  of	  recurrence	  is	  high,	  the	  highest	  risk	  period	  is	  during	  the	  initial	  year	  following	  an	  index	  
stroke,	   with	   approximately	   one	   quarter	   of	   the	   10-­‐year	   cumulative	   recurrent	   event	   risk	  
accounted	   for	   by	   events	   in	   this	   period,	   with	   11.1%	   (95%	   CI,	   9.0	   –	   13.3%)	   experiencing	  
recurrent	  stroke.	  	  The	  first	  30-­‐days	  following	  the	  index	  event	  appeared	  to	  be	  the	  highest	  risk	  
period	  of	  all,	  with	  3.1%	  (95%	  CI,	  1.7	  –	  4.4%)	  of	  patients	  suffering	  recurrence.	  	  
In	   this	   analysis,	   significant	   heterogeneity	   in	   recurrence	   rates	   between	   studies	   was	   noted,	  
reflecting	   differences	   in	   population	   characteristics	   and	   methodology	   among	   published	  
studies.	   	   Irrespective	  of	   this,	   the	   risk	  of	   stroke	   recurrence	  was	  high	  across	  all	   studies,	  with	  
estimates	  ranging	  between	  1.1%	  -­‐	  15%	  by	  one	  year	  and	  14%	  to	  51.3%	  by	  10	  years	  97.	  
	  
1.3.4. Risk	  of	  stroke	  following	  TIA	  
Estimates	   of	   stroke	   risk	   following	   TIA	   also	   vary	   according	   to	   the	   population	   studied	   32.	  	  
However,	  irrespective	  of	  the	  population	  context,	  this	  group	  is	  at	  increased	  risk	  of	  stroke	  and	  
other	  vascular	  events	  compared	  with	  age	  &	  sex	  matched	  controls	  98, 99.	  	  15	  –	  30%	  of	  patients	  
who	  suffer	  a	  disabling	  stroke	  have	  experienced	  a	  prior	  TIA	  100.	  	  In	  the	  OCSP,	  patients	  with	  a	  
TIA	  had	  a	  13-­‐fold	  excess	  risk	  of	  stroke	  in	  the	  subsequent	  12	  months	  and	  7-­‐fold	  excess	  over	  
the	  7	  years	  following	  TIA	  98.	  	  	  
Studies	  indicate	  that	  the	  risk	  of	  early	  and	  very	  early	  stroke	  recurrence	  following	  TIA	  appears	  
to	  be	  higher	  than	  in	  patients	  with	  completed	  stroke.	  	  Whilst	  this	  may,	  at	  least	  in	  part,	  reflect	  
methodological	   aspects	   of	   study	   design,	   this	   has	   prompted	   revision	   of	   the	   approach	   to	  
management	  of	  TIA,	  with	   the	  condition	  now	  regarded	  as	  a	  medical	  emergency,	  potentially	  
heralding	  disabling	  or	  fatal	  stroke	  101.	  	  	  
Amongst	   patients	   who	   presented	   to	   Californian	   hospital	   emergency	   departments	   with	  
suspected	  TIA,	  5.3%	  of	  patients	  re-­‐presented	  with	  completed	  stroke	  within	  48	  hours.	  	  10.5%	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suffered	  stroke	  within	  90	  days	  95.	   	   	   In	   the	  OCSP	  population,	  8.6%	  (95%	  CI	  4.8	  –	  12.4%)	  and	  
12.0%	  (95%	  CI,	  7.6	  –	  16.4%)	  of	  patients,	  respectively,	  suffered	  stroke	  within	  7	  and	  30	  days	  of	  
their	   index	   symptoms	   102.	   	   15	   –	   30%	   of	   patients	   who	   suffer	   a	   disabling	   stroke	   have	  
experienced	  a	  prior	  TIA	  and	  up	  to	  23%	  of	  patients	  who	  suffer	  a	  completed	  stroke	  report	  a	  TIA	  
in	   the	  preceding	  week	   100.	   	   Stroke	   following	  TIA	   is	  disabling	   in	  approximately	   two	   thirds	  of	  
patients	  95.	  	  	  
In	  a	  systematic	  review	  and	  meta-­‐analysis	  of	  studies	  examining	  early	  risk	  of	  stroke	  following	  
TIA	  103,	  heterogeneity	  was	  observed	   in	  recurrence	  rates,	  which	  varied	  between	  populations	  
and	   according	   to	   the	   clinical	   management	   of	   TIA.	   	   Higher	   recurrence	   was	   observed	   in	  
populations	   with	   delayed,	   as	   opposed	   to	   expedited,	   investigation	   and	   commencement	   of	  
secondary	   preventative	   measures.	   	   In	   studies	   examining	   populations	   lacking	   expedited	  
medical	  care,	  2-­‐	  and	  7-­‐day	  stroke	  occurrence	  was	  6.7%	  (95%	  CI,	  3.6	  –	  9.7%)	  and	  10.4%	  (95%	  
CI,	  8.1	  –	  12.6%),	  respectively.	  	  Expedited	  medical	  assessment,	  investigation	  and	  institution	  of	  
secondary	  preventative	  measures	  have	  been	  shown	  to	  reduce	  the	  early	  recurrence	  following	  
TIA	   and	   minor	   stroke	   103, 104.	   	   Nevertheless,	   the	   risk	   of	   stroke	   remains	   high	   even	   in	   this	  
context.	  
Recent	   years	   have	   seen	   the	   development	   and	   validation	   of	   risk	   stratification	   tools	   for	   the	  
assessment	   of	   patients	   following	   TIA,	   identifying	   certain	   patients	   to	   be	   at	   particularly	  
increased	  risk	  relative	  to	  the	  TIA	  population	  as	  a	  whole	  105.	  	  According	  to	  the	  presence	  of	  risk	  
factors	   (age,	   elevated	   BP,	   DM)	   and	   clinical	   features	   (lateralising	   motor	   deficit,	   speech	  
disturbance,	  symptom	  duration),	  patients	  may	  be	  stratified	  variously	  as	  low,	  intermediate	  or	  
high	   risk	  of	  early	   stroke	  occurrence	   following	  TIA.	   	   In	  validation	   studies,	  patients	  with	  high	  
risk	  scores	  have	  been	  reported	  to	  have	  stroke	  rates	  of	  8.1%	  within	  2	  days	  of	  TIA	  106.	  
Patients	  with	  TIA	  and	   ischaemic	   stroke	  of	  mild	   severity	  are	  qualitatively	   similar	   in	   terms	  of	  
age,	   sex	  &	   prevalence	   of	   co-­‐existent	   vascular	   diseases	  &	   risk	   factors	   and	   accordingly	   have	  
similar	  prognosis	  in	  terms	  of	  risk	  of	  subsequent	  stroke	  and	  vascular	  mortality	  107, 108.	  	  The	  risk	  
of	   stroke	   following	   ocular	   TIA	   (amaurosis	   fugax),	   appears	   to	   be	   lower	   to	   that	   following	  
cerebral	  TIA	  102.	  	  Patients	  who	  survive	  the	  initial	  12	  months	  following	  TIA	  event	  free	  remain	  at	  
elevated	  risk,	  with	  a	  recurrent	  stroke	  rate	  of	  approximately	  5%	  per	  annum	  32, 98.	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1.3.5. Risk	  of	  non-­‐stroke	  events	  following	  ischaemic	  stroke	  &	  TIA	  
Whilst	   the	   majority	   of	   vascular	   events	   arising	   subsequent	   to	   a	   stroke	   or	   TIA	   comprise	   a	  
completed	   stroke,	   patients	   also	   appear	   to	   be	   at	   high	   risk	   of	   other	   cardiovascular	   events,	  
including	  coronary	  artery	  disease	  (CAD)	  events	  and	  vascular	  death.	  	  In	  the	  placebo	  arm	  of	  the	  
SPARCL	  study,	  8.9%	  of	  patients	  suffered	  a	  serious	  non-­‐stroke	  cardiovascular	  event	  during	  4.9	  
years	  of	  follow	  up	  109.	  	  The	  risk	  of	  non-­‐stroke	  cardiovascular	  events,	  including	  cardiovascular	  
death	  is	  also	  high	  (25.1%	  of	  patients	  within	  3	  months)	  following	  TIA	  95.	  
	  
1.3.6. Risk	  of	  recurrence	  according	  to	  aetiological	  subtype	  
Following	  both	  stoke	  and	  TIA,	   individual	  risk	  of	  subsequent	  stroke	  is	   influenced	  not	  only	  by	  
the	   timing	   of	   intervention	   with	   medical	   investigation	   and	   institution	   of	   secondary	  
preventative	  therapies	  but	  also	  by	  the	  presence	  or	  absence	  of	  potentially	  culprit	  aetiological	  
&	  risk	  factors.	  	  	  
Population	   studies	   which	   characterised	   patients	   according	   to	   their	   aetiological	   subtype	  
provide	   information	   regarding	   the	   natural	   history	   and	   recurrence	   risk	   according	   to	   the	  
presence	   of	   particular	   aetiological	   factors.	   	   Data	   from	   closely	   monitored	   clinical	   trial	  
populations	   provide	   an	   estimate	   of	   recurrence	   rates	   in	   the	   context	   of	   specific	   and	   well	  
characterised	  aetiological	  subtypes	  of	  stroke.	  
One	   analysis	   of	   population	   based	   studies,	   which	   retrospectively	   applied	   TOAST	   criteria,	  
suggested	  risk	  of	  early	  recurrence	  was	  greatest	  in	  patients	  with	  confirmed	  LAA,	  followed	  by	  
patients	  with	  either	  cardioembolic	  or	  undetermined	  aetiology	  110.	  	  Patients	  with	  SVD	  related	  
lacunar	  strokes	  appear	   to	  be	  at	   reduced	  risk	  of	  early	   recurrence	  compared	  with	   the	  stroke	  
population	   as	   a	   whole.	   	   Conversely,	   analysis	   of	   the	   Erlangen	   stroke	   registry	   111	   reported	  
similar	  risk	  for	  LAA	  and	  CE	  related	  stroke	  early	  after	  the	  incident	  event.	  	  SVD	  related	  stroke	  
was	  again	  associated	  with	  the	  lowest	  rate	  of	  recurrence.	  
It	   appears	   that	   the	   relative	   risk	   (RR)	  of	   stroke	   recurrence	  according	   to	   stroke	   subtype	  may	  
vary	  with	  time	  112.	  	  The	  risk	  of	  recurrence	  with	  LAA	  is	  particularly	  high	  immediately	  following	  
the	  initial	  clinical	  presentation	  but	  declines	  thereafter	  113.	   	  CE	  related	  stroke	  was	  associated	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with	   the	   highest	   risk	   of	   recurrence	   of	   any	   aetiological	   types	   in	   longer	   term	   follow	   up	   111.	  	  
Thus,	  whilst	  very	  early	  recurrence	  may	  be	  less	  in	  CE	  compared	  with	  LAA-­‐related	  stroke	  (the	  
limitations	   of	   incomplete	   investigation	   for	   AF	   and	   consideration	   of	   CE	   related	   stroke	   as	   a	  
single	  entity	  accepted),	  medium	  and	  long	  term	  CE	  related	  risk	  may	  exceed	  that	  for	  LAA.	  	  	  
The	  discussion	  below	  details	   the	   risk	  of	   recurrence	  associated	  with	   the	  various	  aetiological	  
subtypes	   of	   ischaemic	   stroke.	   It	   is	   noteworthy	   that	   less	   data	   are	   available	   for	   the	   TIA	  
population	  114.	  	  As	  described	  above,	  the	  risk	  of	  early	  recurrence	  following	  TIA	  is	  higher	  than	  
following	  ischaemic	  stroke.	  	  Therefore	  identification	  and	  optimised	  treatment	  of	  aetiological	  
factors	  in	  TIA	  patients	  may	  be	  more	  pressing	  than	  for	  ischaemic	  stroke	  patients.	  	  	  
	  
1.3.6.1. Presumed	  arterial	  aetiology	  
The	  PRoFESS	  study	  population	  comprised	  patients	  with	  ischaemic	  stroke	  or	  TIA	  (mean	  age	  66	  
years),	   of	   presumed	   arterial	   origin	   (only	   2.7%	   of	   those	   enrolled	   had	   AF).	   	   Patients	   were	  
treated	   with	   current	   optimal	   antiplatelet	   therapy	   and	   high	   levels	   of	   concomitant	  
antihypertensive	  and	  statin	  therapy.	   	  During	  a	  mean	  follow	  up	  period	  of	  2.5	  years,	  8.8%	  of	  
control	   (Clopidogrel)	   patients	   experienced	   a	   recurrent	   stroke,	   whilst	   13.1%	   suffered	   a	  
secondary	  composite	  outcome	  of	  stroke,	  MI	  or	  vascular	  death	  115.	  
The	   SPARCL	   study	   population	   comprised	   patients	   with	   previous	   ischaemic	   stroke	   or	   TIA	  
(mean	   age	   63	   years)	   of	   presumed	   arterial	   aetiology,	   with	   exclusion	   of	   patients	   with	  
cardioembolic	  mechanisms	  for	  stroke.	   	  During	  a	  mean	  follow	  up	  period	  of	  4.9	  years,	  11.2%	  
and	  14.1%	  of	  patients	   in	   the	  active	   (Atorvastatin)	  group	  experienced	  a	   recurrent	   ischaemic	  
stroke	  any	  major	  cardiovascular	  event,	  respectively	  116.	  
	  
1.3.6.2. Small	  vessel	  disease	  
There	  is	  conflicting	  data	  regarding	  the	  risk	  of	  recurrent	  stroke	  following	  SVD	  related	  stroke.	  	  
In	  a	  meta-­‐analysis	  of	  retrospectively	  applied	  TOAST	  criteria	  to	  the	  OCSP,	  OXVASC,	  Erlangen	  &	  
Rochester	  stroke	  registries,	  7-­‐day	  recurrence	  was	  observed	  in	  no	  patients,	  whilst	  30-­‐day	  and	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1-­‐year	  recurrence	  were	  observed	  in	  only	  2.0%	  (95%	  CI,	  0-­‐4.2%)	  and	  3.4%	  	  (95%	  CI,	  0.6-­‐6.3%)	  
of	   patients,	   respectively	   110.	   	   In	   contrast	   to	   the	   findings	   reported	   by	   Lovett,	   the	   rate	   of	  
recurrence	  in	  patients	  with	  SVD	  in	  the	  PRoFESS	  study	  was	  8.3%	  after	  2.5	  years	  of	  follow	  up,	  
which	  was	  comparable	  to	  the	  combined	  rate	   in	  patients	  with	   	  LAA,	  undetermined,	  other	  &	  
cardioembolism	  related	  stroke	  115.	  	  	  	  	  	  
	  
1.3.6.3. Large	  artery	  atherosclerosis	  
Patients	  with	  LAA	  are	  at	  high	  risk	  of	  stroke	  recurrence,	  with	  the	  greatest	  risk	  observed	  in	  the	  
period	   immediately	   following	   ischaemic	   or	   TIA.	   	   In	   the	   Rochester	   population,	   18.5%	   of	  
patients	   experienced	   30-­‐day	   recurrence,	   rising	   to	   24.2%	   at	   1-­‐year	   and	   29.3%	   2-­‐years	   117.	  	  
Similar	   event	   rates	   were	   reported	   in	   the	   NOMASS	   population,	   with	   14.4%	   suffering	  
recurrence	  within	  30-­‐days,	   rising	   to	  26.5%	  at	  1-­‐year	   118.	   	  Clinical	   trials	  which	  evaluated	   the	  
role	   of	   surgical	   intervention	   in	   patients	   with	   50-­‐69%	   and	   >/=70%	   carotid	   atherosclerotic	  
stenotic	  disease,	   reported	  a	  combined	  endpoint	  at	  5	  year	   follow-­‐up	  of	  an	   ipsilateral	   stroke	  
and	   any	   30-­‐day	   stroke	   or	   death,	   in	   15.9%	   and	   24.4%	   of	  medically	  managed	   control	   group	  
patients,	  respectively	  113.	  	  Risk	  increases	  with	  the	  degree	  of	  arterial	  stenosis	  119.	  	  	  
There	  is	  evidence	  that	  much	  of	  this	  risk	  is	  attributable	  to	  recurrent	  events	  in	  the	  initial	  weeks	  
and	  months	  following	  the	  index	  event	  and	  decays	  thereafter	  120, 121.	   	  The	  risk	  of	  a	  recurrent	  
stroke	  amongst	  patients	  awaiting	  carotid	  endarterectomy	   (CEA)	   surgery	   is	  estimated	  at	  5%	  
per	  week	  in	  the	  initial	  weeks	  following	  stroke	  122.	  	  In	  the	  ECST,	  which	  reported	  annual	  events	  
rates	   for	   a	   mean	   follow-­‐up	   duration	   of	   6.1	   years,	   an	   exponential	   decline	   in	   events	   was	  
observed	  with	  time,	  with	  the	  majority	  of	  events	  occurring	  within	  the	  initial	  3	  years	  of	  follow	  
up	  and	  the	  highest	  risk	  period	  within	  the	   initial	  12	  months	  121, 123.	   	  The	   lower	  rates	   in	   later	  
years	  were	  not	  accounted	   for	  by	  early	  mortality	  amongst	   those	  patients	  with	  more	   severe	  
stenosis.	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1.3.6.4. Cardioembolic	  stroke	  and	  atrial	  fibrillation	  
AF	   represents	   the	   main	   cause	   of	   cardioembolic	   stroke.	   	   However,	   assignment	   of	   risk	   of	  
recurrence	  to	  AF	  as	  an	  aetiological	  factor	  is	  challenging	  for	  several	  reasons:	  	  	  
Firstly,	   AF	   is	   frequently	   reported	   as	   a	   component	   of	   one	   of	   two	   TOAST	   categories,	   either	  
cardioembolic	   or	   undetermined	  pathology.	   	   In	   the	   former	   category,	  AF	   represents	   a	   single	  
component	  of	  all	  cardioembolic	  pathologies	   included	   in	  a	  composite	  definition,	  despite	  the	  
likelihood	  that	  risk	  varies	  according	  to	  the	  specific	  underlying	  cardiac	  abnormality.	  	  Thus	  the	  
risk	   attributable	   to	   the	   commonest	   cardioembolic	   cause	   of	   stroke,	   AF,	   may	   be	  
inappropriately	  estimated	  when	  reported	  as	  a	  composite	  average	  with	  non-­‐AF	  cardioembolic	  
aetiological	  factors	  (e.g.	  an	  isolated	  finding	  of	  a	  PFO).	  	  The	  same	  difficulty	  arises	  when	  AF	  is	  
considered	   as	   a	   component	   of	   the	   latter	   category,	   undetermined	   culprit	   pathology.	   	   This	  
group	  is	  likely	  to	  include	  patients	  with	  heterogeneous	  risk,	  ranging	  from	  very	  high	  risk	  in	  the	  
context	  of	  dual	  or	  multiple	  pathologies	  (e.g.	  coexisting	  AF	  and	  LAA),	  to	  low	  risk	  in	  the	  context	  
of	  “true”	  cryptogenic	  stroke,	  defined	  following	  extensive	  investigation.	  
Secondly,	   there	   has	   been	   geographical	   and	   temporal	   variation	   in	   the	   approach	   to	  
investigation	  to	  identify	  potential	  aetiological	  factors	  for	  stroke.	  	  The	  diagnosis	  of	  presence	  of	  
AF	   in	  many	  of	  the	  early	  population	  studies	  was	  based	  on	  a	  sole	  12-­‐lead	  ECG,	  performed	  at	  
the	  point	  of	  clinical	  presentation	  124.	  	  The	  prevalence	  of	  (and	  risk	  attributable	  to)	  paroxysmal	  
AF	   (PAF)	  may	  potentially	  have	  been	   incorrectly	   estimated	   in	   studies	  which	  did	  not	  employ	  
more	  prolonged	  cardiac	  monitoring.	  
Thirdly,	   population	   characteristics	   influence	   the	  observed	   risk	   of	   recurrence.	   	   In	   particular,	  
the	   age	   of	   the	   population	   affects	   the	   risk	   of	   embolic	   events	   in	   patients	   with	   AF,	  
independently	  of	  the	  increased	  prevalence	  of	  AF	  with	  aging.	  	  Accordingly,	  clinical	  trials,	  which	  
historically	   limited	   the	   upper	   age	   of	   eligibility,	   are	   limited	   in	   assessing	   risk	   of	   recurrence.	  	  
Similarly,	   population	   studies	   reporting	   risk	   as	   a	   composite	   of	   all	   age	   groups	   are	   likely	   to	  
inappropriately	  describe	  risk	  for	  age	  subgroups.	   	  AF	  may	  account	  for	  20%	  of	  all	  strokes	  but	  
likely	   accounts	   for	   a	   greater	   proportion	   in	   the	   more	   elderly.	   	   	   The	   elderly	   population	   is	  
increasing	   and	   therefore	   AF	   is	   likely	   to	   hold	   a	   proportionally	   greater	   responsibility	   for	   the	  
burden	  of	  stroke	  overall	  in	  the	  decades	  to	  come.	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Patients	  with	  AF	  have	  traditionally	  been	  considered	  to	  be	  at	  particularly	  elevated	  risk	  of	  early	  
stroke	  recurrence.	   	   In	  small	   study	  populations,	   the	   risk	  of	  early	   recurrence	   in	  patients	  with	  
ischaemic	  stroke	  and	  AF	  has	  been	  reported	  to	  be	  as	  high	  as	  33%	  within	  2.3	  months	  125.	   	   In	  
another	  study,	  20%	  of	  patients	  with	  AF	  suffered	  recurrent	  embolism	  within	  11	  days	  of	  their	  
index	  event	  126.	  	  	  In	  a	  meta-­‐analysis	  of	  the	  OCSP,	  OXVASC,	  Erlangen	  &	  Rochester	  registries,	  7-­‐
day	   recurrence	  was	   observed	   in	   2.5%	   (95%	   CI,	   0.1	   –	   4.9%)	   of	   patients	  with	   cardioembolic	  
stroke,	   whilst	   30-­‐day	   and	   1-­‐year	   recurrence	   were	   observed	   in	   4.6%	   (95%	   CI,	   1.3-­‐7.9)	   and	  
11.9%	   (95%	   CI,	   6.4-­‐17.4%)	   of	   patients,	   respectively	   110.	   	   More	   detailed	   breakdown	   of	   risk	  
within	   the	   cardioembolic	   group	   was	   not	   reported.	   	   Whilst	   some	   observational	   studies	  
reported	  similar	  risk	  of	  recurrence	  in	  AF	  as	  for	  patients	  in	  sinus	  rhythm	  (this	  likely	  reflected	  
the	   comparator	   being	   all	   non-­‐AF	   stroke	   combined,	   including	   those	   with	   other	   high	   risk	  
aetiological	  factors	  e.g.	  LAA)	  124,	  the	  majority	  of	  population	  based	  studies	  have	  identified	  an	  
increased	   early	   and	   long	   term	   risk	   of	   stroke	   recurrence	   in	   patients	   with	   AF	   127-­‐129.	   	   In	  
population	  studies,	  the	  early	  risk	  (within	  2	  weeks)	  of	  recurrence	  of	  stroke	  in	  patients	  with	  AF	  
has	  been	  variably	  estimated	  at	  between	  0.3	  –	  1.1%	  per	  day	  127, 129-­‐131.	  	  
In	   ischaemic	   stroke	   clinical	   trial	   populations,	   the	   risk	  of	   early	   recurrence	  has	  been	  variably	  
reported.	  	  In	  the	  IST	  (mean	  age	  77.8	  years),	  ischaemic	  stroke	  recurrence	  occurred	  in	  4.9%	  in	  
patients	  with	  AF	  not	  treated	  with	  UFH	  within	  14	  days	  56.	   	   In	  the	  HAEST	  study	  (mean	  age	  80	  
years),	   14-­‐day	   ischaemic	   stroke	   recurrence	   was	   higher,	   observed	   in	   8%	   of	   patients	   58.	   	   A	  
meta-­‐analysis	  of	  acute	  stroke	  patients	  with	  AF	  enrolled	  in	  RCTs	  reported	  a	  stroke	  recurrence	  
rate	   of	   5%	   within	   the	   first	   2	   weeks	   following	   the	   qualifying	   event	   132.	   	   Contrasting	   early	  
recurrence	  rates	  in	  unselected	  stroke	  patient	  trial	  populations	  with	  no	  diagnosis	  of	  AF	  (3.8%	  
of	  patients	  at	  14-­‐days	  in	  the	  IST,	  1.3%	  of	  patients	  at	  7-­‐days	  in	  TOAST	  and	  2.6%	  of	  patients	  at	  
30-­‐days	   in	   CAST	   53, 54, 57),	   it	   is	   apparent	   that	   an	   excess	   of	   risk	   in	   patients	   with	   AF	   might	  
present	   an	   opportunity	   for	   expedited	   diagnosis	   of	   AF	   and	   initiation	   of	   optimised	  
anticoagulant	  based	  secondary	  prevention.	  	  	  
Beyond	  the	  risk	  of	  early	  recurrence,	  patients	  with	  AF	  remain	  at	  very	  high	   intermediate	  and	  
long	  term	  risk	  of	  ischaemic	  stroke	  recurrence.	  	  Marini	  and	  colleagues	  reported	  higher	  1	  year	  
recurrence	  amongst	  patients	  with	  admission	  AF	  compared	  to	  those	  without	  AF	  133.	  	  Whilst	  AF	  
independently	  increases	  the	  risk	  of	  stroke	  five-­‐fold	  in	  the	  general	  population	  134,	  in	  patients	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with	  prior	  ischaemic	  stroke	  or	  TIA,	  the	  risk	  of	  stroke	  /	  SE	  /	  major	  bleeding	  /	  ICH	  &	  mortality	  is	  
increased	  a	  further	  two	  to	  threefold	  135, 136.	  	  In	  population	  studies,	  recurrence	  rates	  between	  
2	   –	   15%	   are	   quoted	   for	   the	   first	   year	   following	   presenting	   stroke	   and	   5%	   each	   year	  	  
thereafter	  91.	   	  Higher	  rates	  of	  recurrence	  were	  observed	  in	  some	  populations	  127.	   	  The	  EAFT	  
enrolled	   patients	   with	   AF	   (mean	   age	   73	   years),	   though	   patients	   with	   other	   concomitant,	  
potentially	   culprit	   pathologies	  were	   not	   excluded.	   	   During	   a	  mean	   follow	   up	   period	   of	   2.3	  
years,	  12%	  of	  placebo	  control	  patients	  experienced	  a	  recurrent	  stroke	  137.	   	  4%	  of	  coumarin	  
treated	  patients	  experienced	  an	  event.	  	  The	  majority	  of	  clinical	  events	  were	  observed	  in	  the	  
initial	  12	  months	  of	  EAFT	  follow	  up.	   	  The	  elevation	   in	  risk	  of	  recurrence	  associated	  with	  AF	  
appears	  to	  be	  irrespective	  of	  the	  aetiological	  mechanism	  for	  the	  incident	  stroke	  138.	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1.4. Secondary	   prevention	   of	   ischaemic	   stroke	   following	   ischaemic	   stroke	  &	  
TIA	  	  
Given	   the	   high	   levels	   of	   incomplete	   recovery	   and	   the	   high	   risk	   of	   stroke	   and	   other	  
cardiovascular	   events	   following	   stroke	   and	   TIA,	   implementation	   of	   optimal	   preventative	  
strategies	  represents	  a	  cornerstone	  of	  the	  management	  of	  cerebrovascular	  disease.	  	  
	  
1.4.1. Lifestyle	  modification	  
Guidelines	   recommend	   smoking	   cessation,	   limited	   alcohol	   consumption,	   weight	   loss	   in	  
obesity	   and	   regular	   physical	   exercise	   as	   lifestyle	   modifications	   likely	   to	   confer	   beneficial	  
effects	  in	  reduced	  risk	  of	  stroke	  recurrence	  19.	  
	  
1.4.2. Antihypertensive	  therapy	  
An	  aetiological	  relationship	  between	  BP	  and	  risk	  of	  stroke	  has	  been	  established	  in	  population	  
studies	  and	  clinical	  trials	  139.	  	  The	  relationship	  appears	  linear,	  with	  changes	  in	  BP	  even	  at	  low	  
and	   “normal”	   levels	   associated	   with	  modified	   risk.	   	   In	   the	   context	   of	   primary	   prevention,	  
antihypertensive	  treatment	  dramatically	  reduces	  the	  risk	  of	  stroke,	  irrespective	  of	  the	  type	  of	  
agent	  used	  140.	  	  
Less	  patient	  data	   is	  available	   in	   the	  context	  of	  secondary	  prevention,	  particularly	   regarding	  
reduction	  of	  BP	  in	  the	  immediate	  aftermath	  of	  ischaemic	  stroke.	  	  However,	  meta-­‐analysis	  of	  
available	   trial	   data	   confirms	   a	   significant	   benefit	   of	   BP	   reduction	   with	   antihypertensive	  
therapy,	  commenced	  between	  3	  weeks	  to	  14	  months	  following	  stroke	  or	  TIA	  141.	  	  Recurrent	  
stroke	  (RR	  0.75,	  95%	  CI	  0.63	  –	  0.92)	  and	  all	  vascular	  events	  (RR	  0.79,	  95%	  CI	  0.66	  –	  0.95)	  were	  
each	  reduced	  with	  antihypertensive	  therapy.	  	  This	  analysis	  identified	  independent	  benefit	  of	  
both	   Thiazide	  monotherapy	   and	   combination	   therapy	  with	   angiotensin	   converting	   enzyme	  
inhibitor	  (ACE-­‐I)	  therapy.	  	  Other	  antihypertensive	  strategies	  were	  not	  significantly	  associated	  
with	   benefit,	   though	   confidence	   intervals	   were	   wide.	   	   The	   greater	   the	   reduction	   in	   BP	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observed,	  the	  greater	  the	  reduction	  in	  clinical	  events.	  	  Direct	  interclass	  antihypertensive	  trials	  
in	  the	  setting	  of	  secondary	  prevention	  following	  stroke	  and	  TIA	  are	  lacking.	  
The	  observed	  benefit	   for	  Thiazide	  and	  Thiazide	   /	  ACE-­‐I	   combination	   therapy	  was	  driven	  by	  
the	   results	   of	   the	  PROGRESS	   study	   142.	   	   In	   this	   placebo	   controlled	   trial,	   6105	  patients	  with	  
stroke	  or	  TIA	  within	  the	  preceding	  5	  years,	  were	  randomised	  to	  receive	  the	  ACE-­‐I	  Perindopril	  
4mg	  daily	  plus	  the	  Thiazide	  diuretic	  Indapamide	  2.5mg	  daily,	  compared	  with	  placebo.	  	  Blood	  
pressure	  was	  significantly	  reduced	  by	  9/4	  mmHg	  with	  active	  treatment	  over	  4	  year	  follow-­‐up.	  	  
Both	  stroke	  RRR	  28%	  (95%	  CI,	  17	  –	  38%)	  and	  all	  major	  vascular	  events	  RRR	  26%	  (95%	  CI,	  16	  –	  
34%),	   were	   each	   significantly	   reduced	   with	   active	   treatment.	   	   On	   subgroup	   analysis,	  
statistically	   significant	   benefit	   was	   only	   observed	   amongst	   patients	   in	   the	   active	   group	  
treated	   with	   combination	   therapy,	   in	   whom	   the	   BP	   reduction	   observed	   was	   12/5	  mmHg,	  
compared	  with	  5/3	  mmHg	  for	  Perindopril	  monotherapy.	  
In	   a	   factorial	   design,	   The	   PRoFESS	   study	   compared	   the	   angiotensin	   receptor	   blocker	   (ARB)	  
Telmisartan	  with	  Placebo	  in	  20,332	  patients	  with	  ischaemic	  stroke	  143.	  	  Despite	  a	  significantly	  
greater	   reduction	   in	   systolic	   BP	   (of	   4	  mmHg)	  with	   Telmisartan	   treatment,	   no	   difference	   in	  
either	  stroke	  recurrence	  or	  combined	  vascular	  events	  was	  observed.	  	  	  
Although	   the	   PRoFESS	   trial	   was	   underpowered	   and	   commentators	   have	   noted	   that	   a	  
treatment	  difference	  may	  have	  emerged	  with	  more	  prolonged	  follow	  up,	  the	  study	  failed	  to	  
support	   the	   specific	   use	   of	   ARB	   treatment	   following	   stroke.	   	   Taken	   together	   with	   the	  
PROGRESS	  study,	  which	  also	  failed	  to	  demonstrate	  clear	  benefit	  with	  a	  modest	  BP	  reduction	  
with	   ACE-­‐I	  monotherapy,	   the	   results	   of	   secondary	   preventative	   data	  meta-­‐analysis	   141	   and	  
other	  BP	  reduction	  trials	  144,	  a	  clear	  conclusion	  appears	  to	  be	  that	  the	  magnitude	  of	  clinical	  
benefit	  appears	   to	  be	   related	   to	   the	  magnitude	  of	  BP	   reduction,	  with	  a	  mean	  reduction	  of	  
10/5	  mmHg	  being	  clinically	  effective	  19.	  	  The	  available	  data	  support	  combination	  therapy	  with	  





1.4.3. Lipid	  lowering	  therapy	  
The	  epidemiological	  association	  between	  raised	  LDL-­‐cholesterol	  and	  increased	  risk	  of	  stroke	  
is	   less	   apparent	   than	   for	   CHD	   145.	   	   In	   addition,	   haemorrhagic	   stroke	   risk,	   evident	   as	  
microbleeds	  detected	  on	  gradient	  echo	  sequence	  MRI,	  may	  be	  increased	  at	  very	  low	  levels	  of	  
total-­‐cholesterol	  and	  the	  highest	   levels	  of	  HDL-­‐cholesterol	  146.	   	  Though	  evidence	  for	  benefit	  
of	  statin	  therapy	  in	  reducing	  risk	  of	  stroke	  exists	  in	  CHD	  patient	  populations	  147,	  randomised	  
evidence	  for	  benefit	  of	  lipid	  lowering	  with	  statin	  therapy	  following	  ischaemic	  stroke	  has	  only	  
emerged	  in	  the	  last	  decade.	  	  	  
In	  the	  Heart	  Protection	  Study,	  treatment	  with	  Simvastatin	  40mg	  daily	  significantly	  reduced	  a	  
composite	  endpoint	  of	  all	  major	  vascular	  events	  amongst	  a	  subgroup	  of	  3280	  patients	  with	  a	  
remote	  history	  (mean	  4.2	  years)	  of	  ischaemic	  cerebrovascular	  disease	  148.	  	  	  
In	   the	  SPARCL	  study,	  4731	  patients	  with	   recent	   (1	  –	  6	  months)	  stroke	  or	  TIA,	  were	   treated	  
with	   Atorvastatin	   80mg	   daily	   or	   placebo	   116.	   	   The	   study	   excluded	   patients	   with	   stroke	   of	  
presumed	   cardioembolic	   aetiology	   and	   patients	   had	   no	   prior	   diagnosis	   of	   CHD.	   	   Over	   a	  
median	   of	   4.9	   year	   follow-­‐up,	   both	   recurrent	   stroke	   (of	   any	   type)	   and	   combined	   vascular	  
events,	  were	   significantly	   reduced	  with	  Atorvastatin,	  HR	  0.84	   (95%	  CI,	  0.71	  –	  0.99)	  and	  HR	  
0.80	   (95%CI,	   0.69	   –	   0.92),	   respectively.	   	   The	   absolute	   risk	   reductions	   for	   these	   endpoints	  
were	  2.2%	  and	  3.5%,	  respectively.	  	  A	  significant	  increase	  in	  risk	  of	  haemorrhagic	  stroke	  was	  
observed	   with	   Atorvastatin	   (HR	   1.66,	   95%	   CI	   1.08	   –	   2.55),	   which	   was	   outweighed	   by	   the	  
reduction	  in	  ischaemic	  events.	  
Though	   the	   increased	   risk	   of	   subsequent	   haemorrhagic	   stroke	   with	   statin	   therapy	   is	  
outweighed	   by	   the	   reduction	   in	   ischaemic	   stroke	   and	   CHD	   events,	   it	   has	   implications	   in	  
considering	   the	   utility	   of	   secondary	   preventative	   statin	   therapy	   in	   patients	   without	  
dyslipidaemia	  or	  other	  clinical	  indications	  for	  statin	  therapy	  following	  ICH	  stroke	  19.	  
	  
1.4.4. Hypoglycaemic	  therapy	  
Diabetes	  mellitus	  is	  an	  independent	  risk	  factor	  for	  stroke	  149, 150.	  	  There	  is	  evidence	  in	  primary	  
prevention	  that	  reductions	  in	  BP	  and	  LDL-­‐cholesterol	  are	  beneficial	  in	  reducing	  the	  incidence	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of	  stroke.	  	  The	  benefits	  of	  aggressive	  glycaemic	  control	  in	  primary	  prevention	  have	  been	  less	  
apparent	   151.	   	   In	  secondary	  prevention	  studies	  examining	  glycaemic	  control,	  aggressive	  and	  
intensive	  lowering	  of	  blood	  sugar	  with	  a	  view	  to	  achieving	  lower	  HbA1C	  concentrations	  has	  
failed	  to	  demonstrate	  benefit	   in	  reduction	   in	  macrovascular	  events,	   including	  stroke	  and	   in	  
some	  cases	  evidence	  of	  harm	  was	  observed	  152.	  	  	  
The	   PROactive	   trial	   compared	   Pioglitazone	   with	   placebo	   in	   patients	   with	   a	   history	   of	  
macrovascular	  disease	  and	  included	  a	  subgroup	  of	  984	  patients	  with	  prior	  stroke	  153.	  	  Active	  
treatment	   was	   associated	   with	   a	   significant	   reduction	   in	   the	   secondary	   endpoints	   of	   any	  
stroke	  [HR	  0.53	  (95%	  CI	  0.34	  –	  0.85)]	  and	  composite	  of	  vascular	  death,	  non-­‐fatal	  MI	  &	  non-­‐
fatal	   stroke	   [HR	   0.72	   (95%CI	   0.52	   –	   1.00)].	   	   A	   trend	   toward	   a	   reduction	   in	   the	   primary	  
endpoint	  of	  death	  and	  major	  vascular	  events	  was	   reported	   [HR	  0.78	   (95%	  CI	  0.60	  –	  1.02)].	  	  
The	   IRIS	   clinical	   trial,	   comparing	   Pioglitazone	   with	   placebo	   in	   a	   population	   with	   previous	  
stroke	  and	  TIA,	  is	  examining	  whether	  these	  secondary	  endpoint	  findings	  are	  reproducible.	  	  
	  
1.4.5. Carotid	  intervention	  
Three	   clinical	   trials	   compared	   conservative,	   medical	   management	   with	   surgical	   carotid	  
endarterectomy	   (CEA),	   in	   the	  management	  of	   internal	   carotid	   stenosis	   in	  patients	  with	  TIA	  
and	  non-­‐disabling	  ischaemic	  stroke:	  the	  ECST	  123,	  NASCET	  120	  &	  and	  VACS	  154	  studies.	   	   	  Each	  
study	  suggested	  benefit	  of	  CEA	  over	  medical	  therapy.	  	  However,	  methodological	  differences	  
in	   assessment	   of	   the	   degree	   of	   carotid	   stenosis	   created	   doubt	   regarding	   patient	   criteria	  
defining	  suitability	  for	  surgery	  rather	  than	  medical	  management.	  
In	  2003,	  an	  individual	  patient	  data	  meta-­‐analysis	  was	  published	  based	  on	  re-­‐categorisation	  of	  
the	  degree	  of	  stenosis,	  based	  on	  the	  NASCET	  method,	  for	  patients	  in	  all	  three	  trials	  119.	  	  This	  
analysis	   reported	   that	   surgical	   benefit	   was	   limited	   to	   patients	   with	   ≥	   50%	   stenosis.	   	   An	  
absolute	   risk	   reduction	   (ARR)	   for	   5-­‐year	   ipsilateral	   ischaemic	   stroke	   of	   4.6%,	   p=0.04,	   was	  
observed	  for	  50	  –	  69%	  stenosis;	  An	  ARR	  of	  16.0%,	  p<0.001,	  was	  observed	  for	  ≥	  70%	  stenosis	  
without	   near	   occlusion.	   	   A	   subsequent	   sub-­‐group	   analysis	   refined	   the	   patient	   criteria	   for	  
which	  benefit	   of	   CEA	  exceeded	  medical	   therapy	   113:	  Amongst	   female	  patients,	   benefit	  was	  
limited	   to	   ≥	   70%	   stenosis	   (without	   near	   occlusion);	   benefit	   of	   CEA	   declined	   with	   time:	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patients	   with	   ≥	   70%	   stenosis	   (without	   near	   occlusion)	   only	   benefited	   if	   surgery	   was	  
performed	  within	  12	  weeks	  and	  patients	  with	  50-­‐69%	  stenosis	  only	  benefited	  if	  surgery	  was	  
performed	  within	  2	  weeks	  of	  the	  index	  symptoms.	  
Not	  all	  patients	  are	  eligible	  for	  treatment	  with	  CEA,	  due	  to	  perceived	  excessive	  operative	  risk.	  	  
The	  potential	   for	  percutaneous	  carotid	  artery	  stenting	   to	  deliver	  minimally	   invasive	  benefit	  
led	   to	   the	   International	   Carotid	   Stenting	   Study	   which	   compared	   CEA	   with	   stenting.	   	   Long	  
term	   follow	  up	   results	  are	  awaited	  but	  120-­‐day	   follow	  up	  data	   suggest	   significantly	  poorer	  
outcomes	   (combined	  MI,	   stroke,	  death)	   amongst	  patients	  managed	  with	   stenting	   [HR	  1.69	  
(95%	  CI,	  1.16	  –	  2.45)]	  155.	  
	  
1.4.6. Antiplatelet	  therapy	  in	  presumed	  arterial	  &	  cryptogenic	  stroke	  	  
Antiplatelet	   therapy	   carries	   a	   substantial	   evidence	   base	   for	   beneficial	   reduction	   in	  
cardiovascular	   events	   following	   ischaemic	   stroke	   or	   TIA	   156-­‐159.	   	   Three	   antiplatelet	   agents	  
recommended	   in	   secondary	   prevention	   are	   ASA,	   Dipyridamole	   and	   Clopidogrel	   19, 79.	  	  
Ticlodipine	  has	  also	  been	  established	  as	  effective	   in	   the	  secondary	  prevention	  of	   ischaemic	  
stroke	  but	  is	  not	  recommended	  for	  use	  due	  to	  its	  adverse	  event	  profile	  19.	  	  A	  meta-­‐analysis	  of	  
trial	  data	  examining	  antiplatelet	  agents	  in	  patients	  with	  prior	  history	  of	  stroke	  demonstrated	  
a	   22%	   reduction	   in	   combined	   endpoint	   of	   stroke,	   myocardial	   infarction	   (MI)	   and	   vascular	  
death	  (mean	  follow	  up	  duration	  29	  months),	  principally	  due	  to	  a	  significant	  reduction	  in	  non-­‐
fatal	  recurrent	  stroke	  157.	  	  	  
Evidence	   for	   benefit	   for	   both	   ASA	   and	   Dipyridamole	   as	   monotherapies	   and	   of	   additive	  
benefit	  for	  combination	  therapy,	  has	  been	  derived	  from	  ESPS,	  ESPS-­‐2	  and	  ESPRIT	  studies.	  	  In	  
the	   ESPS-­‐1	   study,	   the	   combination	   of	   ASA	   with	   Dipyridamole	   was	   associated	   with	   a	   RR	  
reduction	   in	   stroke	   or	   death	   of	   33%,	   p<0.001	   (mean	   duration	   24	  months),	   compared	  with	  
placebo	  160.	   	  The	  ESPS-­‐2	  study,	   in	  patients	  with	  prior	   ischaemic	  stroke	  or	  TIA,	  was	  a	  2	  by	  2	  
factorial	   design	   which	   compared	   the	   combination	   of	   ASA	   &	   Dipyridamole,	   ASA	   alone,	  
Dipyridamole	  alone	  and	  placebo	  161.	  	  Compared	  with	  placebo,	  the	  RRR	  for	  stroke	  was	  18.1%	  
with	   ASA	   (p=0.013),	   16%	  with	   Dipyridamole	   (p=0.039)	   and	   37%	  with	   combination	   therapy	  
(p<0.001).	   	   Compared	   with	   ASA	   alone,	   the	   RRR	   for	   stroke	   was	   23.1%	   with	   combination	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therapy	  (p=0.006).	  	  In	  the	  unblinded	  ESPRIT	  study,	  compared	  with	  ASA	  monotherapy,	  ASA	  &	  
Dipyridamole	   combination	   therapy	   significantly	   reduced	   the	   combined	   risk	   of	   stroke,	   MI,	  
vascular	  death	  &	  major	  bleeding	  events,	  at	  3.5	  years	  (HR	  0.80;	  95%	  CI	  0.66	  to	  0.98)	  162.	  
In	  the	  CAPRIE	  study,	  Clopidogrel	  was	  compared	  with	  ASA	  for	  the	  prevention	  of	  a	  combined	  
endpoint	  of	  MI,	  stroke	  &	  death	  163.	  	  The	  study	  population	  included	  patients	  at	  increased	  risk	  
of	   CV	  events,	   including	   a	   subgroup	  with	  prior	   stroke.	   	   In	   the	   study	  population	   as	   a	  whole,	  
Clopidogrel	   reduced	   annual	   CV	   events	   compared	   with	   ASA	   with	   borderline	   statistical	  
significance	  (RRR	  8.7%;	  95%	  CI,	  0.3	  –	  16.5%,	  p=0.043).	  	  This	  finding	  was	  driven	  by	  a	  reduction	  
in	   events	   amongst	   patients	   with	   peripheral	   arterial	   disease.	   	   Amongst	   patients	   with	   prior	  
stroke,	  no	  significant	  difference	  was	  observed	  between	  treatment	  groups	  (RRR	  7.3%;	  95%	  CI,	  
-­‐6	   –	   19%,	   p=0.26),	   though	   this	   subgroup	   analysis	   lacked	   statistical	   power	   to	   identify	   a	  
treatment	  effect.	  	  	  
The	   observation	   that	   Clopidogrel	   may	   hold	   some	   additional	   benefit	   to	   ASA	   monotherapy	  
whilst	  potentially	  inferior	  to	  the	  combination	  of	  ASA	  and	  Dipyridamole,	  led	  to	  the	  conduct	  of	  
the	  PRoFESS	  study	  115.	  	  In	  a	  non-­‐inferiority	  design,	  patients	  with	  prior	  ischaemic	  stroke	  (or	  TIA	  
with	  acute	  brain	  imaging	  lesion)	  were	  randomised	  to	  receive	  either	  Clopidogrel	  monotherapy	  
or	  the	  combination	  of	  ASA	  and	  MR-­‐Dipyridamole.	  	  No	  significant	  difference	  was	  observed	  in	  
recurrent	   ischaemic	   stroke	  between	   treatment	  groups	   (mean	  duration	  2.5	  years)	   (HR	  1.01;	  
95%	  CI,	  0.92	  to	  1.11),	  or	  for	  any	  stroke	  (HR	  1.05;	  95%	  CI,	  0.96	  –	  1.16).	  	  A	  non-­‐significant	  trend	  
toward	  increased	  bleeding	  events	  was	  observed	  with	  combination	  therapy	  (HR	  1.15;	  95%	  CI,	  
1.00	   –	   1.32),	  which	  was	   also	   associated	  with	   reduced	   concordance	  with	   treatment	   due	   to	  
side	   effects.	   	   The	   hypothesis	   of	   non-­‐inferiority	   of	   ASA	   &	   Dipyridamole	   combination	   to	  
Clopidogrel	   alone	   was	   not	   rejected	   due	   to	   the	   size	   of	   the	   observed	   confidence	   intervals	  
(which	   crossed	   the	   upper	   limit	   of	   the	   non-­‐inferiority	   margin).	   	   However	   survival	   curves	  
indicated	  that	   the	  two	  strategies	  were	  equivalent	  during	  the	  observed	  period	  of	   follow-­‐up.	  	  
Testing	   for	   treatment	   interaction	   between	   LAA	   and	   SVD	   aetiological	   subgroups	   was	   non-­‐
significant	   (P	   >	   0.05).	   	   Clinical	   guidelines	   have	   subsequently	   recommended	   either	   ASA	   in	  
combination	   with	   Dipyridamole-­‐MR,	   or	   Clopidogrel	   monotherapy	   as	   valid	   long	   term	  
antiplatelet	  secondary	  preventative	  strategies	  19, 79.	  
	  32	  
The	   combination	   of	   ASA	   with	   Clopidogrel	   has	   been	   studied	   in	   several	   trials,	   to	   evaluate	  
whether	   similar	   benefits	   as	   have	   been	   observed	   in	   the	   CHD	   population	   with	   combination	  
therapy,	  are	  evident	   following	   ischaemic	  stroke	  or	  TIA.	   	  The	  MATCH	  study,	   in	  patients	  with	  
prior	   TIA	   or	   ischaemic	   stroke,	   compared	   the	   combination	   of	   ASA	   &	   Clopidogrel	   with	  
Clopidogrel	  alone	  164.	  During	  a	  mean	  follow-­‐up	  of	  3.5	  years,	  combination	  therapy	  significantly	  
increased	   bleeding	   events	   without	   a	   reduction	   in	   cardiovascular	   events	   compared	   with	  
Clopidogrel	   alone.	   	   In	   the	   CHARISMA	   study,	   the	   combination	   of	   ASA	   &	   Clopidogrel	   was	  
evaluated,	  in	  comparison	  with	  ASA	  alone.	  	  The	  study	  population	  included	  patients	  with	  CVD	  
or	  multiple	   risk	   factors.	   	   No	   significant	   treatment	   difference	   (in	  MI,	   stroke,	   CV	   death)	  was	  
observed	  in	  the	  overall	  trial	  population	  or	  in	  a	  subgroup	  of	  patients	  with	  previous	  stroke.	  	  An	  
excess	  of	  bleeding	  events	  with	  combination	  therapy	  was	  again	  observed	  165.	  	  More	  recently,	  
in	   a	   Chinese	   population	   of	   patients	   with	   acute	   mild	   severity	   ischaemic	   stroke	   or	   TIA,	   the	  
combination	  of	  ASA	  &	  Clopidogrel	   for	  21	  days	   followed	  by	  Clopidogrel	   to	  90	  days	   reduced	  
recurrent	  stroke	  compared	  with	  ASA	  monotherapy	  (HR	  0.68;	  95%	  CI,	  0.57	  to	  0.81;	  P<0.001),	  
with	  similar	  bleeding	  complications	  observed	  between	  treatment	  groups	  55.	  
	  
1.4.7. Anticoagulant	  therapy	  in	  presumed	  arterial	  &	  cryptogenic	  stroke	  
Anticoagulant	  therapy	  has	  been	  evaluated	  in	  patients	  with	  presumed	  arterial	  and	  cryptogenic	  
stroke.	   	   The	   ESPRIT	   trial	   compared	  warfarin	   (with	   a	   target	   INR	   of	   2	   –	   3)	   with	   antiplatelet	  
therapy	  (either	  ASA	  monotherapy	  or	  combination	  of	  ASA	  /	  MR-­‐Dipyridamole).	  	  A	  borderline	  
significant	   reduction	   in	   ischaemic	   events	   was	   observed	   with	   warfarin	   compared	   with	   ASA	  
monotherapy	  (HR	  0.73;	  95%	  CI	  0.52	  –	  1.01)	  but	  also	  with	  increased	  bleeding	  (HR	  2.56;	  95%	  CI	  
1.48	  –	  4.43)	  166.	  	  The	  SPIRIT	  study	  evaluated	  higher	  target	  INR	  anticoagulation	  compared	  with	  
ASA	  and	  was	  terminated	  early	  due	  to	  excess	  bleeding	  risk	  with	  anticoagulation	  167.	  	  Warfarin,	  
with	  a	  target	  INR	  of	  1.4	  –	  2.8,	  was	  compared	  with	  ASA	  325mg	  od,	  in	  the	  WARSS	  study	  168.	  	  In	  
patients	   with	   non-­‐cardioembolic	   stroke,	   no	   significant	   difference	   was	   observed	   between	  
treatment	  groups	  for	  either	  stroke	  or	  death	  (warfarin	  17.8%,	  ASA	  16.0%)	  or	  bleeding	  events	  
(warfarin	  2.2%,	  ASA	  1.5%).	  	  The	  WASID	  study	  compared	  warfarin	  (target	  INR	  2.0	  –	  3.0)	  with	  
ASA	  in	  patients	  with	  intracranial	  atherosclerosis	  169.	  	  No	  difference	  in	  ischaemic	  stroke	  /	  ICH	  /	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death	  was	  observed	  with	  treatment	  but	  extracranial	  bleeding	  was	  increased	  in	  the	  warfarin	  
group.	  
A	   meta-­‐analysis	   has	   been	   conducted	   170	   examining	   anticoagulant	   use	   in	   minor	   ischaemic	  
stroke	   and	   TIA	   of	   presumed	   arterial	   origin	   compared	  with	   antiplatelet	   therapy.	   	   Recurrent	  
ischaemic	  stroke	  was	  similar	  with	  medium	  intensity	  anticoagulation	  [RR	  0.80,	  95%	  confidence	  
interval	   (CI)	   0.56	   to	   1.14]	   or	   high	   intensity	   anticoagulation	   [RR	   1.02,	   95%	  CI	   0.49	   to	   2.13],	  
compared	  with	  antiplatelet	   therapy.	   	  Medium	   intensity	   (RR	  1.93,	  95%	  CI	  1.27	   to	  2.94)	   and	  
high	  intensity	  (RR	  9.0,	  95%	  CI	  3.9	  to	  21)	  anticoagulation	  were	  each	  associated	  with	  a	  higher	  
risk	   of	   major	   bleeding	   complications	   compared	   with	   antiplatelet	   therapy.	   	   Guidelines	  
recommend	   antiplatelet	   agents	   for	   secondary	   prevention	   rather	   than	   anticoagulants	   in	  
patients	  with	  non-­‐cardioembolic	  stroke	  19.	  
	  
1.4.8. Antiplatelet	  therapy	  in	  ischaemic	  stroke	  &	  TIA	  patients	  with	  AF	  	  
Antiplatelet	   therapy	   in	   patients	   with	   non-­‐valvular	   AF	   has	   been	   found	   to	   be	   effective	   in	  
reducing	   recurrent	   stroke	   in	   studies	   including	   both	   primary	   and	   secondary	   prevention	  
populations.	   	   Absolute	   benefit	   is	   greater	   in	   the	   latter	   such	   that	   there	   is	   debate	   regarding	  
utility	  of	  antiplatelet	  agents	  in	  the	  primary	  prevention	  population	  with	  low	  risk	  of	  stroke,	  due	  
to	  the	  hazard	  for	  bleeding	  complications.	  	  	  
In	  a	  Cochrane	  library	  systematic	  review	  and	  meta-­‐analysis	  of	  trials	  evaluating	  ASA	  in	  patients	  
with	  AF	  but	  no	  prior	  history	  of	  stroke	  or	  TIA,	  amongst	  1965	  patients	  followed	  up	  for	  a	  mean	  
of	   1.3	   years,	   a	   non-­‐significant	   reduction	   in	   all	   strokes	   (OR	   0.70;	   95%	   CI,	   0.46	   –	   1.07)	   and	  
ischaemic	   stroke	   (OR	   0.70;	   95%	   CI,	   0.46	   –	   1.07),	   with	   ASA	   therapy	   was	   observed	   171.	   	   A	  
composite	   outcome	  of	   all	   stroke,	  MI	   or	   vascular	   death	  was	   significantly	   reduced	  with	  ASA	  
therapy	  (OR	  0.71;	  95%	  CI	  0.51	  –	  0.97).	  	  The	  authors	  concluded	  that	  ASA	  likely	  reduces	  stroke	  
and	  vascular	  events	   in	  patients	  with	  non-­‐valvular	  AF	  but	  only	  modestly	  so.	   	  The	  annualised	  
rate	   of	   ischaemic	   stroke	   in	   the	   placebo	   treated	   patients	   of	   approximately	   4%	   per	   year	  
suggests	   that	   12	   ischaemic	   strokes	   would	   be	   prevented	   yearly	   for	   every	   1000	   patients	  
treated	  with	  ASA.	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The	   EAFT	   included	   patients	   with	   AF	   and	   a	   recent	   TIA	   or	   mild	   ischaemic	   stroke	   of	   any	  
aetiological	   type,	   excluding	   only	   patients	   scheduled	   for	   imminent	   carotid	   &	   coronary	  	  	  
surgery	  137.	  	  The	  study	  included	  two	  arms.	  	  The	  first	  randomised	  patients	  to	  receive	  adjusted	  
dose	  warfarin,	  ASA	  or	  placebo.	  	  A	  second	  arm	  randomised	  patients	  considered	  unsuitable	  for	  
anticoagulation	   in	   some	   regard,	   to	   receive	   either	   ASA	   or	   Placebo.	   	   40%	   of	   patients	   were	  
randomised	  within	  14-­‐days	  of	  their	  qualifying	  event.	  	  Outcomes	  in	  ASA	  treated	  patients	  were	  
similar	   in	  the	  two	  arms	  and	  the	  authors	  elected	  to	  report	  the	  ASA	  –	  Placebo	  comparison	  in	  
the	  two	  arms	  as	  composite	  data.	  	  Compared	  with	  placebo,	  ASA	  non-­‐significantly	  reduced	  any	  
stroke	  (HR-­‐adjusted	  0.86;	  95%	  CI,	  0.64	  –	  1.15)	  and	  combined	  vascular	  events	  (HR	  0.83;	  95%	  
CI,	   0.65	   –	   1.05).	   	   The	   lack	   of	   statistical	   benefit	   observed	  with	   ASA	   in	   relation	   to	   recurrent	  
stroke,	  may	   have	   reflected	   a	   lack	   of	   efficacy	   in	   preventing	   AF-­‐related	   cardioembolism	   and	  
lack	  of	  statistical	  power	  to	  detect	  the	  treatment	  effect	  that	  would	  typically	  be	  anticipated	  in	  
relation	  to	  non-­‐cardioembolic	  stroke	  mechanisms.	  	  	  
A	   meta-­‐analysis	   from	   the	   ATTC	   considered	   the	   effect	   of	   ASA	   in	   combined	   primary	   and	  
secondary	   preventative	   groups	   and	   reported	   a	   significant	   25%	   reduction	   in	   the	   risk	   of	  	  	  	  
stroke	   172.	   	   A	   subsequent	   meta-­‐analysis,	   again	   including	   both	   primary	   and	   secondary	  
prevention	  patients	  reported	  a	  22%	  RRR	  for	  any	  stroke	  (95%	  CI,	  2	  –	  39%)	  with	  ASA	  compared	  
with	  placebo	  and	  22%	  RRR	  for	  any	  stroke	  (95%	  CI	  6	  –	  35%)	  for	  any	  antiplatelet	  173.	  	  	  
In	   the	   ACTIVE-­‐A	   study,	   patients	   with	   non-­‐valvular	   AF,	   considered	   unsuitable	   for	   formal	  
anticoagulant	   therapy,	   were	   randomised	   to	   receive	   Clopidogrel	   or	   Placebo	   in	   addition	   to	  	  	  
ASA	  174.	  	  Over	  median	  3.6	  years	  follow-­‐up,	  this	  study	  demonstrated	  superiority	  of	  combined	  
antiplatelet	  therapy	  to	  ASA	  alone	  in	  reducing	  stroke	  event	  (2.4	  versus	  3.3%	  per	  year,	  RR	  0.72;	  
95%	   CI,	   0.62	   –	   0.83)	   but	   at	   the	   expense	   of	   increased	  major	   bleeding	   complications	   (2.0%	  
versus	  1.3%	  per	  year,	  RR	  1.57;	  95%	  CI	  1.29	  –	  1.92)	  .	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1.4.9. Anticoagulant	  therapy	  in	  ischaemic	  stroke	  &	  TIA	  patients	  with	  AF	  
	  
1.4.9.1. Anticoagulant	  therapy	  compared	  with	  placebo	  
A	   Cochrane	   library	   systematic	   review	   and	  meta-­‐analysis	   of	   trials	   evaluating	   adjusted	   dose	  
anticoagulation	  with	  vitamin	  K	  antagonists	  (VKA)	   in	  patients	  with	  AF	  but	  no	  prior	  history	  of	  
stroke	   or	   TIA	   was	   published	   in	   2005.	   	   Data	   for	   2313	   patients	   enrolled	   in	   five	   trials	   were	  
included,	  with	  mean	   follow-­‐up	   of	   1.5	   years.	   The	  mean	   patient	   age	   in	   this	   analysis	  was	   69	  
years,	  with	  only	  20%	  of	  participants	  aged	  over	  75	  years.	  	  The	  authors	  reported	  a	  reduction	  in	  
all	  strokes	  (OR	  0.39;	  95%	  CI,	  0.26	  –	  0.59),	  ischaemic	  stroke	  (OR	  0.34;	  95%	  CI,	  0.23	  –	  0.52)	  and	  
all-­‐cause	  mortality	  (OR	  0.69;	  95%	  CI	  0.50	  –	  0.94)	  with	  anticoagulant	  therapy	  175.	  	  
In	   the	   EAFT	   secondary	   prevention	   study,	   compared	   with	   placebo,	   warfarin	   significantly	  
reduced	   any	   stroke	   (HR-­‐adjusted	  0.34;	   95%	  CI,	   0.20	   –	   0.57)	   and	   combined	   vascular	   events	  
(HR	   0.53;	   95%	   CI,	   0.36	   –	   0.79)	   137.	   	   Data	   from	   the	   EAFT	   were	   combined	   with	   those	   from	  
patients	  with	  prior	  stroke	  included	  in	  the	  VA-­‐SPINAF	  study	  in	  a	  Cochrane	  systematic	  review	  
assessing	  adjusted	  dose	  anticoagulation	  compared	  with	  placebo	   in	  patients	  with	  NRAF	  and	  
prior	  history	  of	  stroke	  or	  TIA	  176.	  	  Recurrent	  stroke	  (any	  type)	  (OR	  0.36;	  95%	  CI,	  0.22	  –	  0.58)	  
and	  all	   vascular	  events	   (stroke,	  MI,	  SE,	   vascular	  death)	   (OR	  0.55;	  95%	  CI	  0.37	  –	  0.82)	  were	  
each	  significantly	  reduced	  with	  anticoagulant	  therapy.	  	  Major	  extracranial	  haemorrhage	  was	  
increased	  with	  anticoagulant	  therapy	  (OR	  4.32;	  95%	  CI	  1.55	  –	  12.10).	  
The	  RR	  reductions	  with	  anticoagulant	   therapy	  compared	  with	  placebo	  were	  similar	   in	  both	  
primary	  and	  secondary	  prevention	  populations.	  	  However,	  absolute	  risk	  reductions	  differ.	  	  In	  
patients	  without	  prior	  stroke,	  the	  annualised	  ischaemic	  stroke	  rate	  in	  the	  control	  group	  was	  
approximately	   4%	   per	   year.	   	   The	   absolute	   reduction	   in	   stroke	   with	   anticoagulation	   was	  
approximately	   2.6%	   per	   year	   (or	   25	   ischaemic	   strokes	   prevented	   yearly	   per	   1000	   treated	  
patients)	  175.	   	   In	  contrast,	  the	  annual	  incidence	  in	  patients	  with	  prior	  stroke	  or	  TIA	  was	  12%	  
per	  year	  176.	   	  90	  vascular	  events	  (mainly	  strokes)	  are	  prevented	  if	  1000	  patients	  are	  treated	  
for	  1	  year	  176.	  	  A	  subsequent	  meta-­‐analysis	  reported	  an	  ARR,	  in	  any	  stroke,	  of	  8.4%	  per	  year	  in	  
patients	  with	  prior	  stroke	  or	  TIA	  and	  2.7%	  per	  year	  in	  the	  context	  of	  primary	  prevention,	  for	  
adjusted	  dose	  anticoagulation	  compared	  with	  placebo	  173.	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It	   is	  noteworthy	  that	  the	  risk	  of	  ischaemic	  stroke	  is	  significantly	  increased	  amongst	  patients	  
who	  experience	  subtherapeutic	   INR	  control.	   	  Compared	  with	  patients	  with	  an	  INR	  of	  2.0	  or	  
higher,	  the	  OR	  for	  ischaemic	  stroke	  in	  patients	  with	  an	  INR	  or	  1.5	  or	  less	  is	  3.3	  (95%	  CI,	  2.4	  –	  
4.6)	   177.	   	   Thus,	   the	   benefits	   of	   anticoagulation	   are	   reliant	   on	   adequate	   control	   within	   the	  
therapeutic	  range.	  
	  
1.4.9.2. Anticoagulant	  therapy	  compared	  with	  antiplatelet	  therapy	  
An	  individual	  patient	  data	  meta-­‐analysis	  of	  clinical	  trial	  data,	  in	  986	  patients	  with	  prior	  stroke	  
or	  TIA,	  reported	  annual	  ischaemic	  stroke	  event	  rate	  of	  10.0%	  per	  100	  patient	  years	  with	  ASA	  
therapy	   compared	  with	   4.0%	   on	   adjusted	   dose	   oral	   anticoagulation	   178.	   	   In	   3,066	   patients	  
without	  prior	  history	  of	  stroke	  or	  TIA,	  the	  annual	   ischaemic	  stroke	  event	  rate	  was	  2.7%	  per	  
100	   patient	   years	   with	   ASA	   therapy	   compared	   with	   1.5%	   on	   adjusted	   dose	   oral	  
anticoagulation.	   	   Two	   Cochrane	   reviews	   have	   subsequently	   compared	   adjusted	   dose	  
anticoagulation	   with	   antiplatelet	   therapy	   in	   patients	   without	   and	   with,	   prior	   history	   of	  
ischaemic	  stroke	  or	  TIA.	  
A	   Cochrane	   library	   systematic	   review	   and	  meta-­‐analysis	   of	   trials	   evaluating	   adjusted	   dose	  
anticoagulation	   with	   VKA,	   compared	   with	   antiplatelet	   therapy,	   in	   patients	   with	   AF	   but	  
predominantly	  (~90%)	  no	  prior	  history	  of	  stroke	  or	  TIA,	  was	  published	  in	  2007	  179.	   	  Data	  for	  
9598	  patients	  enrolled	   in	   five	   trials	  were	   included,	  with	  mean	   follow-­‐up	  of	  1.9	   years.	   	   The	  
authors	   reported	   a	   significant	   reduction	   in	   all	   strokes	   (OR	   0.68;	   95%	   CI,	   0.54	   –	   0.85),	  
ischaemic	   stroke	   (OR	  0.53;	  95%	  CI,	  0.41	  –	  0.68),	   systemic	  embolic	  events	   (OR	  0.48;95%	  CI,	  
0.25	  –	  0.90),	  a	  composite	  outcome	  of	  all	  stroke,	  MI	  or	  vascular	  death	  (OR	  0.74;	  95%	  CI,	  0.61	  –	  
0.90)	   and	   all-­‐cause	  mortality	   (OR	   0.74;	   95%	   CI	   0.61	   –	   0.91),	   with	   anticoagulant	   compared	  
with	  ASA	  therapy.	  
The	  seminal	  EAFT	  is	  the	  only	  randomised	  clinical	  trial	  to	  have	  specifically	  compared	  adjusted	  
dose	   anticoagulation	   with	   ASA	   in	   the	   context	   of	   ischaemic	   stroke	   and	   TIA	   secondary	  
prevention	  137.	   	  Compared	  with	  ASA,	  adjusted	  dose	  warfarin	  significantly	  reduced	  all	  stroke	  
(HR-­‐adjusted	  0.38;	  95%	  CI,	  0.23	  –	  0.64)	  and	  combined	  vascular	  events	  (HR	  0.60;	  95%	  CI,	  0.41	  
	  37	  
–	  0.87).	   	  Survival	  curves	  continued	  to	  diverge	  at	  the	  point	  of	  trial	   termination	  of	   follow-­‐up,	  
suggesting	  that	  treatment	  ought	  to	  continue	  indefinitely.	  	  	  
A	   Cochrane	   library	   systematic	   review	   and	  meta-­‐analysis	   of	   trials	   evaluating	   adjusted	   dose	  
anticoagulation	  with	  VKA	   compared	  with	  antiplatelet	   therapy	   in	  patients	  with	  AF	  and	  with	  
prior	   history	   of	   stroke	   or	   TIA	   was	   published	   in	   2004	   and	   included	   data	   for	   1371	   patients	  
enrolled	   in	   two	   trials;	   the	   EAFT	   and	   the	   SIFA	   (in	  which	   the	   antiplatelet	   agent	   studied	  was	  
Indobufen)	  180.	  	  The	  authors	  reported	  a	  significant	  reduction	  in	  all	  stroke	  (Peto	  OR	  0.49;	  95%	  
CI,	  0.33	  –	  0.72)	  and	  all	  vascular	  events	  (Peto	  OR	  0.67;	  95%	  CI,	  0.50	  –	  0.91),	  compared	  with	  
antiplatelet	   therapy.	   	   Major	   extracranial	   bleeding	   was	   increased	   with	   anticoagulant	  
compared	  with	  antiplatelet	  therapy	  (Peto	  OR	  5.16;	  95%	  CI,	  2.08	  –	  12.83).	  
Based	  on	  an	  annualised	  rate	  of	  ischaemic	  stroke	  of	  4%	  per	  year	  on	  antiplatelet	  therapy	  in	  the	  
primary	   prevention	   population,	   approximately	   19	   events	   per	   year	  would	   be	   prevented	   for	  
every	  1000	  patients	  treated	  with	  anticoagulation	  rather	  than	  antiplatelet	  179.	  	  In	  contrast,	  in	  
the	  EAFT,	  the	  annual	  rate	  for	  any	  stroke	  in	  ASA	  treated	  patients	  was	  10%	  per	  year.	  	  The	  rate	  
in	  anticoagulated	  patients	  was	  approximately	  4%,	  so	  that	  anticoagulation	  is	  associated	  with	  
60	  fewer	  recurrent	  strokes	  per	  year	  per	  1000	  patients	  treated,	  compared	  with	  ASA	  180.	  
A	   subsequent	   meta-­‐analysis,	   which	   included	   the	   results	   of	   the	   large	   ACTIVE-­‐W	   study,	  
reported	  an	  RRR	  for	  any	  stroke	  of	  37%	  (95%	  CI,	  23	  –	  48)	  for	  all	  trials	  comparing	  adjusted	  dose	  
anticoagulation	   with	   antiplatelet	   therapy.	   	   The	   ARR	   for	   any	   stroke,	   with	   adjusted	   dose	  
anticoagulation	  compared	  with	  ASA,	  was	  7.0%	  per	  year	   in	  patients	  with	  prior	  stroke	  or	  TIA	  
and	  0.7%	  per	  year	  in	  the	  context	  of	  primary	  prevention	  173.	  	  	  
In	   the	  ACTIVE-­‐W	  study,	   adjusted	  dose	  Warfarin	  was	   compared	  with	   combination	  of	  ASA	  &	  
Clopidogrel	  181.	   	  The	  study	  was	  discontinued	  prematurely	  due	  to	  the	  superiority	  of	  adjusted	  
dose	   warfarin	   (RR	   1.44;	   95%	   CI	   1.18	   –	   1.76).	   	   Studies	   assessing	   fixed-­‐low-­‐dose	  
anticoagulation,	  in	  combination	  with	  ASA,	  have	  failed	  to	  demonstrate	  a	  significant	  reduction	  
in	  embolic	  events,	  whilst	  bleeding	  was	  increased	  182.	  	  Studies	  targeting	  higher	  range	  INR	  were	  
associated	  with	  excess	  bleeding	  183.	  
The	  AVERROES	   trial	   randomised	  patients	  with	  AF	  at	   increased	   risk	  of	   stroke	  but	  unsuitable	  
for	  treatment	  with	  VKA,	  to	  receive	  either	  Apixaban	  or	  ASA	  184.	  	  During	  mean	  follow-­‐up	  of	  1.1	  
	  38	  
years,	  stroke	  &	  SE	  were	  observed	   less	  frequently	  with	  Apixaban	  than	  ASA	  (HR	  0.45;	  95%	  CI	  
0.32	  –	  0.62).	  	  Major	  bleeding	  events	  were	  similar	  in	  the	  two	  treatment	  groups	  (HR	  1.13;	  95%	  
CI,	   0.74	   –	   1.75).	   	   Treatment	   effects	   were	   consistent	   in	   important	   subgroups,	   including	  
patients	   with	   prior	   stroke	   or	   TIA	   (although	   there	   was	   a	   trend	   toward	   significantly	   greater	  
benefit	  of	  Apixaban	  in	  this	  group).	  	  
Following	  on	  from	  the	  evidence	  for	  superiority	  of	  anticoagulation	  over	  antiplatelet	  therapy	  in	  
AF	   for	   both	   primary	   and	   secondary	   stroke	   prevention	   in	   younger	   adults,	   the	   BAFTA	   study	  
enrolled	   973	   patients	   aged	   75	   years	   and	   over	   185.	   	   During	   mean	   2.7	   years	   follow	   up,	   a	  
composite	   endpoint	   of	   fatal	   /	   disabling	   stroke,	   ICH	   and	   arterial	   embolism	  was	   significantly	  
lower	  in	  warfarin	  treated	  patients	  compared	  with	  ASA	  RR	  0.48;	  95%	  CI	  0.28	  –	  0.80).	  	  	  
	  
1.4.9.3. The	  optimal	  choice	  of	  anticoagulant	  agent	  	  
The	  applicability	  of	  benefits	  of	  anticoagulant	  therapy	  demonstrated	  within	  clinical	  trials	  may	  
not	  be	  universal.	  	  Many	  authors	  and	  clinicians	  believe	  the	  balance	  of	  risk	  and	  benefit	  may	  be	  
completely	   reversed	   in	   particular	   patient	   groups.	   	   Real	   life	   populations	   are	   often	   more	  
elderly,	  frail	  with	  multiple	  co-­‐morbidities	  including	  cognitive	  impairment.	  	  These	  combine	  to	  
make	  the	  practicalities	  of	   therapeutic	  monitoring	  more	  challenging	  and	   increase	  the	  risk	  of	  
either	  under	  or	  over	  anticoagulation	  (with	  adherent	  risks	  of	  bleeding	  complications).	  
The	   utility	   of	   anticoagulation	   in	   patients	   with	   AF	   could	   be	   optimised	   186, 187.	   	   Treatment	  
appears	   to	   be	   underutilised	   in	   the	   wider	   population,	   potentially	   due	   to	   either	   patient	   or	  
physician	   (or	   a	   combination	   of	   both)	   reluctance	   to	   use	   warfarin	   188.	   	   In	   one	   study,	  
approximately	   half	   of	   patients	   with	   no	   apparent	   contraindication	   were	   found	   to	   be	  	  
untreated	   186.	   	   Perceived	   risks	   of	   haemorrhages	   and	   practicalities	   are	   likely	   contributing	  
factors	   to	   such	   reluctance	   189.	   	   The	   current	   proportion	   of	   patients	   with	   identifiable	   AF	  
following	  stroke	  typically	  commenced	  on	  anticoagulant	  treatment	  is	  only	  39%	  23.	  	  Whilst	  it	  is	  
unlikely	   that	   all	   stroke	   patients	   with	   AF	   will	   ever	   be	   suitable	   for	   anticoagulant	   therapy,	  
availability	   of	   new	   direct	   thrombin	   and	   factor	   Xa	   inhibitors	   will	   greatly	   increase	   the	  
proportion	  that	  will	  safely	  benefit	  from	  reduced	  embolic	  phenomena	  through	  treatment.	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Many	   patients	   on	   treatment	   in	   the	   community	   are	   found	   to	   be	   inadequately	  	  	  	  	  
anticoagulated	   188.	   	   This	   also	   occurs	   in	   closely	   monitored	   clinical	   trial	   populations	   137.	  	  
Treatment	   outwith	   the	   therapeutic	   INR	   is	   associated	   with	   increased	   risk	   of	   clinical	  	  	  	  	  	  	  	  	  	  
events	  177, 190.	   	  Prolonged	  periods	  of	  over	  anticoagulation	  are	  associated	  with	  increased	  risk	  
of	  bleeding	  events	  191.	  
Lack	   of	   universal	   applicability	   of	   warfarin	   therapy,	   together	   with	   practical	   challenges	   of	  
monitoring	   and	   maintaining	   patients	   within	   the	   target	   range	   of	   anticoagulation,	   has	  
prompted	   exploration	   of	   alternative	   novel	   anticoagulant	   agents	   (NOACs),	   which	   confer	  
predictable	  anticoagulant	  effects.	  
A	   subgroup	   of	   3,436	   patients	  with	   prior	   ischaemic	   or	   TIA	  were	   included	   in	   the	   ARISTOTLE	  	  
trial	  135, 192.	  	  The	  stroke	  population	  included	  was	  neither	  restricted	  nor	  enriched	  according	  to	  
TOAST	  diagnostic	  criteria.	  	  Over	  median	  follow-­‐up	  of	  1.8	  years,	  4.0%	  of	  patients	  treated	  with	  
Apixaban	  suffered	  any	  stroke	  compared	  with	  5.5%	  of	  patients	  treated	  with	  warfarin	  (HR	  0.71;	  
95%	  CI,	  0.52	  –	  0.98).	   	   ICH	  was	   lower	   in	  Apixaban	  treated	  patients	   (HR	  0.40;	  95%	  CI,	  0.21	  –	  
0.78).	  Observed	   results	   in	   this	   subgroup	  were	   consistent	  with	   those	   in	  non-­‐stroke	  patients	  
across	  all	  endpoints.	   	   In	  the	  ROCKET-­‐AF	  study,	  Rivaroxaban	  was	  found	  to	  be	  non-­‐inferior	  to	  
adjusted	   dose	  warfarin	   in	   patients	  with	   prior	   ischaemic	   stroke	   or	   TIA	   193	   and	   in	   the	   RE-­‐LY	  
study,	  Dabigatran	  was	   found	   to	  be	  non-­‐inferior	   to	  adjusted	  dose	  VKA	   for	   stroke	   reduction,	  
with	  an	  associated	  small	  excess	  in	  MI	  194.	  	  
A	  recent	  meta-­‐analysis	  comparing	  NOAC	  agents	  with	  vitamin	  K	  antagonist	  therapy,	  identified	  
a	   significant	   reduction	   in	   all	   stroke	   (RR	   0·∙81,	   95%	   CI	   0·∙73—0·∙91)	   with	   the	   NOAC	   agents.	  	  
Intracranial	  bleeding	  was	  reduced	  with	  NOAC	  agents	  though	  there	  was	  a	  significant	  increase	  
in	   the	   risk	   of	   gastrointestinal	   bleeding	   195.	   	   Guidelines	   are	   being	   updated	   to	   reflect	   the	  
emerging	  evidence	  base	  regarding	  NOAC	  agents	  in	  relation	  to	  VKA	  and	  antiplatelet	  therapy.	  	  
It	   appears	   likely	   that	   these	   agents	   will	   emerge	   as	   treatments	   of	   choice	   in	   relation	   to	  
cardioembolic	  prophylaxis.	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1.4.10. Rate	  versus	  rhythm	  control	  strategies	  in	  AF	  
Several	   clinical	   trials	   have	   examined	   the	  merits	   of	   a	   “rhythm	   control”	   strategy,	  where	   the	  
goal	   of	   treatment	   is	   to	   maintain	   the	   patient	   in	   sinus	   rhythm,	   as	   compared	   with	   a	   “rate	  
control”	   strategy,	   in	   which	   AF	   is	   accepted	   as	   the	   prevailing	   cardiac	   rhythm	  with	   focus	   on	  
reducing	  complications	  (tachy-­‐cardiomyopathy,	  embolic	  phenomena).	  
The	  largest	  trial	  to	  compare	  these	  strategies	  was	  the	  AFFIRM	  study	  196.	  	  4060	  patients	  (mean	  
age	  69.7	  years)	  with	  AF	  aged	  over	  65	  years	  and	  at	   least	  one	  additional	  CV	  risk	  factor,	  were	  
randomised	   to	   rhythm	   control	   (comprising	   DC	   cardioversion	   following	   a	   period	   of	  
anticoagulation,	  followed	  by	  antiarrhythmic	  drugs)	  or	  rate	  control	  (with	  choice	  of	  medication	  
at	   clinician	   discretion).	   	   Anticoagulant	   therapy	   was	   recommended	   unless	   otherwise	  
contraindicated	  in	  the	  rate	  control	  group	  but	  could	  be	  discontinued	  at	  clinician	  discretion	  if	  
successful	  rhythm	  control	  was	  perceived	  to	  have	  been	  achieved.	  	  During	  mean	  follow-­‐up	  of	  
3.5	  years,	  a	  non-­‐significant	  trend	  toward	  higher	  mortality	  in	  the	  rhythm	  control	  group	  (23.8%	  
versus	  21.3%,	  p=0.08),	  was	  observed.	  	  During	  the	  study	  more	  than	  85%	  those	  patients	  in	  the	  
rate	   control	   group	  were	  maintained	   on	   coumadin,	  while	   in	   the	   rhythm	   control	   group	   that	  
number	  declined	  to	  70%	  after	  the	  first	  four	  months	  (&	  remained	  at	  that	  approximate	  level).	  	  
Despite	  comprising	  a	  smaller	  number	  of	  patients,	  approximately	  twice	  as	  many	  strokes	  were	  
observed	   in	   rhythm	   control	   patients	   as	   rate	   control	   patients	   who	   discontinued	  
anticoagulation	  (44	  versus	  25	  of	  69	   ischaemic	  strokes).	   	  A	  conclusion	  of	   the	  study	  was	  that	  
whilst	   rhythm	   control	   may	   appear	   to	   have	   been	   achieved,	   risk	   of	   cardioembolic	   stroke	  
persisted	   and	   discontinuation	   of	   anticoagulant	   therapy	   was	   associated	   with	   an	   excess	   of	  
clinical	   events,	   which	   appeared	   to	   largely	   explain	   the	   observed	   trend	   in	   mortality	   in	   the	  
rhythm	  control	  group.	  	  	  
Guidelines	   reflect	   these	   findings	   in	   recommending	   rhythm	   control	   for	   symptomatic	  	  
morbidity	  197.	  	  In	  patients	  in	  whom	  maintenance	  of	  sinus	  rhythm	  is	  unlikely	  to	  be	  successful,	  
anticoagulation	  for	  cardioembolic	  prophylaxis	  should	  not	  be	  routinely	  discontinued	  if	  rhythm	  
control	  is	  being	  pursued.	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1.4.11. Non-­‐pharmacological	  approaches	  to	  secondary	  prevention	  in	  AF	  
A	  proportion	  of	  patients	  may	  remain	  unsuitable	  (or	  unwilling)	  for	  anticoagulation	  with	  either	  
warfarin	   or	   the	   novel	   oral	   anticoagulant	   agents	   (NOACs).	   	   Patients	  without	   prior	   stroke	   or	  
other	   risk	   factors	   necessitating	   consideration	   of	   anticoagulation	   may	   experience	  
symptomatic	   morbidity.	   	   These	   patient	   groups	   may	   be	   considered	   for	   non-­‐anticoagulant	  
based	  strategies	  by	  which	  to	  eliminate	  the	  occurrence	  of	  AF	  (rhythm	  control	  through	  either	  
pharmacological	   or	   interventional	   procedures)	   or	   the	   embolic	   complications	   of	   AF	  
(interventional	   procedures).	   	   In	   the	   PROTECT-­‐AF	   study,	   placement	   of	   the	  WATCHMAN	   left	  
atrial	  appendage	  occlusion	  device	  was	  evaluated	  versus	  adjusted	  dose	  warfarin.	  	  The	  authors	  
reported	   that	   the	  WATCHMAN	   device	  may	   be	   non-­‐inferior	   to	   adjusted	   dose	   INR	   warfarin	  
therapy	  in	  reducing	  the	  risk	  of	  embolic	  events	  198.	  	  	  
	  
1.4.12. Cervical	  artery	  dissection	  
Following	   cervical	   artery	   dissection,	   the	   risk	   of	   stroke	   appears	   highest	   in	   the	   days	  
immediately	  following	  the	  dissection	  199.	  	  Beyond	  this,	  stroke	  rates	  appear	  low,	  estimated	  at	  
approximately	  0.3%	  between	  3	  –	  12	  months	  in	  two	  case	  series	  200, 201.	  	  
There	   are	   limited	   data	   available	   to	   guide	   medical	   management	   following	   cervical	   artery	  
dissection.	  	  A	  systematic	  review	  and	  meta-­‐analysis	  comparing	  antiplatelet	  with	  anticoagulant	  
therapy	   in	   carotid	   dissection	   reported	   a	   non-­‐significant	   trend	   toward	   increased	   death	   or	  
disability	   with	   antiplatelet	   compared	   with	   anticoagulant	   therapy	   [OR	   1.94,	   95%	   CI	   0.79	   –	  
4.91]	   202.	   	   A	   separate	  meta-­‐analysis	   included	   both	   carotid	   and	   vertebral	   arterial	   dissection	  
cases	   and	   reported	   no	   difference	   in	   death	   or	   stroke	   rates	   between	   antiplatelet	   and	  
anticoagulant	  therapy	  203.	  	  Neither	  of	  these	  systematic	  reviews	  included	  patients	  enrolled	  in	  
randomised	   comparisons.	   	   Randomised	   trials	   are	   ongoing	   to	   address	   the	   optimal	  
management	   strategy	   and	   no	   specific	   recommendations	   are	   made	   in	   current	   guidelines	  
regarding	  the	  optimal	  choice	  of	  medical	  management	  19.	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1.4.13. Cardioembolic	  stroke	  (other	  than	  related	  to	  AF)	  
	  
1.4.13.1. Patent	  foramen	  ovale	  
A	  patent	  foramen	  ovale	  (PFO)	  may	  be	  present	  in	  up	  to	  25%	  of	  the	  population	  117.	  	  PFO	  may	  
be	   associated	   with	   an	   atrial	   septal	   aneurysm	   and	   the	   latter	   may	   also	   exist	   in	   isolation.	  	  
Epidemiological	  data	  have	  suggested	  PFO	  may	  be	  causally	  related	  to	  incident	  stroke,	  though	  
data	  are	  conflicting.	  
A	   systematic	   review	  of	   population	  based	  data	   identified	   elevated	   risk	   of	   incident	   stroke	   in	  
association	  with	  presence	  of	  PFO.	  	  In	  patients	  <	  55	  years	  of	  age,	  compared	  with	  patients	  with	  
neither	  PFO	  nor	  atrial	  septal	  aneurysm,	  the	  OR	  for	  stroke	  in	  the	  presence	  of	  PFO,	  atrial	  septal	  
aneurysm	  and	  PFO	  with	  atrial	  septal	  aneurysm	  were:	  3.1	  (95%	  CI,	  2.29	  –	  4.21),	  6.14	  (95%	  CI,	  
2.47	   –	   15.22)	   and	   15.59	   (95%	  CI,	   2.83	   –	   85.87),	   respectively	   204.	   	   In	   patients	   >	   55	   years,	   a	  
similar	  pattern	  of	  risk	  albeit	  of	  lower	  relative	  magnitude	  was	  observed.	  
A	   consecutive	  patient	   case-­‐series	   study	   reported	  presence	  of	  PFO	   in	   a	   significantly	   greater	  
proportion	  of	  patients	  with	   cryptogenic	   stroke	   than	   stroke	  of	   known	  cause,	   irrespective	  of	  
patient	  age	  205.	  	  In	  the	  European	  PFO-­‐ASA	  study,	  in	  patients	  aged	  18	  –	  55	  years	  with	  stroke	  of	  
unknown	   cause,	   4-­‐year	   stroke	   recurrence	   in	   patients	   with	   neither	   PFO	   nor	   atrial	   septal	  
aneurysm	  was	  4.2%	  (1.8	  –	  6.6).	  	  Stroke	  recurrence	  was	  lower	  in	  patients	  with	  PFO,	  2.3%	  (0.3	  
–	  4.3)	  and	  higher	  in	  patients	  with	  both	  PFO	  and	  atrial	  septal	  aneurysm,	  15.2%	  (1.8	  –	  28.6)	  206.	  	  
However,	  epidemiological	  data	  are	  conflicting.	   	   In	  the	  Patent	  Foramen	  Ovale	  in	  Cryptogenic	  
Stroke	   (PICSS)	   substudy	   of	   WARSS,	   PFO	   was	   identified	   in	   34%	   of	   patients	   who	   agreed	   to	  
undergo	   transoesophageal	   echocardiography	   207.	   	   2-­‐year	   event	   rates	   for	   recurrent	   stroke	  
were	  14.8%	   in	  patients	  with	  PFO	  and	  15.4%	  without	  PFO	   (HR	  0.96,	  p=0.84).	   	   PFO	   size	   and	  
presence	  of	  atrial	  septal	  aneurysm	  were	  not	  related	  to	  outcome.	  
Optimal	   medical	   management	   of	   patients	   with	   PFO	   is	   uncertain.	   	   In	   the	   WARSS	   PICSS	  
substudy,	  no	  difference	  in	  2-­‐year	  stroke	  recurrence	  was	  seen,	  in	  patients	  with	  PFO,	  between	  
ASA	  (13.2%)	  and	  warfarin	  (16.5%)	  therapy,	  HR	  1.17,	  p=0.65	  207.	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PFO	  closure	  devices	  were	  studied	  extensively	   in	  non-­‐randomised	  comparisons	  with	  medical	  
therapy,	  with	   suggestion	  of	   superiority	  of	   closure	   208.	   	   RCTs	  have	   subsequently	   indicated	  a	  
trend	   toward	   reduced	  stroke	   rates	  with	  closure	  compared	  with	  medical	   therapy	  but	  at	   the	  
expense	  of	  higher	  rates	  of	  AF	  209.	  
	  
1.4.13.2. Left	  ventricular	  systolic	  dysfunction	  
Approximately	  10%	  of	  patients	  with	  prior	  ischaemic	  stroke	  have	  an	  impaired	  left	  ventricular	  
ejection	  fraction	  (LVEF)	  of	  ≤	  30%	  210.	  	  LV	  thrombus	  formation	  is	  common	  in	  such	  patients	  211	  
and	   anticoagulation	  may	  be	  preferable	   to	   antiplatelet	   based	   secondary	   prevention	   in	   such	  
patients,	   even	   in	   the	   absence	   of	   other	   specific	   indications	   for	   anticoagulation	   19.	   	   The	  
WARCEF	  study,	  evaluating	  stroke	  risk	  according	  to	  antithrombotic	  regime	  is	  ongoing	  212.	  
	  	  	  	  
1.4.13.3. Mural	  thrombus	  
Acute	   MI	   is	   a	   common	   complication	   following	   stroke	   or	   TIA.	   	   Similarly	   stroke	   and	   TIA	  
frequently	   occur	   following	   acute	  MI.	   	   Intracardiac	   thrombus	   commonly	   develops	   following	  
acute	   MI	   (approximately	   one	   third	   of	   patients	   with	   untreated	   anterior	   MI	   and	   a	   higher	  
proportion	  of	  patients	  with	   large	   infarcts	   involving	  the	  LV	  apex	  211.	   	  Cerebral	  embolism	  has	  
been	   reported	   to	  occur	   in	   8%	  of	   such	  patients	   213.	   	   Three	   trials	   comparing	   anticoagulation	  
(initially	   with	   heparin,	   followed	   by	   warfarin)	   with	   placebo,	   demonstrated	   a	   reduction	   in	  
embolism	   from	   3%	   to	   1%	   214.	   	   American	   Heart	   Association	   (AHA)	   &	   American	   Stroke	  
Association	   guidelines	   recommend	   that	   acute	   MI	   complicated	   by	   LV	   mural	   thrombus,	  
demonstrable	  on	  cardiac	  imaging,	  should	  be	  treated	  with	  oral	  anticoagulation	  (target	  INR	  of	  
2	  –	  3)	  for	  a	  period	  of	  3	  months	  (after	  which	  the	  risk	  of	  embolism	  declines)	  214.	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1.5. Summary	  &	  aims	  of	  this	  thesis	  
Approximately	   half	   of	   patients	   in	   contemporary	   acute	   stroke	   studies	   still	   experience	   an	  
unfavourable	   outcome	   (death	   or	   dependency)	   at	   90	   days.	   	   The	   risk	   of	   stroke	   and	   other	  
cardiovascular	   events	   following	   an	   index	   stroke	   or	   TIA	   is	   very	   high.	   	   Changing	   population	  
demography	   is	   likely	   to	   result	   in	   an	   increasing	   burden	   of	   cerebrovascular	   disease.	  	  
Accordingly,	  to	  reduce	  this	  burden,	  secondary	  preventative	  strategies	  must	  be	  optimised	  and	  
potential	  novel	  therapeutic	  strategies	  evaluated.	  	  This	  thesis	  addressed	  aspects	  of	  secondary	  
prevention	  in	  each	  of	  these	  regards.	  	  Firstly,	  optimised	  detection	  (and	  thereby	  treatment)	  of	  
atrial	   fibrillation	   after	   ischaemic	   stroke	   and	   TIA.	   	   Secondly,	   evaluation	   of	   a	   potential	  
therapeutic	   strategy	   for	   the	  prevention	  of	   cardiovascular	   disease	   in	   the	   stroke	  population:	  
xanthine	  oxidase	  inhibition	  (XOI).	  
The	   potential	   clinical	   relevance	   of	   enhanced	   AF	   detection	   immediately	   following	   stroke	   is	  
reviewed	  in	  Chapter	  2.	  	  Guidance	  regarding	  investigation	  for	  PAF	  following	  ischaemic	  stroke	  
and	   TIA	   lacks	   a	   robust	   evidence	   base.	   	   Chapter	   3	   details	   a	   randomised	   clinical	   trial,	  which	  
aimed	   to	   provide	   a	   randomised	   evidence	   base	   to	   guide	   clinicians	   managing	   unselected	  
ischaemic	  stroke	  &	  TIA	  patients,	  in	  the	  investigative	  approach	  for	  optimal	  detection	  of	  AF.	  	  A	  
related	  observational	  study	  aimed	  to	  evaluate	  the	  positive	  and	  negative	  predictive	  value	  of	  
AF	  detection	  in	  the	  days	  following	  ischaemic	  stroke,	  for	  presence	  of	  AF	  after	  90	  days	  follow	  
up	  from	  the	  index	  event.	  
In	  Chapter	  4,	  the	  potential	  role	  of	  uric	  acid	  and	  XO	  enzymatic	  activity	  in	  the	  pathogenesis	  and	  
pathophysiology	  of	  cardiovascular	  disease	  is	  reviewed.	  	  In	  Chapter	  5,	  the	  available	  evidence	  
for	  XOI,	  in	  relation	  to	  the	  management	  of	  cardiovascular	  disease,	  is	  examined	  in	  a	  systematic	  
review	  and	  meta-­‐analysis.	  	  Chapter	  6	  reviews	  the	  utility	  of	  carotid	  intima	  media	  thickness,	  BP	  
pulse	  wave	  analysis	   and	  endothelial	   function	  assessment,	   as	  both	  vascular	  biomarkers	   and	  
surrogate	  measurements	   for	  modified	   cardiovascular	   risk	   in	   clinical	   trials.	   	   In	   Chapter	   7,	   a	  
double	  blind	  randomised	  controlled	  trial,	  evaluating	  the	  XOI	  Allopurinol	  in	  a	  population	  with	  
recent	  ischaemic	  stroke	  or	  TIA,	  is	  reported.	  	  This	  study	  sought	  to	  provide	  evidence	  relating	  to	  
sustained	   treatment	   effects	   of	   XOI	   in	   the	   ischaemic	   stroke	   population,	   in	   relation	   to	  
surrogate	  markers	  of	  CV	  health,	  including	  carotid	  intima	  media	  thickness	  and	  central	  BP.	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Chapter	  2 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
The	   role	   of	   atrial	   fibrillation	   in	   the	   aetiology	   of	  
ischaemic	  stroke	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2.1. The	  epidemiology	  of	  AF	  
Atrial	   fibrillation	   is	   the	   commonest	   cardiac	   dysrhythmia	   197.	   	   Incidence	   increases	  with	   age,	  
rising	  exponentially	  from	  0.64,	  in	  males	  <	  55	  years,	  to	  40.06	  per	  1000	  person-­‐years,	  in	  males	  
≥	  85	  years	  215.	  	  The	  incidence	  is	  higher	  in	  males	  than	  females.	  	  In	  addition	  to	  increasing	  age,	  
AF	   is	   observed	   more	   frequently	   in	   individuals	   with	   CVRFs	   and	   established	   cardiovascular	  
disease,	   including	  cardiomyopathy,	  LVH,	  hypertension,	  obesity,	  diabetes,	   respiratory	   failure	  
and	  alcohol	  excess	  216, 217.	  
The	  age-­‐adjusted	  incidence	  of	  AF	  has	  reportedly	  increased	  in	  recent	  decades,	  from	  3.04	  (per	  
1000	   person-­‐years)	   in	   1980	   to	   3.68	   in	   2000	   215.	   	   This	   may	   reflect	   greater	   likelihood	   of	  
detection	   due	   to	   increased	   availability	   of	   more	   extensive	   and	   sensitive	   screening	  
investigations	   in	   recent	   years	   and	   highlights	   the	   potential	   for	   underestimation	   of	   the	   true	  
prevalence	  of	  the	  condition	  due	  to	  underdiagnosis	  of	  patients	  with	  clinically	  silent	  or	  PAF	  218.	  
Several	  large	  population	  studies	  have	  estimated	  the	  prevalence	  of	  AF.	  	  Estimates	  vary,	  in	  part	  
reflecting	   differences	   in	   population	   characteristics	   but	   also	   variation	   in	   the	   modalities,	  
availability	  &	  intensity	  of	  investigative	  strategies	  for	  AF	  between	  studies	  219.	  	  	  
Methodology	   to	   identify	  cases	  of	  AF	  have	   included	  biennial	  ECG	  screening	  and	  case	   record	  
reviews	  in	  the	  Framingham	  population	  134,	  case	  record	  review	  in	  the	  Rochester	  population	  220	  
and	   a	   single	   screening	   ECG	   followed	   by	   patient	   self-­‐reporting	   to	   investigators	   in	   the	  
Cardiovascular	  Health	  Study	  221.	  	  Irrespective	  of	  variability	  in	  estimates	  between	  studies,	  as	  a	  
chronic	   condition,	   with	   age	   related	   increasing	   incidence,	   the	   prevalence	   of	   AF	   increases	  
dramatically	  with	  increasing	  age	  222.	  	  	  In	  these	  studies,	  AF	  prevalence	  was	  estimated	  at	  5.9%	  
in	   individuals	   aged	   over	   65	   years.	   	   In	   the	   ATRIA	   study,	   conducted	   in	   a	   large	   Californian	  
population,	   the	  overall	   adult	   population	  prevalence	  AF	  was	   reported	   to	  be	  0.95%	   (95%	  CI,	  
0.94	   –	   0.95%).	   	   However,	   prevalence	   varied	   considerably	  with	   age	   such	   that	   only	   0.1%	   of	  
individuals	  <	  55	  years	  in	  age	  had	  AF	  compared	  with	  9.0%	  of	   individuals	  aged	  ≥	  80	  years	  223.	  	  
The	  prevalence	  quoted	  in	  this	  study	  excluded	  patients	  with	  transient	  episodes	  of	  AF.	   	  All	  of	  
these	   studies	   have	   the	   potential	   to	   underestimate	   the	   prevalence	   of	   PAF,	   as	   they	   did	   not	  
routinely	   utilize	   prolonged	   cardiac	  monitoring	   techniques.	   	   Those	   studies	  which	   not	   utilise	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any	  ECG	  screening	  (e.g.	  ATRIA,	  Rochester)	  are	  likely	  to	  have	  underestimated	  the	  prevalence	  
of	  asymptomatic	  AF	  of	  any	  type.	  
Population	   demography	   has	   changed	   in	   recent	   years,	   with	   the	   elderly	   population	   both	  
increasing	   in	   number	   and	   as	   a	   proportion	   of	   the	   population	   as	   a	   whole,	   a	   	   trend	   that	   is	  
expected	   to	   continue	   10.	   	   This	  has	  health	  and	  economic	   implications	   for	   chronic	   conditions	  
and	  those	  related	  to	  aging,	  such	  as	  AF	  and	  in	  turn,	  stroke.	  
Based	   on	   the	   observed	   prevalence	   of	   AF	   in	   the	   ATRIA	   study,	   and	   anticipated	   changes	   in	  
population	  demography,	   the	  number	  of	   adults	   in	   the	  USA	  with	  AF	   is	  predicted	   to	   increase	  
from	  approximately	  2.3	  million	  in	  2000,	  to	  5.6	  million	  by	  2050	  223.	  	  More	  than	  50%	  of	  these	  
patients	  would	  be	  over	  80	  years	  in	  age.	  	  
	  
2.2. Pathophysiology	  and	  natural	  history	  of	  AF	  	  
Aetiological	  factors	  for	  the	  development	  of	  AF	  include	  ischaemia	  (e.g.	  CHD),	  increased	  atrial	  
pressure	   &	   distension	   (e.g.	   chronic	   heart	   failure	   (CHF),valvular	   heart	   disease	   and	   left	  
ventricular	   hypertrophy	   224),	   fibrosis	   (e.g.	   ageing,	   following	  MI),	   inflammatory,	   infective	   &	  
infiltrative	  processes	  218.	   	  Risk	   factors	   for	  development	  of	  AF	   include	  age,	  male	  sex,	  cardiac	  
and	  other	  vascular	  conditions	  223, 225.	  	  In	  addition,	  a	  positive	  family	  history	  appears	  to	  confer	  
increased	  risk	  226	  and	  several	  genetic	  factors	  have	  been	  associated	  with	  the	  condition	  227-­‐229.	  	  	  
The	   development	   of	   electrical	   re-­‐entry	   circuits	   within	   the	   atria	   are	   a	   key	   step	   in	   the	  
pathogenesis	  of	  AF.	   	  The	  pulmonary	  veins,	  at	  the	  site	  of	  entry	  to	  the	  left	  atrium	  have	  been	  
identified	   as	   a	   potential	   initial	   ectopic	   focus	   for	   the	   development	   of	   AF	   230.	   	   Aetiological	  
factors	   for	   AF	   frequently	   predispose	   to	   progressive	   or	   permanent	   structural	   and	  
electrophysiological	  myocardial	   remodelling.	   	   AF	   is	   itself	   associated	  with	   such	   remodelling,	  
which	  in	  turn	  predispose	  to	  recurrence,	  or	  maintenance	  of	  the	  dysrhythmia.	  	  This	  has	  led	  to	  
the	  observation	  that	  “AF	  begets	  AF”;	  once	  a	  threshold	  for	  AF	  to	  develop	  has	  been	  reached,	  
remodelling	  confers	  an	  increased	  propensity	  to	  recurrence	  218.	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The	  natural	   history	  of	  AF	   is	   now	  considered	  a	  progression	  between	  paroxysmal,	   persistent	  
and	  permanent	  phases	  of	   the	  dysrhythmia	   197.	   	   Paroxysmal	  AF	  describes	  episodes	  of	  AF	  of	  
brief	   duration,	   with	   spontaneous	   cardioversion	   to	   sinus	   rhythm.	   	   Persistent	   AF	   refers	   to	  
episodes	  of	  AF	  of	  at	  least	  7	  days	  duration.	  	  Cardioversion	  to	  sinus	  rhythm	  may	  be	  successful,	  
albeit	  only	  in	  the	  short	  term.	  	  Permanent	  AF	  describes	  patients	  found	  to	  be	  in	  AF	  at	  all	  times	  
and	   in	   whom	   attempts	   at	   cardioversion	   to	   sinus	   rhythm	   are	   unsuccessful.	   	   Progression	  
through	   these	   phases	   may	   occur	   over	   a	   variable	   period	   of	   time	   according	   to	   individual	  
patient	  characteristics,	  though	  only	  a	  minority	  of	  patients	  will	  fail	  to	  progress,	  usually	  in	  the	  
absence	  of	  any	  other	  CV	  disorders	  231.	  	  Comorbidities	  and	  age	  accelerate	  the	  progression	  of	  
AF	   &	   development	   of	   complications	   232, 233.	   	   Progression	   may	   be	   amenable	   to	  
pharmacological	  or	  other	  intervention	  in	  suitable	  patients	  197.	  
Several	   modifications	   in	   function	   of	   the	   atria	   predispose	   to	   the	   development	   of	   atrial	  
thrombus	  in	  AF,	  which	  in	  turn	  forms	  the	  mechanistic	  basis	  for	  thromboembolic	  complications	  
of	   the	   dysrhythmia.	   	   These	   include	   stasis	   of	   blood,	   particularly	   within	   the	   left	   auricular	  
appendage	   218.	   	   Additionally,	   denuded	   and	   dysfunctional	   endothelium,	   low	   grade	   vascular	  
inflammation	   and	   disordered	   coagulation	   and	   platelet	   activity	   are	   all	   considered	   to	  
contribute	  to	  thrombogenesis	  in	  AF	  234.	  
	  
2.3. Morbidity	  and	  mortality	  related	  to	  AF	  	  
AF	   typically	   presents	   as	   one	   of	   two	   clinical	   syndromes.	   	   The	   first	   is	   a	   symptomatic	  
presentation,	  which	  may	  be	   typically	   indicative	  of	   the	  dysrhythmia	   (e.g.	  palpitations),	   non-­‐
specific	  (e.g.	   lethargy,	  fatigue,	  reduced	  exercise	  capacity,	  dyspnoea)	  or	  haemodynamic	  (e.g.	  
pre-­‐syncope).	   	   The	   second	   clinical	   presentation	   is	   with	   thrombo-­‐embolic	   complication,	  
typically	  ischaemic	  stroke,	  though	  embolic	  events	  to	  non-­‐cerebral	  arterial	  territories	  may	  also	  
occur.	   	   A	   third	   clinical	   presentation,	   with	   a	   tachy-­‐cardiomyopathy,	   related	   to	   persistently	  
elevated	   ventricular	   rate	   and	   decompensation	   in	   cardiac	   function,	   is	   less	   frequently	  
observed.	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AF	  appears	  to	  be	  an	  independent	  predictor	  of	  mortality	  235.	  	  	  In	  the	  Framingham	  population,	  
presence	  of	  AF	  was	  associated	  with	  an	  OR	  for	  death	  of	  1.5	  (95%	  CI,	  1.2	  to	  1.8)	  in	  men	  and	  1.9	  
(95%	  CI,	  1.5	  to	  2.2)	   in	  women,	  after	  adjustment	  for	  age	  and	  CVRFs.	   	  AF	  doubled	  the	  risk	  of	  
mortality	  in	  patients	  without	  any	  history	  of	  CV	  disease	  and	  eliminated	  the	  survival	  advantage	  
females	  hold	  over	  males	  when	  present.	  
	  
2.4. AF	  as	  a	  risk	  factor	  for	  stroke	  	  
Patients	  with	  AF	  are	  at	  increased	  risk	  of	  ischaemic	  stroke	  compared	  to	  individuals	  without	  AF,	  
with	  several	  population	  studies	  identifying	  AF	  to	  be	  an	  independent	  risk	  factor	  for	  stroke.	  	  In	  
the	   Framingham	   population,	   AF	   independently	   increased	   the	   risk	   of	   stroke	   fivefold	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(p	  <0.001)	  134.	  	  In	  this	  population,	  AF	  was	  the	  only	  risk	  factor	  for	  which	  the	  attributable	  risk	  of	  
stroke	  increased	  with	  age,	  rising	  from	  1.5%	  for	  those	  aged	  50	  –	  59	  years	  to	  23.5%	  for	  those	  
aged	  80-­‐89	  years.	  	  
AF	   has	   traditionally	   been	   considered	   to	   account	   for	   one	   fifth	   of	   cases	   of	   ischaemic	  	  	  	  	  	  	  	  	  	  
stroke	  124, 236.	  	  However,	  the	  risk	  associated	  with	  AF	  increases	  with	  age,	  and	  in	  more	  elderly	  
individuals,	  AF	  accounts	  for	  a	  greater	  proportion	  of	  stroke	  cases	  as	  the	  aetiological	  factor	  133.	  	  
Risk	  of	  recurrent	  stroke	  is	  also	  increased	  amongst	  those	  with	  AF	  at	  the	  time	  of	  presentation	  
with	  index	  stroke	  compared	  to	  those	  without	  evidence	  of	  AF	  133, 237.	  
Beyond	  the	  increase	  in	  risk,	  stroke	  severity	  may	  also	  be	  increased	  when	  attributable	  to	  AF	  238.	  	  
Data	   from	   the	   Lausanne	   Stroke	   Registry	   reported	   that	   AF-­‐related	   strokes	   are	   more	   often	  
severe	  and	  are	  associated	  with	  poorer	  prognosis	  239, 240.	  	  Higher	  levels	  of	  disability	  have	  been	  
reported	   in	   long	   term	   follow	   up	   in	   AF	   related	   stroke	   241	   and	   cardioembolic	   stroke	   is	  
associated	  with	  higher	  mortality	   rates	   than	  other	   TOAST	   categories	   at	   both	  30	  days	   and	  5	  
year	   follow	   up	   117.	   	   In-­‐patient	   costs	   for	   stroke	   patients	   with	   AF	   exceed	   those	   without	   242.	  	  
However,	  evidence	  from	  the	  VISTA	  /	  SITS	  thrombolysis	  trial	  registries	  suggest	  that	  outcomes	  
in	  rt-­‐PA	  treated	  AF	  patients	  do	  not	  differ	  significantly	  from	  those	  without	  AF	  243.	  
Beyond	   an	   increase	   in	   symptomatic	   morbidity,	   the	   principal	   clinical	   relevance	   of	   the	  
anticipated	   increased	   population	   prevalence	   of	   AF	   will	   be	   an	   increase	   in	   the	   number	   of	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patients	  suffering	  ischaemic	  stroke	  and	  other	  systemic	  embolic	  events	  as	  a	  complication	  223.	  	  
Given	   that	   the	   increased	   AF	   prevalence	   is	   due	   to	   an	   expanding	   elderly	   population,	   the	  
increase	  in	  stroke	  may	  be	  disproportionately	  large	  for	  the	  increased	  number	  of	  AF	  cases.	  	  In	  
2000,	   approximately	   36.7%	   of	   patients	   with	   AF	   were	   aged	   ≥	   80	   years	   but	   this	   is	   set	   to	  
increase	  to	  increase	  to	  52.6%	  of	  AF	  patients	  by	  2050.	  	  	  
	  
2.5. Risk	  stratification	  in	  patients	  with	  AF	  
Identification	   of	   AF	   and	   implementation	   of	   optimal	   secondary	   preventative	   strategies,	  
particularly	   in	   patient	   subgroups	   with	   the	   highest	   absolute	   risk	   (e.g.	   following	   ischaemic	  
stroke	  &	   TIA	   or	   in	   the	   presence	   of	   other	   risk	   factors),	   will	   be	   a	   crucial	   component	   of	   the	  
strategy	  to	  limit	  the	  anticipated	  burden	  of	  cerebrovascular	  disease.	  
	  
2.5.1. Risk	  stratified	  according	  to	  concomitant	  risk	  factors	  
Epidemiological	  studies	  examining	  the	  relationship	  between	  AF	  and	  risk	  of	  subsequent	  stroke	  
have	   identified	   several	   co-­‐risk	   factors	  which	   independently	   increase	   the	   risk	  of	  an	  event	   in	  
the	  setting	  of	  AF	  134.	  	  	  
The	  Framingham	  study	  authors	  examined	  RR	  according	  to	  age.	  	  Though	  AF	  was	  a	  significant	  
predictor	  of	  risk	  across	  all	  age	  groups,	  the	  strongest	  association	  was	  observed	  amongst	  the	  
most	  elderly.	  	  Following	  adjustment	  for	  other	  risk	  factors,	  the	  influence	  of	  age	  in	  AF-­‐related	  
stroke	  risk	  appeared	  to	  be	  an	  independent	  effect	  134.	  	  In	  patients	  with	  prior	  ischaemic	  stroke	  
/	  TIA,	  the	  risk	  of	  stroke	  /	  SE	  /	  major	  bleeding	  /	  ICH	  &	  mortality	  is	  increased	  a	  further	  two	  to	  
threefold,	  compared	  with	   individuals	  without	  such	  prior	  history	  135, 136.	   	  These	  observations	  
have	   permitted	   the	   development	   of	   risk	   stratification	   tools	   which	   permit	   individualised	  
estimation	  of	  risk.	  	  Large	  population	  studies	  have	  provided	  the	  means	  to	  evaluate	  the	  relative	  
contribution	  of	  such	  factors	  to	  increased	  risk,	  ascertaining	  an	  independent	  contribution	  and	  
combining	  these	  in	  risk	  prediction	  models	  136.	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2.5.2. Risk	  according	  to	  subtype	  of	  AF	  
There	  has	  been	  debate	  as	  to	  whether	  different	  subtypes	  of	  AF	  confer	  similar	  risk	  of	  stroke,	  
independently	   of	   concomitant	   risk	   factor	   burden.	   	   Available	   data	   are	   conflicting,	   with	  
suggestions	   that	   paroxysmal	   AF	   may	   confer	   variously	   less,	   equal	   or	   greater	   risk	   than	  
persistent	  and	  permanent	  forms.	  	  	  
The	  Euro	  Heart	  Survey	  reported	  similar	  risk	  of	  stroke	  for	  paroxysmal	  AF	  as	  for	  persistent	  (OR	  
0.68;	  95%	  CI,	  0.32	  –	  1.46)	  or	  permanent	  AF	   (OR	  0.69;	  95%	  CI	  0.34	  –	  1.38),	  on	  multivariate	  
analysis	  244, 245.	   	  Analysis	  of	  the	  SPAF	  clinical	  trial	  research	  programme	  population	  data	  also	  
suggested	  that	  paroxysmal	  AF	  confers	  similar	   risk	   to	  permanent	  AF,	  with	  annualised	  stroke	  
rates	  of	  3.2%	  and	  3.3%,	  respectively	  246.	  	  Similarly,	  in	  the	  ACTIVE-­‐W	  study,	  the	  annualized	  risk	  
of	  stroke	  or	  SE	  was	  2.0%	  in	  PAF	  patients	  compared	  with	  2.2%	  in	  sustained	  AF	  [RR	  (adjusted	  
for	  confounding	  baseline	  variables)	  0.94;	  95%	  CI,	  0.63	  to	  1.40].	  	  	  
Conversely,	  analysis	  of	  stroke	  rates	   in	  the	  SPORTIF	  clinical	   trials	  programme	  suggested	  that	  
stroke	  and	  SE	  annual	  event	  rates	  were	  higher	  (1.73%)	  in	  persistent	  AF	  than	  in	  paroxysmal	  AF	  
(0.93%),	   HR	   1.87;	   95%	   CI	   1.03	   –	   3.36	   247.	   	   The	   ARISTOTLE	   study	   reported	   a	   modest	   but	  
statistically	  significant,	   lower	  stroke	  &	  SE	  event	  rate	  in	  association	  with	  PAF	  compared	  with	  
either	  persistent	  or	  permanent	  AF	  [HR	  (adjusted)	  0.70;	  95%	  CI,	  0.51	  –	  0.93]	  248.	  	  The	  authors	  
concluded	   that	   previous	   analyses	   which	   failed	   to	   identify	   differential	   risk	   between	   AF	  
subtypes	  may	   have	   lacked	   sufficient	   statistical	   power	   for	   this.	   	   However,	   the	   RE-­‐LY	   study,	  
which	   included	   a	   similar	   number	   of	   patients	   to	   ARISTOTLE,	   reported	   similar	   event	   rates	  
between	  AF	  subtypes	  during	  a	  mean	  follow-­‐up	  period	  of	  2	  years,	  with	  paroxysmal,	  persistent	  
and	   permanent	   AF	   groups	   experiencing	   annual	   event	   rates	   of	   1.32%,	   1.55%	   and	   1.49%	  
respectively	   249.	   	   The	   reasons	   underlying	   the	   differing	   findings	   between	   the	   RE-­‐LY	   and	  
ARISTOTLE	   trials	   are	   open	   to	   speculation.	   	   The	   ROCKET-­‐AF	   study	   may	   provide	   additional	  
information	  in	  this	  regard.	  
If	  PAF	  and	  non-­‐paroxysmal	  AF	  confer	  differential	  risk	  of	  stroke	  and	  embolism,	  the	  difference	  
appears	   likely	   to	   be	   small.	   	   Moreover,	   the	   available	   evidence	   suggests	   that	   PAF	   patients	  
benefit	  from	  anticoagulation	  similarly	  to	  those	  with	  more	  sustained	  forms.	  	  The	  EAFT	  clinical	  
trial,	  which	   demonstrated	   benefit	   of	   anticoagulation	   in	   patients	  with	   AF,	   enrolled	   patients	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with	  both	  paroxysmal	  and	  chronic	  AF,	  with	  approximately	   three	  quarters	  of	  patients	   in	   the	  
latter	   category	   137.	   	   No	   differential	   treatment	   effect	   between	   these	   AF	   subgroups	   was	  
reported.	   	   In	   the	   ACTIVE-­‐W	   study,	   no	   difference	   was	   observed	   in	   the	   efficacy	   of	   either	  
anticoagulant	   (RR	   (adjusted	   for	  other	  risk	   factors)	  1.14;	  95%	  CI	  0.59	  –	  2.20),	  or	  antiplatelet	  
(RR	  (adjusted	  for	  other	  risk	  factors)	  0.84;	  95%	  CI	  0.51	  –	  1.40)	  therapy	  in	  reducing	  stroke	  &	  SE	  
for	   PAF	   compared	   with	   sustained	   AF	   250.	   	   Similarly,	   trials	   comparing	   NOAC	   agents	   with	  
adjusted	  dose	  warfarin	   have	   reported	  no	  differential	   treatment	   effect	   according	   to	   the	  AF	  
subtype	  248, 249.	   	   In	  the	  RE-­‐LY	  study,	   lower	  dose	  Dabigatran	  was	  associated	  with	  significantly	  
greater	   reduction	   in	   stroke	   &	   SE	   in	   PAF	   patients,	   compared	   with	   both	   persistent	   and	  
permanent	  AF	   patients	   (p	   for	   interaction	   =	   0.05).	   	   The	   authors	   concluded	   that	   this	   finding	  
may	  have	  reflected	  play	  of	  chance.	  	  	  
Clinical	   guidelines	   have	   made	   recommendations	   for	   the	   management	   of	   AF	   patients’	  
thromboembolic	   risk	   according	   to	   the	  presence	  of	   additional	   risk	   factors	   for	   stroke,	   rather	  
than	  on	  the	  basis	  of	  the	  subtype	  of	  AF	  (or	  on	  the	  basis	  of	  further	  stratification	  of	  the	  burden	  
of	  AF	  in	  the	  subgroup	  with	  paroxysmal	  AF)	  197.	  
	  
2.5.3. Risk	  according	  to	  AF	  burden	  
Beyond	   the	  debate	   regarding	  whether	  paroxysmal	  AF	  confers	   similar	   risk	   to	  persistent	  and	  
permanent	  AF,	  a	  secondary	  question	  has	  arisen	  as	  to	  whether	  all	  patients	  with	  evidence	  of	  
paroxysmal	   AF	   share	   a	   similar	   risk.	   	   An	   extrapolation	   of	   the	   findings	   in	   the	   ARISTOTLE	  
population	   that	   AF	   subtype	   influences	   risk,	   is	   that	   the	   relationship	   between	   the	   overall	  
burden	  of	  AF	  and	  embolic	  risk	  may	  represent	  a	  continuum.	  	   If	  a	  threshold	  AF	  burden	  exists	  
below	   which	   the	   associated	   risk	   is	   either	   negligible	   or	   insufficiently	   elevated	   to	   justify	  
anticoagulant	  therapy,	  this	  potentially	  holds	  clinical	  relevance	  251.	  	  This	  is	  particularly	  the	  case	  
given	   that	   detection	   of	   brief	   and	   isolated	   episodes	   of	   AF	   has	   been	   enhanced	   with	   the	  
emergence	  and	  availability	  of	  prolonged	  cardiac	  monitoring	   techniques	   252.	   	  Several	  groups	  
have	  attempted	  to	  further	  refine	  risk	  stratification	  within	  the	  paroxysmal	  AF	  group.	  
The	   MOST	   study	   was	   a	   large	   RCT	   comparing	   DDDR	   versus	   VVIR	   pacing	   in	   sinus	   node	  
dysfunction	  patients	  253.	  	  In	  a	  subgroup	  of	  312	  patients,	  PPMs	  were	  programmed	  to	  log	  atrial	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high	   rate	   episodes	   (AHREs).	   	   In	   Cox	   regression,	   the	   presence	   of	   any	   AHRE	   >	   5	   minutes	  
duration	   (observed	   in	   160	   patients)	   independently	   predicted	   subsequent	   risk	   of	   total	  
mortality,	  death,	  non-­‐fatal	  stroke	  and	  diagnosis	  of	  AF.	  
Subsequently,	   in	   the	   TRENDS	   study	   cohort,	   the	   risk	   of	   subsequent	   vascular	   events	   in	   2486	  
patients	   receiving	   pacemakers	   or	   ICDs	   was	   examined	   according	   to	   the	   burden	   of	   atrial	  
tachyarrhythmia	  (AT)	  /	  AF	  detected	  by	  the	  device.	   	   In	  the	  24%	  of	  patients	  with	  any	  AT	  /	  AF	  
episodes	  (of	  ≥	  20	  seconds),	  the	  median	  daily	  burden	  was	  5.5	  hours.	  	  	  The	  annualised	  TE	  rate	  
was	  1.1%	  for	  patients	  with	  zero	  AT	  /	  AF	  burden.	  	  Compared	  with	  zero	  burden,	  patients	  with	  
“low”	  AF	  /	  AT	  burden	  (<	  5.5	  hours)	  were	  at	  similar	  risk	  (HR	  0.98;	  95%	  CI,	  0.34	  –	  2.82)	  whereas	  
those	  with	  “high”	  burden	  of	  AF	  /	  AT	  episodes	  were	  at	  increased	  risk	  (HR	  2.20;	  95%	  CI,	  0.96	  –	  
5.05)	   254.	   	   The	   authors	   concluded	   that	   embolic	   risk	   is	   a	   quantitative	   function	   of	   AT	   /	   AF	  
burden.	  	  
In	   the	   ASSERT	   study	   population,	   amongst	   2580	   patients	  with	   a	   PPM	  or	   ICD,	  without	   prior	  
history	   of	   AF,	   subclinical	   atrial	   tachyarrhythmia	   episodes	   (>	   6	   minutes	   duration)	   were	  
detected	   in	  10.1%	  of	  patients	  within	  3	  months.	   	   These	  episodes	  predicted	  development	  of	  
clinical	  AF	  (HR	  5.56;	  95%	  CI,	  3.78	  -­‐	  8.17)	  and	  of	  ischaemic	  stroke	  /	  SE	  (HR	  2.49;	  95%	  CI,	  1.28	  –	  
4.85),	  compared	  to	  patients	  without	  any	  episodes	  255.	  	  Compared	  with	  patients	  without	  any	  
episodes,	  the	  risk	  of	  stroke	  was	  similarly	  increased	  in	  patients	  with	  AT	  episodes,	  irrespective	  
of	  episode	  duration:	  	  >	  6	  minutes	  (HR	  1.76;	  95%	  CI,	  0.99	  to	  3.11;	  P=0.05);	  >	  6	  hours	  (HR	  2.00;	  
95%	  CI,	  1.13	  to	  3.55,	  p=0.02);	  >	  24	  hours	  (HR	  1.98;	  95%	  CI,	  1.11	  to	  3.51;	  P=0.02).	  	  
In	   725	  patients	  with	  PPMs	   for	   bradycardia,	   device	  detected	  AF	  episodes	  were	   stratified	   as	  
either	  absent,	  of	  ≥	  5	  minutes	  duration	  or	  ≥	  1	  day	  duration.	  	  Following	  adjustment	  for	  other	  
risk	   factors,	   only	   patients	   with	   episodes	   ≥	   1	   day	   duration	   were	   associated	   with	   increased	  
likelihood	   of	   embolic	   events	   (OR	   3.1;	   95%	   CI,	   1.1	   to	   10.5,	   p	   =	   0.044),	   whilst	   episodes	   ≥	   5	  
minutes	  were	  not	  associated	  with	   increased	  risk	   (though	  statistical	  power	  was	   limited	  by	  a	  
small	  number	  of	  observed	  events)	  256.	  
These	   studies	   varied	   considerably	   in	   the	  observed	  burden	  which	  appeared	  associated	  with	  
differential	  risk.	   	  Moreover,	   it	   is	   important	  to	  note	  that	  AHREs	  and	  atrial	  tachycardias	  were	  
not	  characterised	  further	  i.e.	   it	   is	  unclear	  what	  proportion	  of	  these	  represented	  AF.	   	  Of	  the	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studies	  to	  have	  examined	  risk	  in	  relation	  to	  dysrhythmia	  burden,	  the	  briefest	  duration	  which	  
constituted	  an	  event	  was	  20	  seconds	  (in	  the	  TRENDS	  study).	  	  Accordingly	  there	  is	  limited	  data	  
relating	   to	   the	   relevance	   of	   briefer	   episodes,	   except	   that	  which	  may	   be	   inferred	   from	   the	  
above	   studies.	   	   Thus,	   atrial	   high	   rate	   episodes	   and	   ATs	   of	   sustained	   duration	   may	   be	  
associated	  with	  an	  increased	  risk	  of	  CV	  events	  compared	  with	  briefer	  episodes	  but	  definitive	  
conclusions	  relating	  burden	  of	  AF	  with	  risk	  cannot	  yet	  be	  drawn.	  	  	  
	  
2.6. Addressing	  the	  risk	  of	  recurrent	  stroke	  in	  patients	  with	  AF	  
As	  discussed	   in	  chapter	  1.3.6.4,	   the	  risk	  of	   recurrent	  stroke	   is	  elevated	   in	  patients	  with	  AF.	  	  
The	  risk	  of	  early	  stroke	  recurrence	  is	  high	  and	  remains	  so	  in	  the	  longer	  term.	  	  On	  this	  basis,	  
there	  is	  potential	  to	  modify	  risk	  with	  intervention	  on	  both	  an	  immediate	  and	  delayed	  basis.	  	  
The	  merits	  of	  antiplatelet	  and	  anticoagulant	  therapy	  in	  this	  regard	  were	  discussed	  in	  chapter	  
1.2.4	  &	   1.4.8	   and	   1.2.5	  &	   1.4.9,	   respectively.	   	  Whilst	   both	   strategies	   confer	   benefit,	   there	  
remains	  some	  debate	  regarding	  which	  of	  these	  strategies	  represents	  the	  optimal	  initial	  acute	  
intervention	  and	  regarding	  the	  optimal	  timing	  for	  initiation	  of	  anticoagulant	  therapy.	  	  	  
The	   principal	   barrier	   to	   early	   use	   anticoagulation	   following	   ischaemic	   stroke	   is	   the	   risk	   of	  
early	  haemorrhagic	  transformation	  of	  cerebral	  infarcts	  91, 130, 131.	   	  This	  complication	  typically	  
arises	  between	  1	  and	  4	  days	  following	  stroke	  onset	  and	  rates	  of	  haemorrhage	  appear	  to	  be	  
increased	  in	  the	  context	  of	  antithrombotic	  therapy	  125, 131.	  	  This	  has	  led	  to	  concern	  that	  such	  
agents	   should	  be	  avoided	   in	   the	  period	   immediately	   following	  acute	  stroke.	   	  Despite	   these	  
concerns,	   the	   potential	   for	   greater	   reduction	   in	   early	   recurrence	   in	   AF	   patients	   through	  
anticoagulation	  has	  been	  examined	  in	  several	  clinical	  trials,	  including	  the	  IST	  and	  HAEST.	  	  
The	  largest	  study	  to	  evaluate	  therapeutic	  anticoagulation	  in	  this	  setting	  was	  the	  IST.	  	  Patients	  
were	   treated	   with	   subcutaneous	   UFH.	   	   Median	   time	   to	   treatment	   was	   approximately	   19	  
hours	  and	  this	  continued	  for	  14	  days.	  	  On	  the	  basis	  that	  observed	  increased	  rates	  of	  bleeding	  
(s-­‐ICH,	   major	   extracranial	   haemorrhage)	   with	   UFH	   treatment	   negated	   the	   significantly	  
reduced	   ischaemic	   stroke	   recurrence,	   the	   authors	   concluded	   that	   heparin	   should	   not	   be	  
routinely	  used	  in	  acute	  stroke,	   including	  in	  the	  subgroup	  of	  patients	  with	  AF,	   in	  whom	  high	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dose	   UFH	   was	   associated	   with	   a	   haemorrhagic	   stroke	   rate	   of	   2.8%	   compared	   with	   0.4%	  
without	  UFH	  therapy,	  at	  14	  days	  53, 56.	  	  
Methodological	   limitations	   included	   lack	   of	   therapeutic	   monitoring,	   a	   lack	   of	   subgroups	  
analysis	  based	  around	  concomitant	  use	  of	  ASA,	  open	  treatment	  allocation,	  which	  may	  have	  
favoured	   investigation	   for	   haemorrhagic	   complication	   in	   anticoagulated	   group,	   and	  
approximately	  one	  third	  of	  patients	  being	  randomised	  and	  treated	  prior	  to	  exclusion	  of	  ICH	  
with	  CT	  imaging.	  	  The	  proportion	  of	  these	  patients	  with	  ICH	  evident	  on	  initial	  imaging	  was	  not	  
reported	  and	  how	  ICH	  in	  such	  patients	  was	  distinguished	  from	  a	  new	  ICH	  was	  not	  referred	  to	  
in	   the	  methodology.	   	  Assuming	  a	  15%	  haemorrhage	   rate	   in	   those	  without	  CT,	   it	   is	   feasible	  
that	   the	   study	   lacked	   sufficient	   power	   to	   identify	   an	   overall	   treatment	   benefit	   with	  
anticoagulation.	  	  	  
In	   the	   HAEST	   study,	   449	   AF	   patients	   with	   ischaemic	   stroke	   were	   randomised	   to	   14	   days	  
treatment	  with	   IV	  LMWH	  or	  ASA	  58.	   	  Average	  time	  to	  randomised	  treatment	  was	  20	  hours.	  	  
No	  difference	   in	   recurrent	   ischaemic	   stroke,	   ICH	  events	  or	   functional	  outcomes	  was	  noted	  
between	  treatment	  groups.	  However,	  an	  excess	  in	  a	  composite	  of	  adverse	  clinical	  events	  was	  
observed	  with	  Dalteparin.	  	  As	  in	  the	  IST,	  patients	  in	  HAEST	  were	  not	  excluded	  on	  basis	  of	  size	  
of	   cerebral	   infarct	   and	   outcomes	   were	   not	   stratified	   on	   the	   basis	   of	   imaging	   infarct	  
topography.	  	  In	  addition	  the	  population	  was	  a	  relatively	  elderly	  one	  and	  the	  severity	  of	  stroke	  
in	   this	   population	   was	   relatively	   high;	   65%	   of	   patients	   had	   an	   outcome	   of	   death	   or	  
dependency	   at	   90	   days.	   	   In	   addition,	   SBP	   was	   high	   in	   the	   study	   population	   overall	   and	  
significantly	  higher	  in	  the	  LMWH	  group	  compared	  with	  ASA.	  	  Each	  of	  these	  factors	  might	  be	  
considered	   to	   increase	   the	   hazard	   of	   anticoagulation.	   	   However,	   routine	   use	   of	   treatment	  
dose	  LMWH	  cannot	  be	  recommended	  in	  acute	  stroke	  with	  AF	  on	  the	  basis	  of	  this	  study.	  	  	  
A	   meta-­‐analysis	   of	   anticoagulation	   in	   acute	   stroke	   patients	   with	   AF	   concluded	   no	   overall	  
benefit,	  noting	  that	  selected	  subgroups,	  which	  conceptually	  might	  be	  more	  likely	  to	  benefit,	  
have	   not	   been	   studied	   132.	   	   No	   other	   studies	   of	   similar	   size	   to	   the	   IST	   have	   evaluated	  
anticoagulation	   in	  acute	  stroke.	   	  Consequently,	  guidelines	  are	  principally	  based	  on	  the	  data	  
from	  the	  IST	  and	  the	  maxim	  that	  anticoagulation	  has	  no	  “routine”	  role	  in	  the	  management	  of	  
acute	  ischaemic	  stroke	  has	  propagated	  since.	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There	  is	  also	  a	  paucity	  of	  evidence	  regarding	  use	  of	  parenteral	  or	  immediate	  anticoagulation	  
in	  patients	  with	  TIA.	  	  Although	  TIA	  has	  historically	  implied	  a	  lack	  of	  infarct	  burden	  due	  to	  only	  
transient	   arterial	   occlusion	  and	   cerebral	   ischaemia,	   recent	   studies	  with	  MRI	  based	   imaging	  
have	  demonstrated	   that	   a	   high	   proportion	  of	   patients	  with	   clinical	   TIA	   exhibit	   evidence	  of	  
cerebral	  infarction	  107.	  	  It	  may	  be	  inappropriate	  to	  assume	  negligible	  risk	  of	  anticoagulation	  in	  
this	  population,	  who	  equally	  may	  have	  the	  most	  to	  gain	  from	  prompt	  treatment.	  
Although	   there	   is	   methodologically	   limited	   evidence	   regarding	   the	   use	   of	   parenteral	  
anticoagulation	  in	  AF	  patients	  during	  the	  first	  14	  days	  following	  ischaemic	  stroke,	  secondary	  
prevention	  studies	  of	  OAC	  agents	  provide	  a	  robust	  evidence	  base	  for	  treatment	  commenced	  
up	  to	  6	  months	  following	  ischaemic	  stroke.	  	  In	  addition,	  they	  provide	  some	  data	  supporting	  
early	   implementation	   of	   oral	   anticoagulation	   from	   within	   2	   weeks	   of	   ischaemic	   stroke.	  	  
Induction	  of	  treatment	  following	  greater	  delays	  and	  indefinite	  treatment	  is	  recommended	  on	  
the	   basis	   that	   survival	   curves	   continued	   to	   diverge	   at	   the	   end	   of	   study	   follow	   up	   in	   the	  	  	  	  	  
EAFT	  137.	  
In	  patients	  with	  mild	  severity	  ischaemic	  stroke	  or	  TIA,	  oral	  anticoagulation	  with	  VKAs	  from	  2	  
weeks	  after	   stroke	  and	  TIA	  appears	  beneficial.	   	  Approximately	  40%	  of	  patients	   in	   the	  EAFT	  
were	   enrolled	   prior	   to	   this.	   Though	   a	   subgroup	   analysis	   according	   to	   randomisation	   time	  
from	  ictus	  was	  not	  presented,	  this	  provides	  indirect	  evidence	  supporting	  earlier	  institution	  of	  
treatment	  in	  this	  population.	  
There	  is	  limited	  evidence	  for	  commencing	  NOACs	  prior	  to	  14	  days	  subsequent	  to	  stroke,	  with	  
the	  major	  trials	  enrolling	  only	  a	  small	  %	  of	  patients	  prior	  to	  14	  days	  and	  no	  patients	  within	  
the	   first	   7	   days	   after	   stroke.	   	  The	   subgroup	   of	   patients	   in	   ARISTOTLE	  with	   prior	   ischaemic	  
stroke	   or	   TIA	   were	   randomised	   to	   treatment	   only	   after	   a	   minimum	   of	   7	   days	   of	   their	  
qualifying	  event.	   	  6.8%	  of	  those	  in	  this	  subgroup	  were	  randomised	  with	  an	  event	  <	  30	  days	  
prior.	   	   Patients	   in	   this	   group	   had	   non-­‐significantly	   higher	   stroke	   &	   SE	   rates	   than	   those	  
recruited	  >	  30	  days	   (3.71	  vs.	  2.80	  per	  100	  years	   follow	  up,	  HR	  1.31	   (0.76	  –	  2.26).	   	  A	   trend	  
toward	  greater	  benefit	  of	  Apixaban	  was	  noted	  in	  patients	  recruited	  with	  greater	  proximity	  to	  
their	  qualifying	  event.	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In	  both	  the	  RE-­‐LY	  and	  ROCKET-­‐AF	  studies,	  all	  stroke	  patients	  were	  excluded	  with	   ictus	  <	  14	  
days	   and	  major	   strokes	  were	  excluded	  with	   ictus	   <	   6	  months	  &	  <	   3	  months,	   respectively).	  	  
Considered	  together	  with	  the	  EAFT,	  there	  remains	  a	  paucity	  of	  data	  relating	  to	  the	  timing	  of	  
very	  early	  anticoagulation	  efficacy	  &	  safety	  amongst	  patients	  with	  more	  severe	  stroke.	  
In	  summary,	  whilst	  detection	  of	  AF	  in	  the	  period	  immediately	  following	  ischaemic	  stroke	  may	  
prompt	  consideration	  of	  immediate	  anticoagulation	  to	  reduce	  the	  considerable	  risk	  of	  early	  
recurrence,	   there	   is	   no	   evidence	   to	   definitively	   support	   this	   approach.	   	   The	   available	  
evidence,	  methodological	   limitations	  accepted,	   suggests	   that	   in	  unselected	   stroke	  patients,	  
bleeding	  complications	  appear	  to	  negate	  the	  benefit	  of	   immediate	  parental	  anticoagulation	  
in	  reducing	  ischaemic	  event	  recurrence.	  	  The	  available	  evidence	  is	  however	  limited	  and	  there	  
may	   be	   subgroups	   of	   patients	  who	  would	   benefit,	   including	   the	   TIA	   population	   for	  whom	  
evidence	  is	  entirely	   lacking.	   	  Early	  detection	  of	  AF	  will	  facilitate	  prompt	  introduction	  of	  oral	  
anticoagulation	  in	  patients	  with	  mild	  ischaemic	  stroke	  and	  TIA	  without	  delay.	  	  It	  is	  less	  clear	  
how	  quickly	  patients	  with	  more	  severe	  stroke	  should	  commence	  treatment.	  
	  
2.7. The	  prevalence	  of	  AF	  in	  patients	  presenting	  with	  ischaemic	  stroke	  &	  TIA	  
Based	   on	   prior	   history	   and	   the	   admission	   ECG,	   AF	   is	   reported	   to	   be	   present	   in	   present	   in	  
approximately	  15	  -­‐	  25%	  of	  patients	  presenting	  with	  stroke	  or	  TIA.	  	  In	  the	  OCSP,	  18%	  (95%	  CI	  
15	  –	  21%)	  of	   patients	  with	   cerebral	   infarction	  were	   found	   to	  have	  AF	   124.	   	   In	   a	  population	  
registry	   in	   France,	   18.7%	   of	   patients	  with	   ischaemic	   stroke	   had	   their	   event	   categorised	   as	  
cardioembolic	  in	  the	  setting	  of	  AF	  257.	  	  Although	  prevalence	  of	  AF	  in	  patients	  presenting	  with	  
AF	  is	  variably	  estimated	  according	  to	  the	  population	  studied,	  the	  standard	  quoted	  figure	  for	  
the	   entire	   unselected	   stroke	   population	   is	   an	   underestimate	   of	   the	   prevalence	   in	   more	  
elderly	  patients	  with	  acute	  stroke.	  	  In	  the	  Framingham	  study,	  prevalence	  of	  AF	  was	  observed	  
to	  be	  as	  high	  as	  30.7%	  in	  patients	  aged	  80	  –	  89	  years	  and	  only	  6.5%	  in	  patients	  aged	  50	  –	  59	  
years	   134.	   	   In	   the	   AVAIL	   registry,	   which	   included	   patients	   admitted	   to	   ASUs	   with	   either	  
ischaemic	  stroke	  or	  TIA,	  AF	  was	  present	  in	  11.8%	  187.	  	  It	  appears	  that	  AF	  may	  be	  observed	  less	  
frequently	  amongst	  patients	  presenting	  with	  TIA	  than	  with	  ischaemic	  stroke	  258.	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The	   true	  prevalence	  of	  AF	   in	   the	   ischaemic	  stroke	  and	  TIA	  population	   is	   likely	   to	  be	  higher	  
than	   these	   figures.	   	   PAF	   is	   frequently	   asymptomatic	   and	   population	   studies	   have	   typically	  
relied	  on	  a	  single	  12-­‐lead	  ECG	  at	  the	  time	  of	  clinical	  presentation	  in	  estimating	  AF	  prevalence.	  	  	  
As	  discussed	  in	  section	  1.3.2,	  more	  than	  one	  aetiological	  factor	  for	  stroke	  is	  evident	  in	  many	  
patients	  with	   ischaemic	   stroke	  and	  TIA.	   	  Whilst	   some	  authors	  have	  historically	  argued	   that	  
the	  culprit	  aetiology	  for	  the	  index	  event	  may	  dictate	  the	  optimal	  secondary	  prevention	  in	  the	  
context	  of	  co-­‐existent	  pathologies	  259,	  current	  guidelines	  suggest	  that	   in	  such	  circumstance,	  
optimisation	   of	   treatment	   for	   each	   aetiological	   factor	   may	   be	   appropriate,	   reflecting	   the	  
patient	   populations	   included	   in	   clinical	   trials	   19.	   	   This	   approach	   reflects	   the	   secondary	  
prevention	   evidence	   for	   anticoagulant	   therapy	   in	   AF	   being	   derived	   from	   a	   population	   of	  
ischaemic	   stroke	   &	   TIA	   patients	   without	   exclusion	   of	   patients	   with	   potential	   alternative	  
etiological	  factors	  135, 137.	  
Some	  authors	  have	  asserted	  that	  early	  efforts	  to	  diagnose	  AF	  following	  stroke	  are	  misplaced,	  
due	  to	  the	  observation	  similar	  risk	  of	  recurrence	  between	  those	  in	  sinus	  rhythm	  and	  those	  in	  
AF	   124.	   	   This	   observation	   likely	   reflected	   the	   fact	   that	   risk	   in	   the	   sinus	   rhythm	   group	   of	  
patients	  is	  not	  uniform,	  including	  patients	  with	  both	  high	  (LAA)	  and	  low	  (SVD)	  risk	  aetiological	  
factors.	  	  Crucially,	  as	  discussed	  in	  section	  1.3.6.4,	  patients	  with	  AF	  are	  at	  high	  risk	  of	  early	  and	  
subsequent	   recurrence,	   irrespective	   of	   comparable	   risk	   to	   any	   other	   aetiological	   group.	  	  
Moreover,	   AF	   detection	   is	   crucial	   for	   the	   individual	   patient,	   because	   treatment	   with	  
anticoagulation	   in	   AF	   confers	   much	   greater	   protection	   than	   antiplatelet	   based	   secondary	  
prevention.	   	  Whilst	   the	   optimal	   timing	   for	   introduction	   of	   anticoagulation	   is	   debated	   and	  
lacks	  a	  sophisticated	  evidence	  base,	  prompt	  identification	  of	  AF	  permits	  timely	  institution	  of	  
anticoagulant	  therapy	  beyond	  the	  initial	  week	  following	  ischaemic	  stroke.	  
	  
2.8. The	  prevalence	  of	  paroxysmal	  AF	  in	  ischaemic	  stroke	  &	  TIA	  patients	  
Although	  AF	  may	  be	  diagnosed	  at	  the	  time	  of	  clinical	  presentation	  with	  a	  12-­‐lead	  ECG	  or	  on	  
the	  basis	  of	  antecedent	  history,	  an	  additional	  proportion	  of	  patients	  exist	  with	  initially	  occult	  
paroxysmal	  AF.	  	  Evidence	  from	  the	  VISTA	  registry,	  suggests	  that	  6.9%	  (95%	  CI,	  6.0	  –	  8.0%)	  of	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patients	   presenting	   in	   sinus	   rhythm	   and	  without	   prior	   history	   of	   AF,	   will	   be	   diagnosed	   as	  
having	  AF	  within	  the	  subsequent	  90	  days	  260.	  	  Patients	  included	  in	  this	  analysis	  were	  subject	  
to	   two	   routinely	   repeated	   12-­‐lead	   ECGs	   within	   72	   hours	   of	   study	   enrolment	   and	   robust	  
follow	   up	   of	   events	   but	   additional	   investigations	   resulting	   in	   AF	   detection	  were	   otherwise	  
initiated	   at	   the	   discretion	   of	   treating	   clinicians.	   	   The	   majority	   of	   identified	   patients	   were	  
diagnosed	  after	  the	  initial	  48	  hours	  of	  follow	  up.	  	  
The	  true	  prevalence	  of	  AF	  in	  the	  ischaemic	  stroke	  &	  TIA	  population	  remains	  uncertain	  due	  to	  
the	   presence	   of	   a	   population	   with	   initially	   occult	   PAF.	   	   In	   most	   patients,	   the	   majority	   of	  
episodes	   of	   PAF	   are	   clinically	   asymptomatic	   261.	   	   Therefore	   it	   is	   apparent	   that	   routine	   or	  
targeted,	  rather	  than	  opportunistic,	  investigation	  is	  likely	  to	  be	  required	  to	  more	  completely	  
define	  the	  true	  burden	  of	  occult	  PAF.	   	  Though	  numerous	  studies	  have	  addressed	  this	   issue,	  
methodological	  issues	  have	  limited	  conclusions	  regarding	  the	  optimal	  detection	  strategy	  and	  
precise	   estimation	   of	   the	   prevalence	   of	   PAF	   in	   this	   population.	   	   Reported	   studies	   have	  
utilised	  heterogeneous	  detection	  strategies,	  which	  have	  varied	   in	  several	  aspects,	   including	  
AF	  detection	  modality,	  duration	  of	  investigation,	  patient	  population	  and	  study	  design.	  	  
The	  majority	  of	  studies	  have	  included	  both	  patients	  with	  ischaemic	  stroke	  and	  TIA.	  	  However,	  
stratification	  of	  findings	  by	  subgroup	  has	  rarely	  been	  quoted.	  	  There	  is	  a	  paucity	  of	  studies	  to	  
have	  examined	  the	  TIA	  population	  in	  isolation	  262.	  	  Although	  many	  studies	  were	  conducted	  on	  
a	  prospective	  basis,	   they	  did	  not	   include	  consecutive	  patients,	  with	  patient	   inclusion	  based	  
on	  local	  clinician	  discretion	  262-­‐270.	  	  Several	  studies	  included	  only	  patients	  described	  as	  having	  
experienced	  cryptogenic	  stroke	  270-­‐275.	  	  Thus,	  there	  is	  relatively	  limited	  data	  available	  relating	  
to	  the	  unselected	  stroke	  &	  TIA	  population.	  	  Moreover,	  most	  studies	  lacked	  a	  control	  group	  to	  
compare	   strategies	   90, 262, 264-­‐267, 269, 270, 272-­‐280.	   	   Those	   which	   have	   did	   not	   use	  	  	  	  	  	  
randomisation	   93, 263, 281-­‐283.	   	   One	   study,	   including	   a	   population	   with	   cryptogenic	   stroke	  
included	  a	  control	  group	  and	  randomisation	  271.	   	  Several	  studies	  have	  evaluated	  more	  than	  
one	   detection	   modality	   93, 263, 264, 267, 268, 277, 279, 281, 282.	   	   However,	   these	   tended	   to	   be	  
performed	   in	   sequence	   or	   compared	   modalities	   of	   differing	   monitoring	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
duration	  93, 263, 267, 268, 279, 282,	  thus	  limiting	  direct	  comparability.	  	  
Detection	   modalities	   utilised	   in	   studies	   examining	   AF	   prevalence	   following	   stroke	   have	  
included	   Holter	   style	   monitoring	   90, 93, 262-­‐269, 276-­‐282,	   cardiac	   event	   monitors	   (either	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implantable	   or	   non-­‐invasive)	   267, 270, 272, 279,	   continuous	   electrocardiological	   monitoring	  	  	  
(CEM)	   93, 263, 268, 273, 282, 283,	   repeated	   12-­‐lead	   ECGs	   267, 277, 281	   and	   telephonic	   ECG	  	  	  
transmission	  274.	  	  In	  the	  case	  of	  the	  latter	  two,	  intermittent	  scheduled	  recordings	  have	  been	  
performed	   and	   additional	   recordings	   have	   been	   prompted	   by	   patient	   symptomatology.	  	  
Various	   durations	   of	   monitoring	   gave	   been	   performed,	   ranging	   from	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
24-­‐hours	  90, 93, 262-­‐269, 277, 279, 281, 282,	  48	  hours	  268, 282,	  72	  hours	  93, 263, 278, 279,	  7	  days	  267, 276,	  21	  	  	  	  
days	  271, 272,	  1	  month	  270	   to	  many	  months	  272, 275.	   	  Several	  studies	  examined	  extended	  time-­‐
frame	   monitoring	   with	   comparison	   of	   detection	   at	   different	   intervals	   with	   the	   same	  	  	  
modality	   276, 278	  whilst	   others	   examined	   differing	   duration	   of	   investigation	   performed	  with	  
different	  modalities	  93, 263, 267, 268, 279, 282.	  	  	  
There	   have	   been	   a	   limited	   number	   of	   prospective	   observational	   studies	   which	   have	  
evaluated	   routine	  use	  of	   extended	   cardiac	  monitoring	   in	   consecutive	   ischaemic	   stroke	  and	  
TIA	  patients	  284.	  	  Point	  estimates	  for	  AF	  detection	  with	  Holter	  monitoring	  in	  such	  studies	  have	  
ranged	  between	  3.8	  –	  6.1%.	  	  The	  combined	  estimate	  for	  AF	  detection,	  based	  on	  a	  total	  of	  588	  
patients	  with	  predominantly	  24-­‐hour	  duration	  Holter	  was	  4.6%	  (95%	  CI,	  0	  –	  12.7%)	  ,	  although	  
one	  of	  the	  included	  studies	  represented	  data	  in	  a	  cohort	  of	  patients	  investigated	  at	  clinician	  
discretion	  rather	  than	  as	  routine	  268	  and	  one	  study	  included	  monitoring	  of	  duration	  72	  hours	  
rather	  than	  24	  278.	  	  	  
Varied	  duration	  of	  Holter	  monitoring	  has	  been	  compared	  in	  several	  studies.	  	  Stahrenberg	  &	  
colleagues	   found	   that	  monitoring	   for	  7	  days	  more	   than	  doubled	   the	  number	  of	  patients	   in	  
whom	  AF	  was	  identified	  276.	  	  Another	  study	  reported	  detection	  of	  AF	  in	  only	  1.2%	  of	  patients	  
with	   24-­‐hours	  Holter	  monitoring,	   rising	   to	   6.1%	  with	  monitoring	   extended	   to	   72-­‐hours	   278.	  	  
Higher	   detection	   rates	   have	   been	   reported	   with	   Holter	   monitoring	   in	   selected	   patient	  
populations	  264-­‐266, 277.	  	  	  	  	  	  
Cardiac	  event	  monitoring	  provides	  the	  facility	  for	  more	  extended	  periods	  of	  monitoring	  with	  
reduced	   reporting	   time,	   as	   software	   programming	   retains	   rhythm	   disturbances	   of	   likely	  
significance.	   	   Such	   monitoring	   may	   be	   performed	   either	   non-­‐invasively	   267, 279	   or	   with	  
implantable	  loop	  recorders.	  	  Each	  permit	  more	  extended	  monitoring	  periods	  and	  out-­‐patient	  
management.	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Barthelemy	  and	   colleagues	   assessed	   cardiac	  event	  monitoring	  with	   the	  non-­‐invasive	  R-­‐test	  
device	   in	   60	   consecutive	   patients	   with	   ischaemic	   stroke	   or	   TIA	   279.	   	   All	   patients	   were	  
sequentially	  investigated	  with	  12-­‐lead	  ECG,	  24-­‐hour	  Holter	  and	  finally	  R-­‐TE	  (median	  duration	  
4	  days).	   	  AF	  was	  evident	  on	  the	  admission	  ECG	   in	  5	  patients.	   	  Of	  the	  remaining	  55,	  AF	  was	  
detected	   in	   9	   patients	   with	   R-­‐TE	   (10.9%)	   and	   6	   patients	   on	   Holter	   (5.5%).	   	   The	   authors	  
somewhat	   inappropriately	   concluded	   that	   amongst	   patients	   with	   detected	   PAF,	   this	   was	  
significantly	  more	  often	  detected	  with	  R-­‐TE	  than	  Holter.	   	  However,	  detection	  did	  not	  differ	  
significantly	  between	  the	  two	  modalities	  when	  the	  full	  sample	  was	  considered.	  	  Moreover,	  3	  
patients	  with	  AF	  identified	  through	  each	  of	  Holter	  and	  R-­‐TE	  had	  AF	  present	  at	  baseline	  ECG.	  	  
Accordingly,	   the	  most	   appropriate	   conclusion	   should	  have	  been	   that	   additional	  monitoring	  
led	   to	   detection	   of	   AF	   in	   an	   additional	   6	   patients	   (p=ns),	   with	   a	   non-­‐significant	   trend	   to	  
increased	  detection	  with	  R-­‐TE	  compared	  with	  Holter.	  
In	   a	   similar	   design,	   Jabaudon	   and	   colleagues	   reported	   detection	   of	   AF	  with	   7-­‐days	   cardiac	  
event	   monitoring,	   performed	   in	   88	   patients	   derived	   from	   a	   cohort	   of	   149	   consecutive	  
ischaemic	   stroke	   &TIA	   patients	   with	   a	   median	   delay	   of	   55	   days	   after	   the	   cerebral	   event.	  	  
Patients	  were	  excluded	   from	  monitoring	   if	   they	  had	  a	  diagnosis	  of	  AF	  based	  on	   initial	   and	  
sequential	  investigation	  with	  routine	  admission	  12-­‐lead	  ECG,	  clinically	  indicated	  repeated	  12-­‐
lead	  ECGs	  and	  a	  24-­‐hour	  Holter.	  	  In	  addition,	  a	  proportion	  of	  patients	  declined	  the	  additional	  
cardiac	  event	  monitoring.	  	  AF	  was	  detected	  with	  the	  non-­‐invasive	  R-­‐test	  device	  in	  5.7%	  (95%	  
CI	  2.1	  –	  12.9%)	  of	  patients,	   suggesting	   that	   routine	   investigations	  at	   the	   time	  of	  admission	  
with	   stroke,	   including	   24-­‐hour	   Holter,	   may	   be	   inadequate	   for	   the	   detection	   of	   PAF.	   	   A	  
limitation	  in	  interpreting	  the	  results	  reported	  in	  this	  study	  was	  that	  approximately	  one	  fifth	  
of	   patients	   in	  whom	  AF	  was	   identified	   (by	   any	  modality),	   already	   had	   a	   prior	   diagnosis	   of	  	  	  
PAF	  267.	  
Prospective	  studies	  examining	   implantable	  event	   recorders	  are	  ongoing,	   though	  have	  been	  
limited	  to	  selected	  populations	  275.	  
CEM	   appears	   to	   hold	   potential	   for	   detection	   of	   PAF	   in	   the	   period	   immediately	   following	  
presentation	   to	   hospital.	   However,	   studies	   have	   reported	   disparate	   effectiveness	   in	   AF	  
detection.	  	  Groups	  which	  have	  included	  automated	  analysis	  of	  telemetry	  data	  have	  reported	  
high	  diagnostic	  yield	   (7.7%),	  particularly	   in	   the	  case	  of	  monitoring	  extended	  to	  72	  hours	  93.	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Conversely,	   in	   studies	   which	   adopted	   a	   retrospective	   design	   examining	   “real	   world”	  
detection	   of	   AF	   amongst	   patients	   with	   cardiac	   telemetry,	   without	   automated	   or	   offline	  
analysis,	  the	  likelihood	  of	  AF	  detection	  was	  remote	  263.	  
The	   level	   of	   evidence	   available	   in	   support	   of	   any	  one	   strategy	   is	   limited.	   	  No	   studies	   have	  
evaluated	  clinical	  endpoints	  in	  relation	  to	  enhanced	  AF	  detection	  following	  ischaemic	  stroke	  
&	  TIA.	  	  The	  efficacy	  of	  each	  investigative	  modality	  relative	  to	  the	  others	  is	  uncertain.	  	  There	  
are	   few	   controlled	   studies	   which	   have	   compared	   investigative	   strategies	   93, 263, 271, 281-­‐283.	  	  
When	  studies	  have	  utilised	  a	  comparative	  control	  intervention,	  several	  did	  so	  with	  sequential	  
rather	   than	   simultaneous	   investigation	   or	   compared	   modalities	   of	   non-­‐equal	   monitoring	  
duration	  93, 282.	  	  In	  such	  cases	  it	  is	  not	  feasible	  to	  conclude	  whether	  CEM	  is	  superior	  to	  Holter	  
or	  if	  the	  results	  merely	  reflect	  72	  hours	  monitoring	  being	  superior	  to	  24	  hours.	  
In	   addition,	   lack	   of	   blinding	   could	   potentially	   have	   biased	   observed	   results	   in	   controlled	  
studies,	   several	   of	   which	   were	   retrospective	   in	   nature.	   There	   have	   been	   no	   randomised	  
comparisons	  of	  detection	  strategies	  in	  unselected	  stroke	  patients	  and	  only	  a	  single	  small	  RCT	  
in	  a	  cryptogenic	  stroke	  population	  271.	  	  	  
There	   have	   been	   relatively	   few	   prospective	   studies	   of	   consecutive,	   unselected	   ischaemic	  
stroke	   &	   TIA	   patients	   performed.	   	   Studies	   referring	   to	   inclusion	   of	   consecutive	   patients	  
tended	   to	   perform	   analysis	   based	   only	   on	   those	   patients	   who	   received	   additional	  
investigation	   for	   the	   purposes	   of	   AF	   detection,	   i.e.	   a	   population	   enriched	  with	   patients	   in	  
whom	  clinicians	  appeared	  to	  have	  a	  higher	  index	  of	  suspicion	  for	  the	  presence	  of	  AF.	  	  Several	  
studies	   included	  only	  patients	  described	  as	  having	  suffered	  cryptogenic	  stroke,	  with	  criteria	  
by	   which	   cryptogenic	   aetiology	   being	   assigned	   varying	   considerably.	   	   Clinical	   trial	   registry	  
data	   regarding	   AF	   detection	   is	   available	   but	   without	   relation	   to	   a	   specific	   investigation	  
strategy	  for	  the	  detection	  of	  AF.	  	  	  	  	  
Accordingly,	  extrapolation	  of	  reported	  findings	  to	  the	  broader	  population	  is	  challenging	  and	  
consequently	   guidelines	   regarding	   investigation	   for	   occult	   PAF	   following	   ischaemic	   stroke	  
make	  only	  limited	  recommendations.	  	  Despite	  this,	  two	  conclusions	  may	  be	  drawn	  from	  the	  
evidence	  base	  for	  PAF	  detection	  following	  stroke:	  	  Firstly,	  occult	  paroxysmal	  AF	  appears	  to	  be	  
common	   in	  patients	  without	  previously	   known	  AF	  or	  AF	   at	   the	   time	  of	   initial	   presentation	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with	   stroke	   284.	   	   Secondly,	   detection	   rates	   for	   paroxysmal	   AF	   are	   enhanced	   by	   more	  
prolonged	  periods	  of	   cardiac	  monitoring,	   including	  Holter	  monitoring	   276,	  CEM	   93	  &	  cardiac	  
event	  monitoring	  267, 279.	  	  	  
	  
2.9. The	  relevance	  of	  paroxysmal	  AF	  identified	  following	  acute	  stroke	  	  
As	  discussed	   in	   section	  1.3.2,	  multiple	   potential	   aetiological	   risk	   factors	  may	  be	  present	   in	  
patients	   presenting	   with	   ischaemic	   stroke	   &	   TIA.	   	   Initially	   occult	   PAF	   may	   reflect	   the	  
underlying	  aetiological	  mechanism	  for	   the	  presenting	  cerebrovascular	  event.	   	  Alternatively,	  
PAF	  may	   not	   have	   been	   directly	   responsible	   but	  may	   confer	   future	   risk	   of	   cardio-­‐embolic	  
events.	   	   A	   third	   possibility	   is	   that	  AF	  observed	   in	   the	   context	   of	   acute	   stroke	   represents	   a	  
complication	  of	   the	   stroke	   itself.	   	   Following	   stroke,	   sympathetic	   tone	   is	   increased,	   both	   as	  
part	   of	   the	   stress	   response	   to	   the	  neurological	   insult	   and	   as	   a	   component	   of	   the	   systemic	  
response	  to	  peri-­‐stroke	  complications	  such	  as	  sepsis	  124, 285.	  	  Infarct	  topography	  has	  also	  been	  
implicated	  in	  triggering	  episodes	  of	  AF	  285, 286.	  	  	  
It	   has	   been	   postulated	   that	   in	   this	   third	   situation,	   observation	   of	   AF	   in	   the	   immediate	  
aftermath	   of	   stroke	   may	   represent	   transient	   phenomenon,	   which	   confers	   no	   additional	  
subsequent	  risk	  and	  which	  would	  not	  be	  optimally	  managed	  with	  formal	  anticoagulation	   in	  
the	  long	  term	  252, 287.	  	  On	  this	  basis,	  PAF	  demonstrated	  through	  cardiac	  monitoring	  soon	  after	  
presentation	  has	  been	  criticised	  as	  a	  potentially	  floored	  basis	  upon	  which	  to	  base	  secondary	  
preventative	  therapy	  decisions	  287.	  
It	   is	   feasible	   that	  admission	  12-­‐lead	  ECG	  evidence	  of	  AF	  at	   the	  point	  of	  presentation	  might	  
also	   represent	   AF	   triggered	   by	   the	   above	   stressors,	   representing	   only	   a	   transient	  
phenomenon.	  	  However,	  such	  evidence	  of	  AF	  has	  provided	  the	  basis	  for	  the	  inclusion	  of	  the	  
majority	  of	  patients	  enrolled	   in	  anticoagulant	  secondary	  preventative	  studies	  135, 137.	   	  There	  
are	  data	  which	  suggests	  that	  patients	  presenting	  with	  stroke	   in	  AF	  are	   likely	  to	  continue	  to	  
exhibit	   AF	   288.	   	   Data	   are	   lacking	   in	   relation	   to	   the	   predictive	   value	   of	   PAF	   identification	  
through	   extended	   monitoring	   in	   the	   immediate	   aftermath	   of	   stroke	   for	   detectable	   AF	   at	  
some	  subsequent	  time	  point.	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2.10. Current	  guidelines	  &	  clinical	  practice	  	  
Current	  guidelines	  regarding	  investigation	  for	  AF	  following	  stroke	  and	  TIA	  reflect	  the	  limited	  
evidence	  base	  described	   above:	   the	  optimal	  modality,	   duration	   and	   timing	   (relative	   to	   the	  
incident	  event)	  of	   investigative	  strategies	  have	  not	  been	  established.	  	  Guidelines	  make	  only	  
limited	   and	   diverse	   recommendations,	   based	   on	   extrapolation	   of	   detection	   rates	   in	   the	  
available	  uncontrolled	  or	  non-­‐randomised	  assessment	  of	  the	  various	  modalities	  &	  strategies	  
in	  differing	  populations.	  	  	  
For	  unselected	  patients,	  the	  guidelines	  typically	  recommend	  a	  single	  12-­‐lead	  ECG	  and	  initial	  
continuous	  ECG	  monitoring	  29, 79, 289.	  	  This	  is	  recommended	  at	  least	  in	  part	  on	  the	  basis	  of	  the	  
high	   prevalence	   of	   heart	   disease	   in	   patients	   with	   stroke	   and	   high	   rates	   of	   potentially	  
dangerous	  cardiac	  arrhythmias	   in	   the	  setting	  of	  acute	  stroke.	   	  Beyond	  this,	  more	  extensive	  
investigation,	  with	  the	  purpose	  of	  identifying	  aetiological	  rhythm	  disturbance,	  is	  referred	  to	  
only	   with	   reference	   to	   patients	   without	   evidence	   of	   other	   aetiological	   factors	   29.	   	   In	   such	  
patients,	   the	   guidelines	   make	   no	   specific	   recommendation	   regarding	   the	   investigative	  
strategy	  in	  terms	  of	  either	  modality	  or	  duration.	  	  
Scottish	  guidelines	  do	  not	  specifically	  refer	  to	  investigation	  for	  AF,	  making	  reference	  only	  to	  
the	  conduct	  of	  an	  ECG	  at	  the	  time	  of	  presentation	  and	  subsequent	  ECG	  monitoring	  only	  as	  
part	   of	   physiological	   monitoring	   for	   deviation	   in	   heart	   rate	   as	   an	   alert	   to	   stroke	   related	  
complications	  79.	  	  	  
UK	  guidelines	  recommend	  checking	  for	  the	  presence	  of	  AF	  but	  offer	  no	  specific	  guidance	  on	  
how	  to	  do	  this	  beyond	  an	  ECG	  at	  the	  time	  of	  clinical	  presentation	  27.	  	  The	  need	  for	  3-­‐	  or	  7-­‐day	  
cardiac	  monitoring	   is	   suggested	   for	   consideration	   in	   relation	   to	  patients	  with	  no	   identified	  
cause	  for	  their	  stroke	  on	  initial	  screening.	  	  No	  specific	  recommendation	  is	  offered	  with	  regard	  
to	  either	  the	  modality	  or	  patient	  characteristics	  which	  would	  mandate	  investigation.	  	  
European	  guidelines	  recommend	  a	  12-­‐lead	  ECG	  followed	  by	  24	  –	  48	  hours	  of	  continuous	  ECG	  
monitoring,	  though	  no	  recommendation	  is	  made	  regarding	  the	  modality	  of	  CEM	  29.	  	  24-­‐hour	  
Holter	  monitoring	  is	  recommended	  for	  patients	  with	  no	  other	  identified	  cause	  of	  stroke	  (e.g.	  
presence	  of	  LAA).	  	  These	  recommendations	  are	  graded	  as	  Class	  1,	  Level	  A	  and	  appear	  based	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on	   the	  observation	   that	  Holter	  monitoring	  detects	  AF	   in	  patients	   identified	  as	  having	   sinus	  
rhythm	   at	   presentation	   277	   and	   that	   Holter	   will	   detect	   AF	   in	   4.6%	   of	   patients	   otherwise	  
identified	  as	  having	  sinus	  rhythm	  284.	  	  They	  note	  that	  serial	  12-­‐lead	  ECGs	  may	  be	  sufficient	  to	  
detect	  AF	  in	  an	  ASU	  281.	  	  The	  guidelines	  also	  refer	  to	  the	  observation	  that	  further	  extension	  of	  
monitoring,	  event	  monitoring	  &	  more	  selective	  monitoring	  may	  enhance	  detection	  rates	  267.	  	  
No	   recommendations	   are	   made	   regarding	   more	   prolonged	   monitoring	   or	   additional	  
investigation	   in	   the	   unselected	   population	   of	   patients	   with	   evidence	   of	   alternate	   culprit	  
aetiology.	  
North	  American	  guidelines	  recommend	  a	  12-­‐lead	  ECG	  on	  admission	  and	  cardiac	  monitoring	  
in	   the	   first	  24	  hours	   following	  stroke	  28, 289.	   	  Whilst	   it	   is	  acknowledged	  that	  detection	  of	  AF	  
may	  be	  achieved	  in	  this	  manner	  287,	  monitoring	  is	  recommended	  on	  the	  basis	  of	  the	  potential	  
for	  significant	  and	  potentially	  lethal	  cardiac	  disease	  and	  arrhythmia	  289.	   	  The	  use	  of	  24-­‐hour	  
Holter	  monitoring	  or	  prolonged	  event-­‐loop	  recorders	  is	  referred	  to	  in	  the	  detection	  of	  occult	  
arrhythmias	  but	  no	  recommendation	  is	  made	  regarding	  their	  use	  28.	  	  	  
Clinical	  practice	   in	   relation	   to	  detection	  of	  PAF	   in	  patients	  with	   ischaemic	  stroke	  &	  TIA	  has	  
not	  been	  subject	  to	  robust	  audit	  procedures	  on	  national	  or	   international	  scales,	  potentially	  
reflecting	  the	  lack	  of	  a	  reference	  standard	  which	  may	  be	  derived	  from	  the	  current	  guidelines.	  	  
Clinical	   practice	   is	   likely	   to	   vary	   considerably	  between	   centres.	   	   Contemporary	  UK	  practice	  
was	   recently	   evaluated	   through	   a	   survey	   of	   UK	   stroke	   physicians	   290.	   	   Based	   on	   available	  
responses,	   UK	   practice	   appears	   variable.	   	   Some	   stroke	   centres	   may	   reserve	   prolonged	  
monitoring	   for	   patients	   with	   so-­‐called	   cryptogenic	   stroke,	   some	   regard	   24	   hours’	   Holter	  
monitoring	  as	  standard	  and	  others	  may	  restrict	  full	  investigation	  to	  patients	  with	  cortical	  or	  
multiple	  territory	  infarcts.	  	  Strikingly,	  only	  25%	  of	  UK	  stroke	  physicians	  routinely	  use	  any	  form	  
of	  prolonged	  monitoring	  for	  AF	  detection	  and	  40%	  rely	  solely	  on	  the	  admission	  12-­‐lead	  ECG.	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2.11. Chapter	  3	  aims	  &	  hypothesis	  
There	  is	  a	  gap	  in	  the	  evidence	  relating	  to	  the	  optimal	  strategy	  by	  which	  to	  investigate	  for	  the	  
presence	   of	   PAF	   following	   ischaemic	   stroke	   &	   TIA.	   	   No	   randomised	   comparisons	   of	  
investigative	   strategies	   are	   available	   in	   unselected	   patients.	   	   Available	   evidence	   has	   often	  
been	  derived	  in	  selected	  patient	  populations,	  with	  exclusion	  of	  patients	  who	  might	  well	  have	  
PAF	  and	  potentially	  benefit	  from	  detection.	  	  	  
Guideline	   recommendations	  are	  non-­‐specific	   and	   limited.	   	   The	  approach	   to	   the	  unselected	  
patient	   presenting	   with	   ischaemic	   stroke	   or	   TIA	   is	   non-­‐evidenced	   and	   may	   result	   in	  
underdetection	   of	   the	   true	   burden	   of	   PAF	   in	   this	   population,	   denying	   patients	   potentially	  
superior	   secondary	  preventative	   therapy	  with	   anticoagulation.	   	  Data	   regarding	  UK	  practice	  
confirms	  that	  robust	  investigative	  procedures	  are	  not	  utilised.	  
Chapter	   3	   presents	   the	   detail	   and	   findings	   of	   a	   pragmatic	   randomised	   trial,	   which	   tested	  
whether	   the	   effectiveness	   of	   current	   guideline-­‐based	   investigation	   could	   be	   improved,	  
through	   application	   of	   a	   simple	   addition	   to	   routine	   approaches:	   	   The	   study	   aimed	   to	  
determine,	  in	  an	  unselected	  population	  of	  patients	  with	  recent	  ischaemic	  stroke	  or	  TIA,	  with	  
no	  ECG	  evidence	  nor	  prior	  history	  of	  AF,	  whether	   supplementing	   standard	  guideline	  based	  
investigation	   with	   7	   days’	   cardiac	   event	   monitoring	   would:	   1)	   increase	   detection	   of	  
paroxysms	   of	   AF	   of	   duration	   that	   would	   justify	   anticoagulation;	   2)	   increase	   detection	   of	  
paroxysms	   of	   AF	   of	   any	   duration	   (including	   brief	   episodes	   of	   uncertain	   prognostic	  
significance);	   and	   3)	   increase	   use	   of	   anticoagulation	   for	   prophylaxis	   of	   thromboembolism.	  	  
We	  also	  wished	   to	  evaluate	  whether	   stroke	   clinicians	  without	   specialist	   cardiology	   training	  
could	  reliably	  interpret	  the	  supplementary	  cardiac	  event	  monitoring	  data.	  
In	  a	  related	  observational	  study,	  patients	  enrolled	  in	  the	  above	  RCT	  were	  invited	  to	  undergo	  
interval	  non-­‐invasive	  cardiac	  event	  monitoring	  for	  AF,	  3	  months	  after	  their	  index	  event.	  	  The	  
aim	  of	  this	  study	  was	  to	  evaluate	  whether	  AF,	  detected	  in	  the	  period	  immediately	  following	  
ischaemic	   stroke	   or	   TIA,	   is	   predictive	   of	   AF	   detectable	   beyond	   the	   period	   of	   greatest	  
physiological	   stress	   associated	   with	   the	   acute	   stroke.	   	   This	   would	   provide	   indirect	  
information	  regarding	  the	  appropriateness	  of	  basing	  therapeutic	  decisions	  on	  AF	  detection	  in	  
the	  period	  immediately	  following	  the	  acute	  event.	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Chapter	  3 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Optimisation	  of	  paroxysmal	  atrial	  fibrillation	  detection	  
and	  treatment	  following	  ischaemic	  stroke	  and	  TIA	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3.1. Study	   1:	   	   Non-­‐invasive	   cardiac	   event	   monitoring	   to	   detect	   AF	   after	  
ischaemic	  stroke:	  	  A	  randomised	  controlled	  trial	  
	  
3.1.1. Introduction	  
Ischaemic	  stroke	  is	  the	  leading	  cause	  of	  adult	  disability	  in	  the	  developed	  world	  and	  the	  2nd	  
leading	   cause	   of	   mortality.	   	   Healthcare	   related	   costs	   are	   high	   and	   effective	   preventative	  
strategies	  are	  crucial	  in	  reducing	  the	  burden	  of	  disease.	  	  
AF	   predisposes	   to	   the	   formation	   of	   thrombus	   within	   the	   left	   atrium	   and	   consequently	   to	  
thromboembolic	  events,	   typically	   ischaemic	   stroke.	   	  AF	   independently	   increases	   the	   risk	  of	  
stroke	  five-­‐fold	  134	  and	  doubles	  the	  risk	  of	  recurrent	  stroke	  174,	  the	  latter	  irrespective	  of	  the	  
aetiological	   mechanism	   for	   the	   incident	   stroke.	   	   AF-­‐related	   stroke	   is	   associated	   with	  
increased	  stroke	  severity,	  which	  may	  be	  associated	  with	  worse	  outcome	  238.	  	  AF	  is	  common	  
and	  prevalence	  will	  increase	  with	  the	  ageing	  population	  223.	  
Oral	  anticoagulant	  therapy	  dramatically	  reduces	  the	  risk	  of	  ischaemic	  stroke	  in	  patients	  with	  
AF,	   particularly	   those	   with	   prior	   stroke	   or	   TIA	   (TIA)	   173	   regardless	   of	   the	   underlying	  
aetiological	   mechanism.	   	   	   Moreover,	   it	   is	   substantially	   more	   effective	   than	   anti-­‐platelet	  
therapy	  5.173	   	  New	  anticoagulant	  drugs	  such	  as	  the	  direct	  thrombin	  and	  factor	  Xa	   inhibitors	  
may	  be	  yet	  more	  effective	  with	  reduced	  bleeding	  complications	  192, 194.	  
Risk	   of	   recurrent	   stroke	   is	   similar	   with	   both	   sustained	   and	   paroxysmal	   AF	   (PAF)	   and	   both	  
forms	   are	   optimally	   treated	  with	   anticoagulation	   250.	   	   Accordingly,	   detection	   of	   occult	   PAF	  
after	   ischaemic	   stroke	   is	   of	   critical	   importance	   to	   optimise	   uptake	   of	   treatment	   with	   oral	  
anticoagulation	  291.	  
One	  in	  five	  patients	  with	  ischaemic	  stroke	  or	  TIA	  will	  have	  a	  prior	  history	  of	  AF	  or	  is	  revealed	  
to	  have	  AF	  on	  their	   initial	  12–lead	  electrocardiogram	  124	  but	  further	  investigation	  is	  needed	  
to	  detect	  culprit	  PAF	  and	  occult	  PAF	  which	  confers	  future	  risk	  292.	  	  A	  recent	  systematic	  review	  
suggested	  that	  PAF	  will	  be	  detected	  in	  a	  further	  4.6%	  through	  routine	  application	  of	  24-­‐hour	  
Holter	  monitoring,	  the	  conventional	  modality	  for	  investigation	  284,	  though	  individual	  studies	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have	  reported	  widely	  variable	  detection	  rates	  292.	  	  Alternative	  investigation	  strategies	  such	  as	  
extended	   duration	   Holter	   monitoring,	   cardiac	   telemetry	   and	   implantable	   cardiac	   event	  
monitors	   may	   increase	   detection	   rates	   but	   are	   labour	   intensive,	   expensive	   and	   lack	   a	  
definitive	  evidence	  base	  supporting	  their	  routine	  use	  252.	   	   It	   is	  acknowledged	  that	  detection	  
rates	  increase	  with	  more	  prolonged	  monitoring	  252.	  
Though	  detection	  with	  prolonged	  monitoring	  has	  been	  explored	  in	  uncontrolled	  longitudinal	  
studies	  and	  selected	  populations	  (e.g.	  cryptogenic	  stroke),	  no	  randomised	  comparisons	  have	  
been	   reported	   for	   specific	   investigation	   strategies	   in	   unselected	   ischaemic	   stroke	   patients.	  	  
Clinical	   guidelines	   reflect	   this	   uncertainty	   and	   are	   diverse	   in	   their	   conclusions	   regarding	  
investigation.	   	   Typically	   the	   guidelines	   refer	   to	   repeated	   12-­‐lead	   ECGs	   or	   some	   form	   of	  
cardiac	   monitoring	   for	   selected	   patients	   but	   generally	   offer	   no	   specific	   recommendation	  
regarding	   modality	   or	   duration	   19, 27, 29, 79.	   	   Some	   stroke	   centres	   may	   reserve	   prolonged	  
monitoring	   for	   patients	   with	   so-­‐called	   cryptogenic	   stroke,	   some	   regard	   24	   hours’	   Holter	  
monitoring	  as	  standard	  and	  others	  may	  restrict	  full	  investigation	  to	  patients	  with	  cortical	  or	  
multiple	  territory	  infarcts	  290.	  
The	  optimal	   investigation	  strategy,	   including	  modality,	  duration	  of	   investigation	  and	  patient	  
subgroup	   remains	   undefined,	   not	   only	   for	   efficacy	   in	   the	   detection	   of	   AF	   but	   also	   cost-­‐
effectiveness	  within	  healthcare	  systems.	  	  This	  study	  was	  a	  pragmatic	  randomised	  trial,	  to	  test	  
whether	   the	   effectiveness	   of	   current	   guideline-­‐based	   investigation	   could	   be	   improved,	  
through	  application	  of	  a	  simple	  addition	  to	  routine	  approaches.	  
Aims	  
The	  study	  aimed	   to	  determine,	   in	  a	  population	  of	  patients	  with	   recent	   ischaemic	   stroke	  or	  
TIA,	  with	  no	  ECG	  evidence	  nor	  prior	  history	  of	  AF,	  whether	  supplementing	  standard	  guideline	  
based	   investigation	  with	   7	   days’	   cardiac	   event	  monitoring	  would:	   1)	   increase	   detection	   of	  
paroxysms	   of	   AF	   of	   duration	   that	   would	   justify	   anticoagulation;	   2)	   increase	   detection	   of	  
paroxysms	   of	   AF	   of	   any	   duration	   (including	   brief	   episodes	   of	   uncertain	   prognostic	  
significance);	   and	   3)	   increase	   use	   of	   anticoagulation	   for	   prophylaxis	   of	   thromboembolism.	  	  
The	   study	   additionally	   evaluated	   whether	   stroke	   clinicians	   without	   specialist	   cardiology	  





This	   study	   was	   a	   randomised	   controlled	   trial,	   comparing	   standard	   clinical	   practice	   for	   the	  
detection	  of	  AF,	  against	  standard	  practice	  plus	  additional	  cardiac	  event	  monitoring.	  	  
	  
Study	  Population	  
Patients	  were	  eligible	  within	  7	  days	  of	  transient	  or	  persistent	  symptoms	  of	  acute	   ischaemic	  
stroke,	   provided	   they	   had	   an	   admission	   12-­‐lead	   ECG	  demonstrating	   sinus	   rhythm	  and	   had	  
neither	  prior	  history	  of	  AF	  or	  atrial	  flutter	  nor	  any	  irreversible	  contraindication	  for	  long	  term	  
anticoagulation	  (Table	  3-­‐1).	   	  Patients	  or	  their	   legally	  approved	  proxy	  gave	  written	   informed	  




An	  initial	  pilot	  phase	  of	  100	  patients	  was	  conducted	  to	  demonstrate	  feasibility	  of	  early	  seven	  
day	  monitoring	  and	  provide	  estimates	  of	  AF	  detection	  rate	  to	  verify	  assumptions	  relating	  to	  
differences	   in	   AF	   detection	   rates	   and	   use	   of	   anticoagulant	   therapy.	   	   Provisionally,	   in	  
anticipation	   of	   the	   need	   for	   a	   future	   definitive	   trial,	   a	   sample	   size	   of	   5000	   patients	   was	  
calculated	   to	   provide	   95%	   power	   to	   detect	   a	   difference	   between	   3%	   (control)	   and	   5%	  
(intervention)	   detection	   rates	   for	   AF	   and	   90%	   power	   to	   detect	   a	   difference	   between	   2%	  
(control)	  and	  3.5%	  (intervention)	  anticoagulation	  rates.	  	  Upon	  completion	  of	  14	  day	  and	  90-­‐
day	  follow-­‐up	  of	  the	  100	  participants	  in	  the	  pilot	  phase,	  interim	  analyses	  of	  the	  pre-­‐defined	  
primary	  and	  secondary	  endpoints	  was	  planned	  to	   inform	  on	  progression	  to	  the	   larger	  main	  
study	  phase.	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Randomisation	  and	  masking	  
Enrolled	  patients	  were	  randomised,	  via	  an	  interactive	  voice	  randomisation	  system,	  to	  either	  
a	  control	  group	  or	  intervention	  study	  group	  on	  a	  1:1	  basis.	   	  Research	  nursing	  staff	  assigned	  
participants	   to	   their	   intervention	   following	  randomisation.	   	   Investigators	  and	  patients	  were	  
aware	  of	  study	  group	  allocation.	  	  This	  allowed	  pragmatic	  management	  decisions	  to	  be	  made	  
without	  delay	  based	  on	  diagnostic	  information	  gained	  through	  study	  procedures.	  
	  
Table	  3-­‐1:	  	  Principal	  eligibility	  criteria	  
Inclusion	  Criteria	   1.	  Ischaemic	  Stroke	  (including	  TIA,	  where	  symptoms	  last	  less	  than	  24	  
hours).	  
2.	  Brain	  imaging	  not	  suggestive	  of	  an	  alternative	  diagnosis.	  	  
3.	  Sinus	  rhythm	  on	  screening	  ECG	  
4.	  Consent	  to	  participate,	  from	  patient	  or	  approved	  proxy.	  
5.	  Randomisation	  within	  7	  days	  of	  ictus.	  
Exclusion	  Criteria	   1.	  Previously	  documented	  atrial	  fibrillation	  	  
2.	  Known	  durable	  cardiac	  source	  of	  embolism	  (e.g.	  mitral	  stenosis	  or	  
left	  ventricular	  akinesia),	  or	  other	  absolute	  indication	  for	  indefinite	  
anticoagulation	  (based	  on	  antecedent	  history	  prior	  to	  qualifying	  
event)	  
3.	  Existing	  treatment	  with	  long	  term	  anticoagulation	  	  
4.	  Unlikely	  to	  be	  available	  for	  completion	  of	  study	  procedures	  
5.	  Clinical	  decision	  or	  expressed	  refusal	  to	  consider	  long	  term	  
anticoagulation	  at	  a	  future	  date	  if	  cardio-­‐embolism	  may	  be	  
diagnosed	  
6.	  Pre-­‐morbid	  condition	  or	  concomitant	  disease	  that	  would	  render	  
subsequent	  secondary	  prevention	  of	  stroke	  inappropriate	  
7.	  Cognitive	  impairment	  deemed	  sufficient	  to	  compromise	  capacity	  





Study	  intervention,	  data	  collection	  and	  endpoint	  determination	  
Patients	   were	   enrolled	   from	   two	   acute	   stroke	   services	   in	   Glasgow	   (Glasgow	   Western	  
Infirmary	  &	  Glasgow	  Royal	   Infirmary).	   	   Before	  entry,	   every	  patient	  had	  a	   12-­‐lead	  ECG	   that	  
confirmed	   sinus	   rhythm.	   	   Patients	   in	   both	   groups	   received	   standard	   practice	   (SP)	  
investigation	  for	  the	  detection	  of	  AF,	  as	  individually	  determined	  at	  the	  discretion	  of	  the	  local	  
treating	   clinical	   team,	   consistent	   with	   existing	   guidelines	   and	   with	   national	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
practice	   19, 27, 29, 79, 290.	   	   Investigations	   that	   afforded	   the	   opportunity	   for	   AF	   detection	  
comprised	   additional	   12-­‐lead	   ECGs	   (subsequent	   to	   the	   admission	   12-­‐lead	   ECG),	   24-­‐hour	  
Holter	  monitoring	  and	  echocardiography	  (which,	  as	  coupled	  with	  cardiac	  rhythm	  monitoring,	  
afforded	   the	   opportunity	   for	   AF	   detection).	   	   24-­‐hour	   Holter	   recordings	   were	   reported	  
centrally	  at	  the	  recruiting	  hospital	  cardiology	  laboratory	  and	  reviewed	  thereafter	  by	  treating	  
clinicians.	  	  	  
Patients	   randomised	   to	   the	   intervention	   group	   underwent	   usual	   SP	   investigation	   plus	  
additional	  monitoring	  (AM)	  for	  the	  detection	  of	  AF	  (SP-­‐AM).	   	  AM	  comprised	  7	  days	  of	  non-­‐
invasive	  cardiac	  event	  monitoring,	  performed	  with	  the	  Novacor	  “R-­‐test	  Evolution	  3”	  device.	  	  
The	   device	   weighs	   less	   than	   50	   grams	   and	   garners	   cardiac	   rhythm	   data	   through	   two	  
electrodes,	  placed	  respectively	  at	  the	  sternum	  and	  apex.	   	  This	  approximates	  to	  a	  CM5	  lead	  
configuration.	   	   The	   R-­‐test	   device	   used	   a	   loop	   recording	   system	   to	   capture	   cardiac	   rhythm	  
episodes	  of	  30	  seconds	  duration	  (the	  maximum	  period	  of	  dysrhythmia	  recordable	  with	  the	  R-­‐
test	   device	   settings	   employed	   in	   the	   study),	   triggered	   automatically	   by	   possible	   AF	  
recognition.	   	   Ten	   seconds	   of	   rhythm	   preceding	   and	   20	   seconds	   subsequent	   to	   the	   trigger	  
point	  were	  captured.	  	  The	  device	  has	  previously	  been	  validated	  for	  the	  purposes	  of	  detection	  
of	  AF	  detection	  in	  relation	  to	  24-­‐hour	  Holter	  monitoring	  267, 279.	  	  
Monitoring	  commenced	  immediately	  following	  randomisation,	  with	  interim	  downloads	  at	  24,	  
72	  and	  168	  hours	  to	  permit	  interim	  analysis	  of	  any	  captured	  events	  and	  to	  avoid	  “losing”	  any	  
detected	  AF	  episodes	  (with	  a	  20	  minute	  memory,	  the	  device	  automatically	  stores	  the	  most	  
prolonged	  rhythm	  disturbances	  preferentially	  over	  briefer	  ones).	  	  The	  SP-­‐AM	  group	  also	  had	  
digital	   12-­‐lead	   ECGs	   recorded	   at	   24	   and	   72	   hours	   with	   a	   Lexor	   “Cardiolex”	  
electrocardiograph.	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The	   cardiac	   event	   monitoring	   and	   digital	   ECG	   data	   were	   transferred	   to	   a	   central	   cardiac	  
electrocardiology	  laboratory	  (Glasgow	  Royal	  Infirmary)	  led	  by	  one	  of	  the	  authors	  (PWM),	  for	  
storage	   and	   analysis.	   	   This	   is	   an	   accredited	   specialist	   core	   laboratory,	   with	   extensive	  
experience	   in	   ECG	   reporting	   and	   cardiac	  monitoring	   data	   for	  many	   international	   trials.	   	   A	  
trained	   technician	   established	   whether	   the	   recordings	   were	   normal	   or	   showed	   possible	  
evidence	   of	   AF,	   based	   on	   absence	   of	   discernible	   organized	   atrial	   activity	   and	   irregular	  
ventricular	   response.	   	   Recordings	   with	   suspected	   AF	   were	   reviewed	   by	   an	   experienced	  
electrocardiologist	  (PWM).	  	  	  	  	  
	  
Endpoints	  	  	  
Based	  on	   core	   laboratory	   interpretation,	  patients	   identified	  as	  having	  evidence	  of	  AF	  were	  
subsequently	   categorised	  as	   exhibiting	  either	   “sustained”	  or	   “non-­‐sustained”	  paroxysms	  of	  
AF.	   	   “Sustained”	   PAF	   was	   diagnosed	  where	   AF	   was	   recorded	   for	   the	   complete	   20	   second	  
rhythm	   strip	   following	   event	   triggering.	   	   This	   definition	   accords	   closely	   with	   that	  
recommended	  for	  diagnosis	  within	  clinical	  trials	  293	  and	  clinical	  practice	  291	  and	  which	  would	  
justify	  consideration	  of	  formal	  anticoagulant	  therapy.	  	  “Non-­‐sustained”	  PAF	  included	  briefer	  
paroxysms	  of	  a	  minimum	  of	  6	  conducted	  ventricular	  complexes	  but	  <	  20	  seconds’	  duration.	  	  
Such	  episodes	  lack	  a	  substantial	  evidence	  base	  in	  terms	  of	  prognostic	  significance	  and	  there	  
is	   clinical	   uncertainty	   in	   terms	  of	  benefit	   of	   anticoagulant	   therapy.	   	  Hereafter,	   reference	   is	  
made	   to	   detection	   of	   “sustained”	   PAF	   and	   “any	   duration”	   PAF	   (the	   latter	   comprising	   both	  
“sustained”	  and	  “non-­‐sustained”	  PAF	  patients).	  	  	  
In	   addition	   to	   the	  external	   validated	   reporting	  of	  R-­‐test	   data,	   local	   treating	   clinicians	  were	  
able	  to	  review	  data	  captured	  by	  the	  R-­‐test	  device	  on	  a	  “real	  time”	  basis	  as	  recordings	  were	  
collected.	  	  Local	  clinician	  interpretation	  of	  the	  R-­‐test	  data	  in	  this	  manner	  facilitated	  potential	  
adjustment	  to	  patient	  therapy	  without	  delay.	  	  Local	  clinician	  reports	  were	  collated,	  to	  permit	  





Patients	  were	  reviewed	  at	  14	  and	  90	  days,	  either	   through	  a	  patient	  visit	  or,	   if	   this	  was	  not	  
possible,	   through	  telephone	  discussion	  with	  the	  patient	  and	  their	  primary	  care	  practitioner	  
together	  with	  review	  of	  case	  notes	  and	  relevant	  investigation	  reports.	  	  	  
The	  primary	  endpoint	  was	   the	  difference	   in	  AF	  detection	  between	  patients	   randomised	   to	  
receive	  SP-­‐AM	  compared	  with	  SP	  alone	  at	  14	  days.	  	  As	  above,	  detection	  of	  AF	  was	  defined	  as	  
evidence	  of	  “sustained”	  PAF	  and	  “any	  duration”	  PAF.	  
Secondary	  endpoints	  were	  the	  difference	  in	  AF	  detection	  at	  90	  days	  and	  the	  difference	  in	  AF-­‐
thromboembolic	   prophylaxis-­‐related	   anticoagulation	   (e.g.	   warfarin)	   between	   patients	  
randomised	   to	   receive	   SP-­‐AM	   compared	   with	   SP	   alone	   at	   14	   &	   90	   days.	   	   Data	   regarding	  
serious	   adverse	   events	   and	   relevant	   clinical	   endpoints	   (TIA,	   stroke,	   MI,	   death)	   were	   also	  
collected	  to	  14	  and	  90	  days,	  respectively.	  	  	  
The	  use	  of	  other	  investigations	  such	  as	  trans-­‐thoracic	  or	  trans-­‐oesophageal	  echocardiography	  
and	  vascular	  imaging	  were	  recorded	  but	  their	  use	  was	  not	  controlled.	  	  The	  study	  population	  
was	  neither	  one	  of	  cryptogenic	  stroke	  nor	  enriched	  according	  to	  cortical	  or	  multiple	  territory	  
infarcts.	   	   In	   line	  with	   its	  pragmatic	  nature,	   this	   trial	   included	  all	  patients	  with	  sinus	   rhythm	  
who	  may	  eventually	  benefit	  from	  detection	  of	  AF.	  	  
	  
Statistical	  analysis	  	  
Analysis	   was	   performed	   on	   an	   intention	   to	   treat	   basis,	   with	   comparison	   of	   AF	   detection	  
(“sustained”	   and	   “any	   duration”)	   and	   anticoagulation	   status	   by	   difference	   in	   proportions,	  
performed	   at	   14	   and	   90	   days.	   	   The	   Fleiss	   Kappa	   statistic	   was	   used	   to	   assess	   agreement	  
between	  local	  treating	  clinicians	  and	  the	  validated	  core	   laboratory	   in	  R-­‐test	  reporting	  of	  AF	  
(Minitab,	  v	  16).	  	  Survival	  analysis,	  with	  the	  log	  rank	  test,	  was	  performed	  for	  each	  endpoint	  of	  
interest	  at	  90	  days	  (SPSS,	  v	  18).	  	  The	  study	  design	  is	  summarised	  in	  figure	  3-­‐1.	  	  














ASU,	   acute	   stroke	   unit;	   TIA,	   transient	   ischaemic	   attack;	   IS,	   ischaemic	   stroke,	   SP,	   standard	   practice;	   SP-­‐AM,	  
standard	  practice	  plus	  additional	  monitoring;	  ECG,	  electrocardiogram;	  AF,	  atrial	  fibrillation;	  AC,	  anticoagulation	  	  
	  
3.1.3. Results	  
Interim	  analysis	  was	  performed	  following	  90	  day	  follow	  up	  of	  100	  patients	  enrolled	  from	  two	  
stroke	   services	   in	   Glasgow	   between	   May	   2010	   and	   September	   2011.	   	   All	   100	   patients	  
completed	  90	  day	  follow	  up.	  	  There	  were	  no	  significant	  differences	  between	  the	  randomised	  
groups	   in	   either	   baseline	   characteristics	   (Table	   3-­‐2)	   or	   the	   investigations	   performed	  which	  
comprised	  standard	  practice	  (Table	  3-­‐3).	  	  	  	  
	  
Assessment	  for	  eligibility	  (ASU/TIA	  clinic)	  
Randomisation	  (1:1	  basis):	  
Informed	  Consent	   IS	  	  <	  7	  days	  
AF	  detection	  &	  AC	  treatment	  evaluation	  
AF	  detection	  &	  AC	  treatment	  evaluation	  
+	  1	  day	  
+	  3	  days	  
+	  7	  days	  
+	  14	  days	  
+	  90	  days	  
“	   ”	  
12	  -­‐	  lead	  ECG	  /	  24	  -­‐hour	  ECG	  /	  Echo	  
(as	  directed	  by	  clinical	  team)	  
SP”	  Investigation	  
-­‐hour	  ECG	  /	  Echo	  
“	  Intensive	  ”	  
Cardiac	  event	  download	  	  	  	  	  	  +	  	  12	  -­‐	  lead	  ECG	  
Cardiac	  event	  download	  	  	  	  	  	  +	  	  12	  -­‐	  lead	  ECG	  
Cardiac	  event	  download	  
Plus	  
SP-­‐AM”	  Investigation	  
-­‐	  lead	  ECG	  
-­‐	  lead	  ECG	  
Figure	  3-­‐1:	  	  Summary	  of	  Chapter	  3,	  Study	  1	  design	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Table	  3-­‐2:	  	  Chapter	  3,	  Study	  1	  population	  baseline	  characteristics	  
	   Total	  	  
(n	  =	  100)	  
	  
SP	  group	  
(n	  =	  50)	  
SP-­‐AM	  group	  
(n	  =	  50)	  
P	  value	  








2	  (4)	   1	  (3.5)	   1	  (4)	   	  	  0.82	  1	  
SBP	   154.8	  (27.1)	   154.4	  (25.3)	   155.2	  (29.0)	   0.88	  
DBP	   81.5	  (14.5)	   81.5	  (14.4)	   81.5	  (14.7)	   1.00	  
HR	   77.55	  (17.5)	   77.5	  (16.2)	   77.6	  (18.8)	   0.96	  
-­‐OH	  units	  /	  week,	  
Median	  (IQR)	  
3	  (15)	   2.5	  (15)	   3	  (15)	   	  	  0.71	  1	  
Male	  sex	   56%	   64%	   48%	  	   0.10	  
Qualifying	  event	  
Stroke	  
68%	   66%	   70%	  	   0.67	  
Qualifying	  event	  
TIA	  
32%	   34%	   30%	  	   0.67	  
TACS	   14%	   14%	  	   14%	  	   1.00	  
PACS	   41%	   42%	  	   40%	  	   0.84	  
LACS	   33%	   30%	   36%	  	   0.52	  
POCS	   12%	   14%	  	   10%	  	   0.54	  
IHD	   16%	   16%	  	   16%	  	   1.00	  
Hypertension	   58%	   60%	  	   56%	  	   0.69	  
Diabetes	   15%	   22%	  	   8%	  	   	  	  0.09	  2	  
Smoker	   32%	   40%	  	   24%	  	   0.08	  
Aspirin	   55%	   56%	  	   54%	  	   0.84	  
Dipyridamole	  MR	   21%	   22%	  	   20%	  	   0.81	  
Clopidogrel	   27%	   26%	  	   28%	  	   0.82	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Any	  antiplatelet	   75%	   78%	  	   72%	  	   0.49	  
ACE-­‐I	   37%	   38%	  	   36%	  	   0.84	  
ARB	   8%	   6%	  	   10%	  	   	  	  0.72	  2	  
Thiazide	   18%	   14%	  	   22%	  	   0.30	  
CCB	   15%	   14%	  	   16%	  	   0.78	  
Beta-­‐blocker	   17%	   16%	  	   18%	  	   0.79	  
Alpha-­‐blocker	   2%	   0%	  	   4%	  	   	  	  0.50	  2	  
Statin	   58%	   60%	  	   56%	  	   0.69	  
Other	  lipid	  
modifying	  
2%	   4%	  	   0%	  	   	  	  0.50	  2	  
Hypoglycaemic	  
therapy	  
10%	   14%	  	   6%	  	   	  	  0.32	  2	  
Continuous	  baseline	  characteristic	  values	  are	  quoted	  as	  mean	  (SD)	  unless	  otherwise	  stated.	  	  Comparison	  was	  
with	  two-­‐sample	  t-­‐test	  except	  when	  a	  variable	  did	  not	  approximate	  to	  the	  Normal	  distribution,	  when	  
comparison	  with	  the	  Mann-­‐Whitney	  test	  1	  was	  used.	  	  Categorical	  baseline	  characteristics	  are	  quoted	  as	  %.	  	  
Comparison	  between	  groups	  is	  with	  difference	  in	  2	  proportions.	  	  	  	  	  When	  observed	  frequencies	  were	  low,	  
Fisher’s	  exact	  test	  2	  was	  used.	  	  A	  p	  value	  of	  <	  0.05	  was	  considered	  statistically	  significant.	  
SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring;	  CI,	  confidence	  interval;	  NIHSS,	  
National	  Institute	  of	  Health	  Stroke	  Scale;	  IQR,	  inter-­‐quartile	  range;	  SBP,	  systolic	  blood	  pressure,	  DBP,	  diastolic	  
blood	  pressure;	  HR,	  heart	  rate;	  -­‐OH,	  alcohol;	  TACS,	  total	  anterior	  circulation	  syndrome;	  PACS,	  partial	  anterior	  
circulation	  syndrome,	  LACS	  =	  lacunar	  anterior	  circulation	  syndrome;	  POCS,	  posterior	  circulation	  syndrome;	  
TIA,	  transient	  ischaemic	  attack;	  IHD,	  ischaemic	  heart	  disease;	  MR,	  modified	  release;	  ACE-­‐I,	  angiotensin	  
converting	  enzyme	  inhibitor;	  ARB,	  angiotensin	  receptor	  blocker.	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Table	  3-­‐3:	  	  Standard	  practice	  investigations	  affording	  opportunity	  for	  AF	  detection,	  
performed	  to	  14	  &	  90	  days	  
	   SP	  group	  
(	  n	  =	  50)	  
SP-­‐AM	  group	  
(n	  =	  50)	  
P	  value	  




16%	  (7.1	  –	  29.1%)	  
28%	  (16.2	  –	  42.5%)	  
	  
12%	  (4.5	  –	  24.3%)	  








16%	  (7.1	  –	  29.1%)	  
60%	  (45.2	  –	  73.4%)	  
	  
26%	  (14.6	  –	  40.3%)	  








30%	  (17.9	  –	  44.6%)	  
62%	  (47.2	  –	  75.3%)	  
	  
42%	  (28.2	  –	  56.8%)	  








4%	  (0.0	  –	  13.7%)	  
10%	  (3.3	  –	  21.8%)	  
	  
12%	  (4.5	  –	  24.3%)	  
22%	  (11.5	  –	  36.0%)	  
	  
	  	  	  0.27	  2	  
0.10	  




2%	  (0.0	  –	  10.6%)	  
8%	  (2.2	  –	  19.2%)	  
	  
8%	  (2.2	  –	  19.2%)	  
16%	  (7.2	  –	  29.1%)	  
	  
	  	  0.36	  2	  
	  	  0.36	  2	  
Values	  quoted	  are	  %	  (95%	  CI).	  	  Comparison	  between	  groups	  is	  with	  difference	  in	  2	  proportions.	  	  When	  
observed	  frequencies	  were	  low,	  Fisher’s	  exact	  test	  2	  was	  used.	  	  A	  p	  value	  of	  <	  0.05	  was	  considered	  
statistically	  significant.	  	  SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring;	  CI,	  
confidence	  interval;	  ECG,	  electrocardiogram;	  PAF,	  paroxysmal	  atrial	  fibrillation	  
	  
The	  additional	  monitoring	  was	  well	  tolerated,	  with	  high	  completion	  rates	  and	  no	  associated	  
adverse	  events	  (Table	  3-­‐4).	  	  The	  AM	  cumulative	  detection	  rate	  for	  evidence	  of	  AF,	  reported	  
through	  the	  core	  ECG	  laboratory,	  was:	  4/50	  (8%;	  95%	  CI,	  2.2	  –	  19.2%)	  for	  the	  two	  additional	  
digital	   12-­‐lead	   ECGs;	   	   8/50	   (16%;	   95%	   CI,	   7.2	   –	   29.1%)	   for	   “sustained”	   AF	   with	   the	   non-­‐
invasive	   R-­‐test	   cardiac	   event	   monitoring;	   	   21/50	   (42%;	   95%	   CI,	   28.2	   –	   56.8%)	   for	   “any	  
duration”	  AF	  with	  the	  non-­‐invasive	  R-­‐test	  cardiac	  event	  monitoring.	  	  Every	  patient	  in	  whom	  
AF	   was	   identified	   by	   12-­‐lead	   ECG	   at	   24	   or	   72	   hours	   also	   had	   “sustained”	   PAF	   episodes	  
identified	  through	  R-­‐test	  non-­‐invasive	  cardiac	  event	  monitoring.	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Table	  3-­‐4:	  	  Additional	  monitoring	  (AM)	  tolerability	  and	  PAF	  detection,	  
according	  to	  individual	  regime	  components	  
Modality	   Completed	  
satisfactorily	  




24-­‐hour	  12-­‐lead	  ECG	   84%,	  (70.9	  –	  92.8%)	   8%,	  (2.2	  –	  19.2%)	   8%,	  (2.2	  –	  19.2%)	  
72-­‐hour	  12-­‐lead	  ECG	   82%,	  (68.6	  –	  91.4%)	   8%,	  (2.2	  –	  19.2%)	   8%,	  (2.2	  –	  19.2%)	  
24-­‐hour	  R-­‐test	  download	   94%,	  (83.5	  –	  98.7%)	   18%,	  (8.6	  –	  31.4%)	   8%,	  (2.2	  –	  19.2%)	  
72-­‐hour	  R-­‐test	  download	   90%,	  (78.1	  –	  96.7%)	   38%,	  (24.7	  –	  52.8%)	   14%	  (5.8	  –	  26.7%)	  
168-­‐hour	  R-­‐test	  
download	  
82%,	  (68.6	  -­‐	  91.4%)	   42%,	  (28.2	  –	  56.8%)	   16%	  (7.2	  –	  29.1%)	  
Values	  quoted	  are	  %	  (95%	  CI).	  	  PAF,	  paroxysmal	  atrial	  fibrillation;	  CI,	  confidence	  interval;	  ECG,	  
electrocardiogram	  
	  
“Sustained”	  and	  “any	  duration”	  PAF	  episodes	  were	  each	  detected	  more	  frequently	  in	  the	  SP-­‐
AM	  group	  compared	  with	  the	  SP	  group	  at	  both	  14	  and	  90	  days	  (Table	  3-­‐5).	   	  90-­‐day	  survival	  
free	  from	  “sustained”	  and	  “any	  duration”	  PAF	  detection	  are	  shown	  in	  figures	  3-­‐2	  and	  3-­‐3.	  	  	  
Anticoagulant	  therapy	  was	  initiated	  more	  frequently	  in	  the	  SP-­‐AM	  group	  compared	  with	  the	  
SP	  group	  at	  both	  14	  and	  90	  days	  (Table	  3-­‐5).	   	  90-­‐day	  survival	   free	  from	  anticoagulation	  for	  
AF-­‐related	   thromboembolism	  prophylaxis	   is	   shown	   in	   figure	  3-­‐4.	   	  90-­‐day	  survival	   free	   from	  
anticoagulation	  for	  any	  indication	  is	  shown	  in	  figure	  3-­‐5.	  
There	  was	  excellent	  agreement	  between	  the	  ECG	  core	  laboratory	  and	  local	  clinicians	  for	  the	  
presence	  of	  “sustained”	  paroxysms	  of	  AF	  on	  the	  R-­‐test	  event	  monitors:	   	   	  48/50	  cases	  (96%,	  
95%	  CI	  86.3	  –	  99.5),	   Fleiss’	  Kappa	  0.86,	  p	  <	  0.00001.	   	  Agreement	   for	   the	  presence	  of	   “any	  
duration”	   AF	   was	   present	   in	   44/50	   cases	   (88%,	   95%	   CI	   75.7	   –	   95.5),	   Fleiss’	   Kappa	   0.76,	  	  	  	  	  	  	  	  	  	  	  	  
p	  <	  0.00001.	  	  There	  was	  no	  difference	  between	  groups	  for	  recurrent	  stroke,	  TIA,	  MI,	  death	  or	  
any	  combination	  of	  these	  clinical	  endpoints	  (4	  combined	  events	  in	  each	  group).	  	  There	  were	  
no	  serious	  adverse	  events	  associated	  with	  use	  of	  the	  R-­‐test	  device.	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Table	  3-­‐5:	  	  Differences	  between	  groups	  for	  detection	  of	  “any	  duration”	  PAF,	  “sustained”	  
PAF	  and	  treatment	  with	  anticoagulation,	  at	  14	  and	  90	  days	  





14	  days	  	  
4%	  (0.0	  –	  13.7%)	   44%	  (30.0	  –	  58.7%)	   40%	  (25.2	  –	  54.8%)	   	  	  <	  0.001	  2	  
“Any	  duration”	  
PAF	  	  
90	  days	  	  
10%	  (3.3	  –	  21.8%)	   48%	  (33.7	  –	  62.6%)	   38%	  (21.8	  –	  54.1%)	   <	  0.001	  
“Sustained”	  PAF	  	  
14	  days	  	  
2%	  (0.0	  –	  10.6%)	   18%	  (8.6	  –	  31.4%)	   16%	  (4.7	  –	  27.3%)	   	  	  <	  0.05	  2	  
“Sustained”	  PAF	  	  
90	  days	  	  
8%	  (2.2	  –	  19.2%)	   22%	  (11.5	  –	  36.0%)	   14%	  (0.0	  –	  27.7%)	   	  	  	  	  	  0.09	  2	  
AC	  for	  any	  
indication	  	  
14	  days	  
0%	  (0	  –	  5.8%)	   18%	  (8.6	  –	  31.4%)	   18%	  (7.4	  -­‐	  28.6%)	   	  	  <	  0.01	  2	  
AC	  for	  any	  
indication	  	  
90	  days	  
10%	  (3.3	  –	  21.8%)	   26%	  (14.6	  –	  40.3%)	   16%	  (1.2	  –	  30.7%)	   <	  0.05	  
AC	  for	  AF	  TE	  
prophylaxis	  
14	  days	  
0%	  (0	  –	  5.8%)	   16%	  (7.2	  –	  29.1%)	   16%	  (5.8	  –	  26.2%)	   	  	  <	  0.01	  2	  
AC	  for	  AF	  TE	  
prophylaxis	  	  
90	  days	  
6%	  (1.3	  –	  16.5%)	   22%	  (11.5	  –	  36.0%)	   16%	  (2.8	  –	  29.2%)	   	  	  <	  0.05	  2	  
Values	  quoted	  are	  %	  (95%	  CI).	  	  Comparison	  between	  groups	  is	  with	  difference	  in	  2	  proportions.	  	  When	  
observed	  frequencies	  were	  low,	  Fisher’s	  exact	  test	  2	  was	  used.	  	  A	  p	  value	  of	  <	  0.05	  was	  considered	  statistically	  
significant.	  	  SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring;	  CI,	  confidence	  interval;	  
PAF,	  paroxysmal	  atrial	  fibrillation;	  AC,	  anticoagulation;	  TE,	  thromboembolic	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Figure	  3-­‐2:	  	  Kaplan-­‐Meier	  curve	  illustrating	  detection	  of	  “sustained”	  PAF	  episodes	  
	  
	  
SP,	  standard	  practice	  group;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring	  group	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Figure	  3-­‐3:	  	  Kaplan-­‐Meier	  curve	  illustrating	  detection	  of	  “any	  duration”	  PAF	  episodes	  
	  
	  
SP,	  standard	  practice	  group;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring	  group	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Figure	  3-­‐4:	  	  Kaplan-­‐Meier	  survival	  curve	  illustrating	  initiation	  of	  anticoagulation	  attributable	  to	  PAF	  detection	  
	  
	  
SP,	  standard	  practice	  group;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring	  group	  
	   	  
Log	  Rank:	  	  p	  <	  0.05 
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Figure	  3-­‐5:	  	  Kaplan-­‐Meier	  survival	  curve	  illustrating	  initiation	  of	  anticoagulation	  for	  any	  indication	  
	  
	   	  
SP,	  standard	  practice	  group;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring	  group	  	  
Log	  Rank:	  	  p	  <	  0.05 
	  85	  
3.1.4. Discussion	  
This	  trial	  provides	  the	  first	  randomised	  evidence	  in	  an	  unselected	  acute	  ischaemic	  stroke	  and	  
TIA	  patient	  population	  comparing	  investigative	  strategies	  for	  the	  detection	  of	  AF.	  	  The	  study	  
demonstrated	  superior	  effectiveness	  of	  routine	  early,	  extended	  cardiac	  event	  monitoring	  in	  
all	  ischaemic	  stroke	  patients	  with	  sinus	  rhythm,	  versus	  existing	  guideline-­‐based	  practice.	  	  This	  
strategy	   also	   enhanced	   anticoagulation	   rates,	   which	   should	   offer	   improved	   stroke	  
prevention.	  	  Guideline	  based	  practice,	  as	  currently	  implemented	  in	  the	  UK	  &	  elsewhere	  290	  is	  
inadequate	  for	  the	  prevention	  of	  AF-­‐related	  recurrent	  stroke	  and	  can	  readily	  be	  improved.	  
Though	  detection	  with	  prolonged	  monitoring	  has	  been	  explored	  in	  uncontrolled	  longitudinal	  
studies	  and	  selected	  populations	  (e.g.	  cryptogenic	  stroke),	  no	  randomised	  comparisons	  have	  
previously	  been	  reported	  for	  specific	  investigation	  strategies	  in	  unselected	  ischaemic	  stroke	  
patients.	  	  	  
Current	   guidelines	   reflect	   the	   paucity	   of	   randomised	   or	   controlled	   evidence	   evaluating	  
detection	  strategies,	  in	  making	  limited	  and	  diverse	  recommendations	  regarding	  investigation	  
for	  AF	  detection	  following	  stroke.	  	  Typically	  the	  guidelines	  refer	  to	  repeated	  12-­‐lead	  ECGs	  or	  
some	   form	   of	   cardiac	   monitoring	   for	   selected	   patients	   but	   generally	   offer	   no	   specific	  
recommendation	  regarding	  modality	  or	  duration	  19, 27, 29, 79.	   	   In	  the	  UK,	  no	  recommendation	  
beyond	   repeated	   12-­‐lead	   ECGs	   is	   made	   27, 79.	   	   International	   guidelines	   either	   disregard	  
prolonged	   monitoring	   19,	   or	   recommend	   its	   use	   in	   selected	   patients	   only	   29,	   following	   in-­‐
patient	   continuous	   electrophysiological	   monitoring	   (CEM)	   of	   unspecified	   modality	   and	  
duration.	  
Consequently,	  clinical	  practice	  varies	  widely,	  with	  limited	  investigation	  for	  AF	  in	  many	  stroke	  
centres.	  	  	  Some	  stroke	  centres	  may	  reserve	  prolonged	  monitoring	  for	  patients	  with	  so-­‐called	  
cryptogenic	   stroke,	   some	   regard	   24	   hours’	   Holter	  monitoring	   as	   standard	   and	   others	  may	  
restrict	  full	  investigation	  to	  patients	  with	  cortical	  or	  multiple	  territory	  infarcts	  290	  	  In	  the	  UK,	  
only	   25%	   of	   stroke	   physicians	   routinely	   use	   any	   form	   of	   prolonged	   monitoring	   for	   AF	  
detection	   and	   40%	   rely	   solely	   on	   the	   admission	   12-­‐lead	   ECG	   290	   	   Stroke	   units	   may	   lack	  
adequate	   facilities	   for	   routine	   CEM	  monitoring	   and	   in	   the	   absence	   of	   automated	   analysis	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software	  systems,	  the	  likelihood	  of	  AF	  detection	  is	  remote	  263.	   	  Out-­‐patient	  management	  of	  
TIA	  and	  minor	  stroke	  patients	  further	  limits	  viability	  of	  CEM.	  	  	  
UK	   standard	   practice	   reflects	   guidelines	   in	   utilising	   Holter	   devices	   for	   extended	  	  	  	  	  	  	  
monitoring	   290.	   	   Standard	   investigations	   in	   this	   trial	   reflected	   wider	   UK	   practice:	   	   60%	   of	  
patients	  had	  24-­‐hour	  Holter	  monitoring,	  especially	  patients	  with	  suspected	  “embolic”	  stroke	  
aetiology.	  	  The	  AF	  detection	  level	  of	  8%	  in	  the	  SP	  group	  was	  comparable	  with	  rates	  reported	  
in	  the	  absence	  of	  routine	  monitoring	  260	  or	  with	  24-­‐hour	  Holter	  monitoring	  284.	  	  	  
Systematic	   review	  suggests	  Holter	  monitoring	  will	   identify	  AF	   in	  only	  an	  additional	  4.6%	  of	  
patients	  284,	  no	  better	  than	  detection	  rates	  observed	  in	  groups	  lacking	  routine	  monitoring	  260.	  	  
Extending	  the	  duration	  of	  Holter	  monitoring	  should	   increase	  detection	  but	  consumes	  more	  
resources	  276.	   	  Without	  routine	  use	  of	  extended	  cardiac	  monitoring	  following	  stroke,	  AF	  will	  
be	   detected	   in	   only	   6	   –	   8%	   of	   patients	   followed	   for	   90	   days	   260.	   	   Extended	   monitoring	  
increases	  detection	  up	  to	  3-­‐fold	  252, 292.	  	  	  
Detection	   of	   AF	   through	   additional	   monitoring	   in	   this	   study	   compared	   very	   favourably	  
against	   rates	   reported	   for	   24-­‐hour	  Holter	  monitoring	   284	   or	   repeated	   12-­‐lead	   ECGs	   281	   and	  
achieved	   similar	   detection	   rates	   to	   extended	   duration	   Holter	   monitoring	   276,	   automated	  
software	  assisted	  CEM	  	  93	  and	  implantable	  cardiac	  event	  recorders	  275.	  	  	  
Conversely,	   guideline	   based	   practice	   under-­‐detects	   AF.	   	   Additional	   monitoring	   resulted	   in	  
detection	   of	   “sustained”	   PAF	   episodes	   that	   justify	   anticoagulation	   in	   an	   additional	   16%	   of	  
patients,	   within	   14	   days.	   	   This	   allows	   initiation	   of	   treatment	   during	   the	   period	   when	  
recurrence	   risk	   is	  highest.	   	   Current	  guidelines	   suggest	   initiation	  of	   anticoagulant	   treatment	  
two	   weeks	   after	   stroke	   onset	   is	   safe.	   	   As	   discussed	   in	   Chapter	   2,	   there	   may	   be	   patient	  
subgroups	   who	   could	   be	   safely	   treated	   at	   an	   earlier	   stage	   and	   a	   proportion	   of	   patients	  
included	  in	  secondary	  prevention	  anticoagulant	  trials	  were	  enrolled	  prior	  to	  this.	  	  
In	   patients	   with	   cryptogenic	   stroke,	   in	   whom	   simple	  measures	   have	   failed	   to	   identify	   any	  
potential	   cause,	   invasive	   and	  more	   costly	   implantable	   event	   recorders	  with	   their	   adherent	  
risks	  of	  infection	  may	  be	  justified.	  	  They	  offer	  greatly	  extended	  monitoring	  periods	  and	  high	  
detection	   rates	   in	   some	   cohorts	   275.	   	   Conversely,	   a	   recently	   reported	   randomised	   trial	   in	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patients	   with	   cryptogenic	   stroke	   recently	   reported	   that	   prolonged	  monitoring	   brought	   no	  
increase	  in	  diagnostic	  yield	  for	  AF	  271.	  	  	  
For	   the	  majority	   of	   patients,	   however,	   this	   trial	   suggests	   that	   a	   relatively	   brief	   duration	  of	  
non-­‐invasive	   monitoring	   may	   be	   sufficient	   for	   routine	   application,	   with	   88%	   of	   cases	   of	  
“sustained”	  PAF	  identified	  within	  72	  hours.	  	  Excellent	  reporting	  agreement	  between	  treating	  
stroke	   physicians	   and	   the	   electrocardiology	   laboratory	   facilitated	   immediacy	   of	   clinical	  
decisions	  and	  could	  limit	  costs.	  	  	  
A	  non-­‐invasive	  strategy	  that	  had	  few	  technical	  failures,	  no	  adverse	  events	  and	  which	  was	  well	  
tolerated	  is	  an	  attractive	  option	  for	  routine	  application	  in	  unselected	  acute	  patients.	  
Enhanced	   detection	   of	   “sustained”	   PAF	   episodes	   will	   facilitate	   delivery	   of	   anticoagulant,	  
rather	   than	   antiplatelet,	   based	   secondary	   prevention,	   conferring	   an	   additional	   6%	   annual	  
absolute	  risk	  reduction	  178	  for	  these	  patients.	  	  The	  study	  anticoagulation	  rate	  of	  75%	  was	  high	  
but	  even	  using	  more	  typical	  rates	  of	  39%	  23,	  significant	  reductions	  in	  stroke	  recurrence	  would	  
be	  anticipated	  due	  to	  enhanced	  AF	  detection..	   	  The	  emergence	  of	  NOACs	  may	  increase	  the	  
proportion	   of	   patients	   with	   AF	   who	   might	   be	   treated	   with	   anticoagulant	   rather	   than	  
antiplatelet	  based	  therapy.	  
“Any	  duration”	  PAF	  episodes	  were	  also	  detected	   in	  40%	  more	  patients	   receiving	  additional	  
monitoring.	   	   Extrapolating	   across	   the	  UK,	   this	  would	   identify	   an	   additional	   46,080	  patients	  
annually.	  	  	  However,	  these	  brief,	  non-­‐sustained	  paroxysms	  of	  AF	  are	  distinct	  from	  “sustained”	  
PAF.	   	   The	   risk	   they	   confer	   is	   uncertain	   253, 255,	   and	   anticoagulant	   therapy	   is	   of	   unproven	  	  	  	  
value	  31.	  	  Though	  permanent	  and	  paroxysmal	  AF	  share	  an	  equal	  risk	  of	  stroke	  250,	  we	  need	  a	  
large	  scale	  prospective	  study	  to	  evaluate	  the	  risk	  associated	  with	  these	  very	  brief	  paroxysms	  
of	  AF	  that	  are	  now	  readily	  detected.	  	  
The	  cost	  per	  QALY	  gained	  by	  outpatient	  monitoring	  for	  AF	  detection	  is	  estimated	  at	  only	  [US]	  
$13,000	  294.	   	  This	   figure	  excluded	   indirect	  savings	   (e.g.	  carers'	  costs)	  associated	  with	  stroke	  
prevention	  and	  was	  based	  on	  only	  a	  4.45%	  increment	  in	  AF	  detection.	  	  Additional	  monitoring,	  




Generalisability	   of	   this	   trial	   is	   limited	   by	   the	   sample	   size	   and	   its	   derivation	   from	   only	   two	  
centres	  in	  a	  single	  country;	  however,	  equipoise	  was	  lost	  after	  such	  striking	  differences	  were	  
seen	  at	  conclusion	  of	  the	  pilot	  phase.	  	  Study	  patients	  had	  relatively	  mild	  stroke	  or	  TIA	  but	  this	  
group	  potentially	  has	  most	   to	  gain	   from	  expedited	  AF	  detection	  and	  treatment.	   	  The	  study	  
did	  not	  aim	  to	  characterise	  AF	  detection	  according	  to	  TOAST	  criteria.	  	  This	  was	  intentional,	  as	  
the	   original	   randomised	   trial	   sought	   to	   provide	   evidence	   in	   an	   unselected	   ischemic	   stroke	  
and	   TIA	   population,	   allowing	   greater	   generalisation	   of	   findings.	   	   Detection	   rates	   could	   be	  
higher	   among	   patients	   with	   extensive	   cortical	   stroke,	   which	   is	   indicative	   of	   an	   embolic	  
aetiological	  mechanism,	  though	  many	  such	  patients	  were	  ineligible	  because	  AF	  was	  already	  
present.	  	  	  	  	  
The	  study	   lacked	  power	  to	  examine	  clinical	  endpoints	  as	  an	  outcome,	   though	  the	  available	  
evidence	   suggests	   that	   the	   significant	   increase	   in	  detection	  of	   “sustained”	  episodes	  of	  PAF	  
should	   reduce	   stroke	   recurrence	   through	  optimised	  use	  of	   anticoagulant	   therapy.	   	   Further	  
study	  is	  needed	  in	  relation	  to	  the	  significance	  of	  PAF	  episodes	  of	  briefer	  duration.	  	  
How	   readily	  applicable	   these	  data	  are	   to	  non-­‐UK	  based	  populations	  may	  be	  debated.	   	   The	  
study	  design	  did	  not	   standardise	   investigations	   to	   any	  particular	   investigational	   strategy	   in	  
the	  standard	  care	  group,	  as	  this	  does	  not	  reflect	  UK	  clinical	  practice	  nor	  existing	  guidelines	  
from	  the	  UK,	  Europe	  or	  the	  USA.	  	  All	  acknowledge	  that	  prolonged	  monitoring	  may	  be	  needed	  
but	   this	   is	  essentially	   left	   to	  physician	  discretion.	   	  Echocardiography	  or	  other	   investigations	  
were	   not	   used	   to	   screen	   study	   patients	   first	   for	   aetiological	   mechanisms;	   however,	  
indiscriminate	   transthoracic	   and	   transoesophageal	   echocardiography	   offer	   low	   returns	   295	  
and	  undirected	  tests	  are	  discouraged	  in	  our	  health	  service	  29, 79.	  	  The	  study	  sought	  to	  provide	  
evidence	  for	  the	  approach	  to	  unselected	  patients	  presenting	  with	   ischaemic	  stroke	  and	  TIA	  
rather	  than	  for	  a	  cryptogenic	  stroke	  population.	  	  	  
SP	   investigations	   in	   the	   centres	   and	   across	   the	   UK	   290,	   likely	   lie	   towards	   one	   end	   of	   a	  
spectrum	  of	  guideline	  interpretation	  19, 27, 29, 79,	  across	  which	  healthcare	  funding	  approaches	  
may	  exert	   an	   influence.	   	  Whilst	   some	   centres	  may	   routinely	  perform	  extended	  monitoring	  
and	  other	  additional	  investigations	  as	  routine,	  funding	  for	  health	  care	  interventions	  in	  many	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health	   care	   systems	   is	   reliant	   on	   randomised	   evidence	   of	   effectiveness:	   this	   study	   should	  
allow	  the	  level	  of	  evidence	  to	  be	  raised	  and	  to	  improve	  implementation.	  	  Whilst	  the	  control	  
group	   design	   may	   weaken	   generalisation	   to	   some	   environments,	   equally	   it	   strengthens	  
applicability	  to	  others	  and	  we	  hope	  that	  highlighting	  the	  deficiency	  may	  lead	  to	  improvement	  
in	  guidelines	  and	  practice.	  
It	   is	   feasible	  that	  the	  observed	  difference	   in	  AF	  detection	  rates	  between	  the	  SP	  and	  SP-­‐AM	  
study	  groups	  might	  reflect	  a	  greater	  prevalence	  of	  AF	  in	  the	  SP-­‐AM	  group,	  arising	  by	  chance	  
despite	  randomisation.	  	  It	  is	  reassuring	  to	  some	  extent	  that	  SP	  investigations	  were	  balanced	  
between	  treatment	  groups	  as	  was	  the	  detection	  of	  AF	  with	  SP	  investigations.	  
Technical	  limitations	  of	  the	  existing	  R-­‐test	  device	  precluded	  quantification	  of	  the	  total	  burden	  
of	  AF.	  	  Improved	  memory	  and	  detection	  algorithms	  are	  now	  available	  that	  could	  underpin	  a	  
registry	  study	  of	  stroke	  recurrence	  risk	  in	  relation	  to	  burden	  of	  non-­‐sustained	  AF	  episodes.	  
	  
Conclusion	  
This	   trial	   provides	   randomised	   evidence	   that	   routine	   extended	   monitoring	   for	   AF	   in	  
unselected	  patients	  with	  acute	  ischaemic	  stroke	  delivers	  clinically	  meaningful	  and	  statistically	  
significant	   improvements	   in	   detection	   and	   treatment	   rates	   versus	   current	   guideline	   based	  
practice.	  	  Non-­‐invasive	  cardiac	  event	  monitoring	  should	  be	  routinely	  adopted	  as	  the	  standard	  
of	  care	  in	  all	  stroke	  patients	  who	  appear	  to	  be	  in	  sinus	  rhythm.	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3.2. Study	  2:	   	  Predictive	  value	  of	  newly	  detected	  atrial	  fibrillation	  paroxysms	  
in	  acute	  ischaemic	  stroke	  and	  TIA,	  for	  presence	  of	  AF	  after	  90	  days	  
	  
3.2.1. Introduction	  
AF	  observed	  in	  the	  context	  of	  acute	  stroke	  may	  represent	  a	  complication	  of	  the	  stroke	  itself,	  
attributable	   to	   the	   stress	   response	   to	   the	  neurological	   insult	   and	  peri-­‐stroke	   complications	  
such	   as	   sepsis	   124, 285	   or	   in	   association	   with	   involvement	   of	   specific	   areas	   of	   cerebral	  
ischaemia	  285, 286.	   	   If	  such	  episodes	  of	  AF	  represent	  a	  transient	  phenomenon	  only,	  they	  may	  
confer	   no	   additional	   subsequent	   risk	   and	   would	   not	   be	   optimally	   managed	   with	   formal	  
anticoagulation	  in	  the	  long	  term.	  
Intensive	  and	  extended	  monitoring	  for	  PAF	  immediately	  following	  stroke	  increases	  detection	  
of	  PAF	  episodes	  of	  both	  “sustained”	  and	  brief	  duration	  296.	  	  Data	  are	  lacking	  in	  relation	  to	  the	  
predictive	   value	   of	   PAF	   identification	   through	   such	  monitoring,	   for	   AF	   detectable	   at	   some	  
subsequent	  time	  point,	  distant	  from	  the	  acute	  neurological	  injury.	  	  In	  addition,	  there	  are	  few	  
data	  relating	  to	  the	  predictive	  value	  of	  PAF	  episodes	  of	  brief	  duration	  for	  more	  “sustained”	  
episodes	  on	  subsequent	  follow	  up.	  
This	  study	  sought	   to	  evaluate	   the	  predictive	  value	  of	  AF	  detection	   in	   the	  days	   immediately	  
following	  ischaemic	  stroke	  or	  TIA,	  for	  subsequent	  AF	  detection	  through	  non-­‐invasive	  cardiac	  
event	   monitoring,	   performed	   following	   a	   90	   day	   interval	   from	   the	   index	   event.	   	   The	  
predictive	  value	  of	  both	  “any	  duration”	  and	  “sustained”	  duration	  PAF	  episodes	  for	  episodes	  
of	   corresponding	   episodes	   on	   subsequent	   monitoring	   were	   assessed.	   	   In	   addition,	   the	  
predictive	   value	   of	   “any	   duration”	   PAF	   episodes	   for	   subsequently	   identified	   “sustained”	  
duration	  PAF	  episodes	  was	  assessed.	  	  	  
This	   would	   provide	   information	   regarding	   the	   appropriateness	   of	   basing	   therapeutic	  
decisions	   on	   AF	   detected	   in	   the	   period	   immediately	   following	   the	   acute	   event,	   which	   has	  
been	  proposed	  as	  a	  potentially	  unreliable	  measure	  of	  long	  term	  risk	  124.	  	  





This	  study	  was	  an	  observational	  substudy	  extension	  of	  the	  RCT	  described	  in	  section	  3.1.	  	  All	  
participants	  were	  invited	  to	  attend	  for	  7	  days	  non-­‐invasive	  cardiac	  event	  monitoring	  90	  days	  
following	  their	  enrolment.	  	  	  
	  
Study	  Population	  
Details	   of	   the	   study	   population,	   recruitment,	   cardiac	   event	   monitoring	   methodology	   and	  
endpoint	  assessment	  have	  been	  detailed	  in	  chapter	  3.1.2.	  
	  
Follow	  Up	  
After	  90	  days,	  patients	  who	  were	  able	  to	  attend	  for	  interval	  R-­‐test	  monitoring	  underwent	  a	  
further	   7	   day	   monitoring	   period.	   Data	   from	   the	   interval	   monitoring	   was	   downloaded	   as	  
described	  in	  section	  3.1.2.	  	  Thereafter,	  captured	  rhythm	  strips	  were	  reviewed	  for	  evidence	  of	  
AF.	   	  Observed	  episodes	  were	  categorised	  as	  either	  “sustained”	  or	  “non-­‐sustained”	  and	   the	  
combination	   of	   either	   was	   reported	   as	   episodes	   of	   “any	   duration”,	   as	   described	   in	  	  	  	  	  	  	  	  	  
section	  3.1.2.	  
	  
Statistical	  analysis	  	  
Baseline	   characteristics	   and	   AF	   detection	   at	   both	   follow	   up	   time	   points	   in	   Study	   1	   were	  
compared	   between	   the	   group	   of	   patients	   who	   underwent	   interval	   R-­‐test	   monitoring	   and	  
those	  who	  were	  unable	  to,	  to	  assess	  for	  any	  differences	  between	  these	  populations.	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Comparison	  of	  AF	  detection	  (“sustained”	  and	  “any	  duration”)	  between	   initial	   investigations	  
and	   the	   subsequent	   interval	   R-­‐test	   analysis	   was	   performed	   considering	   the	   interval	   R-­‐test	  
analysis	   as	   the	   “Gold	   standard”	   measurement,	   being	   performed	   under	   stable	   conditions	  
distant	   from	   elevated	   sympathetic	   tone	   and	   cerebral	   ischaemia	   which	   might	   potentially	  
influence	  findings	  of	  investigation	  performed	  immediately	  following	  the	  index	  event.	  
Sensitivity,	   specificity,	   negative	   and	   positive	   predictive	   values	   (NPV	   &	   PPV,	   respectively),	  
together	  with	   95%	  CIs,	  were	   each	   calculated	   for	   both	   “sustained”	   and	   “any	   duration”	   PAF	  
episodes	  detected	  by	  each	  of:	   initial	  R-­‐test	   alone;	   initial	   SP	   investigation	  alone	   (at	  both	  14	  
and	   90	   days);	   combined	   initial	   R-­‐test	   and	   SP	   investigation	   (at	   both	   14	   and	   90	   days;,	   for	  
corresponding	  “sustained”	  and	  “any	  duration”	  PAF	  episodes	   identified	   through	   the	   interval	  
R-­‐test.	  
In	  addition,	  sensitivity,	  specificity,	  NPV	  &	  PPV,	  together	  with	  95%	  CIs,	  were	  each	  calculated	  
for	   “any	   duration”	   PAF	   episodes	   detected	   by	   each	   of:	   initial	   R-­‐test	   alone;	   initial	   SP	  
investigation	  alone	  (at	  both	  14	  and	  90	  days);	  combined	  initial	  R-­‐test	  and	  SP	  investigation	  (at	  
both	  14	  and	  90	  days);	  in	  relation	  to	  “sustained”	  PAF	  episodes,	  identified	  though	  the	  interval	  
R-­‐test.	  
Minitab	  (version	  16)	  was	  used	  to	  perform	  statistical	  analysis.	  
	  
3.2.3. Results	  
Interval	   R-­‐testing	   was	   performed	   in	   49	   patients	   (26	   patients	   from	   the	   SP	   group	   and	   23	  
patients	  from	  the	  SP-­‐AM	  group).	  	  There	  were	  no	  technical	  failures	  in	  the	  interval	  R-­‐tests.	  
Baseline	   characteristics	   in	   patients	   who	   participated	   in	   this	   sub	   study	   appeared	   balanced	  
with	   those	   who	   did	   not.	   	   Baseline	   NIHSS	   was	   lower	   and	   treatment	   with	   ACE-­‐I	   &	   calcium	  
channel	  blocker	   (CCB)	  were	  each	  higher	  amongst	  patients	  who	  underwent	   interval	   testing.	  	  
Both	  “sustained”	  and	  “any	  duration”	  PAF	  episode	  detection	  were	  non-­‐significantly	  higher	  in	  
the	   group	  who	   underwent	   interval	   R-­‐test	   testing	   at	   90	   day	   follow-­‐up.	   	   Table	   3-­‐6	   includes	  
baseline	  characteristics	  and	  AF	  detection	  during	  study	  1	   for	   the	  population	  as	  a	  whole	  and	  
the	  subgroups	  who	  did	  not	  and	  did	  undergo	  interval	  R-­‐testing.	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Table	  3-­‐6:	  	  Baseline	  characteristics	  and	  standard	  practice	  investigation	  AF	  detection	  rates,	  
stratified	  according	  to	  availability	  of	  interval	  R-­‐test	  examination	  
	   Total	  










Age	   65.8	  (12.3)	   65.0	  	  	  (14.7)	   66.73	  	  	  (9.19)	   0.47	  
Ictus	  to	  randomisation,	  
Median	  (IQR)	  
1	  (1)	   1	  (2)	   1	  (1)	   	  	  0.99	  1	  
NIHSS	  (stroke	  patients	  
only),	  Median	  (IQR)	  
2	  (4)	   4	  (5)	   2	  (3)	   	  	  0.03	  1	  
SBP	   154.8	  (27.1)	   156.9	  	  	  (28.4)	   152.7	  	  	  (25.9)	   0.44	  
DBP	   81.5	  (14.5)	   83.8	  	  	  (15.5)	   79.2	  	  	  (13.1)	   0.11	  
HR	   77.55	  (17.5)	   78.1	  	  	  (18.0)	   77.0	  	  	  (17.1)	   0.75	  
Alcohol	  units	  /	  week,	  
Median	  (IQR)	  
3	  (15)	   4	  (19)	   2	  (14)	   	  	  0.24	  1	  
Male	  sex	   56	  %	  	   58.8	  %	   51.0	  %	   0.32	  
Qualifying	  event	  Stroke	   68	  %	  	   68.6	  %	   67.3	  %	   0.89	  
Qualifying	  event	  TIA	   32	  %	   31.4	  %	   32.7	  %	   0.89	  
TACS	   14	  %	   19.6	  %	   8.2%	  %	   	  	  0.15	  2	  
PACS	   41	  %	   37.3	  %	  	   44.9	  %	   0.43	  
LACS	   33	  %	   33.3	  %	  	   32.7	  %	   0.94	  
POCS	   12	  %	   9.8	  %	   14.3	  %	   0.49	  
IHD	   16	  %	   13.7	  %	   18.4	  %	   0.53	  
Hypertension	   58	  %	   54.9	  %	   61.2	  %	   0.52	  
Diabetes	   15	  %	   13.7	  %	   16.3	  %	   0.72	  
Smoker	   32	  %	   35.3	  %	   28.6	  %	   0.47	  
Aspirin	   55	  %	   62.7	  %	  
	  
46.9	  %	   0.11	  
Dipyridamole	  MR	   21%	   27.5	  %	   14.3	  %	   0.10	  
Clopidogrel	   27	  %	   21.6	  %	   32.7	  %	   0.21	  
Any	  antiplatelet	   75	  %	   78.4	  %	   71.4	  %	   0.42	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ACE-­‐I	   37	  %	   27.5	  %	   46.9	  %	   0.04	  
ARB	   8	  %	   9.8	  %	   6.1	  %	   	  	  0.71	  2	  
Thiazide	   18	  %	   15.7	  %	   20.4	  %	   0.54	  
CCB	   15	  %	   7.8	  %	   22.4	  %	   	  	  0.05	  2	  
Beta-­‐blocker	   17	  %	   19.6	  %	   14.3	  %	   0.48	  
Alpha-­‐blocker	   2	  %	   2.0	  %	   2.0	  %	   	  	  1.00	  2	  
Statin	   58	  %	   51.0	  %	   65.3	  %	   0.14	  
Other	  lipid	  modifying	   2	  %	   2.0	  %	  	  	   2.0	  %	   	  	  1.00	  2	  
Hypoglycaemic	  therapy	   10	  %	   9.8%	   10.2	  %	   0.95	  
“Any	  duration”	  PAF	  
detected	  (14	  days)	  
8.0	  %	   7.8	  %	   8.2	  %	   	  	  1.00	  2	  
“Any	  duration”	  PAF	  
detected	  (90	  days)	  
16	  %	   11.8	  %	   20.4	  %	   0.24	  
“Sustained”	  PAF	  
detected	  (14	  days)	  
5	  %	   3.9	  %	   6.1	  %	   	  	  0.68	  2	  
“Sustained”	  PAF	  
detected	  (90	  days)	  
12	  %	   7.8	  %	   16.3	  %	   	  	  0.23	  2	  
Continuous	  baseline	  characteristic	  values	  are	  quoted	  as	  mean	  (SD)	  unless	  otherwise	  stated.	  	  Comparison	  was	  
with	  two-­‐sample	  t-­‐test	  except	  when	  a	  variable	  did	  not	  approximate	  to	  the	  Normal	  distribution,	  when	  
comparison	  with	  the	  Mann-­‐Whitney	  test	  1	  was	  used.	  	  Categorical	  baseline	  characteristics	  are	  quoted	  as	  %	  
(95%	  CI).	  	  Comparison	  between	  groups	  (no	  interval	  versus	  interval),	  is	  with	  difference	  in	  2	  proportions.	  	  
When	  observed	  frequencies	  were	  low,	  Fisher’s	  exact	  test	  2	  was	  used.	  	  A	  p	  value	  of	  <	  0.05	  was	  considered	  
statistically	  significant.	  
SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring;	  CI,	  confidence	  interval;	  NIHSS,	  
National	  Institute	  of	  Health	  Stroke	  Scale;	  IQR,	  inter-­‐quartile	  range;	  SBP,	  systolic	  blood	  pressure,	  DBP,	  diastolic	  
blood	  pressure;	  HR,	  heart	  rate;	  TACS,	  total	  anterior	  circulation	  syndrome;	  PACS,	  partial	  anterior	  circulation	  
syndrome,	  LACS	  =	  lacunar	  anterior	  circulation	  syndrome;	  POCS,	  posterior	  circulation	  syndrome;	  TIA,	  
transient	  ischaemic	  attack;	  IHD,	  ischaemic	  heart	  disease;	  MR,	  modified	  release;	  ACE-­‐I,	  angiotensin	  converting	  
enzyme	  inhibitor;	  ARB,	  angiotensin	  receptor	  blocker;	  PAF,	  paroxysmal	  atrial	  fibrillation	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Paroxysms	  of	  AF	  of	  “sustained”	  duration	  were	  observed	  in	  14	  of	  49	  individuals	  with	  interval	  
R-­‐testing	  (7	  patients	  in	  each	  of	  the	  SP	  and	  SP-­‐AM	  groups).	  	  Of	  these	  14	  cases,	  7	  patients	  (5	  in	  
the	  SP	  group,	  2	  in	  the	  SP-­‐AM	  group)	  had	  not	  had	  sustained	  paroxysms	  identified	  during	  the	  
90	  day	  follow	  up	  period	  during	  Study	  1.	  
Paroxysms	   of	   AF	   of	   “any	   duration”	  were	   observed	   in	   30	   of	   49	   individuals	  with	   interval	   R-­‐
testing	  (16	  patients	  in	  the	  SP	  group	  and	  14	  patients	  in	  the	  SP-­‐AM	  group).	  	  Of	  these	  30	  cases,	  
16	  patients	  (13	  from	  the	  SP	  group,	  3	  from	  the	  SP-­‐AM	  group)	  had	  not	  had	  AF	  identified	  during	  
the	  90	  follow	  up	  period	  during	  Study	  1.	  
Tables	   3-­‐7,	   3-­‐8	   &	   3-­‐9	   detail	   sensitivity,	   specificity,	   PPV	   &	   NPV	   of	   “sustained’	   and	   “any	  
duration”	   PAF	   episodes	   detected	   by,	   respectively:	   initial	   R-­‐test	   in	   the	   SP-­‐AM	   group;	   SP	  
investigations	  at	  14	  days	  (in	  each	  of	  the	  SP,	  SP-­‐AM	  and	  combined	  groups);	  and	  any	  Study	  1	  
investigation	   at	   14	   days	   (in	   each	   of	   the	   SP-­‐AM	   and	   combined	   groups)	   for	   corresponding	  
“sustained”	   and	   “any	   duration”	   PAF	   episodes	   detected	   on	   interval	   R-­‐test.	   	   The	   predictive	  
values	   of	   SP	   investigation	   and	   any	   Study	   1	   investigation,	   performed	   up	   to	   90	   days,	   are	  
detailed	  in	  Appendix	  A;	  tables	  A1	  &	  A2,	  respectively.	  	  	  
Study	  1	  R-­‐test	  detection	  of	  PAF,	  performed	  in	  the	  7	  days	  following	  recruitment,	  carried	  high	  
specificity	   and	   PPV	   for	   PAF	   detection	   on	   interval	   R-­‐testing,	   for	   both	   “sustained”	   and	   “any	  
duration”	   episodes.	   	   Sensitivity	   was	   however	   modest	   for	   subsequent	   interval	   detected	  
episodes.	  	  NPV	  of	  initial	  R-­‐test	  investigation	  was	  modest.	  	  
AF	  detection	   through	  Study	  1	   standard	  practice	   investigations	  also	  held	  high	   specificity	   for	  
detection	  of	  AF	  on	   interval	  testing,	  particularly	  for	  episodes	  of	  “any	  duration”.	   	  Accordingly	  
PPV	   of	   AF	   detected	   on	   SP	   investigations	   in	   study	   1	   was	   good.	   	   However,	   Study	   1	   SP	  
investigations	  carried	  low	  sensitivity	  and	  poor	  NPV	  for	  subsequent	  interval	  R-­‐test	  detectable	  
PAF	  episodes,	  at	  both	  14	  and	  90	  day	  follow	  up	  points.	  	  	  
When	   AF	   was	   detected	   with	   any	   Study	   1	   investigation	   modality,	   specificity	   and	   PPV	   for	  
subsequently	   identified	   AF	   on	   interval	   R-­‐test	   was	   high.	   	   However,	   sensitivity	   was	   low,	  
reflecting	  the	  low	  sensitivity	  of	  SP	  investigation.	  	  NPV	  value	  for	  subsequent	  interval	  detected	  
episodes	  was	  also	  low.	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Table	  3-­‐7:	  	  Sensitivity,	  Specificity,	  PPV,	  and	  NPV	  for	  initial	  R-­‐test	  investigation	  detected	  AF,	  
for	  presence	  of	  corresponding	  duration	  AF	  episodes	  after	  90	  days,	  in	  the	  SP-­‐AM	  study	  group	  
	   Sensitivity	   Specificity	   PPV	   NPV	  
R-­‐test	  “Sustained”	   57	  (18	  -­‐	  90)	   100	  (83	  -­‐	  100)	   100	  (47	  -­‐	  100)	   84	  (60	  -­‐	  97)	  
R-­‐test	  “any	  duration”	   64	  (35	  -­‐	  87)	   100	  (72	  -­‐	  100)	   100	  (72	  -­‐	  100)	   64	  (35	  -­‐	  87)	  
Data	  are	  presented	  as	  %	  (95%	  CI).	  	  PPV,	  positive	  predictive	  value;	  NPV,	  negative	  predictive	  value	  
	  
	  
Table	  3-­‐8:	  	  Sensitivity,	  Specificity,	  PPV,	  and	  NPV	  for	  SP	  investigation	  detected	  AF	  at	  14	  days,	  for	  presence	  of	  
corresponding	  duration	  AF	  episodes	  after	  90	  days,	  in	  the	  SP,	  SP-­‐AM	  and	  combined	  study	  groups	  
	   Sensitivity	   Specificity	   PPV	   NPV	  
SP	  group	  14	  
“Sustained”	  PAF	  
14	  (0	  -­‐	  58)	   100	  (85	  -­‐	  100)	   100	  (5	  -­‐	  100)	   76	  (55	  -­‐	  91)	  
SP	  group	  14	  “any	  
duration”	  PAF	  
6	  (0	  -­‐	  32)	   100	  (74	  -­‐	  100)	   100	  (5	  -­‐	  100)	   40	  (21	  -­‐	  61)	  
SP-­‐AM	  group	  14	  
“Sustained”	  PAF	  
29	  (4	  –	  71)	   100	  (83	  –	  100)	   100	  (22	  -­‐	  100)	   76	  (52–	  92)	  
SP-­‐AM	  group	  14	  “any	  
duration”	  PAF	  
21	  (5	  –	  51)	   100	  (72	  –	  100)	   100	  (37	  –	  100)	   45	  (23	  –	  69)	  
Combined	  group	  14	  
“Sustained”	  PAF	  
21	  (5	  -­‐	  51)	   100	  (92	  -­‐	  100)	   100	  (37	  -­‐	  100)	   76	  (61	  -­‐	  87)	  
Combined	  group	  14	  
“any	  duration”	  PAF	  
13	  (4	  -­‐	  31)	   100	  (85	  -­‐	  100)	   100	  (47	  -­‐	  100)	   42	  (28	  -­‐	  58)	  
Data	  are	  presented	  as	  %	  (95%	  CI).	  	  SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring;	  
PAF,	  paroxysmal	  atrial	  fibrillation;	  PPV,	  positive	  predictive	  value;	  NPV,	  negative	  predictive	  value	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Table	  3-­‐9:	  	  Sensitivity,	  Specificity,	  PPV,	  NPV	  for	  all	  combined	  Study	  1	  investigation	  detected	  AF	  at	  14	  days,	  for	  
presence	  of	  corresponding	  duration	  AF	  episodes	  after	  90	  days,	  in	  the	  SP-­‐AM	  and	  combined	  study	  groups	  
	   Sensitivity	   Specificity	   PPV	   NPV	  
SP-­‐AM	  Group	  14	  
“Sustained”	  PAF	  
57	  (18	  -­‐	  90)	   100	  (83	  -­‐	  100)	   100	  (47	  –	  100)	   84	  (60	  -­‐	  97)	  
SP-­‐AM	  Group	  14	  
“any	  duration”	  PAF	  
64	  (35	  -­‐	  87)	   100	  (72	  -­‐	  100)	   100	  (72	  -­‐	  100)	   64	  (35	  -­‐	  87)	  
Combined	  Group	  14	  
“Sustained”	  PAF	  
36	  (13	  –	  65)	   100	  (92	  –	  100)	   100	  (55	  –	  100)	   80	  (65	  –	  90)	  
Combined	  Group	  14	  
“any	  duration”	  PAF	  
37	  (20	  –	  56)	   100	  (85	  –	  100)	   100	  (76	  –	  100)	   50	  (33	  –	  67)	  
Data	  are	  presented	  as	  %	  (95%	  CI).	  	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring;	  PAF,	  paroxysmal	  atrial	  
fibrillation;	  PPV,	  positive	  predictive	  value;	  NPV,	  negative	  predictive	  value	  
	  
Tables	   3-­‐10,	   3-­‐11	   &	   3-­‐12	   detail	   sensitivity,	   specificity,	   PPV	   &	   NPV	   of	   “any	   duration”	   PAF	  
episodes	  detected	  by,	  respectively:	  initial	  R-­‐test	  in	  the	  SP-­‐AM	  group;	  SP	  investigations	  at	  14	  
days	   (in	  each	  of	   the	  SP,	  SP-­‐AM	  and	  combined	  groups);	  and	  any	  Study	  1	   investigation	  at	  14	  
days	  (in	  each	  of	  the	  SP-­‐AM	  and	  combined	  groups),	  for	  “sustained”	  PAF	  episodes	  detected	  on	  
90-­‐day	   interval	   R-­‐test.	   	   The	   predictive	   values	   of	   SP	   investigation	   and	   any	   Study	   1	  
investigation,	   performed	   up	   to	   90	   days,	   are	   detailed	   in	   Appendix	   A;	   tables	   A-­‐3	   and	   A-­‐4,	  
respectively.	  	  	  
Study	   1	   R-­‐test	   detection	   of	   “any	   duration”	   PAF,	   performed	   in	   the	   7	   days	   following	  
recruitment,	  carried	  moderate	  specificity	  and	  PPV	  for	  “sustained”	  PAF	  detection	  on	  interval	  
R-­‐testing.	   	   Sensitivity	  was	  moderate	  and	  NPV	  good	   for	   interval	  R-­‐test	  detected	  “sustained”	  
PAF	  episodes.	  
“Any	  duration”	  AF	  episode	  detection	   through	  Study	  1	  standard	  practice	   investigations	  held	  
good	   specificity	   and	   moderate	   PPV	   for	   detection	   of	   “sustained”	   PAF	   episodes	   on	   interval	  
testing.	   	   Sensitivity	   was	   poor	   however,	   with	   moderate	   NPV.	   	   When	   “any	   duration”	   PAF	  
episodes	  were	  detected	  with	  any	  Study	  1	  investigation	  modality,	  specificity,	  sensitivity,	  PPV	  
and	  NPV	  were	  all	  moderate	  for	  subsequent	  interval	  detected	  “sustained”	  PAF	  episodes.	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Table	  3-­‐10:	  	  Sensitivity,	  Specificity,	  PPV,	  NPV	  of	  “any	  duration”	  PAF	  detection	  on	  initial	  R-­‐test	  investigation	  in	  
the	  SP-­‐AM	  study	  group,	  for	  “sustained”	  duration	  PAF	  on	  interval	  R-­‐test	  investigation	  after	  90	  days	  
	  
Table	  3-­‐11:	  	  Sensitivity,	  Specificity,	  PPV,	  NPV	  of	  “any	  duration”	  PAF	  detection	  on	  SP	  investigation	  at	  14	  days,	  
in	  the	  SP,	  SP-­‐AM	  and	  combined	  study	  groups,	  for	  “sustained”	  duration	  PAF	  on	  interval	  R-­‐test	  investigation	  
after	  90	  days	  
	   Sensitivity	   Specificity	   PPV	   NPV	  
SP-­‐AM	  Group	  SP	  14	   29	  (4	  –	  71)	   94	  (70	  –	  100)	   67	  (9	  –	  99)	   75	  (51	  –	  91)	  
SP	  Group	  SP	  14	   14	  (0	  –	  58)	   100	  (85	  –	  100)	   100	  (5	  –	  100)	   76	  (55	  –	  91)	  
Combined	   Group	  
SP	  14	  
21	  	  (5	  –	  51)	   97	  (85	  –	  100)	   75	  (19	  –	  99)	   76	  (61	  –	  87)	  
Data	  are	  presented	  as	  %	  (95%	  CI).	  	  SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  
monitoring;	  PAF,	  paroxysmal	  atrial	  fibrillation;	  PPV,	  positive	  predictive	  value;	  NPV,	  negative	  predictive	  value	  
	  
Table	  3-­‐12:	  	  Sensitivity,	  Specificity,	  PPV,	  NPV	  of	  “any	  duration”	  PAF	  detection	  on	  all	  combined	  Study	  1	  
investigations	  at	  14	  days,	  in	  the	  SP-­‐AM	  and	  combined	  study	  groups,	  for	  “sustained”	  duration	  PAF	  on	  interval	  
R-­‐test	  investigation	  after	  90	  days	  
	   Sensitivity	   Specificity	   PPV	   NPV	  
SP-­‐AM	  Group	  initial	  
R	  &	  SP	  14	  
86	  (42	  –	  100)	   75	  (48	  –	  93)	   60	  (26	  –	  88)	   92	  (64	  –	  100)	  
Combined	  Group	  R	  
&	  SP	  14	  
50	  (23	  –	  77)	   89	  (73	  –	  97)	   64	  (31	  –	  89)	   82	  (66	  –	  92)	  
Data	  are	  presented	  as	  %	  (95%	  CI).	  	  SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  
monitoring;	  PAF,	  paroxysmal	  atrial	  fibrillation;	  PPV,	  positive	  predictive	  value;	  NPV,	  negative	  predictive	  value	  
	  
	   Sensitivity	   Specificity	   PPV	   NPV	  
SP-­‐AM	  initial	  R	  	   86	  (42	  –	  100)	   81	  (54	  –	  96)	   67	  (30	  –	  93)	   93	  (66	  –	  100)	  
Data	  are	  presented	  as	  %	  (95%	  CI).	  	  SP-­‐AM,	  standard	  practice	  plus	  additional	  monitoring;	  PAF,	  paroxysmal	  atrial	  
fibrillation;	  PPV,	  positive	  predictive	  value;	  NPV,	  negative	  predictive	  value	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3.2.4. Discussion	  
This	   sub	   study	   examined	   the	   predictive	   value	   of	   testing	   for	   occult	   AF	   in	   the	   immediate	  
aftermath	  and	  up	  to	  90	  days	  after	  acute	  ischaemic	  stroke	  or	  TIA,	  relative	  to	  AF	  detection	  by	  
non-­‐invasive	   cardiac	   event	   monitoring	   evaluation	   performed	   90	   days	   following	   the	   index	  
event.	  	  	  
The	   study	   had	   limitations	   including	   sample	   size	   and	   potential	   for	   bias	   due	   to	   convenience	  
sampling.	   	   Nevertheless,	   the	   results	   suggest	   that	   following	   ischaemic	   stroke	   &	   TIA,	   early	  
detection	  of	  AF,	   including	  within	   the	   initial	   7	   days	  of	   ictus	   by	  R-­‐test	   event	  monitoring	   and	  
within	   14	   days	   by	   SP	   investigations,	   holds	   high	   PPV	   for	   detection	   the	   of	   AF	   by	   R-­‐test	  
monitoring	   beyond	   3	   months	   of	   event	   ictus.	   	   These	   findings	   are	   in	   keeping	   with	   the	  
observation	   that	  AF,	  detected	  at	   the	   time	  of	   clinical	  presentation	  with	   ischaemic	   stroke	  by	  
admission	   12-­‐lead	   ECG,	   is	   associated	   with	   subsequently	   detectable	   AF	   288	   and	   provide	  
support	   for	   basing	   treatment	   decisions	   on	   the	   detection	   of	   AF	   in	   the	   period	   immediately	  
after	  stroke.	  	  In	  addition,	  the	  results	  indicate	  that	  the	  NPV	  of	  a	  single	  episode	  of	  non-­‐invasive	  
event	  monitoring	  may	  be	  insufficient	  to	  justify	  performing	  any	  additional	  investigation	  for	  AF.	  	  
It	  has	  been	  suggested	  that	  the	  occurrence	  of	  AF	  early	  following	  stroke	  may	  be	  attributable	  to	  
a	  stress	  response	  to	  either	  the	  neurological	  insult	  or	  an	  associated	  medical	  complication	  (e.g.	  
sepsis,	  acute	  coronary	  syndrome	  (ACS)).	  	  Alternatively	  cortical	  ischaemia	  may	  precipitate	  the	  
dysrhythmia	   124, 285, 286.	   	   As	   these	   stressors	   will	   resolve	   in	   survivors	   over	   time,	   such	  
observation	  of	  AF	  may	  be	  a	  transient	  phenomenon	  only,	  with	  low	  likelihood	  of	  persistence	  or	  
recurrence	   on	   follow	   up.	   	   Thus,	   demonstrable	   AF	   may	   neither	   reflect	   the	   aetiological	  
mechanism	  for	  the	  clinical	  presentation	  nor	  confer	  elevated	  risk	  of	  cardioembolic	  recurrent	  
events	   287.	   	   In	   such	   cases,	   institution	   of	   anticoagulant	   therapy	   would	   not	   be	   expected	   to	  
confer	  additional	  benefit	  to	  a	  patient	  with	  restored	  and	  maintained	  sinus	  rhythm	  252.	  
Whilst	  having	  a	  conceptual	  basis,	  such	  concerns	  are	  relatively	  poorly	  evidenced.	  	  Secondary	  
prevention	   studies	   which	   have	   demonstrated	   benefit	   of	   anticoagulant	   therapy	   in	   patients	  
with	  AF	  did	  so	  having	   included	  patients	  for	  which	  evidence	  of	  AF	  was	  predominantly	  based	  
on	  the	  admission	  ECG	  at	  the	  point	  of	  presentation	  with	  stroke	  or	  TIA	  135, 137.	  	  Only	  a	  minority	  
of	  patients	  were	   included	  on	  the	  basis	  of	  antecedent	  history	  of	  AF.	   	  No	   interval	  ECGs	  were	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required	   to	   confirm	  AF	   in	   the	  EAFT	  which	  demonstrated	  benefit	   of	   anticoagulation	  on	   this	  
basis.	   	   Nevertheless,	   it	   is	   reassuring	   to	   confirm	   that	   demonstrable	   AF	   in	   the	   period	  
immediately	   following	   ischaemic	   stroke	   &	   TIA,	   detected	   by	   prolonged	   monitoring,	  
corresponds	  to	  persistent	  evidence	  of	  PAF	  after	  a	  90	  day	  interval.	  	  
The	   findings	   of	   this	   sub	   study	   reinforce	   those	   of	   the	   first	   RCT	   described	   in	   Chapter	   3.1:	  
standard	  practice	  investigative	  procedures	  based	  on	  existing	  guidelines	  appear	  inadequate	  in	  
detecting	  occult	  PAF.	  	  The	  sensitivity	  of	  SP	  investigation	  to	  interval	  R-­‐test	  detectable	  AF	  was	  
poor	   in	  each	  of	   the	  SP,	   SP-­‐AM	  and	  combined	   study	  population	  groups.	   	  Consequently,	   the	  
NPV	  of	  SP	  investigation	  for	  interval	  detected	  AF	  was	  also	  poor.	  	  	  
Detection	  of	  AF,	  by	  either	  SP	  investigation	  or	  through	  the	  initial	  R-­‐test,	  was	  highly	  specific	  for	  
AF	  detected	  on	   interval	  R-­‐testing,	  with	  a	  high	  PPV.	   	  The	  sample	  size	  was	  modest	  such	  that	  
confidence	   intervals	   were	   wide.	   	   However,	   all	   patients	   in	   whom	   initial	   event	   monitoring	  
detected	   AF	   also	   had	   demonstrable	   AF	   on	   interval	   monitoring,	   for	   both	   paroxysms	   of	  
“sustained”	   and	   “any	   duration”.	   	   Thus,	   with	   greater	   sensitivity	   than	   SP	   investigative	  
procedures	   and	   high	   specificity,	   the	   sub	   study	   results	   re-­‐affirm	   the	   findings	   in	   Study	   1,	  
supporting	   use	   of	   cardiac	   event	   monitoring	   for	   the	   detection	   of	   PAF	   following	   ischaemic	  
stroke	  &	  TIA	  over	  existing	  guideline	  approaches.	  
This	  finding	  provides	  reassurance	  that	  the	  observation	  of	  higher	  AF	  detection	   in	  the	  SP-­‐AM	  
group	  in	  Study	  1	  did	  not	  reflect	  a	  chance	  observation	  attributable	  to	  higher	  AF	  prevalence	  in	  
that	   group:	   the	   proportion	   of	   patients	   in	   the	   SP	   group	  with	   interval	   demonstrable	  AF	  was	  
similar	  to	  that	  in	  the	  SP-­‐AM	  group	  in	  Study	  1	  and	  on	  interval	  R-­‐test	  follow	  up.	  
It	   is	   noteworthy	   that	   the	   NPV	   of	   the	   initial	   R-­‐test	   was	   good	   but	   not	   high	   enough	   that	  
clinicians	   would	   necessarily	   be	   assured	   that	   no	   further	   investigation	   for	   AF	   was	   required.	  	  
This	  study	  lacked	  power	  to	  examine	  which	  factors	  might	  indicate	  the	  necessity	  for	  repeated	  
monitoring.	  	  Invasive	  cardiac	  event	  monitoring	  has	  been	  proposed	  as	  a	  means	  to	  investigate	  
patients	  for	  occult	  PAF	   in	  cryptogenic	  stroke	  286.	   	  The	  findings	  of	  additional	  diagnostic	  yield	  
with	  interval	  R-­‐test	  monitoring	  in	  this	  study	  might	  indicate	  that	  simpler	  strategies,	  including	  
repeated	  or	  prolonged	  monitoring,	  could	  be	  effective	  in	  this	  regard.	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Given	   that	   the	   significance	   of	   briefer	   paroxysms	   of	   AF	   in	   conferring	   risk	   remains	  	  	  	  	  	  	  	  	  
uncertain	  252, 256,	   this	  study	  explored	  the	  predictive	  value	  of	  detection	  of	  “any	  duration”	  AF	  
episodes,	   through	   initial	   Study	   1	   investigations,	   for	   “sustained”	   episodes	   on	   subsequent	  
interval	   cardiac	   event	   monitoring.	   	   The	   NPV	   of	   this	   approach	   was	   high	   for	   initial	   R-­‐test	  
investigation.	  	  I.e.	  if	  the	  initial	  R-­‐test	  failed	  to	  identify	  episodes	  of	  “any	  duration”	  PAF,	  it	  was	  
unlikely	  that	  more	  “sustained”	  episodes	  would	  be	  evident	  on	  interval	  testing.	  	  However,	  the	  
PPV	   was	   only	   modest,	   such	   that	   “any	   duration”	   episodes	   on	   initial	   testing	   were	   only	  
associated	  with	   “sustained”	  duration	  episodes	  on	   interval	   testing	   in	   two	   thirds	  of	  patients.	  	  
SP	  investigation	  detection	  of	  “any	  duration”	  PAF	  were	  highly	  specific	  for	  subsequent	  interval	  
detected	  “sustained”	  episodes.	  	  However,	  NPV	  was	  low,	  reflecting	  the	  overall	  poor	  sensitivity	  
of	  the	  SP	  investigation	  approach.	  
It	   is	  worth	   considering	   that	   the	   natural	   history	   in	   AF	   is	   progression	   from	  PAF	   to	   the	  more	  
sustained	  subtypes	  of	  AF	  over	  time	  244, 297.	   	  The	  studies	  to	  have	  differentiated	  risk	  between	  
subtypes	  had	  relatively	  short	   follow-­‐up	  248.	   	  Assuming	  patients	  undergo	  transition	  between	  
subtypes,	   it	   is	   reasonable	   to	   assume	   that	   more	   prolonged	   follow	   up	   would	   minimise	   any	  
difference	  observed	  between	  subtypes	  at	  baseline.	  	  
	  
Limitations	  
The	   main	   limitation	   of	   this	   study	   is	   that	   the	   available	   sample	   represented	   a	   convenience	  
sample	  from	  a	  larger	  study	  population.	  	  However,	  all	  patients	  were	  invited	  to	  participate	  and	  
approximately	  50%	  of	   the	  eligible	  population	  was	   included.	   	   Those	   included	   in	   the	   interval	  
analysis	   did	   not	   appear	   to	   differ	   significantly	   from	   those	  who	  were	   not,	   in	   either	   baseline	  
characteristics	   or	   the	   frequency	   with	   which	   AF	   was	   detected	   in	   the	   period	   immediately	  
following	  ischaemic	  stroke	  or	  TIA.	  	  The	  notable	  exception	  to	  this	  was	  that	  the	  NIHSS	  amongst	  
stroke	   patients	   was	   lower	   amongst	   those	   in	   the	   interval	   analysis,	   potentially	   reflecting	  
greater	   ease	   in	   repeated	   hospital	   attendance	   amongst	   those	   with	   milder	   stroke	   severity.	  	  
ACE-­‐I	   and	   CCB	   treatment	   were	   each	   higher	   in	   the	   interval	   R-­‐test	   group	   at	   baseline.	   	   This	  
difference	  would	  not	  immediately	  raise	  suspicion	  of	  intrinsic	  differences	  in	  observation	  of	  AF	  
at	  interval	  follow	  up.	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Secondly,	  detection	  of	  both	  “sustained”	  or	  “any	  duration”	  paroxysms	  of	  AF,	  through	  standard	  
practice	   investigation	   modalities,	   did	   not	   differ	   between	   those	   with	   and	   without	   R-­‐test	  
interval	  testing.	  Nevertheless,	  there	   is	  potential	   for	  bias	  to	  have	  arisen	   in	  this	  regard	  which	  
might	  potentially	   limit	  the	  generalisability	  of	  results.	   	  By	  chance,	  patients	  who	  attended	  for	  
interval	  R-­‐test	  may	  have	  had	  a	  greater	  propensity	  to	  exhibit	  AF	  on	  subsequent	  testing	  (due	  to	  
intrinsic	   propensity,	   particular	   medication	   use	   or	   development	   of	   other	   predisposing	   risk	  
factors	  for	  AF).	  	  
A	  third	   limitation	   is	   the	  sample	  size	  available	   for	   the	   interval	  R-­‐test	  analysis.	   	  Though	  point	  
estimates	   suggested	   clinically	   relevant	   information	   is	   yielded	   from	   initial	   investigation	   in	  
terms	  of	  PPV,	   confidence	   intervals	  were	  wide.	   	  A	   larger	   sample	   size	  would	  provide	  greater	  
precision	   and	   also	   permit	   exploration	   of	   subgroups	   and	   potential	   identification	   of	   factors	  
associated	  with	  reduced	  specificity	  of	  early	  investigation.	  
Finally,	   the	  clinical	   relevance	  of	  assessing	  predictive	  value	  of	  early	  detectable	  AF	  compared	  
with	  interval	  detected	  AF	  relies	  on	  the	  assumption	  that	  R-­‐test	  detected	  AF	  distant	  from	  the	  
index	   event	   holds	   clinical	   relevance.	   	   As	   discussed	   in	   chapter	   2.5	   and	   2.6,	   there	   is	   no	  
convincing	   evidence	   which	   undermines	   the	   available	   clinical	   trial	   data	   supporting	   use	   of	  
anticoagulant	  therapy	  in	  patients	  with	  “sustained”	  duration	  paroxysms	  of	  AF	  detected	  in	  the	  
aftermath	  of	  acute	  stroke	  or	  on	  interval	  testing.	  	  
	  
Conclusions	  
This	  study	  provides	  evidence	  that	  AF	  identified	  in	  the	  period	  immediately	  following	  stroke	  is	  
likely	   to	   be	   evident	   on	   interval	   testing,	   performed	   3	   months	   after	   ictus.	   	   This	   provides	   a	  
supportive	  basis	  for	  early	  investigation	  and	  treatment	  decisions	  based	  on	  early	  identification	  
of	   cases.	   	   Despite	   the	   small	   sample	   size,	   the	   NPV	   of	   SP	   investigation	   is	   poor	   and	   is	   only	  
modest	   for	   early	  R-­‐test	  monitoring.	   	   Together,	   these	   findings	   support	   the	   conduct	  of	   early	  
cardiac	  event	  monitoring	  investigation	  in	  all	  patients	  and	  point	  toward	  a	  potential	  need	  for	  
repeated	  interval	  monitoring.	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The	  potential	  role	  of	  uric	  acid	  and	  xanthine	  oxidase	  in	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An	   association	   between	   elevated	   serum	   uric	   acid	   (SUA)	   levels	   and	   increased	   risk	   of	  
cardiovascular	  events	  &	  mortality	  has	  been	  described	  in	  the	  literature	  for	  several	  decades	  298.	  	  
This	   has	   led	   many	   authors	   to	   hypothesise	   the	   existence	   of	   an	   aetiological	   relationship	  
between	   UA	   and	   atherosclerotic	   disease.	   	   In	   recent	   years,	   a	   second	   hypothesis	   has	   been	  
proposed	   to	   explain	   the	   relationship	   between	   elevated	   SUA	   and	   increased	   risk	   of	  
cardiovascular	   disease;	   Rather	   than	   UA	   holding	   a	   direct	   atherogenic	   role	   per	   se,	   SUA	   has	  
been	  proposed	  as	   representing	  a	   surrogate	  marker	   for	  harmful	   levels	  of	   vascular	  oxidative	  
stress,	  produced	  by	  the	  xanthine	  oxidase	  (XO)	  enzymatic	  system	  299.	  	  	  	  
However,	  such	  an	  aetiological	  relationship	  remains	  unproven	  and	  a	  source	  of	  debate.	  	  There	  
is	  inconsistency	  in	  the	  strength	  of	  the	  association	  reported	  between	  epidemiological	  studies.	  	  
In	   addition,	   SUA	   elevation	   clusters	   with	   traditional	   CV	   risk	   factors,	   leading	   some	  
commentators	  to	  cast	  doubt	  on	  the	  validity	  of	  the	  epidemiological	  associations	  representing	  
a	   novel	   aetiological	   relationship.	  Moreover,	   definitive	   studies	   evaluating	   these	   hypotheses	  
have	   not	   been	   forthcoming.	   	   Consequently,	   the	   potential	   therapeutic	   strategy	   of	   UA	  
reduction	  through	  XO	  inhibition	  (XOI)	  in	  the	  prevention	  of	  cardiovascular	  disease	  remains	  an	  
area	  that	  awaits	  definite	  evaluation.	  
	  
4.1. Biochemistry	  of	  uric	  acid	  and	  the	  xanthine	  oxidase	  enzymatic	  system	  
DNA	  and	  RNA	  molecules	  undergo	  degradation	  to	  purine	  nucleotides	  and	  bases.	  	  Adenine	  and	  
Guanine	   are	   subsequently	   either	   recycled	   in	   nucleic	   acid	   synthesis	   processes	   or	   undergo	  
further	  metabolism	  prior	  to	  excretion.	  	  Uric	  acid	  represents	  the	  final	  metabolic	  product	  in	  the	  
degradation	  pathway	  of	  these	  purines	  300.	  	  	  
Adenine	   is	   formed	   from	   IMP	   (which	   itself	   is	  derived	   from	  AMP).	   	  Removal	  of	   a	   ribose	  unit	  
from	  Adenine	  results	   in	  the	  formation	  of	  Hypoxanthine.	   	  Guanine	   is	   formed	  from	  GMP	  and	  
subsequently	  undergoes	  deamination,	  resulting	  in	  the	  formation	  of	  xanthine.	  	  Subsequently,	  
under	  the	  activity	  of	  the	  enzyme	  XO,	  hypoxanthine	  is	  oxidized,	  resulting	  in	  the	  formation	  of	  
xanthine.	  	  Xanthine,	  produced	  by	  either	  pathway,	  is	  further	  oxidized	  to	  UA,	  again	  under	  the	  
activity	  of	   the	  enzyme	  XO.	   	   In	  most	  non-­‐human	  mammals,	  under	  the	  action	  of	   the	  enzyme	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uricase,	   UA	   undergoes	   further	   metabolism	   to	   Allantoin,	   which	   is	   then	   excreted	   in	   urine.	  	  
However,	   humans	   and	   higher	   primates	   lack	   uricase	   and	   UA	   undergoes	   no	   further	  
metabolism.	  	  It	  is	  excreted	  via	  predominantly	  renal	  elimination.	  	  
Xanthine	  oxidase	   is	   from	   the	  molybdenum	   iron-­‐sulfur	   flavin	  hydroxylase	  group	  of	  enzymes	  
and	  is	  found	  predominantly	  in	  the	  liver	  and	  gastrointestinal	  tract	  but	  also	  in	  the	  kidney	  and	  
brain.	  It	  is	  also	  found	  throughout	  the	  cardiovascular	  system	  301.	  	  While	  the	  major	  role	  of	  XO	  is	  
conversion	   of	   hypoxanthine	   and	   xanthine	   to	   UA,	   an	   interconvertible	   form,	   xanthine	  
dehydrogenase,	  also	  exists	  and	  is	  responsible	  for	  conversion	  of	  NAD+	  to	  NADH	  302.	  	  XO	  activity	  
is	  associated	  with	  production	  of	  reactive	  oxygen	  species	  (ROS),	  including	  hydrogen	  peroxide	  
and	   superoxide.	   	  ROS	  add	   to	  and	  may	   initiate,	   through	   reaction	  with	  NO	  and	   formation	  of	  
peroxynitrite,	  vascular	  oxidative	  stress	  303.	  	  
Sources	   of	   purine	   substrate	   for	   the	   XO	   metabolic	   pathway	   include	   endogenous	   DNA	   and	  
RNA,	   and	   exogenous	   ingested	   dietary	   purines	   (e.g.	   in	   alcoholic	   beverages	   and	   red	   meat).	  
Thus,	  SUA	  may	  be	  increased	  through	  conditions	  in	  which	  cellular	  turnover	  is	  increased,	  with	  
high	   levels	  of	  DNA	  and	  RNA	  degradation	  (e.g.	   tumour	   lysis	  syndromes)	  or	   in	   the	  context	  of	  
increased	  dietary	  exposure	  304.	  	  
Serum	  UA	  levels	  are	  determined	  by	  excretion	  through	  the	  kidneys.	  	  Excretion	  may	  also	  occur	  
through	  the	  intestinal	  tract	  but	  does	  not	  appear	  subject	  to	  regulation	  or	  variation.	  	  Uric	  acid	  
is	  filtered	  at	  the	  renal	  glomerulus	  but	  may	  be	  reabsorbed	  in	  the	  proximal	  convoluted	  tubule	  
under	   the	   action	   of	   the	   URAT1	   transporter	   305.	   	   Inter	   individual	   variations	   in	   SUA	   in	   the	  
setting	  of	  stable	  dietary	  intake	  are	  likely	  to	  be	  attributable	  to	  variable	  renal	  excretion	  305, 306.	  	  
SUA	  is	  typically	  higher	  in	  males	  than	  females	  and	  rises	  in	  females	  with	  ageing.	  	  Discrepancies	  
between	   the	   sexes	   and	   following	   the	  menopause	   suggest	   a	   responsiveness	   of	   SUA	   to	   sex	  
hormones	  307, 308.	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Figure	  4-­‐1:	  	  Illustration	  of	  purine	  metabolism	  	  
(reproduced	  from	  Pacher	  et	  al,	  Pharmacol	  Review	  2006)	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Abnormal	  elevations	  in	  UA	  are	  associated	  with	  a	  number	  of	  medical	  morbidities,	  particularly	  
conditions	   which	   predispose	   to	   the	   development	   of	   cardiovascular	   events,	   including	   renal	  
impairment	  300.	  	  SUA	  is	  typically	  elevated	  in	  the	  context	  of	  DM	  309	  and	  increased	  body	  mass	  
index	  (BMI)	  310.	  These	  observations,	  together	  with	  findings	  of	  HU	  in	  states	  of	  relative	  insulin	  
resistance	   311, 312,	  have	   led	   to	  a	  hypothesis	   that	  UA	   levels	  may	  either	   reflect,	  or	   conversely	  
mediate,	   insulin	   sensitivity.	   	   SUA	   is	   also	   found	   to	   be	   elevated	   in	   the	   context	   of	  	  	  	  	  
hypertension	   313, 314	   dyslipidaemia	   315,	   smoking	   316	   and	   is	   a	   component	   of	   the	   metabolic	  
syndrome	  317.	  	  Levels	  are	  consistently	  elevated	  in	  both	  renal	  318	  and	  cardiac	  dysfunction.	  	  SUA	  
is	  also	  elevated	  amongst	  patients	  treated	  with	  diuretics	  319.	  
	  
4.2. Association	  of	  serum	  uric	  acid	  with	  incident	  cardiovascular	  disease	  
Epidemiological	   studies	   have	   reported	   an	   association	   between	   UA	   levels	   and	   risk	   of	  
cardiovascular	  disease	  and	  mortality	   for	  several	  decades.	   	  Over	   this	  period,	   the	  majority	  of	  
published	  studies	  have	  reported	  a	  positive	  association,	  though	  not	  universally	  so.	  	  Conflicting	  
evidence	  has	  been	  attributed	   to	  differences	   in	   study	  methodology,	  particularly	   adjustment	  
for	   risk	   factors	   and	  medical	   therapy	   and	   to	   differences	   in	   the	   populations	   studied.	   	  More	  
recently,	  attempts	  have	  been	  made	  to	  combine	  the	  available	  evidence	  in	  meta-­‐analysis.	  
The	  largest	  single	  prospective	  cohort	  study	  published	  to	  date,	  included	  nearly	  90,000	  healthy	  
Taiwanese	   individuals	  aged	  over	  35	  years.	   	  During	  mean	  follow-­‐up	  of	  8	  years,	  5,427	  deaths	  
occurred.	  	  Those	  with	  hyperuricaemia	  (defined	  as	  SUA	  >7mg/dl),	  were	  at	  increased	  risk	  of	  all-­‐
cause	   mortality,	   combined	   cardiovascular	   disease	   events	   and	   stroke.	   	   This	   association	  
remained	   significant	   following	   adjustment	   for	   conventional	   CV	   risk	   factors	   and	   was	   also	  
observed	  within	  subgroups	  with	  specific	  CVRFs,	  including	  hypertension	  and	  diabetes	  320.	  	  The	  
NHANES	  cross	  sectional	  population	  study	  included	  5926	  healthy	  North	  American	  individuals,	  
aged	  25	  -­‐	  74	  years,	  with	  available	  SUA	  measurements.	  	  During	  mean	  follow	  up	  of	  16.4	  years,	  
IHD	   deaths	   were	   increased	   amongst	   those	   individuals	   in	   the	   highest	   compared	   with	   the	  
lowest	  UA	  quartile	  at	  baseline	  (risk	  ratio	  1.77	  95%	  CI	  1.08	  -­‐	  3.98)	  321.	   	  Stack	  and	  colleagues	  
reported	   an	   analysis	   based	   on	   the	   NHNESIII	   study	   population,	   which	   included	   15,773	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participants	   322.	   	   For	   every	   1mg/dl	   increase	   in	   SUA,	   both	  ACM	  and	   CVM	  were	   significantly	  
increased.	  	  
SUA	   has	   also	   been	   reported	   to	   predict	   both	   mortality	   and	   cardiovascular	   events	   in	  
populations	  with	   either	   established	   CV	   disease	   or	   risk	   factor	   conditions	   for	   cardiovascular	  
events.	   	  Amongst	  the	  subgroup	  of	   individuals	   in	  the	  NHNESIII	  study	  with	  DM,	  elevated	  SUA	  
was	  associated	  with	  ACM	   323.	   	   SUA	  has	  been	   found	   to	  predict	  ACM	  amongst	  patients	  with	  
CAD	   324, 325,	   and	   to	   predict	   CVM	   in	   patients	   with	   hypertension	   326.	   	   SUA	   is	   predictive	   of	  
cardiovascular	  events	  in	  those	  with	  hypertension	  327-­‐329,	  and	  stroke	  and	  diabetes	  330, 331.	  
Several	  studies	  have	  reported	  the	  relationship	  between	  SUA	  and	  risk	  of	  stroke	  as	  a	  specific	  
CV	   outcome.	   	   Chen	  &	   colleagues	   observed	   increased	   ischaemic	   stroke	   related	  mortality	   in	  
Healthy	  Taiwanese	  individuals	  320	  and	  Strasak	  and	  colleagues	  reported	  similar	  findings	  in	  an	  
Australian	   population	   332.	   	   A	   positive	   association	   with	   stroke	   related	   mortality	   has	   been	  
observed	   in	   hypertensive	   populations	   326.	   	   In	   patients	   with	   prior	   stroke,	   risk	   of	   recurrent	  
stroke	   events,	   are	   associated	  with	   increased	   SUA	   	   333	   as	   is	   the	   risk	   of	   recurrent	   combined	  
vascular	  events	  330,	  including	  in	  the	  subgroup	  of	  patients	  with	  DM	  331.	  
However,	  not	  all	  published	  studies	  have	  reported	  an	  independent	  association	  between	  SUA	  
and	  subsequent	  risk.	   	  Culleton	  and	  colleagues,	  performed	  an	  analysis	  of	  6763	   individuals	   in	  
the	  Framingham	  population	  study	   334.	   	  During	  23	  years	   follow	  up,	  1460	  deaths	  occurred	  of	  
which	   429	  were	   characterised	   as	   being	   of	   CV	   aetiology.	   	   Unadjusted	   analysis	   suggested	   a	  
highly	   significant	  association	  of	   increasing	  SUA	  with	   risk	  of	  both	  ACM	  and	  CVM.	   	  However,	  
following	   adjustment	   for	   age,	   sex,	   traditional	   CVRFs,	   including	   measures	   of	   obesity	   and	  
insulin	   resistance	   and	   diuretic	   based	   therapy,	   no	   significant	   association	   was	   observed.	   	   In	  
males,	   following	   adjustment,	   the	   direction	   of	   correlation	   was	   reversed	   toward	   a	   negative	  
association	  of	  risk	  with	  SUA.	  	  The	  authors	  concluded	  that	  UA	  merely	  represents	  a	  surrogate	  
marker	  for	  risk	  attributable	  to	  established	  CV	  risk	  factors	  and	  use	  of	  therapies,	  which	  may	  in	  
turn	  indicate	  risk	  factor	  disease	  severity.	  	  In	  a	  Korean	  population	  of	  22,698	  individuals	  aged	  
30-­‐77	  years,	  Jee	  and	  colleagues	  also	  observed	  a	  non-­‐significant	  association	  between	  SUA	  and	  
subsequent	  ACM	  and	  CVM	  335.	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Explanations	  for	  the	  conflicting	  findings	  reported	  between	  population	  studies	  are	  not	  readily	  
forthcoming.	   	  Similar	  methodology	   to	   that	  employed	   in	   the	  Framingham	  analysis,	   including	  
adjustment	  for	  the	  same	  co-­‐morbidities	  and	  therapeutic	  burden,	  has	  subsequently	  resulted	  
in	  identification	  of	  positive	  associations	  in	  other	  populations	  320, 321, 332, 336.	  	  	  
SUA	  has	  been	   found	   to	  hold	   independent	  predictive	   value	  within	  populations	  with	   specific	  
cardiovascular	   risk	   conditions	   which	   were	   adjusted	   for	   in	   the	   general	   population	  	  	  	  	  	  	  	  	  
analyses	   321, 336.	   	   This	   could	   potentially	   indicate	   SUA	   truly	   holding	   independent	   predictive	  
value.	   	   An	   alternative	   explanation	   includes	   the	   possibility	   that	   SUA	   represents	   a	   surrogate	  
marker	  for	  severity	  of	  derangement	  for	  each	  of	  these	  established	  risk	  factors.	  
Of	  note,	  several	  studies	  have	   identified	  sex	  specific	  differences	   in	  the	  relationship	  between	  
SUA	  and	   risk	  of	  mortality	   and	  of	  CV	  events.	   	   The	   relationship	   appears	   to	  be	   attenuated	   in	  
males	  relative	  to	  females	  320, 321.	  	  A	  meta-­‐analysis,	  including	  data	  from	  26	  studies	  and	  402,997	  
adults,	   reported	   that	   HU	   was	   associated	   with	   both	   CHD	   incidence	   and	   mortality	   in	   the	  
population	  as	   a	  whole	   337.	   	  However,	  no	   significant	   association	  was	  associated	   in	   the	  male	  
population.	   	   In	   addition,	   the	   relationship	   between	   SUA	   and	   risk	   in	   females	   appears	   to	   be	  
stronger	   in	   post-­‐menopausal	   individuals	   338.	   	   These	   findings	   may	   suggest	   an	   interaction	  
between	  sex	  hormones	  and	  the	  influence	  of	  UA.	  
In	  some	  studies,	   the	  relationship	  between	  SUA	  and	  risk	  appears	  to	  be	  J-­‐shaped,	  with	  some	  
recrudescence	   of	   risk	   at	   the	   lowest	   levels	   of	   SUA	   339-­‐342.	   	   Theoretical	   explanations	   include	  
reference	  to	  physiological	  levels	  of	  UA	  potentially	  holding	  beneficial	  effects.	  	  This	  possibility	  is	  
discussed	  in	  greater	  detail	  below.	  
Despite	   failure	   to	   identify	   an	   independent	   relationship	   between	   SUA	   and	   outcomes	   in	  
selected	   populations,	   the	   balance	   of	   published	   evidence	   appears	   supportive	   of	   such	   a	  
relationship.	   	   In	   a	  meta-­‐analysis	   of	   prospective	   study	   data,	   including	   172,123	   participants,	  
Zhao	  and	  colleagues	  found	  that	  elevated	  SUA	  was	  associated	  with	  both	  increased	  ACM	  and	  
CVM	  343.	   	  There	  was	   limited	  data	  available	   for	  very	   low	   levels	  of	  SUA	  from	  which	  to	  derive	  
strong	  conclusions.	  
A	  systematic	   review	  and	  meta-­‐analysis	  of	  prospective	  cohort	  studies	  which	   included	  risk	  of	  
stroke	  incidence	  in	  relation	  to	  SUA	  level	  was	  reported	  by	  Kim	  and	  colleagues	  in	  2009	  344.	  	  The	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authors	   identified	   16	   such	   studies,	   totalling	   238,499	   individuals.	   	   Hyperuricaemia	   was	  
associated	  with	  both	   increased	  stroke	   incidence	  (6	  studies;	  RR	  1.41,	  95%	  CI	  1.05,	  1.76)	  and	  
mortality	  (6	  studies;	  RR	  1.36,	  95%	  CI	  1.03,	  1.69)	  (unadjusted	  analyses).	  An	  analysis	  based	  only	  
on	   studies	   which	   included	   adjustment	   for	   conventional	   CV	   risk	   factors,	   also	   indicated	  
increased	  risk	  with	  hyperuricaemia	  for	  both	  stroke	  incidence	  (4	  studies;	  RR	  1.47,	  95%	  CI	  1.19,	  
1.76)	  and	  mortality	  (6	  studies;	  RR	  1.26,	  95%	  CI	  1.12,	  1.39).	  
Table	   4-­‐1	   summarises	   the	   reported	   associations	   between	   elevated	   SUA	   and	   risk	   of	   stroke.	  	  
Table	  4-­‐2	  summarises	  the	  reported	  associations	  between	  elevated	  SUA	  and	  risk	  of	  all-­‐cause	  
mortality,	  cardiovascular	  mortality	  and	  cardiovascular	  events	  in	  patients	  with	  established	  CV	  
disease,	   CV	   risk	   factors	   and	   general	   populations.	   	   Risk	   associations	   have	   typically	   been	  
reported	  for	  incremental	  increases	  in	  SUA	  concentration	  or	  alternatively	  as	  comparative	  risk	  
between	  patients	  with	  highest	  stratification	  of	  SUA	  level	  to	  those	  with	  the	  lowest	  SUA	  level	  
(e.g.	  tertiles,	  quartiles,	  quintiles).	  
Table	  4-­‐1:	  	  Relationship	  between	  SUA	  and	  risk	  of	  stroke	  
Study	   Population	   Risk	  of	  Stroke	  Outcome	  
Lehto	   Diabetes	   HR	  1.91	  (1.24-­‐2.94)	  for	  stroke	  a	  
Wang	   Hypertension	   HR	  1.34	  (1.14-­‐1.57)	  for	  fatal	  stroke	  b	  
Chen	   Healthy	  Volunteers	   HR	  1.35	  (1.04–1.76)	  for	  IS	  related	  mortality	  c	  
HR	  1.09	  (1.05–1.14)	  for	  IS	  related	  mortality	  d	  
Strasak	   Healthy	  Volunteers	   HR	  1.37	  (1.09-­‐1.74)	  for	  stroke	  related	  mortality	  a	  
HR1.07	  (1.01–1.13)	  for	  stroke	  related	  mortality	  e	  
Schretlen	   Healthy	  Volunteers	   OR	   2.6	   (1.2-­‐5.4)	   for	   white	   matter	   hyperintense	  
signals	  on	  MRI	  imaging	  a	  
Results	  expressed	  as	  ratio	  and	  95%	  CI.	  	  a	  =	  for	  highest	  vs.	  lowest	  group;	  b	  =	  for	  each	  50µmol/L	  increment	  in	  
SUA;	  c	  =	  SUA	  >	  7	  mg/dl	  vs.	  <	  7	  mg/dl;	  d	  =	  per	  additional	  0.1mmol/l	  in	  SUA;	  e	  =	  for	  each	  59.48	  micro	  mol	  
increase	  in	  UA	  level.	  	  HR,	  hazard	  ratio;	  OR,	  odds	  ratio;	  IS,	  ischaemic	  stroke;	  MRI,	  magnetic	  resonance	  imaging	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Table	  4-­‐2:	  	  Relationship	  between	  SUA	  and	  cardiovascular	  risk	  
Reference	   Population	   Risk	  of	  CV	  Outcome	  
Weir	   Acute	  stroke	   RR	  1.27	  (1.18-­‐1.36)	  for	  recurrent	  vascular	  events	  a	  
Newman	   Diabetes	  &	  	  stroke	   HR	  1.49	  (1.21-­‐1.84)	  	  for	  recurrent	  CV	  event	  a	  
Madsen	   Coronary	  Disease	   HR	  1.5	  (1.02-­‐2.1)	  	  for	  all-­‐cause	  mortality	  b	  
Bichel	   Coronary	  Disease	   HR	  1.23	  (1.11-­‐1.36)	  	  for	  all-­‐cause	  mortality	  c	  
Franse	   Hypertension	   HR	  1.32	  (1.03-­‐1.69),	  for	  CV	  events	  b	  
Alderman	   Hypertension	   HR	  1.22	  (1.11-­‐1.35)	  for	  CV	  disease	  d	  
Wang	   Hypertension	   HR	  1.14	  (1.02-­‐1.27)	  	  for	  CV	  mortality	  e	  	  
Verdacchia	   Hypertension	   HR	  1.73	  (1.01-­‐3)	  for	  CV	  event	  rates	  b	  
de	  Leeuw	   Hypertension	   HR	  1.03	  (0.93-­‐1.14)	  	  for	  CV	  mortality	  e	  
HR	  1.06	  (0.99-­‐1.13)	  	  for	  all	  CV	  events	  e	  
Fang	   Healthy	  individuals	   HR	  1.109	  (1.02	  -­‐	  1.18)	  for	  CV	  mortality	  f	  
Chen	   Healthy	  individuals	   HR	  1.16	  (p<0.001)	  for	  all-­‐cause	  mortality	  b	  
Strasak	   Healthy	  individuals	   HR	  1.35	  (1.20-­‐1.52)	  for	  CV	  mortality	  b	  
HR	  1.37	  (1.09-­‐1.74)	  for	  stroke	  b	  
Meisinger	   Healthy	  individuals	   HR	  1.40	  (1.13-­‐1.74)	  ACM	  a	  
Culleton	   Healthy	  individuals	   HR	  0.98	  (0.78	  –	  1.24)	  a	  &	  0.97	  (0.91-­‐1.03)	  f,*for	  ACM	  
HR	  1.16	  (0.89	  –	  1.51)	  a	  &	  1.03	  (0.97-­‐1.09)	  f,#	  for	  ACM	  
Stack	   General	  population	   HR	  1.16	  (1.10-­‐1.22)	  f	  (ACM)	  &	  1.16	  (1.10-­‐1.22)	  	  (CVM)	  f	  
Results	  expressed	  as	   ratio	  and	  95%	  CI.	  a	  =	  per	  additional	  0.1mmol/l	   in	  serum	  UA,	  b	  =	   for	  highest	  vs.	   lowest	  
group,	  c,d	  =	  per	  additional	  0.6	  and	  0.86mmol/l	  in	  SUA	  respectively,	  	  e	  =	  for	  each	  50µmol/L	  increment	  in	  SUA.	  f	  
=	  for	  each	  59.48	  micro	  mol	  increase	  in	  UA	  level.	  *	  =	  male.	  	  #	  =	  female.	  	  RR,	  relative	  risk;	  CV,	  cardiovascular;	  HR,	  




4.3. Putative	  vasculopathic	  role	  for	  uric	  acid	  
Uric	  acid	  crystals	  have	  the	  potential	  to	  induce	  profound	  inflammation,	  evident	  in	  their	  role	  in	  
the	  pathogenesis	  of	  gout.	  	  UA	  holds	  properties	  which	  may	  contribute	  to	  the	  pathogenesis	  of	  
atherothrombotic	   disease	   exist	   at	   each	   of	   the	   molecular,	   cellular	   and	   tissue	   levels	   and	   is	  
associated	  with	  several	  surrogate	  markers	  of	  impaired	  cardiovascular	  health	  and	  function.	  
Uric	  acid	  is	  associated	  with	  increased	  oxygenation	  of	  LDL	  345,	  a	  key	  step	  in	  atherogenesis.	  	  HU	  
is	   associated	   with	   induction	   of	   vasoconstrictive	   mediators	   including	   endothelin-­‐1	   346	   and	  
angiotensin	   II	   347.	   	  Uric	  acid	  crystals	  have	  also	  have	  been	  shown	  to	  stimulate	  release	  of	  the	  
platelet	   constituents	   serotonin,	  ATP	  and	  ADP	   348.	   In	  addition,	  UA	  has	  been	  associated	  with	  
elevated	  levels	  of	  free	  radical	  formation	  349	  and	  elevated	  levels	  of	  oxidative	  stress	  350, 351.	  	  As	  
discussed	  below,	  these	  latter	  findings	  may	  reflect	  not	  only	  direct	  effects	  of	  uric	  acid	  per	  se,	  
but	  also	  the	  activity	  of	  the	  XO	  enzymatic	  system.	  UA	  has	  been	  implicated	  in	  reduced	  insulin	  
sensitivity	  352.	  Serum	  UA	  levels	  have	  also	  been	  linked	  to	  levels	  of	  pro-­‐inflammatory	  cytokines	  
and	   may	   have	   a	   role	   in	   perpetuating	   the	   inflammatory	   response	   that	   characterises	  
atherosclerosis.	  
At	   the	   cellular	   level,	   HU	   is	   associated	   with	   promotion	   of	   vascular	   smooth	   muscle	   cell	  
proliferation	   353.	   	   Platelet	   function	   is	   altered	   by	   UA,	   with	   evidence	   of	   increased	  	  	  	  
adhesiveness	  348.	  	  Hyperuricaemia	  is	  also	  associated	  with	  endothelial	  dysfunction	  74.	  
Uric	  acid	  has	  a	  putative	  role	  in	  the	  development	  of	  hypertension,	  via	  effects	  on	  nitric	  oxide	  
(NO)	  production	  in	  the	  macula	  densa	  354, 355,	  renal	  salt	  handling	  356	  and	  effects	  on	  the	  Renin	  
Angiotensin	  system	  357.	  	  Aside	  from	  the	  association	  with	  cardiovascular	  events	  and	  mortality	  
in	   healthy	   individuals,	   UA	   also	   appears	   to	   be	   independently	   predictive	   of	   new	   onset	  
hypertension	  358.	  	  Studies	  have	  shown	  that	  UA	  reduction	  with	  allopurinol	  can	  improve	  BP	  in	  
adolescents	  with	  newly	  diagnosed	  hypertension	  359.	  	  
In	   the	   Korean	   Multi-­‐Rural	   Communities	   Cohort	   study,	   the	   relationship	   between	   SUA	   and	  
surrogate	  markers	  of	  CV	  health	  was	  examined	   in	  5,568	   individuals.	   	  Ba-­‐PWV	  was	   increased	  
amongst	   individual	  with	  hyperuricaemia,	  with	   a	  positive	   correlation	  and	   linear	   relationship	  
observed	  in	  both	  male	  and	  female	  individuals.	  	  Serum	  UA	  has	  also	  been	  related	  to	  markers	  of	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arterial	   stiffness	   in	   other	   populations,	   including	   post-­‐menopausal	   women	   360,	   Japanese	  
individuals	  361	  and	  patients	  with	  cerebrovascular	  disease	  362.	  	  Conversely,	  other	  studies	  have	  
failed	  to	  identify	  an	  association	  between	  SUA	  and	  arterial	  stiffness	  363, 364.	  
In	   the	   ARIC	   study,	   SUA	   was	   related	   to	   CIMT	   but	   only	   in	   male	   individuals	   365.	   	   Tavil	   and	  
colleagues	  found	  that	  in	  a	  population	  of	  hypertensive	  patients,	  CIMT	  was	  increased	  amongst	  
patients	  with	  HU	  and	  that	  SUA	  was	  independently	  associated	  with	  CIMT	  366.	   	  Conversely,	   in	  
the	   Korean	   Communities	   cohort	   study,	   no	   relationship	   between	   SUA	   and	   CIMT	   was	  	  	  
observed	  367.	  	  In	  a	  population	  of	  8144	  Japanese	  individuals	  undergoing	  health	  screening,	  SUA	  
was	  independently	  associated	  with	  increased	  odds	  of	  presence	  of	  carotid	  plaques	  368.	  	  
	  
4.4. Uric	  acid	  -­‐	  a	  surrogate	  marker	  for	  vascular	  oxidative	  stress	  
The	  observation	  of	   clustering	  of	  HU	  with	  established	  CVRFs	  has	   led	   to	   speculation	   that	  UA	  
may	   represent	   a	   surrogate	   marker	   for	   increased	   risk	   of	   cardiovascular	   disease	   which	   is	  
attributable	   to	   the	  presence	  of	  other	  established	   risk	   factors.	   	  Authors	  have	  proposed	   that	  
UA	  potentially	  represents	  an	  embedded	  component	  of	  traditional	  risk	  factors	  369	  and	  as	  such	  
may	  not	  itself	  carry	  any	  individual	  mediating	  role	  per	  se.	  	  	  Conversely,	  as	  discussed	  above,	  UA	  
holds	  atherogenic	  properties	  which	  might	  explain	  the	  observed	  epidemiological	  associations.	  	  
An	   alternative	   explanation	   might	   be	   that	   UA	   represents	   a	   surrogate	   marker	   for	   an	  
alternative,	  novel	  mediator	  of	   increased	  risk:	   increased	   levels	  of	  harmful	  vascular	  oxidative	  
stress	  produced	  by	  activity	  of	  the	  XO	  enzymatic	  system.	  
The	   role	   of	   ROS	   in	   the	   pathogenesis	   of	   cardiovascular	   disease	   has	   been	   extensively	  	  	  
described	   370-­‐373.	   	   Through	   contributing	   to	   endothelial	   dysfunction,	   oxidative	   stress	   is	  
considered	   an	   early	   event	   in	   pathogenesis	   of	   atherosclerotic	   disease.	   	   As	   a	   byproduct	   of	  
purine	  metabolism	  to	  UA,	  activity	  of	  XO	  also	  results	  in	  generation	  of	  superoxide	  anions,	  and	  
represents	  one	  of	  the	  principle	  sources	  of	  ROS	  in	  the	  human	  vasculature	  374, 375.	  	  	  
Traditionally,	   XO	   has	   been	   considered	   less	   important	   than	   NADPH	   oxidase	   as	   a	   source	   of	  
oxidative	   stress	   in	   the	   vasculature.	   	   Emerging	   evidence	   suggests	   the	   reverse	  may	  be	  more	  
representative	  of	  the	  in	  vivo	  situation	  376.	  Studies	  suggest	  that	  XO	  activity	  is	  greatly	  increased	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in	  those	  with	  heart	  failure	  and	  in	  response	  to	  ischaemic	  conditions	  377, 378.	  	  In	  these	  studies,	  
Landmesser	   and	   colleagues	   demonstrated	   that	   Angiotensin	   II	   increases	   endothelial	  
expression	  of	   XO.	   	  Moreover,	   endothelial	   XO	  activity	  was	   reduced	  with	   an	  ARB	   (Losartan),	  
which	   also	   ameliorated	   the	   beneficial	   effect	   of	   Oxypurinol	   on	   endothelial	   function,	  
suggesting	  that	  the	  mechanism	  of	  ARB	  benefit	  may,	  in	  part,	  be	  related	  to	  reduced	  XO	  activity.	  	  
Expression	  of	  an	  endothelial	  bound	  form	  of	  XO	  has	  been	  shown	  to	  increase	  in	  ischaemia	  and	  
in	   response	   to	   increased	   levels	  of	  pro-­‐inflammatory	  cytokines	   379.	   	  On	  a	  practical	   level,	   the	  
potential	  clinical	  relevance	  of	  XO	  as	  a	  source	  of	  oxidative	  stress	   is	  much	  greater	  than	  other	  
contributing	  pathways	  such	  as	  NADPH	  oxidase;	  a	  licensed	  and	  commonly	  used	  inhibitor	  of	  XO	  
exists,	  with	  a	  defined	  tolerability	  and	  safety	  record.	  
The	   hypothesis	   that	   increased	   SUA	   may	   be	   a	   surrogate	   for	   increased	   CV	   risk	   conferred	  
through	   XO	  mediated	   oxidative	   stress,	   is	   supported	   by	   clinical	   trials	   data	   in	   patients	   with	  	  	  
CHF	  299.	  	  In	  this	  population,	  reduction	  of	  UA	  with	  the	  uricosuric	  agent	  Probenecid	  yielded	  no	  
improvement	   in	   endothelial	   dysfunction.	   	   Conversely,	   similar	   magnitude	   of	   UA	   reduction	  
achieved	   through	   XOI	   with	   Allopurinol,	   resulted	   in	   significant	   improvement	   in	   endothelial	  
function.	  	  These	  findings	  suggest	  that	  the	  mechanism	  of	  UA	  reduction	  may	  be	  more	  relevant	  
than	  uric	  acid	  reduction	  per	  se.	  
	  
4.5. Uric	   acid	   and	   xanthine	   oxidase	   -­‐	   physiological	   &	   pathophysiological	  
properties	  
The	  hypothesis	  that	  elevated	  SUA	  levels	  are	  harmful	  to	  the	  vasculature	  conflicts	  with	  a	  key	  
property	   of	   UA:	   it	   is	   an	   effective	   anti-­‐oxidant,	   with	   activity	   against	   peroxynitrite	   and	  
hypochlorous	  acid	   (but	  not	  superoxide,	  a	  by-­‐product	   to	   its	  own	  production)	   380, 381.	   	  During	  
evolution,	  humans	  appear	  to	  have	  lost	  the	  ability	  to	  make	  the	  uricase	  enzyme	  and	  developed	  
the	  ability	  to	  actively	  reabsorb	  UA	  in	  the	  kidney.	   	  Both	  these	  mechanisms	  contribute	  to	  the	  
higher	  SUA	  levels	  seen	  in	  humans.	  The	  human	  life	  span	  has	   increased	  during	  evolution	  and	  
this	   may	   in	   part	   reflect	   a	   reduction	   in	   early	   cancer	   rates	   compared	   to	   other	   mammalian	  
species.	   	   It	   has	   been	   argued	   that	   this	   is	   due	   to	   evolution	   of	   more	   effective	   antioxidant	  
mechanisms	  and	  that	  higher	  levels	  of	  SUA	  are	  a	  key	  component	  of	  such	  mechanisms	  382,	  UA	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being	   as	   effective	   as	   ascorbic	   acid	   in	   this	   regard.	   	   Given	   that	   UA	   is	   the	   most	   abundant	  
antioxidant	   in	  plasma,	   it	   is	   feasible	   that	   this	   change	   in	  UA	  metabolism	  has	  been	  beneficial	  
and	  contributed	  to	  our	  prolonged	  survival.	  	  	  
This	  hypothesis	  is	  further	  supported	  by	  data	  showing	  that	  in	  healthy	  human	  volunteers,	  UA	  
administration	   increases	   total	   serum	   antioxidant	   capacity	   383	   and	   reduces	   oxidative	   stress	  
associated	  with	  exercise	  384.	  	  The	  systemic	  administration	  of	  UA	  has	  also	  been	  demonstrated	  
to	  improve	  endothelial	  function	  385.	  
Under	   pathophysiological	   circumstances,	   the	   antioxidant	   properties	   of	  UA	   ought	   to	   confer	  
potential	  benefit.	  	  In	  the	  context	  of	  acute	  ischaemia,	  antioxidant	  activity	  could	  be	  considered	  
highly	   beneficial	   in	   reducing	   tissue	  damage.	   	   SUA	   levels	   increase	   after	   an	   ischaemic	   insult,	  
including	  within	   the	  brain	   in	  animal	  models	  of	  cerebral	   ischaemia	   386, 387.	   	  Many	  argue	  that	  
elevated	   SUA	   represents	   a	   physiological	   and	   protective	   response	   to	   oxidative	   stress	   and	  
acute	   vascular	   insults	   388, 389.	   	   In	   a	   transient	   ischaemia	   model,	   infusion	   of	   UA	   led	   to	   a	  
reduction	   of	   infarct	   volume	   and	   improved	   behavioural	   outcome	   387	   suggesting	   therapeutic	  
potential	   of	   SUA	   in	   conditions	   of	   acute	   ischaemia.	   	   Similar	   findings	  were	   demonstrated	   in	  
models	  of	  traumatic	  brain	  injury	  and	  multiple	  sclerosis	  390, 391.	  	  
This	   hypothesis	   is	   potentially	   supported	   by	   the	   observation	   in	   800	   patients	   with	   acute	  
ischaemic	  stroke	  that	  increasing	  SUA	  levels	  were	  associated	  with	  a	  good	  outcome	  (OR	  1.12,	  
95%	   CI	   1	   -­‐1.25,	   per	   additional	   mg/dl	   SUA)	   at	   seven	   days	   392.	   	   However,	   epidemiological	  
evidence	   is	   conflicting.	   	   In	   another	   population	   with	   acute	   stroke,	   reduced	   likelihood	   of	  
favourable	  outcome	  at	  90	  days	  was	  associated	  with	  elevated	  baseline	  SUA	  (OR	  0.78,	  95%	  CI	  
0.67-­‐0.91	  per	  additional	  0.1	  mmol/L	  SUA)	  and	  an	  increased	  risk	  of	  recurrent	  vascular	  events	  
was	   also	   observed	   330.	   This	   association	   was	   more	   prominent	   in	   those	   with	   diabetes	   331.	  	  
Others	   have	   suggested	   increased	   risk	   of	   early	   clinical	   deterioration	   following	   ischaemic	  	  
stroke	  393	  in	  those	  with	  increased	  SUA	  level.	   	   In	  another	  acute	  stroke	  population,	  increasing	  
UA	  levels	  did	  link	  with	  increased	  odds	  of	  poor	  outcome	  (but	  not	  in	  an	  independent	  fashion)	  
and	   there	   was	   no	   evidence	   that	   increasing	   SUA	   conveyed	   protection	   to	   the	   ischaemic	  	  	  	  	  	  
brain	   394	   and	   others	   have	   recently	   shown	   a	   risk	   with	   increased	   death	   early	   death	   after	  	  	  	  
stroke	  395.	  	  Table	  4-­‐3	  summarises	  the	  studies	  which	  have	  examined	  the	  relationship	  between	  
SUA	  and	  outcome	  following	  stroke.	  
	  116	  
Recently,	   the	   therapeutic	  potential	   of	  UA	  administration	  after	   stroke	  has	  been	  explored	   in	  
humans.	   In	   a	   small	   study	   of	   individuals	   treated	   with	   intravenous	   thrombolytic	   therapy,	  
intravenous	   infusion	   of	   UA	   in	   the	   early	   period	   after	   ischaemic	   stroke	   reduced	  markers	   of	  
oxidative	  stress	  396.	  
	  
Table	  4-­‐3:	  	  Relationship	  between	  serum	  uric	  acid	  in	  acute	  stroke	  and	  clinical	  outcome	  
Reference	   Population	   Change	  in	  Outcome	  Measure	  
Cherubini	   Acute	  stroke	   Early	  clinical	  deterioration	  with	  higher	  SUA	  levels	  (p=0.001)	  
Karagiannis	   Acute	  Stroke	   OR	  1.37	  (1.13-­‐1.67)	  for	  early	  death	  a	  
Chamorro	   Acute	  Stroke	   OR	  1.12	  (1-­‐1.25)	  for	  good	  clinical	  outcome	  b	  
Dawson	   Acute	  Stroke	   OR	  1.57	  (1.02-­‐2.42)	  for	  poor	  clinical	  outcome	  c	  
Newman	   DM	  and	  	  stroke	   HR	  1.49	  (1.21-­‐1.84)	  	  for	  recurrent	  CV	  event	  d	  
Results	  expressed	  as	  ratio	  and	  95%	  CI.	  a	  =	  for	  highest	  vs.	  lowest	  group;	  b	  =	  for	  each	  59.48	  micro	  mol	  increase	  
in	  UA	  level;	  c	  =	  on	  univariate	  analysis;	  d	  =	  per	  additional	  0.1mmol/l	   in	  SUA.	   	  SUA,	  serum	  uric	  acid;	  OR,	  Odds	  
ratio,	  HR,	  Hazard	  ratio;	  DM,	  diabetes	  mellitus;	  CV,	  Cardiovascular	  
	  
Thus,	   whilst	   a	   consistent	   observation	   of	   increased	   risk	   of	   cardiovascular	   events	   has	   been	  
observed	  for	  elevated	  SUA	  in	  a	  variety	  of	  populations,	  the	  influence	  of	  SUA	  in	  the	  context	  of	  
an	  acute	  ischaemic	  event	  is	  less	  certain	  and	  brings	  in	  to	  focus	  the	  issue	  of	  the	  potential	  role	  
of	  both	  UA	  and	  XO	  in	  both	  physiological	  and	  pathophysiological	  conditions.	  
The	  epidemiological	  evidence	  does	  suggest	  that	  elevated	  SUA	  links	  with	  increased	  incidence	  
and	  severity	  of	  a	  variety	  of	  cardiovascular	  diseases.	   	  Data	  exist	   to	  support	  detrimental	  and	  
prothrombotic	  effects	  of	  UA	  on	  platelet	  and	  endothelial	   function	  and	  a	  growing	  number	  of	  
clinical	   studies	   suggest	   that	   UA	   lowering	   strategies	   improve	   surrogate	  markers	   of	   vascular	  
risk,	   although	   for	   the	  most	   part	   the	   evidence	   concerns	   use	   of	   allopurinol	  which	  may	   have	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other	   beneficial	   effects;	   XO	   mediated	   oxidative	   stress	   may	   play	   a	   significant	   role	   in	   the	  
development	  of	  atherosclerosis.	   	  Yet	  we	  also	  know	  that	  UA	  has	  antioxidant	  properties	  and	  
small	   pre-­‐clinical	   and	   clinical	   studies	   suggest	   that	   SUA	  may	   be	   neuroprotective.	   	   Thus,	   on	  
initial	   inspection,	  UA	  appears	   to	  hold	  both	   vasculoprotective	   and	   vasculopathic	  properties.	  	  
Its	  enzymatic	  source	  of	  production	  may	  also	  be	  vasculopathic.	  	  
It	   is	   important	   to	  note	   that	   these	  hypotheses	   are	  not	  mutually	   exclusive.	   Firstly,	   increased	  
local	   tissue	   levels	  of	  UA	   in	   ischaemia	  and	  brain	   injury	  may	   reflect	   levels	  of	  oxidative	   stress	  
and	   XO	   activity,	   and	   thus	   the	  mechanism	   of	   harm	   and	   not	   an	   innate	   protective	   response.	  	  
Essentially,	  the	  substance	  itself	  may	  well	  have	  antioxidant	  properties	  but	  its	  generation	  and	  
associated	  superoxide	  anion	  production	  may	  be	  of	  much	  greater	  significance	  and	  detriment	  
in	  both	  acute	   ischaemia	  (during	  which	  XO	  activity	   is	   increased	  and	   is	   likely	  to	  contribute	  to	  
ischaemic	  and	  reperfusion	  injury)	  397	  and	  the	  longer	  term.	  	  Whilst	  the	  antioxidant	  properties	  
of	   UA	   could	   well	   be	   harnessed	   to	   improve	   clinical	   outcomes	   in	   the	   acute	   phase	   of	  
cardiovascular	   and	   neurological	   illness,	   inhibition	   of	   the	   enzymatic	   system	   responsible	   for	  
endogenous	  UA	  production	  might	  also	  be	  beneficial.	  	  
Furthermore,	  the	  measurement	  of	  UA	  levels	  in	  those	  at	  risk	  of	  disease	  may	  identify	  those	  at	  
high	  risk	  who	  may	  benefit	  from	  treatments	  such	  as	  allopurinol,	  either	  because	  of	  UA	  itself	  or	  
XO	   activity	   and	   oxidative	   stress.	   	   Data	   from	   the	  OPT-­‐CHF	   study	   supports	   the	   concept	   of	   a	  
need	  for	  targeted	  reduction	  of	  UA	  and	  /	  or	  XOI;	  benefit	  from	  UA	  reduction	  may	  only	  be	  seen	  
in	  those	  with	  SUA	  high	  enough	  to	  harm	  platelet	  and	  endothelial	  function	  while	  UA	  reduction	  
in	  those	  with	  lower	  levels	  may	  compromise	  plasma	  oxidant	  activity	  such	  that	  this	  could	  be	  of	  
detriment	  398.	  
	  
4.6. Therapeutic	   strategies:	   Uric	   acid	   reduction	   and	   xanthine	   oxidase	  
inhibition	  
There	  are	  several	  drugs	  which	  reduce	  SUA	  through	  varying	  mechanisms.	   	  Uricosuric	  agents	  
reduce	   SUA	   through	   increased	   renal	   excretion	   (e.g.	   Probenecid,	   Sulfinpyrazone).	  	  	  
Fenofibrate	  399	  and	  Losartan	  400	  also	  possess	  modest	  uricosuric	  activity.	  	  Breakdown	  of	  UA	  to	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Allantoin,	  as	  occurs	  in	  non-­‐primate	  mammals,	  is	  feasible	  with	  exogenous	  recombinant	  urate-­‐
oxidase	  enzyme	  (rasburicase),	  resulting	  in	  reduction	  of	  SUA.	   	  Reduction	  in	  SUA	  may	  also	  be	  
achieved	   through	   reduced	  production	   via	   inhibition	  of	   the	   XO	  enzymatic	   system	   (e.g.	  with	  
Allopurinol,	  Oxypurinol	  or	  Febuxostat).	  
Uricosuric	  agents	  do	  not	  affect	  XO	  activity	  directly	  and	  as	  such	  do	  not	  limit	  oxidative	  stress.	  	  
Xanthine	  oxidase	  inhibitors	  carry	  the	  potentially	  dual	  vasculoprotective	  properties	  of	  both	  UA	  
reduction	   and	   reduced	   vascular	   oxidative	   stress.	   	   Rasburicase	   is	   typically	   utilised	   as	   an	  
adjunct	   to	   cytotoxic	   therapy	   in	   the	   management	   of	   malignant	   disease.	   	   It	   is	   not	   readily	  
administrable	  on	  a	  long	  term	  basis	  and	  ought	  not	  to	  influence	  the	  XO	  system	  activity.	  	  	  
Allopurinol	   is	   the	  XO	   inhibitor	  most	   frequently	   encountered	   in	   clinical	   practice,	   typically	   in	  
the	  prophylaxis	  of	  gout	  401,	  but	  also	  in	  patients	  with	  malignancy.	  	  Allopurinol	  is	  metabolised	  
to	   an	   active	   metabolite,	   Oxypurinol	   which	   is	   a	   structural	   analogue	   of	   hypoxanthine	   and	  
functions	  as	  a	   competitive	  agonist	   to	   inhibit	  XO	  activity	   402, 403.	   	   It	   is	   considered	   to	  be	  well	  
tolerated	  with	  few	  side-­‐effects,	  which	  typically	  comprise	  rash	  or	  gastrointestinal	  symptoms.	  	  
Idiosyncratic	   adverse	   drug	   reactions	   have	   been	   reported,	   albeit	   infrequently	   with	   an	  
incidence	  of	  less	  than	  1	  in	  1000	  patients	  treated	  404, 405.	   	  However,	  reactions	  may	  be	  severe	  
and	   include	  eosinophilia,	   interstitial	  nephritis,	  hepatic	  dysfunction,	  vasculitis	  and	  exfoliative	  
dermatitis.	   	   Leucopenia	   and	   thrombocytopenia	   are	   also	   reported.	   	   The	   risk	   of	   adverse	  
reactions	  appears	  heightened	   in	   the	  context	  of	   renal	   impairment	  and	  concurrent	  antibiotic	  
therapy	   406.	   	   More	   recently,	   an	   association	   with	   HLA-­‐B5801	   has	   been	   identified,	   which	  
identifies	   a	   group	   of	   patients	   at	   significantly	   increased	   risk	   of	   severe	   reactions,	   including	  
Stevens–Johnson	   syndrome	   &	   toxic	   epidermal	   necrolysis	   407.	   	   Screening	   for	   this	   HLA	   type	  
prior	  to	  commencing	  treatment	  ought	  to	  reduce	  the	  likelihood	  of	  severe	  adverse	  reactions.	  	  
In	   general,	   the	   adverse	   reaction	   profile	   is	   comparable	   to	   other	   drugs	   established	   in	   the	  
primary	  and	  secondary	  prevention	  of	  cardiovascular	  disease.	  	  
There	  are	  no	  adequately	  powered	  clinical	  endpoint	   trials	  of	  UA	   lowering	   strategies.	   	   Three	  
drugs	   known	   to	   reduce	   cardiovascular	   mortality	   have	   been	   shown	   to	   reduce	   SUA,	   which,	  
hypothetically,	  may	  explain	  some	  of	  their	  beneficial	  effect.	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Fenofibrate	   lowers	   triglyceride,	   total	   and	   LDL	   cholesterol	   levels	   and	   increases	   HDL	  	  
cholesterol	   408.	   	   It	   also	   reduces	   SUA	   level	   (via	   increased	   renal	   excretion)	   by	   as	   much	   as	  	  	  	  	  	  	  
46%	  409.	  	  Losartan	  is	  an	  angiotensin	  II	  receptor	  antagonist	  known	  to	  reduce	  SUA	  levels	  by	  up	  
to	  30%	  410,	  via	  increased	  renal	  UA	  excretion	  411.	  	  Nearly	  a	  third	  of	  the	  RR	  reduction	  seen	  with	  
Losartan	  use	   in	  the	  LIFE	  study	  has	  been	  reported	  as	  potentially	  attributable	  to	   its	  effect	  on	  
SUA	   412.	   	   Atorvastatin	   has	   been	   shown	   to	   reduce	   SUA	   (by	   approximately	   8%),	   even	   after	  
adjustment	   for	   risk	   factors,	   including	   change	   in	   renal	   function.	   Each	  60µmol/l	   reduction	   in	  
SUA	  following	  Atorvastatin	  use	  was	  associated	  with	  a	  reduction	   in	  vascular	  event	  rates	  (HR	  
0.76,	  95%	  CI	  0.62-­‐0.89)	  413.	  
Probenecid,	  a	  uricosuric	  agent	  which	  does	  not	  affect	  XO,	  has	  been	  studied	   in	  patients	  with	  
heart	   failure.	   	   In	   a	   randomised	   crossover	   design,	   Probenecid	   500mg	   bd	   for	   three	   weeks	  
reduced	  SUA	  (to	  0.25	  mmol/l)	  in	  comparison	  to	  placebo	  (where	  it	  remained	  elevated	  at	  0.44	  
mmol/l).	  	  This	  reduction	  was	  similar	  to	  that	  observed	  with	  allopurinol	  300mg	  od	  but	  whereas	  
Allopurinol	   improved	   endothelial	   function,	   Probenecid	   did	   not,	   suggesting	   that	   the	  
mechanism	  of	  benefit	  of	  allopurinol	  was	  UA-­‐independent	  299.	  
Recent	   clinical	   research	   has	   focused	   on	   the	   use	   of	   the	   XO	   inhibitors	   allopurinol	   and	  
Oxypurinol	  in	  the	  prevention	  of	  cardiovascular	  diseases.	  	  XOI	  lowers	  SUA	  levels,	  free	  radical	  
production	  and	  there	  is	  evidence	  that	  the	  drug	  has	  a	  direct	  scavenging	  effect	  on	  free	  radicals.	  
Specifically	   with	   regard	   to	   stroke,	   allopurinol	   attenuates	   the	   rise	   in	   inflammatory	  markers	  
seen	   after	   stroke	   414	   and	   improves	   basal	   levels	   of	   cerebrovascular	   NO	   in	   those	   with	  	  	  	  	  
diabetes	  415.	  	  	  
The	  results	  from	  the	  largest	  study	  of	  XOI	  to	  date	  were	  disappointing.	  	  In	  the	  OPT-­‐CHF	  trial	  398,	  
405	  participants	  with	  heart	  failure	  were	  randomised	  to	  receive	  either	  Oxypurinol	  600	  mg	  or	  
placebo	  for	  6	  months.	  	  The	  dose	  of	  Oxypurinol	  used	  in	  this	  trial	  was	  equivalent	  to	  only	  81mg	  
of	  Allopurinol,	  limiting	  interpretation	  of	  the	  findings.	  	  The	  primary	  endpoint	  was	  defined	  as	  a	  
change	   in	   clinical	   status	   based	   upon	   changes	   in	   a	   variety	   of	   clinical	   parameters,	   including	  
mortality	   and	   common	  measures	   of	   heart	   failure	   severity.	   There	  was	   no	   difference	   in	   the	  
proportion	   of	   patients	  who	   improved	   or	  worsened	   between	   treatment	   groups.	   	   However,	  
post-­‐hoc	  analyses	   suggested	   that	   in	   those	  with	  elevated	  SUA,	  Oxypurinol	   improved	   clinical	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status,	   whereas	   the	   opposite	   occurred	   in	   those	   with	   lower	   UA	   levels.	   In	   the	   Oxypurinol	  
cohort	   as	   a	  whole,	   those	  who	   improved	   had	   significantly	   greater	   reductions	   in	   SUA	   levels	  
than	   those	  who	  worsened.	   	   These	   findings	   are	   difficult	   to	   interpret.	   On	   the	   one-­‐hand	   the	  
post-­‐hoc	  analyses	  suggest	  benefit	   in	  those	  with	  high	  UA	  levels	  and	  that	  the	  greater	  the	  fall	  
following	  Oxypurinol	  in	  such	  patients,	  the	  better	  the	  outcome.	  	  They	  also	  raise	  the	  possibility	  
that	  Oxypurinol	  can	  cause	  harm	  in	  some.	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4.6.1. Chapter	  5	  aims	  &	  hypothesis	  
There	  is	  extensive	  epidemiological	  evidence	  which	  demonstrates	  an	  independent	  association	  
between	   elevated	   SUA	   and	   risk	   of	   both	   CV	   events	   &	   mortality,	   including	   stroke	   disease	  
outcomes.	  	  This	  evidence	  has	  given	  rise	  to	  the	  hypothesis	  that	  UA	  is	  either	  causally	  related	  to	  
CV	   disease,	   or	   alternatively	   represents	   a	   surrogate	   measure	   of	   an	   alternative	   novel	  
mechanism	  of	  risk;	  XO	  related	  oxidative	  stress.	  	  Discrepancies	  in	  this	  relationship	  have	  been	  
observed	  in	  some	  populations	  and	  a	  counterpoint	  hypothesis	  is	  that	  UA	  merely	  represents	  a	  
surrogate	   measure	   of	   heightened	   risk	   due	   to	   prevalence	   and	   severity	   of	   concomitant	  
established	  CVRF	  burden.	  
Uric	   acid	   holds	   mechanistic	   properties	   which	   theoretically	   confer	   increased	   risk	   of	  
atherosclerotic	  disease.	  	  Similarly,	  the	  enzymatic	  pathway	  responsible	  for	  UA	  production	  is	  a	  
significant	   source	   of	   the	   ROS	   and	   vascular	   oxidative	   stress	   that	   are	   implicated	   in	  
atherogenesis.	   	  Conversely,	  UA	  holds	  antioxidant	  properties	  which	  are	  potentially	  beneficial	  
in	  the	  context	  of	  ischaemic	  conditions	  and	  can	  improve	  endothelial	  function.	  
Xanthine	  oxidase	  inhibition	  appears	  to	  be	  the	  likeliest	  UA	  lowering	  strategy	  to	  hold	  potential	  
benefit	   in	  relation	  to	  cardiovascular	  disease,	  given	  its	  dual	  mechanism	  of	  action	  in	  reducing	  
both	  UA	  and	  oxidative	  stress.	  	  There	  is	  emerging	  evidence	  in	  the	  human	  population	  relating	  
to	  reduction	  of	  UA	  via	  XOI.	  	  However,	  there	  are	  limited	  studies	  that	  have	  examined	  outcomes	  
in	   large	   samples.	   	   Several	   small	   and	   medium	   sized	   studies	   have	   examined	   the	   effect	   of	  
pharmacological	   XOI	   on	   cardiovascular	   function,	   in	   a	   variety	   of	   patient	   populations.	   	   The	  
reporting	  of	  positive	  outcomes	  has	  prompted	  calls	  for	  large-­‐scale	  clinical	  trials,	  with	  definitive	  
outcome	  parameters,	   to	  be	  conducted.	   	  However,	   the	   indication	   for	  such	  studies	  has	  been	  
debated	  as	  there	  have	  also	  been	  equivocal	  reports	  in	  the	  literature.	  	  	  
Chapter	  5	  reports	  the	  detail	  and	  findings	  of	  a	  systematic	  review	  which	  evaluated	  the	  role	  of	  
XOI	  as	  a	  potential	  therapeutic	  strategy	  in	  relation	  to	  cardiovascular	  disease.	  	  The	  aim	  of	  the	  
study	  was	   to	   clarify	   the	   extent	   of	   available	   evidence	   that	   has	   evaluated	   the	   effect	   of	   XOI	  
upon	   clinical	   or	   surrogate	   markers	   of	   cardiovascular	   disease	   and	   function	   in	   the	   human	  
population.	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Chapter	  5 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Xanthine	   oxidase	   inhibition	   for	   the	   treatment	   of	  
cardiovascular	  disease:	  A	  systematic	  review	  and	  meta-­‐
analysis	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5.1. Introduction	  
Despite	   widespread	   implementation	   of	   available	   preventative	   therapies,	   the	   incidence	   of	  
cardiovascular	  disease	  remains	  high	  416.	  	  Novel	  therapeutic	  strategies	  are	  required	  to	  further	  
reduce	  this	  disease	  burden.	  	  	  
A	  potential	   role	   for	  uric	  acid	   (UA)	   in	   the	  pathogenesis	  of	   cardiovascular	  disease	  has	  drawn	  
attention	   in	   recent	   years	   300, 417.	   	   Post-­‐hoc	   analyses	   of	   clinical	   trial	   data	   suggest	   that	   UA	  
reduction	  may	  contribute	  to	  the	  reduced	  vascular	  risk	  afforded	  by	  some	  therapeutic	  agents,	  
including	   angiotensin	   II	   receptor	   antagonists	   412	   and	   statins	   413.	   	   Conversely,	   short-­‐term	  
administration	  of	  UA	  has	  produced	  favourable	  responses	  in	  endothelial	  function	  385.	  
Xanthine	   oxidase,	   the	   enzyme	   responsible	   for	   UA	   production,	   has	   been	   identified	   as	   a	  
significant	  source	  of	  oxidative	  stress	  in	  the	  vasculature	  378.	  	  	  Oxidative	  stress,	  in	  turn,	  holds	  a	  
pivotal	  role	  in	  the	  pathogenesis	  of	  cardiovascular	  disease	  371,	  largely	  through	  its	  contribution	  
to	  endothelial	  dysfunction.	   	   Thus,	  whilst	  a	  direct	  pathogenic	   role	   for	  UA	   in	   the	  vasculature	  
remains	  unproven,	  its	  presence	  at	  elevated	  concentrations	  may	  indicate	  increased	  oxidative	  
stress	  and	  consequent	  risk.	  	  	  
Several	  small	  and	  medium	  sized	  studies	  have	  examined	  the	  effect	  of	  pharmacological	  XOI	  on	  
cardiovascular	   function	   in	   a	   variety	   of	   patient	   populations.	   	   The	   reporting	   of	   positive	  
outcomes	   has	   prompted	   calls	   for	   large-­‐scale	   clinical	   trials,	   with	   definitive	   outcome	  
parameters,	  to	  be	  conducted.	  	  However,	  the	  indication	  for	  such	  studies	  has	  been	  debated	  as	  
there	  have	  also	  been	  equivocal	  reports	  in	  the	  literature.	  	  	  
Through	  systematic	  review,	  this	  study	  sought	  to	  clarify	  the	  extent	  of	  available	  evidence	  that	  
has	  evaluated	  the	  effect	  of	  XOI	  upon	  clinical	  or	  surrogate	  markers	  of	  cardiovascular	  disease	  
and	  function	  in	  humans.	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5.2. Methods	  
The	  “Meta-­‐analysis	  of	  Observational	  Studies	   in	  Epidemiology:	  A	  Proposal	  for	  Reporting”	  418,	  
the	   “Preferred	   Reporting	   Items	   for	   Systematic	   Reviews	   and	   Meta-­‐Analyses:	   The	   PRISMA	  
Statement”	  419	  and	  “The	  Quality	  of	  Reporting	  of	  Meta-­‐analyses”	  (QUOROM)	  statement,	  were	  
used	  as	  a	  framework	  for	  conduct	  of	  the	  review.	  
Studies	  were	  included	  that	  assessed	  effects	  of	  pharmacological	  XOI	  upon	  clinical	  or	  surrogate	  
markers	   of	   cardiovascular	   disease	   /	   function	   in	   humans.	   	   All	   studies	   published	   in	   English,	  
regardless	   of	   baseline	   characteristics,	   treatment	   dose,	   duration	   or	   administration	   method	  
were	  considered.	  	  We	  excluded	  studies	  assessing	  only	  peri-­‐operative	  or	  renal	  endpoints.	  
	  
Search	  Method	  
A	   computer-­‐assisted	   literature	   search	   was	   performed	   using	   the	   database	   Ovid	   MEDLINE	  
(1948	  -­‐	  February	  Week	  2	  2011)	  and	  the	  database	  EMBASE	  (1980	  to	  2011	  Week	  7).	   	  Briefly,	  
the	   search	   sought	   to	   identify	   all	   studies	   examining	   XOI	   in	   populations	   with	   established	  
vascular	  disease	  (or	  vascular	  risk	  factors)	  or	  any	  population	  in	  which	  an	  outcome	  measure	  of	  
vascular	   relevance	   was	   included.	   	   To	   maintain	   some	   homogeneity,	   studies	   based	   in	  
populations	  with	  either	  chronic	  renal	  failure	  or	  surgical	  disease,	  were	  excluded.	  	  The	  search	  
terms	   used	   were	   inclusive	   and	   are	   detailed	   in	   Table	   5-­‐1.	   	   Reference	   lists	   of	   all	   identified	  
relevant	  articles	  and	  reviews	  along	  with	  articles	  notified	  to	  us	  by	  direct	  communication	  were	  
screened	  to	  identify	  other	  potentially	  eligible	  studies.	  	  
Abstracts	  of	  all	  potentially	  relevant	  references	  were	  evaluated	  to	  determine	  suitability	  for	  full	  
text	   retrieval.	   	  Retrieved	  studies	  were	  assessed	   for	  eligibility	  according	   to	   the	  pre-­‐specified	  
inclusion	   criteria	  without	   consideration	   of	   their	   results.	   	   An	   assessment	   of	  methodological	  
quality	  of	  each	  included	  trial	  was	  made	  using	  the	  Cochrane	  risk	  of	  bias	  assessment	  tool	  and	  
the	  Jadad	  Score	  420	  .	  This	  instrument	  assigns	  scores	  for	  reported	  randomization,	  blinding,	  and	  
withdrawals.	   	   Non-­‐randomized	   and	   uncontrolled	   studies	   were	   given	   a	   default	   score	   of	   0.	  	  
Two	  authors	  (PH	  and	  JD)	  independently	  conducted	  the	  search.	  	  Differences	  were	  resolved	  by	  
consensus.	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Data	  extraction	  	  
Data	   were	   extracted	   to	   a	   pre-­‐defined	   form	   that	   included	   details	   on	   study	   methods,	  
population,	  intervention,	  quality	  score	  and	  outcome	  measure.	  
	  
Statistical	  Analysis	  
Data	   are	   reported	   in	   descriptive	   terms.	   	  Where	   an	   individual	   outcome	  measurement	   was	  
reported	   in	  several	  studies	   (>	  3),	  meta-­‐analysis	  was	  planned	   in	  an	  attempt	  to	  combine	  and	  
quantitatively	   evaluate	   the	   available	   data.	   	   Only	   studies	   including	   a	   control	   group	   and	  
randomization	  (identified	  through	  application	  of	  the	  Cochrane	  risk	  of	  bias	  tool)	  were	  included	  
in	  meta-­‐analysis.	  	  The	  results	  for	  treatment	  effects	  in	  groups	  of	  healthy	  subjects,	  included	  in	  
some	  studies	  in	  addition	  to	  the	  population	  of	  interest,	  were	  not	  included.	  	  Analysis	  was	  based	  
upon	   summary	   statistics	   (sample	   size,	   mean	   value	   for	   the	   outcome	   of	   interest	   and	  
corresponding	  SD),	  relating	  to	  completion	  of	  treatment	  phases.	  	  Review	  Manager	  5	  software	  
(Cochrane	  library)	  was	  used	  to	  conduct	  combined	  analysis.	  	  	  
In	   the	   event	   of	   either	   clinical	   heterogeneity	   (in	   study	   population	   or	   design)	   or	   significant	  
statistical	   heterogeneity	   being	   noted	   between	   studies	   included	   in	   combined	   analysis,	  
adoption	   of	   a	   random	   effect	   analysis	   model	   was	   planned.	   	   P	   values	   were	   two	   tailed	   and	  
statistical	   significance	   was	   set	   at	   the	   0.05	   level.	   	   Funnel	   plots	   were	   constructed	   for	   each	  
analysis.	   	   Application	   of	   hypothesis	   testing	   with	   Egger’s	   regression	   asymmetry	   test	   was	  
planned	  in	  the	  event	  that	  the	  included	  studies	  in	  any	  given	  analysis	  numbered	  greater	  than	  
ten.	   	   Simple	   visual	   assessment	  was	   planned	   in	   the	   case	   of	   fewer	   studies.	   	   In	   the	   event	   of	  
either	  methodological	   or	   statistical	   heterogeneity,	   sensitivity	   analysis,	   with	   study	   by	   study	  




Table	  5-­‐1:	  	  Systematic	  review	  search	  term	  details	  
1	  	  	  	  	  vascular.m_titl.	  	  
2	  	  	  	  	  Cardiovascular.m_titl.	  
3	  	  	  	  	  Cerebrovascular.m_titl.	  
4	  	  	  	  	  Peripheral	  vascular.m_titl.	  	  
5	  	  	  	  	  artery.m_titl.	  	  
6	  	  	  	  	  arterial.m_titl.	  	  
7	  	  	  	  	  Coronary.m_titl.	  	  
8	  	  	  	  	  Carotid.m_titl.	  	  
9	  	  	  	  	  PAD.m_titl.	  	  
10	  	  	  	  	  PVD.m_titl.	  	  
11	  	  	  	  	  CVA.m_titl.	  	  
12	  	  	  	  	  Stroke.m_titl.	  	  
13	  	  	  	  	  TIA.m_titl.	  	  
14	  	  	  	  	  Transient	  ischaemic	  attack.m_titl.	  	  
15	  	  	  	  	  Transient	  ischemic	  attack.m_titl.	  	  
16	  	  	  	  	  mini-­‐stroke.m_titl.	  	  
17	  	  	  	  	  ministroke.m_titl.	  	  
18	  	  	  	  	  Cerebral	  infarct.m_titl.	  	  
19	  	  	  	  	  cerebral	  ischaemia.m_titl.	  	  
20	  	  	  	  	  cerebral	  ischemia.m_titl.	  	  
21	  	  	  	  	  Ischaemic	  heart	  disease.m_titl.	  	  
22	  	  	  	  	  Ischemic	  heart	  disease.m_titl.	  	  
23	  	  	  	  	  IHD.m_titl.	  	  
24	  	  	  	  	  CAD.m_titl.	  	  
25	  	  	  	  	  MI.m_titl.	  	  
26	  	  	  	  	  myocardial	  infarction.m_titl.	  	  
27	  	  	  	  	  angina.m_titl.	  	  
28	  	  	  	  	  ACS.m_titl.	  	  
29	  	  	  	  	  Cardiac.m_titl.	  	  
30	  	  	  	  	  Heart.m_titl.	  	  
31	  	  	  	  	  Cardiomyopathy.m_titl.	  	  
32	  	  	  	  	  atheroma.m_titl.	  	  
33	  	  	  	  	  atherosclerosis.m_titl.	  	  
34	  	  	  	  	  atherosclerotic.m_titl.	  	  
35	  	  	  	  	  hypertension.m_titl.	  	  
36	  	  	  	  	  hypertensive.m_titl.	  	  
37	  	  	  	  	  blood	  pressure.m_titl.	  	  
38	  	  	  	  	  metabolic	  syndrome.m_titl.	  	  
39	  	  	  	  	  diabetes.m_titl.	  	  
40	  	  	  	  	  diabetic.m_titl.	  	  
41	  	  	  	  	  cholesterol.m_titl.	  	  
42	  	  	  	  	  hypercholesterolaemia.m_titl.	  	  
	  
43	  	  	  	  	  hypercholesterolaemic.m_titl.	  	  
44	  	  	  	  	  hypercholesterolemic.m_titl.	  	  
45	  	  	  	  	  hypercholesterolemia.m_titl.	  	  
46	  	  	  	  	  hyperlipidaemia.m_titl.	  	  
47	  	  	  	  	  hyperlipidemia.m_titl.	  	  
48	  	  	  	  	  dyslipidaemia.m_titl.	  	  
49	  	  	  	  	  dyslipidemia.m_titl.	  	  
50	  	  	  	  	  Smokers.m_titl.	  	  
51	  	  	  	  	  Smoking.m_titl.	  	  
52	  	  	  	  	  endothelium.m_titl.	  	  
53	  	  	  	  	  endothelial.m_titl.	  	  
54	  	  	  	  	  forearm	  blood	  flow.m_titl.	  	  
55	  	  	  	  	  flow	  mediated	  dilatation.m_titl.	  	  
56	  	  	  	  	  oxidative	  stress.m_titl.	  	  
57	  	  	  	  	  mortality.m_titl.	  	  
58	  	  	  	  	  morbidity.m_titl.	  	  
59	  	  	  	  	  Allopurinol.m_titl.	  	  
60	  	  	  	  	  Zyloprim.m_titl.	  	  
61	  	  	  	  	  zyloric.m_titl.	  	  
62	  	  	  	  	  allohexal.m_titl.	  	  
63	  	  	  	  	  allosig.m_titl.	  	  
64	  	  	  	  	  progout.m_titl.	  	  
65	  	  	  	  	  puricos.m_titl.	  	  
66	  	  	  	  	  oxypurinol.m_titl.	  	  
67	  	  	  	  	  Oxipurinol.m_titl.	  	  
68	  	  	  	  	  Ossipurinolo.m_titl.	  	  
69	  	  	  	  	  Oxoallopurinol.m_titl.	  	  
70	  	  	  	  	  Oxypurinolum.m_titl.	  	  
71	  	  	  	  	  alloxanthine.m_titl.	  	  
72	  	  	  	  	  Alloxanthin.m_titl.	  	  
73	  	  	  	  	  DHPP.m_titl.	  	  
74	  	  	  	  	  Febuxostat.m_titl.	  	  
75	  	  	  	  	  Adenuric.m_titl.	  	  
76	  	  	  	  	  Uloric.m_titl.	  	  
77	  	  	  	  	  Tisopurine.m_titl.	  	  
78	  	  	  	  	  Thiopurinol.m_titl.	  	  
79	  	  	  	  	  xanthine	  oxidase.m_titl.	  	  
80	  	  	  	  	  xanthine	  oxidoreductase.m_titl.	  	  
81	  	  	  	  	  uric	  acid.m_titl.	  	  
82	  	  	  	  	  urate.m_titl.	  	  
83	  	  	  	  	  hyperuricaemia.m_titl.	  	  
84	  	  	  	  	  hyperuricemia.m_titl.	  	  
	  
85	  	  	  	  	  33	  or	  32	  or	  21	  or	  7	  or	  26	  or	  17	  or	  2	  or	  1	  or	  18	  or	  30	  or	  16	  or	  44	  or	  55	  or	  27	  or	  25	  or	  28	  or	  57	  or	  40	  or	  20	  
or	  14	  or	  49	  or	  24	  or	  10	  or	  31	  or	  35	  or	  11	  or	  53	  or	  48	  or	  42	  or	  22	  or	  46	  or	  13	  or	  23	  or	  29	  or	  6	  or	  50	  or	  39	  or	  36	  
or	  3	  or	  51	  or	  9	  or	  58	  or	  41	  or	  12	  or	  47	  or	  15	  or	  52	  or	  38	  or	  8	  or	  4	  or	  34	  or	  56	  or	  45	  or	  37	  or	  43	  or	  19	  or	  54	  or	  5	  
(1329520)	  
86	  	  	  	  	  67	  or	  63	  or	  71	  or	  70	  or	  80	  or	  68	  or	  78	  or	  79	  or	  77	  or	  72	  or	  65	  or	  82	  or	  84	  or	  74	  or	  83	  or	  64	  or	  75	  or	  61	  or	  
81	  or	  59	  or	  69	  or	  60	  or	  66	  or	  73	  or	  76	  or	  62	  	  
87	  	  	  	  	  85	  and	  86	  	  
88	  	  	  	  	  limit	  87	  to	  humans	  (1175	  articles	  identified	  through	  MEDLINE,	  1329	  articles	  identified	  through	  EMBASE)	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5.3. Results	  
1329	  citations	  were	  identified	  using	  the	  defined	  search	  strategy	  to	  interrogate	  the	  MEDLINE	  
database.	  	  1175	  citations	  were	  identified	  using	  the	  defined	  search	  strategy	  to	  interrogate	  the	  
EMBASE	  database.	   	   1269	   citations	  were	  excluded	  on	   the	  basis	   of	   title	   and	   abstract	   review	  
alone.	  	  60	  citations	  were	  identified	  for	  full	  text	  retrieval.	  	  Of	  these,	  20	  were	  excluded	  on	  the	  
basis	   of	   being	   non-­‐human	   studies,	   surgical	   or	   chronic	   renal	   failure	   populations,	   ongoing	  
studies,	  unavailable	   in	  English	   language	   (2	   studies),	  non	  XOI	   intervention	   studies	  or	   review	  
article.	   	   	  40	  articles	  that	  met	  the	  pre-­‐specified	   inclusion	  and	  exclusion	  criteria	   in	  evaluating	  
the	  effect	  of	  XOI	  on	  measures	  of	  vascular	  health	  were	  identified.	  	  Two	  papers	  each	  reported	  
results	   of	   two	   separate	   modes	   of	   XOI	   377, 421,	   resulting	   in	   a	   total	   of	   42	   identified	   studies.	  	  
Figure	  5-­‐1	  shows	  details	  of	  study	  selection.	  	  	  
	  
Study	  Types	  
Eleven	   studies	   used	   a	   parallel	   group,	   randomized	   controlled	   trial	   design	   398, 414, 422-­‐430.	   	   Of	  
these,	   three	   did	   not	   report	   randomization	   method	   398, 422, 425	   and	   one	   randomized	  
inappropriately	  (allocation	  to	  treatment	  based	  on	  alternate	  entry	  into	  study)	  426.	  	  Two	  were	  
single	  blind	  (to	  the	  end-­‐point	  assessor	  only)	  and	  did	  not	  utilise	  placebo	   in	  controls,	  as	  such	  
appearing	   to	   constitute	   a	   prospective,	   randomized,	   open-­‐label,	   blinded	   endpoint	   (PROBE)	  
design	  425, 426.	  	  	  
Sixteen	  studies	  used	  a	  randomized	  controlled	  crossover	  design	  299, 359, 415, 421, 431-­‐442.	  	  Method	  
of	   randomization	   was	   not	   reported	   299, 359, 421, 431-­‐433, 435-­‐438, 440, 441	   in	   most	   and	   two	   again	  
appeared	  to	  utilise	  a	  PROBE	  design	   437, 438.	   	  One	  publication	  additionally	   reported	  a	  second	  
study,	   featuring	   cross	   over	   between	   treatment	   arms	   but	   lacking	   randomization	   421.	   	   This	  
design	  was	  used	  in	  one	  further	  study	  443.	  	  	  
Remaining	   studies	   used	   a	   prospective,	   open	   label	   intervention	   design,	   without	   control	  	  	  
group	  377, 444-­‐448	  or	  a	  population	  based	  cohort	  design	   449-­‐453.	   	  Whilst	   reporting	  a	  prospective	  
open-­‐label	  intervention,	  one	  publication	  reported	  a	  second	  study	  that	  featured	  intervention	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and	   placebo-­‐controlled	   treatment	   groups	   but	   lacked	   randomization	   between	   treatment	  	  
arms	  377.	  	  	  
Despite	  the	  majority	  of	  randomised	  studies	  including	  robust	  design	  features	  with	  respect	  to	  
randomisation	  and	  blinding,	  potential	  sources	  of	  bias	  were	  present	  in	  the	  form	  of	  either	  lack	  
of	  complete	  outcome	  data	  reporting	  425	  or	  lack	  of	  clarity	  as	  to	  whether	  all	  included	  patients	  
had	   outcome	   data	   available	   422, 424, 428, 431, 433, 435, 437, 440, 442,	   evidence	   of	   selective	  	  	  	  	  	  	  	  
reporting	  421, 442	  or	  lack	  of	  clarity	  in	  reporting	  of	  outcomes	  428,	  or	  some	  other	  potential	  source	  
of	  bias	  398, 414, 415, 422, 423, 426, 427, 430, 432, 434.	  	  	  
In	  the	  case	  of	  the	  latter,	  for	  crossover	  studies,	  lack	  of	  measurement	  of	  a	  pre-­‐treatment	  phase	  
baseline	   was	   evident	   in	   several	   studies	   299, 431, 433, 435, 437, 438, 440-­‐442	   or	   a	   single	   baseline	  
measurement	  was	  performed	  without	   repeat	  measurement	   following	  washout	  prior	   to	   the	  
second	  crossover	  treatment	  phase	  421, 434, 436, 439.	   	  Several	  studies	  did	  not	  include	  a	  washout	  
period	  between	  treatment	  phases	  299, 421, 431, 435-­‐438, 440, 441.	   	  Some	  parallel	  studies	  examining	  
continuous	   outcome	  parameters	   also	   lacked	   baseline	  measurements	   from	  which	   to	   derive	  
differences	  in	  change	  between	  groups	  during	  the	  study	  period	  424, 425, 429.	  	  	  	  
None	   of	   the	   FBF	   response	   studies	   included	   a	   baseline.	   	   This	   may	   have	   been	   acceptable	  
however	  as	  the	  outcome	  assessed	  was	  responsiveness	  to	  vasoactive	  mediators	  (endothelium	  
dependent	  &	  independent).	  	  
Table	   5-­‐2	   provides	   a	   summary	   of	   characteristics	   of	   the	   randomised	   controlled	   studies	  
assessed	  according	  to	  the	  Cochrane	  risk	  assessment	  criteria.	  	  Further	  study	  details	  including	  
study	  design,	   included	  patient	  population,	  drug	  used	  and	  duration	  of	   therapy	  are	  shown	   in	  
table	   5-­‐3	   (studies	   in	   patients	   with	   established	   vascular	   disease)	   and	   table	   5-­‐4	   (studies	   in	  
patients	  with	  no	  established	  vascular	  disease,	  with	  or	  without	  vascular	  risk	  factors).	  
	  
Study	  Populations	  
Full	  details	  are	  included	  in	  tables	  5-­‐3	  &	  5-­‐4.	  	  In	  addition,	  five	  studies	  also	  examined	  responses	  
in	  healthy	  participants	  431, 437, 438, 442, 443.	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Table	  5-­‐2:	  	  Cochrane	  risk	  of	  bias	  characteristics	  for	  included	  studies	  
	  




















Yes	   Yes	   Yes	   Yes	   Yes	   Yes	   No	  
Khan	  	  
2008	  
Yes	   Yes	   Yes	   Yes	   Yes	   Yes	   Yes	  
Rentoukas	  
2010	  
Unclear	   Unclear	   Unclear	   Unclear	   Yes	   Yes	   No	  
Muir	  	  
2008	  
Yes	   Yes	   Yes	   Yes	   Yes	   Yes	   Yes	  
Hare	  	  
2008	  
Yes	   Yes	   Yes	   Yes	   Yes	   Yes	   Yes	  
Yiginer	  	  
2008	  
Yes	   Yes	   Yes	   Yes	   Yes	   Yes	   Yes	  
Afshari	  	  
2004	  
Yes	   Yes	   No	   Yes	   Unclear	   Yes	   Yes	  
Guan	  	  
2003	  
Yes	   Unclear	   No	   No	   No	   Yes	   No	  
Heunks	  	  
1999	  
Yes	   No	   No	   No	   Yes	   Yes	   Yes	  
Parmley	  
1992	  
Yes	   No	   Yes	   Yes	   Unclear	   Unclear	   No	  
Desco	  	  
2002	  
Yes	   Unclear	   Yes	   Yes	   Unclear	   Yes	   No	  
Dawson	  	  
2009	  
Yes	   Yes	   Yes	   Yes	   Yes	   Yes	   Yes	  
Delample	  
2008	  
Yes	   Unclear	   Yes	   Yes	   Unclear	   Yes	   No	  
Feig	  	  
2008	  
Yes	   Yes	   Yes	   Yes	   Yes	   Yes	   Yes	  
George	  	  
2006	  
Yes	   Yes	   Yes	   Yes	   Yes	   Yes	   No	  
Cingolani	  
2006	  
Yes	   Unclear	   Yes	   Yes	   Yes	   Yes	   Yes	  
El	  Solh	  	  
2006	  




Yes	   Yes	   Yes	   Yes	   Unclear	   No	   No	  
Gavin	  	  
2005	  
Yes	   Unclear	   Yes	   Yes	   Yes	   Yes	   No	  
Guthikonda	  
2004	  
Yes	   Unclear	   No	   Yes	   Yes	   Yes	   No	  
Guthikonda	  
2003	  
Yes	   Unclear	   No	   Yes	   Unclear	   Yes	   No	  
Farquharson	  
2002	  
Yes	   Yes	   Yes	   Yes	   Unclear	   Yes	   No	  
Shehab	  	  
2001	  
Yes	   Unclear	   Yes	   Yes	   Yes	   Yes	   No	  
Butler	  	  
2000	  
Yes	   Yes	   Yes	   Yes	   Unclear	   Yes	   No	  
O’Driscoll	  
1999	  
Yes	   Yes	   Yes	   Yes	   Unclear	   Yes	   No	  
Dawson	  	  
2009	  
Yes	   Yes	   Yes	   Yes	   Yes	   Yes	   Yes	  
Noman	  	  
2010	  
Yes	   Yes	   Yes	   Yes	   Yes	   Yes	   No	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Table	  5-­‐3:	  	  Study	  characteristics	  in	  populations	  with	  established	  vascular	  disease	  
	  
Study	   Population	  
(n)	  
Design	   Intervention	  
Hare	  2008	   CHF	  	  
(n	  =	  405)	  
Parallel	  RCT	   Oxypurinol	  600mg	  
24	  weeks	  
Doehner	  2002	   CHF	  	  
(n	  =	  14)	  
Crossover	  RCT	   Allopurinol	  300mg	  
1	  week	  
George	  2006	   CHF	  
(n	  =	  29)	  
Crossover	  RCT	   Allopurinol	  	  
300mg	  /	  600mg	  
4	  weeks	  
Cingolani	  2006	   CHF	  
(n	  =	  60)	  
Crossover	  RCT	   Oxypurinol	  600mg	  
4	  weeks	  
Gavin	  2005	   CHF	  
(n	  =	  50)	  
Crossover	  RCT	   Allopurinol	  300mg	  
12	  weeks	  
Farquharson	  2002	   CHF	  
(n	  =	  11)	  
Crossover	  RCT	   Allopurinol	  300mg	  
4	  weeks	  
Shehab	  2001	   CHF	  
(n	  =	  16)	  
Crossover	  RCT	   Allopurinol	  300mg	  
8	  weeks	  
Doehner	  2002	   CHF	  




Single	  IA	  infusion	  	  
Baldus	  2006	   CHF	  





Cappola	  2001	   CHF	  




Single	  IA	  infusion	  	  
Struthers	  2002	   CHF	  
(n	  =	  1760)	  
Population	  cohort	   Allopurinol	  	  
No	   use	   /	   100mg	   /	  
300mg	  
>	  4	  years	  
Wei	  2009	   CHF	  
(n	  =	  4785)	  
Population	  cohort	   Allopurinol	  	  
No	   use	   /	   <300mg	   /	  
300mg	  +	  
4.8	  years	  (median)	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Thanassoulis	  2010	   CHF	  
(n	  =	  25090)	  
Population	  cohort	   Allopurinol	  
Current	   use	   (≤	   /	   >	  
100mg)	   /	   No	   current	  
use	  
2.1	  years	  (median)	  
Wu	  2010	   CHF	  
(n	  =	  1152)	  
Population	  cohort	   Allopurinol	  
(Any	  use	  /	  No	  use)	  
14	  months	  (median)	  
Parmley	  2002	   CAD	  
(n	  =	  140)	  
Parallel	  RCT	   Allopurinol	  
600mg	  
Duration	  not	  specified	  
Rentoukas	  2009	   CAD	  
(n	  =	  40)	  
Parallel	  RCT	   Allopurinol	  
400mg	   loading	   dose	  
then	  100mg	  
1	  month	  
Noman	  2010	   CAD	  
(n	  =	  60)	  
Crossover	  RCT	   Allopurinol	  
600mg	  
6	  weeks	  
Guan	  2003	   CAD	  
(n	  =	  38)	  
PROBE	   Allopurinol	  400mg	  
1	  day	  
Landmesser	  2007	   CAD	  





Landmesser	  2007	   CAD	  




Single	  IA	  infusion	  
Baldus	  2005	   CAD	  





Khan	  2008	   Stroke	  
(n	  =	  30)	  
Parallel	  RCT	   Allopurinol	  300mg	  
8	  weeks	  
Muir	  2008	   Stroke	  
(n	  =	  50)	  
Parallel	  RCT	   Allopurinol	  
100mg	  /	  300mg	  	  
6	  weeks	  
Dawson	  2009	   Stroke	  
(n	  =	  45)	  
Parallel	  RCT	   Allopurinol	  
300mg	  
3	  months	  
Table	  footnote:	  CHF	  –	  chronic	  heart	  failure,	  CAD	  –	  coronary	  artery	  disease,	  n	  –	  number,	  RCT	  –	  
randomized	  controlled	  trial,	  PROBE	  –	  prospective	  randomized	  open-­‐label	  blinded	  endpoint,	  mg	  –	  
milligram,	  IA	  –	  intra-­‐arterial.	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Table	  5-­‐4:	  	  Study	  characteristics	  in	  populations	  with	  vascular	  risk	  factors	  
Study	   Population	  (n)	   Design	   Intervention	  
Afshari	  2004	   DM	  
(n	  =	  41)	  
Parallel	  RCT	   Allopurinol	  300mg	  
2	  weeks	  
Desco	  2002	   DM	  
(n	  =	  12)	  
Parallel	  RCT	   Allopurinol	  300mg	  
2	  weeks	  
Butler	  2000	   DM	  
(n	  =	  11)	  
Crossover	  RCT	   Allopurinol	  300mg	  
4	  weeks	  
Dawson	  2009	   DM	  
(n	  =	  14)	  
Crossover	  RCT	   Allopurinol	  300mg	  
2	  weeks	  
Feig	  2008	   Hypertension	  
(n	  =	  30)	  
Crossover	  RCT	   Allopurinol	  400mg	  
4	  weeks	  
Cardillo	  1997	   Hypertension	  /	  HC	  




Single	  IA	  infusion	  	  
O’Driscoll	  1999	   HC	  
(n	  =	  9)	  
Crossover	  RCT	   Allopurinol	  300mg	  
4	  weeks	  
Mercuro	  2004	   High	  CV	  risk	  





Yiginer	  2008	   Metabolic	  syndrome	  
(n	  =	  50)	  
Parallel	  RCT	   Allopurinol	  300mg	  
4	  weeks	  
Guthikonda	  2004	   Smokers	  
(n	  =	  12)	  
PROBE	  (crossover)	   Allopurinol	  600mg	  
1	  day	  
Guthikonda	  2003	   Smokers	  
(n	  =	  14)	  
PROBE	  (crossover)	   Allopurinol	  600mg	  
1	  day	  
Heunks	  1999	   COPD	  
(n	  =	  8)	  
PROBE	   Allopurinol	  600mg	  
1	  day	  
Delample	  2008	   COPD	  
(n	  =	  9)	  
Crossover	  RCT	   Allopurinol	  600mg	  
1	  day	  
El	  Solh	  2006	   Obstructive	   sleep	  
apnoea	  (n	  =	  12)	  
Crossover	  RCT	   Allopurinol	  300mg	  
2	  weeks	  
Spahr	  2007	   Liver	  disease	  





Eskurza	  2006	   Elderly	  
(n	  =	  9)	  
Crossover	  RCT	   Allopurinol	  600mg	  
1	  day	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Kanbay	  2007	   Hyperuricaemia	  





Luk	  2009	   Hyperuricaemia	  
(n	  =	  9924)	  
Population	  cohort	   Allopurinol	  
Any	  use	  /	  no	  use	  
DM,	  diabetes	  mellitus;	  HC,	  hypercholesterolaemia;	  CV,	  cardiovascular;	  COPD,	  chronic	  obstructive	  
pulmonary	  disease;	  n,	  number;	  RCT;	  randomised	  controlled	  trial;	  PROBE,	  prospective	  randomised	  




Details	  of	  dose	  /	  24	  hours	  and	  duration	  of	  treatment	  are	  given	  in	  tables	  1	  &	  2.	  	  Most	  studies	  
utilised	  one	  dosing	  regimen	  only	  in	  design.	  	  One	  study	  used	  a	  loading	  dose	  (400mg)	  followed	  
by	  100mg	  once	  daily	   for	  one	  month	  429.	   	  The	  effect	  of	  variable	  dose	   (100mg	  /	  300mg	  once	  
daily)	   414	  and	   (300mg	  once	  daily	  /	  300mg	  twice	  daily)	   299	  was	  also	  studied.	   	  The	  population	  
cohort	  studies	  compared	  therapy	  (including	  low	  or	  high	  dose)	  with	  no	  treatment	  449-­‐453.	  	  One	  
study	   did	   not	   specify	   treatment	   duration	   (though	   this	   appeared	   to	   have	   been	   a	   period	   of	  
several	  days)	   428.	   	  Four	  studies	  examined	   intra-­‐arterial	   treatment,	  via	   the	  brachial	   421, 443	  or	  
coronary	  arteries	   377, 454	  and	  were	  conducted	  on	  a	  single	  day.	   	  The	  remainder	   involved	  oral	  
treatment	  except	  two	  in	  which	  it	  was	  intravenous	  444, 445.	  	  	  
	  
Outcome	  Measures	  
The	   primary	   and	   secondary	   end-­‐points	   used	   are	   summarised	   below	   according	   to	   broad	  
groups	  of	  outcome	  measure.	  
Studies	   assessing	   endothelial	   function	   –	   Seventeen	   publications	   utilised	   a	   measure	   of	  
endothelial	  function	  299, 377, 415, 421, 423, 427, 430, 431, 434, 435, 437, 438, 440, 442-­‐444, 447	  (nineteen	  studies	  
in	  total	  as	  two	  publications	  each	  reported	  two	  separate	  studies)	  377, 421.	  	  	  
Nine	  studies	  reported	  effect	  upon	  flow-­‐mediated	  dilatation	  (FMD)	  of	  the	  brachial	  artery	  (as	  a	  
percentage	   change	   from	   baseline)	   377, 421, 430, 434, 438, 442, 444, 447,	   (one	   publication	   reporting	  
FMD	  as	  an	  outcome	  for	  two	  separate	  studies	  377).	  	  One	  publication	  included	  a	  second	  study	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that	   reported	   brachial	   artery	   diameter	   as	   a	   response	   to	   flow-­‐mediated	   stimulus,	   without	  
detailing	  the	  degree	  of	  dilatation	  421.	  	  	  
Six	  studies	  reported	  forearm	  blood	  flow	  (FBF)	  responses	  to	  vasoactive	  mediators,	  determined	  
by	   venous	   occlusion	   plethysmography	   (expressed	   as	   absolute	   change	   in	   ml/min/100ml	  
forearm	  tissue	  and	  /	  or	  as	  percentage	  change	  in	  flow	  relative	  to	  the	  non-­‐infused	  control	  arm	  
in	   each	   subject)	   299, 431, 435, 437, 440, 443.	   	   One	   paper	   reported	   forearm	   and	   leg	   blood	   flow	  
responses	   to	   ischaemia	   421	   and	   brachial	   artery	   diameter	   as	   a	   response	   to	   acetylcholine	  
infusion	  (not	  expressed	  in	  terms	  of	  FBF)	  421.	  	  	  
Other	  studies	  examined	  cerebrovascular	  responses	  to	  NG-­‐Monomethyl-­‐L-­‐Arginine	  (L-­‐NMMA)	  
infusion	   415,	   cerebrovascular	   reactivity	   to	   Acetazolamide	   423,	   coronary	   blood	   flow	  	  	  	  	  	  
responses	  444,	  augmentation	  index	  (AI)	  423, 427	  and	  pulse	  wave	  velocity	  423.	  	  	  
Studies	   assessing	   oxidative	   stress	   -­‐	   Twelve	   publications	   examined	   circulating	   markers	   of	  
oxidative	  stress	  421, 422, 424-­‐426, 430, 431, 433-­‐435, 442, 448.	   	  Malondialdehyde	  422, 424, 426, 430, 431, 434, 435, 
448,	   Glutathione	   424, 426, 430,	   Allantoin	   421,	   8-­‐epi-­‐prostaglandin-­‐F2	   425,	   oxidised-­‐LDL	   442,	   FRAP	  
(total	   antioxidant	   power)	   422,	   advanced	   oxidation	   protein	   product	   (AOPP)	   /	   Isoprostanes	   /	  
TAS	  (total	  antioxidant	  power)	  /	  Vitamin	  E	  433	  were	  measured.	  	  	  
Studies	  assessing	  cardiac	  outcomes	  -­‐	  Eleven	  studies	  examined	  cardiac	  outcomes.	  	  One	  used	  a	  
combined	   clinical	   heart	   failure	   outcome	   398,	   four	   examined	   effects	   on	   cardiac	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
function	  425, 429, 432, 445,	  one	  efficiency	  of	  myocardial	  energy	  use	  454,	  one	   infarct	  extension	   in	  
the	  ACS	  setting	  428,	  one	  cardiac	  enzyme	  levels	  in	  the	  setting	  of	  ST-­‐elevation	  MI	  treated	  with	  
primary	  angioplasty	  and	  recurrent	  vascular	  events	  in	  this	  group	  during	  one	  month	  of	  follow	  
up	   thereafter	   429	   and	   one	   effect	   on	   dysrhythmia	   counts	   and	   autonomic	   tone	   441.	   Four	  
population	  based	  cohort	  studies	  examined	  CHF	  related	  morbidity	  and	  mortality	  450-­‐453	  whilst	  
another	  examined	  all-­‐cause	  mortality	  449.	  
Studies	   assessing	   exercise	   capacity	   -­‐	   Five	   studies	   examined	   exercise	   capacity:	   four	   with	  
walking	   tests,	  modified	  or	   standard	  Bruce	  protocol	   398, 432, 436, 439	   and	  one	  effect	  on	  muscle	  
power	  and	  endurance	  433.	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Studies	  assessing	  haemodynamic	  measurements	  -­‐	  Two	  studies	  examined	  effects	  on	  BP	  359, 446	  
while	   a	   further	   fifteen	   studies	   made	   reference	   to	   effects	   on	   heart	   rate	   and	   BP	  	  	  
measurements	  299, 421, 426, 427, 431, 432, 435-­‐438, 440, 443, 445, 447, 454.	  
Studies	   assessing	   inflammatory	   /	   humoral	   indices	   -­‐	  Several	   studies	   examined	   inflammatory	  
indices	   299, 414, 415, 423, 430, 436, 439, 446, 448,	   routine	  haematological	  and	  biochemical	   findings	   299, 
415, 421-­‐423, 426, 432, 436, 439, 446,	  markers	  of	  haemodynamic	  or	  cardiac	   function	  299, 359, 436, 439	  and	  




Improvement	   in	   FMD	   following	   XOI	  was	   observed	   in	   eight	   studies	   377, 421, 430, 434, 438, 444, 447	  
(including	   both	   studies	   in	   one	   publication	   377).	   In	   one,	   improvement	   was	   noted	   only	   in	  
participants	  stratified	  as	  hyperuricaemic	  447.	  	  One	  study	  which	  included	  elderly	  but	  otherwise	  
healthy	   subjects	   found	   no	   improvement	   442.	   	   No	   treatment	   effect	   was	   observed	   amongst	  
healthy	  subjects	  438, 442.	  	  	  
Five	  FMD	  studies	  could	  be	  combined	  in	  meta-­‐analysis,	  treatment	  with	  XOI	  n	  =	  75,	  control	  n	  =	  
69	   421, 430, 434, 438, 442.	   	   Four	   studies	   were	   excluded	   because	   of	   lack	   of	   control	   group	   or	  
randomization	  377, 444, 447	  (including	  both	  studies	  in	  one	  publication	  377).	  	  Following	  treatment,	  
patients	   treated	   with	   XO	   inhibition	   exhibited	   a	   2.50	   [95%	   confidence	   interval	   (CI),	   0.15	   –	  
4.84]	  higher	  FMD	  of	  the	  brachial	  artery,	  compared	  with	  control	  (expressed	  as	  a	  %	  change	  in	  
vessel	   diameter,	   figure	  5-­‐2;	   figure	  detailing	   individual	   study	  data	  presented	   in	  Appendix	  B,	  
figure	  B-­‐1).	  	  The	  corresponding	  funnel	  plot	  is	  detailed	  in	  figure	  5-­‐3.	  
Improvement	   in	   FBF	   response	   to	   acetylcholine	   infusion	   was	   observed	   in	   five	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
studies	  299, 431, 435, 437, 443	  following	  XOI.	  FBF	  response	  to	  induced	  ischaemia	  421	  also	  improved.	  	  
One	   study	   in	   hypercholesterolaemic	   patients	   failed	   to	   identify	   benefit	   440.	   	   Conversely,	  
another	   showed	   improvement	   in	   hypercholesterolaemic	   but	   not	   hypertensive	   patients	   443.	  	  
No	  treatment	  effect	  was	  seen	  amongst	  healthy	  subjects	  431, 437, 443.	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Five	  FBF	  studies	  could	  be	  combined	  in	  meta-­‐analysis,	  treatment	  with	  XOI	  n	  =	  74,	  control	  n	  =	  
74	  299, 431, 435, 437, 440.	  	  One	  study	  compared	  both	  300mg	  once	  daily	  and	  300mg	  twice	  daily	  with	  
placebo	  and	  data	  with	  the	  lower	  dose	  was	  included	  in	  the	  combined	  analysis	  299.	  	  One	  study	  
was	  excluded	  as	   it	   lacked	  randomization	  443	  and	  one	  other	  as	   it	  examined	  FBF	  responses	  to	  
induced	   ischaemia	   rather	   than	   to	   acetylcholine	   infusion	   421.	   	   Following	   treatment,	   patients	  
treated	  with	  XO	  inhibition	  exhibited	  a	  69%	  [95%	  CI,	  19	  –	  119%]	  higher	  FBF	  response	  to	  ACh,	  
compared	  with	  control	   (expressed	  as	  %	  change	   in	  flow	  relative	  to	  non-­‐infused	  control	  arm,	  
figure	  5-­‐4;	   figure	  detailing	   individual	   study	  data	  presented	   in	  Appendix	  B,	   figure	  B-­‐2).	   	   The	  
corresponding	  funnel	  plot	  is	  detailed	  in	  figure	  5-­‐5.	  
The	  study	  examining	  brachial	  artery	  diameter	  responses	  to	  acetylcholine	   infusion	  and	  flow-­‐
mediated	  stimulus	  demonstrated	  improvement	  in	  both	  cases	  421,	  though	  only	  amongst	  those	  
who	  were	  hyperuricaemic.	  	  Coronary	  blood	  flow	  was	  augmented	  by	  allopurinol	  therapy	  444	  as	  
was	   bioavailability	   of	   cerebrovascular	   NO	   415,	   though	   cerebrovascular	   reactivity	   to	  
Acetazolamide	  was	   unchanged	   423.	   	   Augmentation	   index	   reduced	   in	   one	   study	   427	   but	  was	  
unchanged	  in	  another	  which	  also	  found	  no	  change	  in	  PWV	  423.	  

















Figure	  5-­‐2:	  	  Forrest	  plot	  detailing	  end	  of	  treatment	  phase	  brachial	  artery	  FMD	  
(%	  change	  in	  vessel	  diameter)	  
	  







	   	  
Figure	  5-­‐5:	  	  Funnel	  plot	  detailing	  end	  of	  treatment	  phase	  FBF	  response	  to	  Ach	  studies	  
Figure	  5-­‐4:	  	  Forrest	  plot	  detailing	  end	  of	  treatment	  phase	  FBF	  response	  to	  ACh	  	  
(%	  change	  in	  flow	  relative	  to	  non-­‐infused	  control	  arm)	  
	  141	  
Oxidative	  Stress	  Markers	  	  
Improvement	  was	  observed	  in	  ten	  studies	  421, 425, 426, 430, 431, 433, 433-­‐435, 448	  following	  XOI,	  whilst	  
four	  reported	  neutral	  results	  422, 424, 433, 442,	   though	  not	   in	  all	  measured	  parameters	   in	  three	  
cases;	   in	  one	  study	  whilst	  GSH	  levels	  were	  unchanged,	  GSSG	  and	  the	  GSSG/GSH	  ratio	  were	  
favourably	   affected	   424;	   one	   study	   concluded	   no	   benefit	   despite	   a	   significant	   reduction	   in	  
Malondialdehyde	  with	  active	  treatment,	  as	  similar	  reduction	  was	  observed	  with	  placebo	  422;	  
in	  one	  study,	  no	  change	  in	  vitamin	  E	  was	  identified	  though	  AOPP,	  TAS	  and	  isoprostanes	  were	  
all	  favourably	  modified	  433.	  	  No	  treatment	  effect	  was	  identified	  in	  healthy	  subjects	  431, 442	  or	  in	  
elderly	  but	  otherwise	  healthy	  subjects	  442.	  	  
Malondialdehyde	   was	   the	   only	   oxidative	   stress	   parameter	   examined	   in	   more	   than	   three	  
studies.	   	   Six	  Malondialdehyde	   studies	   could	  be	   combined	   in	  meta-­‐analysis,	   treatment	  with	  
XOI	  n	  =	  78,	   control	  n	  =	  68	   424, 426, 430, 431, 434, 435.	   	  One	  study	  was	  excluded	  as	   it	   included	  no	  
control	  group	  448	  and	  one	  as	  unit	  of	  reporting	  was	  unclear	  422.	  	  Following	  treatment,	  patients	  
treated	   with	   XO	   inhibition	   exhibited	   a	   0.56	   (95%	   CI,	   0.26	   –	   0.87)	   lower	  Malondialdehyde	  
level,	   compared	   with	   control	   (nmol/ml,	   figure	   5-­‐6;	   figure	   detailing	   individual	   study	   data	  
presented	  in	  Appendix	  B,	  figure	  B-­‐3).	  	  The	  corresponding	  funnel	  plot	  is	  detailed	  in	  figure	  5-­‐7.	  
Whilst	  hypothesis	  test	  were	  not	  applied	  to	  funnel	  plots	  for	  any	  of	  the	  combined	  analyses	  due	  
to	   the	  number	  of	   studies	   included	   in	  each,	  brief	   inspection	  suggested	   that	  publication	  bias	  
could	  not	  be	  excluded	  based	  upon	  the	  available	  data.	  	  
The	   I2	   statistic	  was	  >	  50%	   for	   each	  of	   the	   three	   combined	  endpoint	   analyses,	   suggesting	  a	  
high	  degree	  of	  variation	  across	  studies	  due	  to	  heterogeneity,	  rather	  than	  chance.	  	  In	  addition,	  
the	  populations	  included	  in	  the	  combined	  analyses	  differed	  from	  one	  another,	  being	  defined	  
through	  the	  presence	  of	  a	  specific	  risk	  factor	  in	  each	  case.	  	  Sensitivity	  analysis,	  with	  study	  by	  
study	   omission	   from	   combined	   analysis	   are	   presented	   for	   FMD,	   FBF	   and	   oxidative	   stress	  
outcome	  in	  Appendix	  B;	  tables	  B-­‐1,	  B-­‐2	  &	  B-­‐3,	  respectively.	  








	   	  
Figure	  5-­‐7:	  	  Funnel	  plot	  for	  serum	  MDA	  level	  studies 
Figure	  5-­‐6:	  	  Forrest	  plot	  detailing	  end	  of	  treatment	  phase	  circulating	  MDA	  (nmol/ml)	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Cardiac	  outcomes	  	  
Four	   studies	   demonstrated	   improvements	   in	   cardiac	   physiology,	   including	   left	   ventricular	  
ejection	   fraction	   (LVEF)	   425, 432, 445,	  cardiac	   index	   425,	  end-­‐systolic	  volume	  445	  and	  myocardial	  
efficiency	  454.	  	  No	  difference	  was	  observed	  with	  treatment	  upon	  dysrhythmia	  counts	  441	  and	  
one	   study	   found	   no	   effect	   upon	   LVEF	   429.	   	   In	   the	   ACS	   setting,	   higher	   levels	   of	   “infarct	  
extension”	   were	   seen	   in	   the	   allopurinol	   group	   428	   whilst	   in	   acute	  MI	   patients	   undergoing	  
primary	   angioplasty,	   elevations	   in	   cardiac	   enzymes	   were	   retarded	   429.	   	   This	   study,	   with	   a	  
sample	   size	   of	   forty	   patients,	   reported	   non-­‐significantly	   fewer	   recurrent	   events	   over	   one	  
month	  of	  follow	  up	  in	  those	  treated	  with	  allopurinol	  (four	  events)	  than	  those	  on	  placebo	  (six	  
events).	  
Two	   population	   based	   cohort	   studies	   identified	   lower	   heart	   failure	   related	   mortality	   in	  
patients	   treated	   with	   high	   dose	   allopurinol	   but	   increased	   mortality	   in	   those	   on	   low	   dose	  
treatment	  450, 452.	  	  One	  cohort	  study	  reported	  reduced	  heart	  failure	  combined	  morbidity	  and	  
mortality	  but	  only	  amongst	  patients	  with	  a	  history	  of	  gout	  451.	  	  Another	  identified	  increased	  
mortality	   in	  association	  with	  allopurinol	  treatment	  when	  compared	  with	  untreated	  patients	  
with	  the	  lowest	  levels	  of	  UA	  453.	  	  As	  UA	  level	  was	  not	  accounted	  for	  in	  the	  treated	  population,	  
the	   authors	   drew	   no	   conclusion	   as	   to	   an	   aetiological	   relationship	   between	   treatment	   and	  
outcome.	   	   Another	   cohort	   study	   reported	   reduced	   all-­‐cause	   mortality	   amongst	  
hyperuricaemic	   subjects	   on	   treatment	   449.	   	   No	   improvement	   in	   combined	   heart	   failure	  
morbidity	  &	  mortality	  was	  seen	   in	  a	  prospective	  study,	   though	  post-­‐hoc	  analysis	  suggested	  
benefit	   amongst	   hyperuricaemic	   patients	   398.	   	   Heterogeneity	   in	   use	   of	   cardiac	   outcome	  
measurements	  precluded	  combined	  meta-­‐analysis.	  
	  
Exercise	  capacity	  
Four	   studies	   reported	   no	   improvement	   in	   exercise	   capacity	   398, 432, 433, 436.	   	   One	   study,	   in	  
patients	   with	   CAD,	   reported	   an	   increase	   in	   total	   exercise	   time,	   time	   to	   onset	   of	   anginal	  
symptoms	  and	  time	  to	  ECG	  ST-­‐segment	  depression	  439.	  	  Heterogeneity	  in	  assessment	  method	  
of	  exercise	  capacity	  precluded	  any	  combined	  meta-­‐analysis.	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Haemodynamic	  measurements	  
Two	   studies	   that	   sought	   to	   examine	   BP	   response	   identified	   a	   reduction	   with	  	  	  	  	  	  	  	  	  	  	  	  	  	  
treatment	  359, 446.	   	  One	  study,	  in	  the	  context	  of	  improved	  cardiac	  function,	  reported	  a	  trend	  
to	   increased	   aortic	   pressure	   acutely	   following	   Oxypurinol	   administration	   445.	   	   No	   other	  
studies	  making	  reference	  to	  routine	  haemodynamics	  reported	  any	  significant	  change	  299, 421, 
426, 427, 431, 432, 435-­‐438, 440, 443, 447, 454.	  	  
	  
Humoral	  /	  Inflammatory	  Indices	  
CRP	  was	  reduced	  in	  one	  study	  446	  and	  was	  unchanged	  in	  seven	  others	  299, 414, 415, 423, 430, 436, 439.	  	  
Myeloperoxidase	   reduced	   in	   one	   study	   430.	   	   ICAM-­‐1	   reduced	   in	   one	   study	   414	   but	   not	   in	  
another	  415.	  	  Il-­‐6	  was	  unchanged	  414, 448	  as	  was	  fibrinogen	  430,	  e-­‐selectin	  and	  VEGF	  415, 423.	  	  
One	   study	  observed	  benefit	   in	   lipid	  profile	   436	  with	  no	   change	   in	   two	  others	   299, 440.	   	   Renal	  
parameters	   improved	   in	   one	   study	   446	   but	   were	   unchanged	   in	   four	   others	   299, 421, 432, 436.	  	  
Haemoglobin	   reduced	   in	   one	   study	   436	   and	  was	   unchanged	   in	   another	   426	   [21].	   	   HbA1C	  was	  
unchanged	  422.	  
Reductions	   in	  Renin	  359	  and	  BNP	  were	  reported	  436, 439	  though	  not	  universally	   in	  the	  case	  of	  
the	  latter	  299.	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5.4. Discussion	  
This	  systematic	  review	  and	  meta-­‐analysis	  describes	  the	  published	  evidence	  examining	  XOI	  in	  
the	  human	  population	  in	  relation	  to	  cardiovascular	  health	  and	  function.	  	  This	  represents	  the	  
only	  systematic	  review	  of	  the	  evidence	  in	  this	  area.	  	  The	  available	  data	  are	  heterogeneous	  in	  
terms	   of	   study	   methodology,	   including	   the	   patient	   populations,	   treatment	   protocol	   and	  
outcome	  parameters	  studied.	  	  There	  is	  a	  relative	  paucity	  of	  studies	  without	  potential	  sources	  
of	  bias.	  	  However,	  there	  is	  a	  body	  of	  well-­‐designed	  studies,	  the	  results	  of	  which	  suggest	  this	  
strategy	   merits	   further	   study.	   	   It	   may	   represent	   a	   novel	   preventative	   strategy	   for	  
cardiovascular	  disease.	  	  	  
It	  is	  important	  to	  acknowledge	  that	  there	  are	  limitations	  to	  the	  available	  evidence.	  	  There	  is	  
only	  one	  large	  prospective	  randomised	  clinical	  trial	   in	  the	  literature.	  In	  general,	  prospective	  
trials	   have	   been	   small,	   conducted	   in	   highly	   defined	   patient	   populations	   and	   were	   not	  
universally	   inclusive	   of	   a	   control	   group.	   	   Moreover,	   when	   control	   groups	   were	   included,	  
randomization	   between	   treatment	   arms	   and	   use	   of	   appropriate	   placebo	   amongst	   controls	  
was	   sometimes	   lacking.	   	   Despite	   these	   flaws,	   there	   exists	   a	   body	   of	  well-­‐designed	   studies	  
that	  have	  examined	  a	  broad	  range	  of	  outcomes.	  	  Combined	  analysis	  was	  feasible	  for	  some	  of	  
these	  outcome	  measures.	  	  
Improvements	   in	   measures	   of	   endothelial	   function,	   oxidative	   stress,	   cardiac	   function,	  
haemodynamics	   and	   certain	   inflammatory	   indices	   have	   been	   demonstrated.	   	   Population	  
based	   cohort	   studies	   have	   identified	   reductions	   in	   all-­‐cause	   and	   heart	   failure-­‐related	  
mortality	   in	  association	  with	  allopurinol	  treatment,	  although,	   intriguingly,	   low	  dose	  therapy	  
was	  linked	  with	  adverse	  outcome.	  	  The	  largest	  prospective	  clinical	  trial	  was	  conducted	  in	  CHF	  
patients	  398.	  	  Though	  no	  overall	  benefit	  was	  seen	  in	  the	  primary	  outcome	  of	  the	  study,	  post-­‐
hoc	  analysis	  suggested	  benefit	  amongst	  patients	  with	  baseline	  hyperuricaemia.	  	  Limitation	  of	  
benefit	   to	  participants	  with	  hyperuricaemia	  was	  reported	   in	  other	  populations	   identified	   in	  
this	  review	  421, 447.	  	  	  
The	  combined	  analysis	  suggests	  endothelial	  function	  (determined	  by	  either	  FBF	  responses	  or	  
FMD)	   can	  be	  beneficially	  modified	  by	  XOI.	   	   XO	  activity	   up-­‐regulation	  has	  been	   reported	   in	  
pathological	   states	   such	   as	   atherosclerotic	   disease	   455.	   	   The	   hypothesis	   that	   impaired	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endothelial	  function	  and	  increased	  XO	  activity	  are	  related	  is	  supported	  by	  the	  observation,	  in	  
certain	   populations,	   that	   patients	  with	   hyperuricaemia	   appear	   to	   experience	   a	   differential	  
response	  to	  treatment	  398, 421, 447.	  
However,	  such	  benefit	  was	  not	  universally	  reported	  in	  identified	  studies.	  	  Conflicting	  results	  
in	  patients	  with	  hypercholesterolaemia	  440, 443	  and	  lack	  of	  benefit	  amongst	  hypertensives	  443	  
and	   healthy	   elderly	   participants	   442	   (who	   exhibit	   impaired	   endothelial	   function)	   were	  
reported.	   	   No	   treatment	   effect	   was	   identified	   when	   therapy	   was	   examined	   in	   healthy	  
participants	   431, 437, 438, 442, 443.	   	   If	  we	  assume	  that	  XO	  activity	   is	  unlikely	   to	  be	  adversely	  up-­‐
regulated	  in	  such	  individuals,	  this	  finding	  may	  be	  expected.	  	  	  
However,	   lack	   of	   benefit	   in	   certain	   patient	   populations	   raises	   the	   possibility	   that	   up-­‐
regulation	   of	   XO	   activity	   may	   not	   be	   ubiquitous	   in	   all	   pathological	   states	   associated	   with	  
endothelial	   dysfunction.	   	   This,	   combined	   with	   the	   differential	   response	   to	   treatment	   in	  
relation	  to	  UA	  levels,	  may	  suggest	  that	  particular	  patient	  subgroups	  may	  be	  more,	  or	  indeed	  
less,	  amenable	  to	  therapeutic	  XOI.	  	  	  
The	  optimal	  concentration	  of	  UA	   in	  man	  remains	  undefined	  and	  a	  better	  understanding	  of	  
the	   biologic	   functions	   of	   UA,	   including	   its	   intracellular	   role,	   may	   prove	   vital	   if	   XOI	   is	   to	  
progress	  as	  an	  effective	  therapeutic	  strategy	  in	  cardiovascular	  disease.	  	  The	  potential	  optimal	  
level	   of	   SUA	   and	   the	   observed	   neutral	   results	   in	   some	   studies,	   should	   be	   considered	  
alongside	   the	   observed	   dose	   dependent	   improvement	   in	   endothelial	   function	   299	   and	  
circulating	   inflammatory	  molecules	   414	   that	  were	   reported.	   	   Consideration	   of	   optimal	   dose	  
seems	  essential	  in	  the	  design	  of	  future	  studies.	  
Whilst	  several	  studies	  failed	  to	  identify	  treatment	  effect	  on	  exercise	  capacity,	  only	  one	  study	  
reported	   adverse	   outcome	   with	   XOI	   428.	   	   The	   observed	   increase	   in	   “infarct	   extension”	  
amongst	   patients	   with	   unstable	   angina	   and	   MI	   should	   prompt	   caution.	   	   However,	   the	  
redefinition	  of	   some	  patients	  as	  having	  unstable	  angina	  or	  a	  MI	  after	   recruitment	   into	   this	  
study,	  in	  addition	  to	  the	  authors	  reporting	  lack	  of	  homogeneity	  between	  treatment	  groups	  in	  
terms	   of	   concurrent	   therapy	   (including	   invasive	   revascularisation	   procedures),	   makes	   it	  
difficult	  to	  draw	  robust	  conclusions	  from	  this	  study.	  	  Moreover,	  in	  a	  similar	  study	  population	  
with	   acute	   MI,	   XOI	   was	   associated	   with	   retardation	   in	   cardiac	   enzyme	   elevation	   and	   no	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evidence	  of	  harm	  429.	   	   	  The	  available	  data	  suggest	  potential	  benefit	  of	  XOI	  in	  the	  context	  of	  
acute	  ischemic	  events,	   in	  addition	  to	  the	  chronic	  effects	  within	  the	  arterial	  vasculature	  that	  
have	  been	  the	  predominant	  focus	  of	  study.	  
	  
Clinical	  relevance	  
It	   is	  unclear	  how	  changes	  in	  surrogate	  markers	  of	  vascular	  health	  may	  translate	  into	  clinical	  
benefit.	   	   For	   the	   endothelial	   function	   parameters	   which	   were	   included	   in	   combined	   data	  
analysis,	  both	  FBF	  responses	  to	  acetylcholine	  and	  brachial	  artery	  FMD	  have	  been	   identified	  
as	   predictors	   of	   risk	   in	   the	   setting	   of	   both	   established	   vascular	   disease	   456, 457	   and	  
cardiovascular	   risk	   states	   458, 459.	   	   As	   such,	   the	   endothelium	   and	   its	   function	   may	   be	  
considered	  a	  potential	  therapeutic	  target.	  
The	   clinical	   benefits	   of	   statins	   and	   angiotensin-­‐converting	   enzyme	   inhibitors	   have,	   in	   part,	  
been	  attributed	  to	  their	  effects	  upon	  the	  endothelium	  460.	  	  It	  appears,	  from	  the	  current	  study	  
combined	  analysis,	  that	  XOI	  may	  produce	  improvement	  in	  FBF	  responses	  in	  the	  same	  order	  
of	  effect	  as	  statin	  therapy	  461	  and	  similar	   improvement	   in	  brachial	  artery	  FMD	  as	  that	  seen	  
with	   angiotensin	   receptor	   antagonists	   462	   and	   statins	   463.	   	   Whilst	   both	   these	   drug	   classes	  
clearly	   exert	   effects	   beyond	   improvement	   in	   endothelial	   function,	   it	   is	   promising	   that	   the	  
current	  findings	  suggest	  a	  similar	  magnitude	  of	  beneficial	  effect	  with	  therapeutic	  XOI.	  
Most	   identified	   studies	   reported	   favourable	   XOI	   effects	   upon	  markers	   of	   oxidative	   stress.	  	  
The	  most	   frequently	  measured	   of	   these	   was	  Malondialdehyde	   and	   the	   combined	   analysis	  
suggested	  a	  significant,	  albeit	  modest,	  reduction	  in	  circulating	  levels	  that,	  in	  principle,	  ought	  
to	  confer	  protection	  over	  endothelial	  function	  371.	  	  	  
	  
Limitations	  of	  this	  review	  
Broad	   selection	   criteria	  were	   used	   to	   avoid	   selection	   bias	   but	   did	   not	   include	  unpublished	  
data	  and	  did	  not	  include	  articles	  unavailable	  in	  the	  English	  language.	  	  The	  search	  strategy	  was	  
systematic	  however	  data	  relevant	  to	  this	  review	  may	  have	  been	  published	   in	  a	  context	  not	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identified	  by	  the	  search	  strategy.	  	  The	  search	  was	  based	  on	  inclusion	  of	  search	  terms	  within	  
the	   title	  of	   the	  article.	   	  As	  such	  we	  may	  have	   failed	   to	   identify	  outcomes	  of	   interest	  which	  
were	  referred	  to	  only	  within	  the	  text	  of	  the	  published	  studies.	   	  The	  search	  strategy	  related	  
three	   concepts;	   population,	   patients	   with	   or	   at	   risk	   of	   CV	   disease;	   intervention,	   XOI;	   and	  
outcome,	  CV	  function	  /	  health	  parameters.	  	  Through	  incorporating	  the	  outcome	  concept,	  the	  
sensitivity	   for	   identifying	   studies	   reporting	   outcomes	   which	   were	   not	   detailed	   within	   the	  
search	  criteria	  terms	  may	  have	  been	  reduced.	  
Studies	   in	   the	   chronic	   renal	   failure	   and	   surgical	   patient	   populations	  were	   excluded,	  with	   a	  
view	   to	   maintaining	   a	   degree	   of	   homogeneity	   in	   the	   included	   studies.	   	   Allopurinol	   is	  
associated	   with	   adverse	   drug	   reactions,	   the	   propensity	   to	   which	   is	   increased	   in	   impaired	  
renal	   function.	   	  Nevertheless,	   several	   studies	  have	  been	   conducted	   in	   this	  population	  with	  
reference	  to	  cardiovascular	  outcomes	  which	  may	  potentially	  add	  to	  the	  understanding	  of	  the	  
potential	  application	  of	  XOI	  as	  a	  therapeutic	  strategy.	  	  	  
There	   was	   heterogeneity	   in	   terms	   of	   treatment	   duration	   and	   the	   population	   in	   which	  
combined	  treatment	  effects	  were	  studied.	  	  Statistical	  heterogeneity	  (I2)	  was	  also	  evident	  for	  
each	  of	  the	  outcome	  measures	  which	  were	  included	  in	  combined	  analysis.	  	  Too	  few	  studies	  
met	   the	   inclusion	   criteria	   for	   combined	   analysis	   to	   permit	   further	   statistical	   exploration	  of	  
these	  differences.	  	  	  
Given	   the	   evidence	   of	   heterogeneity	   between	   studies	   varying	   beyond	   chance,	   a	   random	  
effect	  model	  was	  used	  to	  estimate	  overall	  treatment	  effects,	  providing	  a	  best	  estimate	  of	  the	  
intervention	  effect	  (rather	  than	  defining	  the	  average	  treatment	  effect,	  as	   in	  a	  fixed	  model).	  	  
In	  only	  including	  studies	  in	  combined	  analysis	  which	  satisfied	  methodological	  quality	  criteria,	  
the	  methodology	  minimised	  the	  risk	  of	  bias	  in	  estimating	  treatment	  effect.	  	  Other	  sources	  of	  
bias	  due	  to	  population	  differences	  cannot	  be	  excluded.	  	  	  
The	  combined	  analysis	  included	  a	  small	  proportion	  of	  the	  total	  number	  of	  identified	  studies,	  
reflecting	  the	  overall	  limitations	  of	  XOI	  study	  designs	  (particularly	  the	  lack	  of	  use	  of	  a	  control	  
group	   and	   randomization	   issues).	   	   This	   will	   have	   limited	   the	   ability	   of	   the	   random	   effects	  
model	  to	  estimate	  the	  width	  of	  the	  distribution	  of	  intervention	  effects.	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Though	  formal	  testing	  for	  publication	  bias	  was	  not	  applied,	  visual	  inspection	  of	  funnel	  plots	  
raises	  this	  possibility.	  	  Sensitivity	  analysis,	  with	  sequential	  omission	  of	  individual	  studies,	  did	  
not	  affect	  the	  observed	  treatment	  effect	  on	  MDA.	  	  However,	  sequential	  removal	  of	  the	  data	  
for	   each	   study	   in	   the	   FMD	   analysis	   resulted	   in	   loss	   of	   overall	   statistical	   significance.	   	   The	  
exception	  to	  this	  was	  the	  removal	  of	  data	  from	  Eskurza	  et	  al,	  which	  appeared	  responsible	  for	  
the	  observed	  statistical	  heterogeneity.	   	  Similarly,	  removal	  of	  the	  data	  from	  Butler	  et	  al	  and	  
George	  et	  al	  in	  the	  FBF	  analysis	  resulted	  in	  the	  overall	  treatment	  effect	  observed	  reducing	  to	  
a	  non-­‐significant	  trend.	   	  These	  findings	  provided	   incomplete	  reassurance	  that	  the	  observed	  
results	   within	   the	   random	   effects	   model	   did	   not	   reflect	   exacerbating	   effects	   of	   either	  
publication	  bias	  or	  within	  study-­‐bias.	  The	  lack	  of	  benefit	  in	  the	  population	  studied	  by	  Ezkurza,	  
which	   contributed	   to	   significant	   heterogeneity,	   may	   reflect	   the	   inclusion	   of	   elderly	   but	  
otherwise	  healthy	  subjects,	  who	  may	  have	  had	  little	  to	  gain	  in	  terms	  of	  improvement.	  
lndividual	  patient	  data	  was	  unavailable,	  with	  analysis	  based	  upon	  summary	  statistics	  included	  
in	  publications,	   representing	  values	  obtained	  upon	  completion	  of	   treatment	  phases	   (rather	  
than	  the	  change	  which	  occurred	  within	  each	  treatment	  group).	  	  On	  this	  basis,	  the	  observed	  
heterogeneity	   between	   studies	   could	   not	   be	   explored	   further	   and	   analysis	   based	   upon	  
individual	  patient	  characteristics	  was	  not	  performed.	  
	  
Conclusions	  
This	  study	  represented	  the	  first	  systematic	  review	  and	  meta-­‐analysis	  of	  published	  evidence	  
relating	   to	   effects	   of	   XOI	   in	   relation	   to	   cardiovascular	   disease.	   	   A	   body	   of	   well-­‐designed	  
studies	  exists	  which	  have	  identified	  favourable	  responses	  in	  surrogate	  measures	  of	  vascular	  
health	   following	   XOI.	   	   Whilst	   robust	   prospective	   clinical	   outcome	   data	   is	   lacking,	   clinical	  
benefit	  has	  been	  suggested	  amongst	  patients	  with	  heart	  failure	  and	  with	  hyperuricaemia	  in	  
cohort	  studies.	   	  There	  is	  an	  expanding	  evidence	  base	  which	  highlights	  the	  potential	  role	  for	  
XOI	  in	  the	  management	  of	  cardiovascular	  disease	  which	  provides	  support	  for	  the	  conduct	  of	  
large	  clinical	  trials	  to	  evaluate	  this	  strategy.	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Chapter	  6 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Carotid	   intima	   media	   thickness,	   central	   blood	  
pressure,	   arterial	   stiffness	   &	   endothelial	   function	   as	  
surrogate	  markers	  of	  cardiovascular	  health	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6.1. Rationale	  for	  use	  of	  carotid	  artery	  intima	  media	  thickness	  as	  a	  measure	  of	  
cardiovascular	  function	  
	  
6.1.1. Carotid	  intima	  media	  thickness	  &	  its	  determinants	  	  
Atherosclerotic	   disease	   becomes	   clinically	   manifest	   in	   its	   advanced	   stages,	   when	  
atherosclerotic	   plaque	   gives	   rise	   to	   either	   haemodynamic	   limitation	   and	   ischaemic	  
symptoms,	  or	  plaque	  rupture	  results	  in	  an	  atherothrombotic	  event	  464.	  	  However,	  subclinical	  
atherosclerosis	  develops	  over	  years	  to	  decades	  465,	  with	  the	  process	  beginning	  in	  young	  age,	  
with	  the	  presence	  of	  carotid	  intima	  lesions	  and	  fatty	  streaks	  evident	  in	  the	  early	  decades	  of	  
life	   466.	   	   Tests	   for	   the	   presence	   of	   subclinical	   atherosclerotic	   disease	   are	   of	   interest	   as	   a	  
potential	   means	   to	   stratify	   individual	   risk	   of	   cardiovascular	   disease	   and	   to	   guide	   use	   of	  
preventative	  strategies.	  	  They	  may	  also	  hold	  value	  in	  monitoring	  response	  to	  treatment.	  	  
Intima	  media	   thickness	   (IMT)	   is	  defined	  as	  a	   composite	  measure	  of	  both	   the	   tunica	   intima	  
and	  tunica	  media	  layers	  of	  the	  arterial	  wall.	  	  IMT	  measurement	  is	  conventionally	  performed	  
at	  the	  Carotid	  artery	  (CIMT),	  with	  high	  resolution	  B	  mode	  ultrasonography	  467.	   	  This	  readily	  
displays	  the	  vascular	  wall	  as	  a	  regular	  pattern	  that	  correlates	  with	  its	  anatomical	  layers.	  	  The	  
technique	   is	   non-­‐invasive,	   well	   tolerated,	   reproducible	   and	   is	   considered	   the	   preferred	  
modality	  for	  this	  purpose	  468.	  
Morphological	   abnormalities	   in	   IMT	   that	   reflect	   both	   the	   initial	   and	   advanced	   stages	   in	  
development	   of	   atherosclerotic	   disease	   are	   identifiable	   through	   ultrasonography,	  
respectively	  manifest	  as	  IMT	  thickening	  and	  presence	  of	  focal	  atherosclerotic	  plaque	  469, 470.	  	  
CIMT	   measurement	   represents	   a	   surrogate	   for	   histological	   assessment,	   correlating	   with	  





Figure	  6-­‐1:	  	  Illustration	  of	  carotid	  intima	  media	  layers	  as	  visualised	  through	  B	  mode	  ultrasonography	  
	  
	  
6.1.2. Relationship	  between	  CIMT	  and	  cardiovascular	  risk	  factors	  	  
CIMT	   is	   associated	   with	   traditional	   risk	   factors	   for	   the	   development	   of	   atherosclerotic	  
cardiovascular	   events,	   with	   numerous	   population	   based	   studies	   demonstrating	   a	   graded	  
relationship	  between	  elevated	  levels	  of	  CV	  risk	  factors	  and	  increased	  CIMT	  471.	  	  	  
CIMT	   is	   increased	   amongst	   hypercholesterolaemic	   patients	   compared	  with	   controls	   472.	   	   In	  
patients	  with	   familial	  hypercholesterolaemia,	  CIMT	  progression	   is	  accelerated,	  beginning	  at	  
an	  early	   age	   473.	   	   In	   a	   systematic	   review,	  a	   liner	   relationship	  between	   LDL-­‐c	   and	  CIMT	  was	  
observed	  147.	  
In	   the	   Kuopio	   Ischaemic	   Heart	   Disease	   (KIHD)	   Risk	   Factor	   Study,	   higher	   CIMT	   levels	   were	  
more	   prevalent	   amongst	   individuals	   with	   systolic	   BP	   greater	   than	   175mmHG	   (after	  
adjustment	   for	   other	   risk	   factors)	   (457).	   	   The	   presence	   of	   hypertension	   is	   significantly	  
	  153	  
correlated	  with	  increased	  CIMT	  474	  and	  progression	  in	  CIMT	  is	  independently	  associated	  with	  
baseline	  systolic	  BP	  (p<0.001	  for	  linear	  trend)	  475.	  	  	  
In	   the	  ARIC	  population,	   Folsom	  and	  colleagues	   reported	   that	  diabetes	  and	  other	   surrogate	  
risk	   factors	   for	   diabetes,	   including	   waist	   to	   hip	   ratio,	   were	   associated	   with	   carotid	   wall	  
thickness	  476.	   	  CIMT	  was	  0.07mm	  thicker	  amongst	  diabetics	  than	  non-­‐diabetics.	   	   In	  the	  IRAS	  
population,	   both	   diabetes	   and	  mean	   fasting	   glucose	   level	   were	   positively	   associated	   with	  
common	  carotid	  artery	   (CCA)	   IMT	   (p<0.05,	   following	  adjustment	   for	  other	  conventional	  CV	  
risk	  factors)	  477.	  
Higher	   CIMT	   values	   were	   observed	   amongst	   smokers	   compared	   with	   non-­‐smokers	   in	   the	  
ARIC	   population,	   with	   a	   0.11mm	   difference	   observed	   478	   and	   both	   active	   smoking	   and	  
environmental	   exposure	   to	   cigarette	   smoking	  were	   associated	  with	   greater	   progression	   in	  
CIMT	  over	  time	  and	  the	  number	  of	  pack	  years	  is	  a	  powerful	  predictor	  of	  both	  baseline	  CIMT	  
and	  progression	  479.	  	  	  
In	   the	   Carotid	   Atherosclerosis	   Progression	   Study	   (CAPS),	   which	   included	   5,056	   individuals	  
aged	  19	  –	  90	  years,	  both	  baseline	  mean	  CIMT	  and	  mean	  ICA-­‐CIMT	  measurements	  were	  each	  
significantly	   correlated	   with	   baseline	   CVRFs,	   including	   age,	   male	   gender,	   hypertension,	  
diabetes,	  LDL-­‐c	  and	  smoking	  474.	  	  Similar	  independent	  associations	  with	  mean	  common	  CIMT	  
were	   observed	   in	   the	   Baltimore	   Longitudinal	   Study	   of	   Aging	   480	   and	   in	   a	   younger	   adult	  
population.	   	  Between	  the	  ages	  of	  20	  –	  90	  years,	  mean	  common	  CIMT	   increases	  more	  than	  
two-­‐fold	   and	   in	  more	   elderly	   individuals,	   aged	   60	   –	   80	   years,	   CIMT	   increases	   continuously	  
with	  increasing	  age	  481.	  	  	  
CIMT	  also	  appears	   related	   to	  novel	   risk	   factors,	   including	   lipoprotein	  a	   482,	  oxidised	  LDL	   483	  
and	   homocysteine	   484.	   	   Cardiovascular	   events	   are	   common	   amongst	   patients	   with	   chronic	  
inflammatory	  disorders	  and	  surrogate	  markers	  of	  systemic	  inflammation	  are	  associated	  with	  
CIMT,	   including	   CRP	   485.	   	   Genetic	   determinants	   of	   CIMT	   have	   been	   reported	   in	   linkage	  
analysis	  studies	  486.	  	  	  
Several	  small	  studies	  have	  reported	  an	  association	  between	  SUA	  and	  CIMT.	   	   In	  124	  healthy	  
individuals	  with	  normal	  range	  SUA,	  CIMT	  was	  significantly	  correlated	  with	  SUA	  concentration	  
(r	  =	  0.346,	  p	  <	  0.0001)	  487,	  independently	  of	  other	  CVRFs.	  	  In	  an	  elderly	  Japanese	  population,	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SUA	  was	   found	  to	  be	   independently	  associated	  with	  CIMT	  488.	   	   In	   the	  CARDIA	  study,	  which	  
included	   young	   individuals	   aged	   18	   –	   30,	   an	   independent	   association	   between	   mean	  
maximum	  common	  CIMT	  and	  elevated	  levels	  of	  baseline	  SUA	  was	  observed	  489.	  	  In	  two	  small	  
studies	  adopting	  a	  case	  control	  design	  in	  patients	  with	  hypertension,	  a	  modest	  but	  significant	  
independent	  association	  between	  SUA	  and	  CIMT	  was	  observed	  366, 490.	  	  However,	  there	  have	  
been	  few	  large	  population	  studies	  which	  examined	  the	  relationship	  between	  SUA	  and	  CIMT.	  	  
In	  the	  Korean	  Multi-­‐Rural	  Communities	  Cohort	  Study,	  which	  included	  5,568	  participants,	  no	  
significant	  correlation	  was	  identified	  between	  SUA	  and	  a	  poorly	  defined	  measure	  of	  common	  
CIMT	  367.	  
	  
6.1.3. Relationship	  between	  CIMT	  and	  atherosclerotic	  disease	  burden	  
In	   the	   ARIC	   study	   population,	   CIMT	   was	   higher	   amongst	   participants	   with	   prevalent	   CV	  
disease	   compared	   to	   those	   without	   and	   prevalence	   of	   CV	   disease	   was	   higher	   amongst	  
individuals	  with	  increased	  CIMT	  491.	  	  This	  finding	  was	  observed	  for	  coronary,	  cerebrovascular	  
and	  peripheral	  arterial	  disease.	  	  An	  association	  between	  CIMT	  and	  both	  lower	  limb	  peripheral	  
arterial	   disease	   and	   abdominal	   aortic	   atherosclerosis	   has	   been	   reported	   481, 492, 493.	   	   These	  
findings	   provide	   supportive	   evidence	   for	   CIMT	   as	   a	   biomarker	   for	   systemic	   atherosclerotic	  
disease.	  	  
CIMT	  has	  been	  associated	  with	  evidence	  of	  atherosclerotic	  disease	  burden	   in	  other	  arterial	  
territories.	  	  Coronary	  artery	  calcification,	  measured	  with	  computed	  tomography	  scanning,	  is	  
a	  surrogate	  marker	  for	  the	  presence	  of	  coronary	  atherosclerosis,	  an	  independent	  predictor	  of	  
CHD	   events	   and	   a	   significant	   association	   between	   coronary	   artery	   calcification	   (CAC)	   and	  
CIMT	  has	  been	  reported	  in	  both	  males	  and	  females	  494.	  	  	  A	  graded	  association	  between	  CAC	  
and	   CIMT	   was	   observed	   amongst	   older	   adults	   in	   the	   Rotterdam	   Coronary	   Calcification	  	  	  	  	  
study	   495	   but	   CIMT	   is	   also	   significantly	   associated	   with	   identification	   of	   CAC	   in	   younger	  
populations,	  aged	  33-­‐42	  years	  494.	  	  	  
CIMT	   has	   been	   associated	   with	   angiographically	   demonstrable	   coronary	   artery	  
atherosclerosis	   in	   a	   number	   of	   populations	   496-­‐498.	   	   High	   sensitivity	   and	   specificity	   for	   CAD	  
through	   CIMT	  measurement	   has	   been	   reported	   499.	   	   Conversely,	   other	   groups	   found	   only	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modest	  associations	  500,	  concluding	  that	  CIMT	  may	  not	  be	  useful	  as	  a	  surrogate	  for	  coronary	  
atherosclerosis	   as	   it	   was	   neither	   sensitive	   nor	   specific	   enough	   to	   identify	   patients	  with	   or	  
without	   significant	   coronary	   disease.	   	   Other	   studies	   reported	   that	   significant	   correlations	  
were	   limited	   to	   CIMT	   measurements	   obtained	   from	   more	   distal	   segments	   of	   the	   carotid	  
artery	   497.	   	   These	  differences	  are	   likely	   to	   reflect,	   at	   least	   in	  part,	  differing	  methodology	   in	  
terms	   of	   definitions	   of	   CAD	   (high	   grade	   versus	   low	   grade)	   and	   in	   the	   CIMT	  measurement	  
utilised.	   	   Sample	   size	   may	   also	   have	   limited	   power	   to	   identify	   true	   associations.	   	   In	   the	  
Cholesterol	   Lowering	   Atherosclerosis	   Study,	   Mack	   and	   colleagues	   observed	   a	   significant	  
correlation	  (r=0.28,	  P=0.002),	  between	  change	  in	  CIMT	  and	  change	  in	  angiographic	  coronary	  
disease	  amongst	  133	  male	  patients	  with	  mild	  /	  moderate	  coronary	  stenotic	  disease	  501.	  	  	  	  An	  
association	  was	  less	  evident	  for	  high	  grade	  coronary	  lesions.	  	  	  
CIMT	  is	  associated	  with	  endothelial	  function.	  	  Amongst	  2109	  healthy	  young	  adults	  (aged	  24	  –	  
39	  years),	  brachial	  artery	  FMD	  was	  inversely	  associated	  with	  IMT	  (p<0.001)	  502.	  	  	  In	  this	  study,	  
the	   number	   of	   prevalent	   risk	   factors	   for	   CV	   disease	   was	   correlated	   with	   IMT	   amongst	  
patients	   with	   impaired	   FMD	   but	   not	   amongst	   those	   with	   preserved	   FMD,	   prompting	   the	  
authors	   to	   conclude	   that	  endothelial	   dysfunction	  may	  modify	   the	  association	  between	   risk	  
factors	   and	   atherosclerosis,	   with	   endothelial	   dysfunction	   potentially	   representing	   an	   early	  
event	   in	   atherosclerosis.	   	   CIMT	   is	   also	   inversely	   associated	   with	   FMD	   in	   patients	   with	  
suspected	  CAD	  503.	  	  	  
	  
6.1.4. Relationship	   between	   CIMT	   and	   risk	   of	   subsequent	   cardiovascular	  
events	  
Several	   population	   studies	   have	   examined	   the	   relationship	   between	   CIMT	   and	   the	   risk	   of	  
subsequent	   CV	   events.	   	   CIMT	   was	   first	   reported	   to	   predict	   cardiovascular	   events	   in	   the	  
Danish	   Kuopio	   Heart	   Disease	   Risk	   Factor	   Study,	   which	   included	   1287	   middle	   aged,	   male	  
individuals.	   	  For	  every	  0.1mm	  increment	   in	  CIMT,	  determined	  as	  maximum	  common	  CIMT,	  
the	  risk	  of	  MI	  increased	  by	  11%	  (p<0.001)	  504.	  	  	  
The	   Atherosclerosis	   Risk	   in	   Communities	   (ARIC)	   Study	   provided	   evidence	   of	   independent	  
predictive	   value	   of	   CIMT	  measurement	   in	   a	   middle	   aged,	   asymptomatic	   population.	   	   This	  
	  156	  
study	   included	  12,841	   individuals	  aged	  45	  –	  64	  years	  without	  prior	  history	  of	  CHD	  505.	   	  The	  
authors	  reported	  a	  significantly	  increased	  risk	  of	  CHD	  events	  in	  male	  individuals	  with	  CIMT	  ≥	  
1mm	  compared	  with	  <	  1mm	  (HR	  5.07;	  95%	  CI	  3.08	  –	  8.36).	  	  A	  significant	  though	  less	  powerful	  
relationship	  was	  also	  observed	  in	  female	  individuals	  (HR	  1.85;	  95%	  CI	  1.29	  –	  2.69).	  	  An	  HR	  of	  
1.42	  (95%	  CI,	  1.24	  –	  1.64)	  per	  single	  SD	  increase	  in	  baseline	  mean	  common	  CIMT	  (~0.19mm,	  
adjusted	  for	  major	  CVRFs)	  was	  reported	  in	  males.	  	  	  
In	  a	  separate	  analysis	  of	  the	  ARIC	  population	  data,	  in	  14,214	  patients	  without	  prior	  stroke,	  an	  
increased	  risk	  of	  incident	  stroke	  for	  patients	  with	  CIMT	  ≥	  1mm	  compares	  to	  those	  with	  CIMT	  
<	  0.6mm,	  in	  both	  men	  (HR	  3.6;	  95%	  CI	  1.5	  –	  9.2)	  and	  women	  (HR	  8.5;	  95%	  CI	  3.5	  –	  20.7)	  was	  
observed	   506.	   	   An	  HR	  of	   1.38	   (95%CI,	   1.16	   –	   1.65)	   per	   single	   SD	   increase	   in	   baseline	  mean	  
common	  CIMT	   (~0.19mm,	   adjusted	   for	  major	   CVRFs)	  was	   reported	   in	  males.	   	   The	   authors	  
reported	   a	   graded	   but	   non-­‐linear	   relationship,	   with	   the	   hazard	   increasing	  more	   rapidly	   at	  
lower	  CIMT	  values.	  
The	  Rotterdam	  study	  employed	  a	  retrospective,	  nested	  case-­‐control	  design	  to	  examine	  the	  
relationship	   between	   baseline	  mean	   common	   CIMT	   and	   risk	   of	   subsequent	   cardiovascular	  
events.	  	  The	  analysis	  included	  over	  1300	  individuals	  aged	  ≥	  55	  years,	  with	  or	  without	  prior	  CV	  
disease,	   for	   whom	   CIMT	   analysis	   information	   was	   available	   507.	   	   The	   authors	   reported	   an	  
increased	  risk	  of	  stroke	  (OR	  1.34;	  95%	  CI,	  1.08	  –	  1.67)	  per	  single	  SD	  increase	  in	  baseline	  mean	  
common	  CIMT	  (~0.163mm,	  adjusted	  for	  age,	  sex	  and	  other	  CVRFs).	  	  The	  risk	  of	  MI	  was	  non-­‐
significantly	  increased	  (OR	  1.25:	  95%	  CI,	  0.98	  –	  1.58)	  although	  in	  individuals	  without	  a	  prior	  
history	   of	   cardiovascular	   disease,	   a	   significant	   association	   was	   observed	   508.	   	   Risk	   was	  
similarly	  increased	  irrespective	  of	  sex.	  
The	  Cardiovascular	  Health	  Study	  provided	  evidence	  of	  independent	  predictive	  value	  of	  CIMT	  
measurement	   in	   a	  more	   elderly	   population.	   	   This	   study	   included	   4476	   patients	   aged	   ≥	   65	  
years	   from	   4	   communities	   in	   the	   USA,	   without	   prior	   history	   of	   cardiovascular	   disease	   509.	  	  
During	  median	  follow-­‐up	  6.2	  years,	  compared	  with	  patients	  in	  the	  lowest	  quintile,	  patients	  in	  
the	  highest	  mean	  maximum	  CIMT	  quintile	  were	  at	  increased	  risk	  of	  CV	  events	  (RR	  3.15;	  95%	  
CI,	  2.19	  –	  4.52).	   	  The	  authors	  reported	  significantly	   increased	  risk	   for	  both	  mean	  maximum	  
common	   CIMT	   (RR	   1.27;	   95%	   CI	   1.17	   –	   1.38)	   per	   single	   SD	   increase	   in	   CIMT	   (0.20mm,	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adjusted	  for	  conventional	  CVRFs)	  and	  mean	  maximum	  internal	  CIMT	  (RR	  1.30;	  95%	  CI	  1.20	  –	  
1.41)	  per	  single	  SD	  increase	  in	  CIMT	  (0.55mm,	  adjusted	  for	  conventional	  CVRFs).	  	  	  
The	  LILAC	  study	  reported	  significant	   independent	  predictive	  value	  of	  CIMT	  measurement	   in	  
relation	  to	  CVM	  in	  a	  population	  of	  298	  individuals	  aged	  75	  and	  over	  and	  reported	  increased	  
RR	   of	   ACM	   and	   vascular	   mortality	   during	   a	   mean	   1152	   days	   follow	   up	   for	   higher	   CIMT	  	  	  	  
values	  510.	  
The	   Carotid	   Atherosclerosis	   Progression	   Study	   (CAPS)	   study	   included	   5056	   individuals	  
between	  19	  –	  90	  years	  old	  511.	   	  Hazard	  rate	  ratios	   [HRRs]	  per	  1	  SD	  mean	  CCA-­‐IMT	   increase	  
were	  1.43	  [95%	  CI:	  1.35	  to	  1.51]	  for	  MI,	  1.47	  [1.35	  to	  1.60]	  for	  stroke,	  and	  1.45	  [1.38	  to	  1.52]	  
for	  MI,	   stroke	  or	  death.	   	  CIMT	  was	  predictive	  of	  endpoints	  at	  all	   carotid	   levels.	   	  This	   study	  
provided	   evidence	   of	   independent	   predictive	   value	   of	   CIMT	   across	   a	   wide	   age	   range.	  	  
However,	  the	  authors	  reported	  a	  stronger	  association	  between	  CIMT	  and	  clinical	  endpoints	  
for	  younger	  (HRR	  per	  0.1mm	  mean	  common	  CIMT	  1.34;	  95%	  CI	  1.16	  –	  1.55)	  than	  for	  older	  
adults	   (HRR	   per	   0.1mm	  mean	   common	   CIMT	   1.10;	   95%	   CI	   1.05	   –	   1.15).	   	   This	   interaction	  
between	  age	  and	  IMT	  prompted	  the	  authors	  to	  conclude	  that	  rather	  than	  chronological	  age	  
per	  se,	  vascular	  age	  (determined	  as	  mean	  common	  CIMT)	  may	  be	  a	  more	  powerful	  predictor	  
of	  cardiovascular	  risk	  
In	  all	  of	  these	  studies,	  CIMT	  independently	  predicted	  CV	  events	  following	  adjustment	  for	  age,	  
sex	  and	   traditional	  CVRFs.	   	   Some	  notable	  differences	   in	   findings	  of	   these	   large	  prospective	  
studies	  were	  observed.	  	  Some	  studies	  reported	  a	  stronger	  association	  between	  CIMT	  and	  CV	  
risk	   for	   males	   than	   in	   females	   505	   whilst	   others	   found	   no	   such	   difference	   507.	   	   In	   most	  
populations,	   the	   relationship	   between	   CIMT	   and	   risk	   of	   either	   CHD	   or	   stroke	   events	   was	  
similar.	   	   One	   study	   reported	   a	   weaker	   association	   for	   stroke	   than	   for	   CHD,	   though	   this	  
population	  examined	  a	  younger	  population	  and	  was	  underpowered	  511.	  	  	  
Much	   of	   the	   prospectively	   collected	   data	   relating	   CIMT	   with	   CV	   outcomes	   has	   been	  
combined	   in	   meta-­‐analysis	   (meta-­‐regression)	   by	   Lorenz	   and	   colleagues	   512.	   	   The	   adjusted	  
(age,	  sex	  &	  traditional	  CV	  risk	  factors)	  HR	  per	  1	  SD	  difference	  in	  CCA-­‐IMT	  was	  1.17	  (95%	  CI,	  
1.13	  –	  1.28)	  for	  MI	  and	  1.23	  (95%	  CI,	  1.18	  –	  1.28)	  for	  stroke.	  	  This	  was	  based	  on	  inclusion	  of	  
various	  CIMT	  definitions.	  	  To	  achieve	  some	  homogeneity,	  adjusted	  HRs	  per	  0.1mm	  difference	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in	  CIMT	  were	  calculated	  for	  mean	  CCA	  CIMT.	  	  The	  HR	  was	  1.08	  (95%	  CI,	  1.04	  –	  1.12)	  for	  MI	  
and	   1.14	   (95%	   CI,	   1.10	   –	   1.18)	   for	   stroke.	   	   Despite,	   individual	   studies	   reporting	   subtle	  
differences	   between	   the	   association	   for	   CHD	   and	   stroke,	   CIMT	   appears	   to	   independently	  
predict	  both	  CHD	  and	  stroke	  events.	  
	  
6.1.5. The	  relevance	  of	  carotid	  plaque	  in	  CIMT	  measurement	  
Atherosclerotic	   plaque	  may	   be	   identified	   during	   carotid	   IMT	   scanning,	   identifiable	   as	   focal	  
thickening,	   with	   or	   without	  mineralisation	   and	   encroachment	   in	   to	   the	   arterial	   lumen	   513.	  	  
The	   presence	   of	   plaque	   indicates	   the	   existence	   of	   focal	   advanced	   atherosclerotic	   disease.	  	  
Measurement	   of	   plaque,	   both	   qualitatively	   and	   quantitatively,	   has	   been	   proposed	   as	   a	  
potentially	   superior	   strategy	   to	  CIMT	  measurement	   for	   the	  purposes	  of	   cardiovascular	   risk	  
stratification.	  	  	  
A	   graded	   association	   between	   CAC	   and	   carotid	   plaque	   has	   been	   observed	   in	  middle	   aged	  
adults,	  which	  appeared	  stronger	   for	  plaque	   than	  with	  CIMT	  495, 514	  and	  CIMT	  bulb	  segment	  
plaque	   is	   significantly	   correlated	   with	   angiographically	   demonstrable	   coronary	  
atherosclerosis	   497.	   	   In	   elderly	  male	   individuals,	   detection	   of	   carotid	   plaque	   lesions	  with	   B	  
mode	   US,	   independently	   predicted	   risk	   of	   all-­‐cause	   mortality	   515.	   	   The	   CAFE-­‐CAVES	   study	  
analysed	   carotid	   US	   imaging	   and	   categorically	   stratified	   patients	   according	   to	   evidence	   of	  
subclinical	  atherosclerosis.	  	  After	  10	  years	  follow	  up,	  8.6%	  of	  patients	  with	  increased	  baseline	  
CIMT	  experienced	  incident	  CV	  events,	  compared	  with	  39.28%	  of	  patients	  with	  non-­‐stenosing	  
focal	   plaque,	   indicating	   a	   differential	   increase	   in	   risk	   of	   events	   in	   the	   presence	   of	   carotid	  
plaque	  516.	  	  	  	  
In	  an	  ischaemic	  stroke	  population,	  both	  CIMT	  and	  carotid	  plaque	  were	  each	  correlated	  with	  
risk	   of	   stroke,	   determined	   as	   the	   Framingham	   stroke	   risk	   score.	   	   However,	   carotid	   plaque	  
appeared	  to	  hold	  greater	  predictive	  value	  517	  and	  CIMT	  was	  a	  more	  powerful	  predictor	  in	  the	  
absence	  of	  plaque.	  	  	  
An	  analysis	  of	   the	  Rotterdam	  baseline	  US	   images	   for	  plaque	  and	  CIMT	   identified	   that	  both	  
factors	  (Carotid	  plaque	  HR	  1.83;	  95%	  CI	  1.27	  –	  2.62,	  CIMT	  HR	  1.95;	  95%	  CI	  1.19	  to	  3.19),	  were	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significant	  predictors	  of	  risk	  of	  incident	  MI,	  each	  independently	  of	  the	  other	  508.	  	  This	  finding	  
suggests	   additive	   value	   in	   identification	   of	   plaque	   for	   risk	   stratification	   purposes,	  
complimentary	  to	  measurement	  of	  CIMT.	  	  
Population	   studies	  which	   identified	   an	   independent	   association	   between	   CIMT	   and	   risk	   of	  
subsequent	   cardiovascular	   events,	   typically	   incorporated	   focal	   regions	   of	   plaque	   (when	  
present),	   within	   the	   CIMT	  measurement.	   	   Thus,	   it	   is	   possible	   that	   the	   positive	   association	  
observed	   in	   these	   studies	  was	  driven	  by	   the	  presence	  of	  plaque	  disease,	   rather	   than	  CIMT	  
thickening	   independent	   of	   the	   presence	   of	   plaque.	   	   This	   issue	   has	   been	   addressed	   in	  
subsequent	  prospective	  studies.	  	  In	  5163	  Swedish	  middle	  aged	  individuals,	  both	  plaque	  and	  
CIMT	   (after	   adjustment	   for	   the	   presence	   of	   carotid	   plaque)	   were	   each	   independently	  
associated	  with	  risk	  of	  both	  incident	  stroke	  518	  and	  coronary	  events	  519.	  	  The	  authors	  reported	  
that	  a	  graded	  association	  between	  CIMT	  and	   risk	  was	  observed	   for	  both	  patients	  with	  and	  
without	  plaque.	  	  	  
Overall,	   the	   presence	   of	   plaque	   appears	   to	   identify	   patients	   at	   increased	   risk	   to	   those	  
without.	   	   CIMT	   measurement	   holds	   independent	   predictive	   value	   even	   in	   the	   context	   of	  
either	  presence	  or	  absence	  of	  plaque	  lesions.	  	  On	  this	  basis,	  both	  plaque	  and	  CIMT	  hold	  value	  
as	  biomarkers	  of	  atherosclerotic	  disease.	  
	  
6.1.6. CIMT	  measurement	  in	  cardiovascular	  risk	  stratification	  
The	  incremental	  increase	  in	  risk	  between	  patients	  with	  the	  highest	  and	  lowest	  IMT	  values	  is	  
of	   sufficient	   magnitude	   to	   potentially	   provide	   additive	   information	   to	   risk	   stratification	  
according	  to	  conventional	  risk	  factors	  520.	  
Incorporation	   of	   CIMT	  measurements	   to	   the	   Framingham	   cardiovascular	   risk	   stratification	  
model	   in	  the	  ARIC	  study	  population	  was	  found	  to	  refine	  its	  predictive	  power,	  with	  principal	  
utility	  in	  the	  reclassification	  of	  individuals	  stratified	  as	  having	  intermediate	  risk	  of	  future	  CV	  
events	  521.	   	  This	  group	  have	  also	  reported	  data	  which	  suggests	  that	  complete	  measurement	  
of	  CIMT	  at	  all	  levels	  of	  the	  carotid	  adds	  no	  additional	  value	  for	  purposes	  of	  risk	  stratification	  
compared	  with	  analysis	  of	  the	  common	  segment	  alone	  522.	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However,	  such	  improvement	  in	  risk	  stratification	  has	  not	  been	  reported	  for	  all	  populations.	  	  
In	   the	   CAPS	   population,	   incorporation	   of	   the	   common	   CIMT	   measurement	   led	   to	  
reclassification	   of	   8.1%	   of	   the	   population	   but	  with	   a	   net	   reclassification	   improvement	   of	   -­‐
1.41%	  (p=ns)	  523.	  	  The	  authors	  concluded	  that	  CIMT	  measurement	  did	  not	  add	  to	  existing	  risk	  
stratification	   procedures.	   	   More	   recently,	   Polak	   and	   colleagues	   assessed	   the	   relationship	  
between	   CIMT	   measurement,	   risk	   of	   subsequent	   vascular	   events	   and	   the	   ability	   of	   CIMT	  
measurement	   to	   improve	   risk	   stratification	   in	   the	   Framingham	  Offspring	   Cohort	   Study	   524.	  	  
The	   authors	   found	   that	   both	   mean	   common	   CIMT	   and	   mean	   internal	   CIMT	   were	   each	  
independently	   predictive	   of	   subsequent	   vascular	   events	   but	   that	   only	  mean	   internal	   CIMT	  
improved	  risk	  stratification	  using	  the	  Framingham	  risk	  assessment	  tool.	  
A	  meta-­‐analysis	  of	  individual	  patient	  data	  from	  14	  population	  based	  cohort	  studies,	  including	  
45,828	   individuals,	   found	   that	   incorporation	   of	  mean	   common	   CIMT	  measurement	   to	   the	  
Framingham	  risk	  assessment	  tool	  was	  associated	  with	  a	  significant	  but	  small	  improvement	  in	  
risk	   stratification	   for	   incident	   MI	   or	   stroke	   525.	   	   However,	   the	   overall	   net	   reclassification	  
improvement	   was	   small	   at	   0.8%	   (95%	   CI,	   0.1	   –	   1.6%).	   	   Net	   reclassification	   was	   higher	  
amongst	  patients	  at	  intermediate	  risk	  (3.6%;	  95%	  CI	  2.7	  –	  4.6%).	  	  The	  authors	  concluded	  that	  
although	  significant,	   the	  magnitude	  of	   improved	  risk	  stratification	  through	   incorporation	  of	  
CIMT	  measurement	  to	  the	  Framingham	  model	  was	  of	  doubtful	  clinical	  significance.	  
Thus,	   whilst	   holding	   independent	   predictive	   power	   for	   CV	   events,	   CIMT	   measurement	  
incorporation	   to	   existing	   risk	   classification	   assessment	   tools	   only	  modestly	   enhances	   their	  
predictive	   accuracy.	   	   Whilst	   commentators	   have	   therefore	   suggested	   that	   this	   limits	   the	  
value	  of	  CIMT	  measurement	  for	  risk	  stratification	  purposes,	  potential	  as	  a	  surrogate	  marker	  
for	  modified	  CV	  risk	  in	  clinical	  trials	  is	  not	  excluded	  on	  this	  basis.	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6.1.7. CIMT	  progression	  and	  risk	  of	  cardiovascular	  events	  	  
Beyond	   the	   predictive	   value	   for	   cardiovascular	   risk	   of	   CIMT	   as	   a	   single	   measurement,	  
progression	   in	   CIMT	   over	   time	   has	   also	   been	   reported	   to	   be	   independently	   predictive	   of	  
cardiovascular	   events	   526.	   	   In	   a	   substudy	  of	   the	  Cholesterol	   lowering	   atherosclerosis	   study,	  
CIMT	  was	  recorded	  at	  baseline	  and	  again	  at	  24	  months.	  	  	  	  	  Patients	  were	  followed	  up	  for	  an	  
average	  of	  8.8	  years	  in	  relation	  to	  clinical	  vascular	  events.	  	  For	  each	  0.03mm	  annual	  increase	  
in	  CIMT,	  the	  authors	  observed	  an	  increased	  RR	  for	  non-­‐fatal	  MI	  /	  CHD	  death	  of	  2.2	  (95%	  CI	  
1.4	  –	  3.6),	  independent	  of	  coronary	  measures	  of	  atherosclerosis	  and	  lipid	  measurements.	  	  	  
Other	   epidemiological	   studies	   have	   identified	   a	   similar	   relationship.	   	   Amongst	   5,028	  
individuals	   in	   the	   Multi-­‐Ethnic	   Study	   of	   Atherosclerosis	   (MESA),	   CCA	   CIMT	   progression	  
(measured	  in	  segments	  free	  of	  plaque)	  was	  associated	  with	  incident	  stroke	  (HR,	  1.23	  per	  0.05	  
mm/year	  progression	  in	  CIMT;	  95%	  CI,	  1.02-­‐1.48)	  527.	  	  
On	   the	   basis	   of	   these	   findings,	   coupled	   with	   the	   predictive	   power	   of	   absolute	   CIMT	  
measurements	   and	   additional	   assorted	   evidence	   identifying	   CIMT	   as	   a	   biomarker	   for	  
systemic	   burden	   of	   atherosclerosis,	   CIMT	   progression	   has	   been	   utilised	   as	   a	   surrogate	  
endpoint	  for	  modified	  CV	  risk	  in	  clinical	  trials	  over	  the	  last	  two	  decades	  471.	  	  Use	  of	  CIMT	  as	  a	  
surrogate	  outcome	  holds	   the	  potential	   advantage	  of	   reducing	   the	   sample	   size	   required	   for	  
clinical	   trials	   but	   is	   reliant	   on	   the	   assumption	   (or	   demonstration)	   that	   change	   in	   CIMT	  
progression	  corresponds	  to	  change	  in	  cardiovascular	  risk.	  	  	  
	  
6.1.8. CIMT	  as	  an	  outcome	  parameter	  in	  clinical	  trials	  
Statin	   therapy	   has	   the	   most	   substantial	   evidence	   base	   for	   a	   treatment	   effect	   on	   CIMT	  
progression.	  	  In	  patients	  with	  CAD	  but	  moderately	  elevated	  or	  normal	  cholesterol	  level,	  CIMT	  
was	   reduced	   by	   0.014mm	   over	   an	   average	   of	   4	   years	   follow	   up	   with	   Pravastatin	   therapy	  
compared	   with	   a	   0.048mm	   increase	   with	   placebo	   528.	   	   Amongst	   asymptomatic	  
hypercholesterolaemic	   patients,	   CIMT	   was	   significantly	   reduced	   with	   treatment	   with	  
Lovastatin	   529.	   	   In	   a	   population	   of	   patients	   with	   familial	   hypercholesterolaemia,	   high	   dose	  
Atorvastatin	  reduced	  CIMT	  by	  0.031mm	  after	  2	  years	  whereas	  CIMT	  increased	  by	  0.036mm	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over	  the	  same	  period	  with	  conventional	  dose	  Simvastatin	  530.	  	  Similarly,	  in	  the	  ARBITER	  study,	  
high	   dose	   Atorvastatin	   induced	   CIMT	   regression	   of	   0.034mm	   within	   12	   months,	   whereas	  
Pravastatin	  was	  associated	  with	  progression	   in	  CIMT	  of	  0.025mm	  531.	   	   In	  a	  meta-­‐analysis	  of	  
statin	   therapy,	   reduction	   in	   LDL-­‐C	   was	   found	   to	   be	   strongly	   correlated	   with	   CIMT	  	  	  	  	  	  
reduction	  147.	  	  Each	  10%	  reduction	  in	  LDL-­‐C	  was	  estimated	  to	  reduce	  the	  risk	  of	  all	  strokes	  by	  
15.6%	  (95%	  CI,	  6.7	  to	  23.6)	  and	  carotid	  IMT	  by	  0.73%	  per	  year	  (95%	  CI,	  0.27	  to	  1.19%).	  
Although	   lipid	   levels	  are	   linearly	  associated	  with	  both	  CIMT	  147	  and	   risk	  of	  CHD	  events	  and	  
LDL-­‐c	   represents	   a	   pathological	   component	   of	   the	   atherosclerotic	   process,	   lipid	   lowering	  
therapy	   is	   not	   universally	   associated	   with	   retardation	   in	   CIMT	   progression	   532.	   	   The	  
observation	  that	  agents	  which	  have	  apparently	  failed	  to	  reduce	  CIMT	  also	   lack	  an	  evidence	  
base	   for	   efficacy	   in	   reduction	   in	   clinical	   events,	   has	   lent	   support	   to	   the	   concept	   that	  
therapeutic	  strategies	  likely	  to	  affect	  a	  reduction	  in	  endpoints	  require	  a	  CIMT	  reducing	  effect	  
as	  a	  mechanistic	  pathway	   to	  such	  benefit.	   	   Statins	  have	  been	  shown	  to	  hold	   this	  property,	  
whereas	   Ezetimibe	   has	   not,	   despite	   significantly	   reducing	   LDL-­‐c.	   	   Several	   potential	  
explanations	   have	   been	   proposed	   for	   this	   finding,	   including	   pre-­‐treatment	   with	   statin	  
therapy	  reducing	  the	  potential	  for	  additional	  CIMT	  reduction	  with	  Ezetimibe.	  
In	   addition	   to	   LDL-­‐c	   related	   reductions	   in	   CIMT,	   several	   other	   pharmacological	   strategies	  
have	   been	   evaluated	   in	   relation	   to	   CIMT	   progression.	   	   PPAR-­‐gamma	   agonists	   533,	  
antihypertensive	   agents	   including	   Amlodipine	   534,	   Beta-­‐blockers	   535	   ACE-­‐Is	   536, 537	   (although	  
not	   in	   all	   studies	   533)	   and	   intensive	   anti-­‐diabetic	   therapy	   538	   have	   all	   been	   associated	  with	  
reduced	  CIMT	  progression.	  
A	   meta-­‐analysis	   has	   been	   undertaken	   examining	   treatment	   effects	   of	   antihypertensive	  
agents	   on	   CIMT	   539.	   	   In	   patients	   with	   CAD,	   diabetes	   and	   hypertension,	   antihypertensive	  
therapy	  with	   a	   variety	   of	   agents	  was	   found	   to	  be	  beneficial	   in	   reducing	  CIMT	  progression.	  	  
The	   authors	   found	   some	   evidence	   of	   differential	   benefit	   in	   CIMT	   reduction	   for	   similar	  
brachial	  artery	  BP	  lowering	  effects	  with	  newer	  type	  anti-­‐hypertensive	  agents.	  
In	   addition	   to	   the	   treatment	   effects	   reported	   in	   the	   therapeutic	   studies,	   several	   non-­‐
pharmacological	  interventions	  have	  been	  assessed	  in	  relation	  to	  CIMT	  progression.	  	  Based	  on	  
the	   relative	   contribution	   of	   risk	   factors	   to	   CIMT	   progression,	   multimodal	   lifestyle	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modification	  has	  been	  calculated	   to	  potentially	  achieve	  a	   reduction	   in	  CIMT	  progression	  of	  
0.13mm/year	  540.	  	  
	  
6.1.9. CIMT	  progression	  &	  modified	  cardiovascular	  risk	  in	  clinical	  trials	  
Subsequent	   to	   the	   initial	   reported	   epidemiological	   associations	   between	   CIMT	  progression	  
and	  cardiovascular	  risk,	  conflicting	  evidence	  has	  emerged	  as	  to	  whether	  such	  a	  relationship	  
exists.	   	   Clinical	   trial	   data	   examining	   both	   clinical	   endpoints	   and	   CIMT	   progression	  
concurrently	   have,	   thus	   far,	   failed	   to	   find	   an	   association	   between	   CIMT	   progression	   and	  
observed	   clinical	   events.	   	   The	   ELSA	   study	   evaluated	   Lacidipine	   in	   2,334	   hypertensive	  	  	  
patients	   541.	   	   The	   authors	   found	   that	   baseline	   CIMT	   was	   predictive	   of	   subsequent	   clinical	  
events	  but	  that	  the	  progression	  in	  CIMT	  appeared	  unrelated	  to	  the	  risk	  of	  clinical	  endpoints.	  	  
The	  authors	  commented	  that	   failure	   to	   identify	  such	  a	   relationship	  may	  have	  reflected	   the	  
small	  magnitude	  of	  CIMT	  progression	  observed,	  relative	  to	  baseline	  CIMT	  variation.	  
In	  addition,	  evidence	  has	  emerged	  that	  agents	  which	  appear	  to	  have	  beneficial	  effects	  with	  
respect	   to	   CIMT	   progression,	   do	   not	   confer	   significant	   benefit	   in	   terms	   of	   reduction	   of	  
cardiovascular	   events.	   	   Niacin	   has	   been	   observed	   to	   significantly	   reduce	   CIMT	   progression	  
compared	  with	   Ezetimibe	   (despite	   lower	   LDL	   reductions),	   after	   only	   14	  months	   treatment	  
(p=0.003)	  542.	  	  In	  addition,	  reduced	  carotid	  artery	  atherosclerotic	  plaque	  burden	  (determined	  
as	  cross	  sectional	  carotid	  wall	  area	  on	  MRI)	  was	  observed	  with	  12	  months	  of	  Niacin	  therapy	  
compared	  with	  placebo	  543.	  	  	  
Despite	   these	   promising	   effects,	   clinical	   trial	   data	   suggests	   that	   Niacin	   does	   not	   reduce	  
cardiovascular	   events	   compared	  with	   placebo.	   	   The	  AIM-­‐HIGH	   study,	  which	   included	   3414	  
patients	  followed	  up	  for	  36	  months,	  was	  terminated	  prematurely	  due	  to	  apparent	  futility	  in	  a	  
randomised	  comparison	  of	  Niacin	  with	  Placebo,	  with	   respect	   to	  a	  combined	  cardiovascular	  
events	   endpoint	   (HR	   1.02,	   95%	   CI;	   0.87	   –	   1.21)	   .	   	   Subsequently,	   the	   results	   of	   the	   HPS-­‐
2/THRIVE	  study,	  which	  included	  25,673	  patients,	  were	  presented	  at	  the	  American	  College	  of	  
Cardiology	  Conference	   in	  2013.	   	  Niacin	  was	  associated	  with	  no	   significant	   treatment	  effect	  
for	   a	   primary	   endpoint	   of	   combined	   cardiovascular	   events	   (Risk	   ratio	   0.96,	   95%	  CI;	   0.90	   –	  
1.03).	   	   Although	   patients	   enrolled	   in	   these	   studies	  were	   already	   intensively	  managed	  with	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cardiovascular	   risk	   reducing	   agents,	   including	   statin	   therapy,	   the	   authors	   concluded	   that	  
despite	   beneficial	   effects	   on	   lipid	   profiles	   and	   surrogate	   outcomes,	   treatment	   with	   Niacin	  
could	  not	  be	  recommended	  544.	  
Two	  meta-­‐analyses	  of	  studies	  which	  examined	  CIMT	  progression	  in	  relation	  to	  cardiovascular	  
risk,	  each	  failed	  to	  identify	  a	  significant	  association.	  	  Costanzo	  and	  colleagues	  used	  summary	  
statistics	   from	   clinical	   trials	   to	   have	   examined	   interventions	   in	   relation	   to	   both	   CIMT	  
progression	   and	   clinical	   outcomes,	   in	   a	   meta-­‐regression	   analysis	   545.	   	   41	   trials,	   including	  
18,307	   participants,	   were	   included.	   	   The	   authors	   reported	   no	   significant	   relationship	  
between	  CIMT	  regression	  and	  CV	  events	  and	  concluded	  that	   induced	  CIMT	  regression	  does	  
not	  reflect	  a	  reduction	  in	  CV	  risk.	  	  A	  separate	  analysis,	  utilising	  similar	  methodology,	  included	  
data	  for	  15,598	  patients	  enrolled	  in	  28	  RCTs	  546.	  	  The	  authors	  identified	  a	  significant	  reduction	  
in	  odds	  of	  non-­‐fatal	  MI	   (OR	  0.82;	  95%	  CI	  0.69	  –	  0.96)	   in	  association	  with	  CIMT	   regression.	  	  
However	  heterogeneity	  was	  observed	  between	  trial	  outcomes.	  	  The	  authors	  of	  these	  studies	  
suggested	  caution	  in	  considering	  CIMT	  as	  a	  primary	  outcome	  measure	  in	  clinical	  trials.	  	  	  
This	   conclusion	   has	   been	   debated	   on	   the	   basis	   that	   meta-­‐regression	   represented	   an	  
unsuitable	  methodological	  approach	  for	  the	  aims	  of	  these	  studies	  and	  that	  lack	  of	  individual	  
patient	   data	   left	   open	   the	   potential	   for	   confounding	   factors	   to	   have	   influenced	   the	  	  	  	  	  	  
findings	   547.	   	   Subsequently,	   an	   individual	   patient	   data	   meta-­‐analysis,	   including	   36,984	  
participants,	  assessed	  CV	  risk	  according	  to	  annualised	  CIMT	  progression	  rate	  (median	  interval	  
between	  measurements	  of	  4	  years).	  	  CIMT	  progression	  was	  positively	  correlated	  with	  CV	  risk	  
based	   on	   conventional	   CVRFs.	   	   The	   HR	   for	   an	   endpoint	   of	   combined	   vascular	   events	  
associated	  with	  mean	  common	  CIMT	  progression	  (following	  adjustment	  for	  CV	  risk	  factors),	  
was	  0.98	  (95%	  CI	  0.95	  –	  1.01).	  	  The	  authors	  concluded	  that	  no	  supportive	  conclusion	  could	  be	  
drawn	  for	  the	  use	  of	  CIMT	  progression	  as	  a	  surrogate	  outcome	  in	  clinical	  trials	  548.	  
Thus	   whilst	   serial	   measurements	   of	   CIMT	   allow	   the	   effect	   of	   interventions	   on	   CIMT	  
progression	   to	   be	   assessed,	   there	   remains	   a	   lack	   of	   definitive	   evidence	   relating	   the	  
parameter	  of	  “CIMT	  progression”	  to	  change	  in	  cardiovascular	  risk.	  	  Despite	  a	  lack	  of	  definitive	  
evidence	  supporting	  the	  use	  of	  CIMT	  progression	  as	  a	  surrogate	  endpoint	  in	  clinical	  trials,	  it	  
remains	  a	  biomarker	  of	  vascular	  health	  for	  research	  549	  and	  is	  recommended	  in	  guidelines	  for	  
this	  purpose	  550.	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6.1.10. What	  is	  the	  optimal	  CIMT	  measurement	  methodology?	  
There	  exist	  various	  permutations	  of	  measurement	  and	  analysis	  from	  which	  a	  CIMT	  value	  may	  
be	  derived.	  	  The	  most	  commonly	  reported	  analysis	  parameters	  include	  mean	  common	  CIMT	  
and	  mean	  maximum	  CIMT	  and	  these	  represent	  the	  parameters	  recommended	  for	  reporting	  
by	  current	  guidelines	  520, 550, 551.	  
Mean	  common	  CIMT	  is	  usually	  derived	  as	  the	  arithmetic	  mean	  of	  multiple	  measurements	  of	  
CIMT	   taken	   within	   a	   10mm	   segment	   AOI,	   typically	   the	   10mm	   segment	   of	   the	   CCA	  
immediately	  proximal	  to	  the	  carotid	  bulb	  dilatation.	  	  Mean	  maximum	  CIMT	  is	  usually	  derived	  
as	   the	   arithmetic	  mean	   of	   the	  maximum	   single	   point	  measurement	   of	   IMT	   at	   each	   of	   12	  
standard	  carotid	  artery	  segments:	  measurement	  of	  both	  far	  &	  near	  wall,	  at	  three	  segments	  
(common,	  bulb	  and	  internal),	  for	  both	  the	  right	  and	  left	  carotid	  arteries.	  
Mean	   common	  CIMT	   is	   a	  more	   reproducible	  measure	   than	  mean	  maximum	  CIMT	  because	  
multiple	  points	  of	  measurement	  within	  an	  AOI	  are	  reported	  as	  a	  mean	  value.	  	  As	  such	  it	  may	  
be	  a	  more	  suitable	  measurement	  for	  examining	  change	  in	  CIMT	  over	  time,	  though	  it	  is	  likely	  
to	  be	   less	   sensitive	   to	   change	   than	   the	   less	   reproducible	  measurement	  of	  mean	  maximum	  
CIMT.	   	   The	  mean	   common	  measurement	   is	   also	   associated	  with	  more	   complete	   technical	  
feasibility	  of	  measurement	  471.	  	  	  
Whilst	  these	  derivations	  of	  CIMT	  represent	  those	  most	  frequently	  reported	  in	  recommended	  
in	  current	  guidelines,	  it	  is	  important	  to	  highlight	  that	  most	  studies	  reported	  only	  one	  of	  these	  
two	   parameters.	   	   Moreover,	   methodology	   for	   the	   measurement	   of	   these	   recommended	  
CIMT	  parameters	  has	  been	  highly	  variable	  between	  studies.	  	  	  
Mean	   common	   CIMT	   in	   some	   trials	   was	   derived	   as	   an	   arithmetic	   mean	   of	   a	   single	   point	  
measurement	   recorded	   within	   the	   AOI	   504,	   rather	   than	   as	   the	   mean	   of	   multiple	  
measurements	  within	  the	  specified	  AOI	  507, 510, 511, 518, 519.	  	  Many	  studies	  have	  reported	  other	  
variations	  in	  CIMT	  derivation,	  including	  arithmetic	  means	  of	  repeated	  AOI	  measurements	  at	  
multiple	  carotid	  segments	  505, 506	  and	  mean	  non-­‐common	  segment	  CIMT	  values	  505, 506,	  with	  
or	  without	  505, 506	  weighting	  based	  on	  the	  length	  of	  the	  AOI	  measurements	  available.	  	  Several	  
studies	  have	  included	  measurement	  of	  far	  wall	  CIMT	  only	  505, 506, 511.	   	  Mean	  maximum	  CIMT	  
has	  been	  reported	  in	  some	  studies	  552, 553,	  without	  inclusion	  of	  particular	  segments	  within	  the	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scanning	   protocol	   in	   some	   cases,	   for	   example	   the	   carotid	   bulb	   measurements	   were	   not	  
included	   in	   the	   Cardiovascular	  Health	   Study	   509.	   	   Idiosyncratic	   CIMT	   derivations	   have	   been	  
reported	   in	   noteworthy	   studies.	   	   Irrespective	   of	   the	   particular	   CIMT	  parameter	   derivation,	  
these	  studies	  consistently	  reported	  an	  independent	  relationship	  between	  CIMT	  and	  risk	  of	  CV	  
events.	  	  
	  
6.1.11. Guidelines	  &	  consensus	  statements	  regarding	  CIMT	  measurement	  
Given	  the	  extensive	  heterogeneity	  in	  the	  published	  literature	  relating	  to	  IMT	  measurement,	  
difficulties	  arise	   in	   comparing	   the	  available	  data	  between	  populations.	   	  Homogenisation	  of	  
the	  methodology	  employed	  to	  acquire	  data	  in	  studies	  assessing	  IMT	  as	  an	  outcome	  is	  clearly	  
desirable,	  not	  only	  for	  the	  reasons	  above	  but	  also	  for	  the	  advantages	  in	  relation	  to	  potential	  
meta-­‐analysis.	   	   Consequently	   recommendations	   and	   consensus	   documents	   have	   been	  
produced	  in	  attempts	  to	  encourage	  a	  standardised	  approach	  to	  measurement	  and	  harmonise	  
future	   research	   examining	   IMT	   as	   an	   outcome	   measure	   and	   its	   use	   in	   determination	   of	  
cardiovascular	  risk	  471, 520, 551.	  
For	   the	  purposes	  of	  cardiovascular	   risk	  assessment,	  CIMT	  measurement	  at	  multiple	  carotid	  
segment	  levels,	  for	  example	  with	  mean	  maximum	  CIMT,	  is	  superior	  to	  analysis	  limited	  to	  the	  
common	   segment	   alone	   471, 520, 551.	   	   The	   basis	   for	   this	   is	   that	   presence	   of	   plaque	   lesions	  
appears	  to	   identify	  patients	  at	   increased	  risk	  compared	  to	  patients	  without	  plaque	  and	  the	  
common	  carotid	  segment	  is	  typically	  spared	  from	  development	  of	  such	  focal	   lesions.	   	  A	  full	  
inspection	   of	   the	   carotid	  may	   therefore	   better	   reflect	   systemic	   atherosclerotic	   burden	   471.	  	  
Though	   current	   guidelines	   recommend	   screening	   for	   plaque	   as	   part	   of	   IMT	   scanning,	   this	  
pertains	  to	  the	  additional	   information	  provided	   in	  relation	  to	  stratifying	  cardiovascular	  risk,	  
as	  opposed	  to	  inclusion	  as	  a	  therapeutic	  target	  or	  monitoring	  of	  treatment	  effect	  and	  some	  
authors	  have	  recommended	  that	  mean	  common	  CIMT	  be	  reported	  as	  the	  measure	  of	  choice	  
for	  interval	  monitoring	  520.	  	  	  
In	   deriving	   mean	   common	   CIMT,	   current	   guidelines	   recommend	   repeated	   CIMT	  
measurement	  within	  a	  10mm	  length	  (or	  shorter	   if	   full	  10mm	  not	  available)	  of	  the	  common	  
carotid	  segment	  immediately	  proximal	  to	  the	  carotid	  bulb	  dilatation.	  	  Measurements	  should	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entail	  the	  far	  wall	  alone	  (as	  this	  is	  associated	  with	  greater	  reproducibility)	  and	  be	  performed	  
from	  three	  separate	  angles	  (again	  proposed	  as	  likely	  to	  reduce	  variability	  and	  potential	  bias	  
compared	   with	   single	   “optimal”	   measurements).	   	   An	   arithmetic	   mean	   based	   on	   these	  
repeated	   measurements	   should	   be	   reported.	   	   In	   deriving	   mean	   maximum-­‐CIMT,	   current	  
guidelines	  recommend	  that	  12	  arterial	  segments	  be	  utilised	  in	  measurement.	  	  Guidelines	  also	  
recommend	  that	  each	  of	  the	  12	  points	  be	  measured	  from	  three	  separate	  angles.	  	  Thus	  mean	  
maximum-­‐CIMT	  would	  be	   a	  mean	  of	   the	  maximum	  values	   identified	  on	  36	   images,	  with	   3	  
images	  at	  each	  desired	  segment	  520, 551.	  	  	  
Contemporary	   guidelines	   recommend	   the	   application	   of	   semi-­‐automated	   edge-­‐detection	  
software	   systems	   based	   on	   the	   “leading	   edge”	   principle	   for	   analysis	   of	   US	   images	   in	  
measuring	  CIMT	  551.	  	  Whilst	  such	  software	  tend	  to	  improve	  reproducibility	  of	  measurement,	  
they	  tend	  to	  report	  higher	  CIMT	  values	  than	  manual	  image	  analysis,	  as	  was	  utilized	  in	  many	  
of	  the	  large	  epidemiological	  studies	  to	  examine	  the	  role	  of	  c-­‐IMT.	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6.2. Rationale	  for	  use	  of	  blood	  pressure	  pulse	  wave	  and	  endothelial	  function	  
analysis	  as	  measures	  of	  cardiovascular	  function	  
	  
6.2.1. Blood	  pressure	  as	  a	  risk	  factor	  for	  cardiovascular	  disease	  
There	  is	  a	  well-­‐established	  aetiological	  relationship	  between	  BP	  and	  the	  risk	  of	  cardiovascular	  
disease.	  	  Both	  peripheral	  systolic	  and	  diastolic	  BP	  are	  independently	  related	  to	  increasing	  risk	  
of	  IHD	  in	  a	  linear	  manner	  554.	  	  Therapeutic	  reduction	  of	  BP	  has	  been	  demonstrated	  to	  reduce	  
the	  incidence	  of	  both	  IHD	  and	  stroke,	  in	  proportion	  to	  the	  degree	  of	  BP	  reduction	  achieved	  	  
This	   relationship	   has	   traditionally	   been	   described	   in	   relation	   to	   the	   measurement	   of	   two	  
discrete	   parameters,	   the	   systolic	   and	   diastolic	   BP,	   typically	   measured	   at	   the	   brachial	  	  	  	  	  	  	  
artery	   554.	   	  Accordingly,	   the	  application	  of	  BP	   to	   cardiovascular	  disease	   risk	   stratification	   in	  
clinical	   practice	   (and	   the	   decision	   to	   treat	   hypertension)	   is	   conventionally	   based	   upon	  
measurement	  brachial	  artery	  systolic	  and	  diastolic	  BP	  555.	  	  
	  
6.2.2. Blood	  pressure	  as	  a	  cyclic	  pulse	  wave	  
Blood	   pressure	   is	   exerted	   on	   the	   arterial	   tree	   as	   a	   pulse	  wave	   (BP-­‐PW),	   generated	   by	   the	  
ejection	   of	   a	   volume	   of	   blood	   from	   the	   left	   ventricle	   during	   systolic	   contraction	   556.	  	  
Accordingly,	  the	  BP-­‐PW	  propagates	  through	  the	  arterial	  tree	  on	  a	  cyclic	  basis,	  corresponding	  
to	  each	  cardiac	  cycle.	  	  Conventional	  systolic	  and	  diastolic	  BP	  values,	  measured	  at	  the	  brachial	  
artery	   with	   a	   sphygmomanometer,	   represent	   the	   maximum	   and	   minimum	   points,	  
respectively,	  of	  the	  cyclic	  BP-­‐PW	  (at	  the	  brachial	  artery)	  556, 557.	  	  	  
Blood	  pressure	   is	   considered	   to	  exert	   its	   deleterious	  effect	  on	   the	  arterial	  wall	   through	   its	  
action	  as	  a	  mechanical	  force	  557.	   	  The	  BP-­‐PW	  continually	  exerts	  a	  range	  of	  pressures	  on	  the	  
arterial	   wall.	   	   Explanation	   of	   its	   effect	   through	   its	   maximum	   and	   minimum	   (systolic	   and	  
diastolic)	   levels	   alone,	   disregards	   pressure	   effects	   throughout	   the	   majority	   of	   the	   cyclic	  
pulsation	   557, 558,	   with	   the	   total	   pressure	   exerted	   on	   the	   arterial	   wall	   more	   accurately	  
represented	  by	  the	  area	  beneath	  the	  BP	  pulse	  wave	  curve	  556, 558.	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These	   observations	   have	   given	   rise	   to	   interest	   in	   the	   potential	   application	   of	   more	  
comprehensive	  assessment	  of	  BP-­‐PW	  morphology;	  blood	  pressure	  pulse	  wave	  analysis	   (BP-­‐
PWA)	  558.	  
	  
6.2.3. Morphology	  of	  the	  blood	  pressure	  pulse	  wave	  
The	  morphology	  of	  the	  BP-­‐PW	  undergoes	  transition	  as	  it	  propagates	  through	  the	  arterial	  tree	  
due	  to	  a	  combination	  of	  ventricular	  systolic	  ejection	  characteristics,	  arterial	  compliance	  and	  
sites	   of	   impedance	   mismatch	   (which	   contribute	   to	   incident	   wave	   reflection)	   556, 558.	   	   In	  
addition,	   BP-­‐PW	   morphology	   also	   differs	   (including	   in	   amplitude)	   according	   to	   modified	  
arterial	  characteristics	  that	  occur	  with	  aging	  and	  in	  cardiovascular	  disease	  556, 558.	  
The	   BP-­‐PW	   is	   generated	   by	   left	   ventricular	   systolic	   contraction.	   	   An	   “incident”	   wave,	   the	  
initial	   characteristic	   of	   which	   is	   dependent	   upon	   the	   form	   and	   duration	   of	   ventricular	  
ejection,	   propagates	   from	   the	   heart	   throughout	   the	   arterial	   tree	   556, 558, 559.	   	   At	   sites	   of	  
impedance	  mismatch,	  typically	  points	  of	  arterial	  branching	  and	  the	  high	  resistance	  peripheral	  
arterioles,	   reflection	  of	   the	   incident	  wave	  occurs	  559.	   	  Both	  the	   incident	  and	  reflected	  wave	  
propagate	   through	   the	   arterial	   tree	   at	   a	   velocity	   in	   the	   order	   of	   metres	   per	   second.	  	  
Accordingly,	   the	   morphology	   of	   the	   BP-­‐PW,	   recorded	   at	   any	   site	   within	   the	   arterial	   tree,	  
represents	   a	   composite	   summation	   of	   both	   the	   incident	   and	   returning	   reflected	   pressure	  
waves	  556, 558, 559.	  	  	  	  	  
Relative	  to	  central	  arteries,	  the	  incident	  wave	  arrives	  at	  peripheral	  arterial	  sites	  progressively	  
later	  within	  the	  cardiac	  cycle.	  	  Conversely,	  the	  reflected	  wave	  arrives	  appears	  relatively	  early	  
within	  the	  cardiac	  cycle	  in	  peripheral	  vessels.	  	  Thus,	  a	  peripheral	  artery	  BP-­‐PW	  measurement,	  
recorded	  close	  to	  the	  predominant	  site	  of	  wave	  reflection,	  will	  feature	  incident	  and	  reflected	  
waves	  with	  a	  closer	  temporal	   relation	  to	  that	  observed	  centrally.	   	  Typically	   this	   results	   in	  a	  
composite	  waveform	  in	  which	  the	  arrival	  of	  the	  reflected	  waveform	  “augments”	  the	  incident	  
wave	  pressure	  peak	  in	  peripheral	  arteries,	  during	  systole.	  	  In	  central	  arteries,	  with	  relatively	  
delayed	  arrival	  of	  the	  reflected	  wave,	  augmentation	  of	  the	  incident	  wave	  occurs	  in	  diastole,	  	  	  
resulting	  in	  augmentation	  of	  coronary	  blood	  flow	  559.	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Arteries	  are	  compliant	  vessels	  which	  buffer	   the	   intermittent	   increase	   in	  pressure	  produced	  
by	   left	   ventricular	   contraction.	   	   A	   compliant	   vessel	   absorbs	   a	   greater	   proportion	   of	   the	  
pressure	   wave	   energy	   than	   a	   rigid	   vessel	   and	   the	   pulse	   wave	   propagates	   less	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
quickly	  556, 558, 559.	   	  Both	  the	  amplitude	  and	  the	  velocity	  of	  the	   incident	  and	  reflected	  waves	  
(and	   in	   turn	   the	   morphology	   of	   the	   composite	   BP-­‐PW)	   are	   further	   influenced	   by	   arterial	  
geometry	  and	  functional	  characteristics	  556, 559.	  	  	  
Central,	   predominantly	   elastic	   arteries	   tend	   to	   exhibit	   greater	   compliance	   than	   peripheral,	  
predominantly	   muscular	   arteries	   due	   to	   their	   relatively	   high	   elastin	   content	   in	   the	   vessel	  	  	  
wall	  560, 561.	  	  This	  function	  allows	  for	  pressure	  generated	  by	  ventricular	  systole	  to	  be	  buffered	  
and	   the	   energy	   released	   to	   be	   accommodated,	   stored	   and	   then	   released	   in	   diastole,	  
facilitating	  both	  diastolic	  coronary	  perfusion	  and	  smooth	  continuous	  end-­‐organ	  perfusion	  557.	  	  
Aside	   from	   their	   structural	   elastin	   content,	   functional	   arterial	   properties,	   including	  
endothelium	   dependent	   smooth	   muscle	   relaxation,	   also	   contribute	   to	   arterial	  	  	  	  	  	  	  	  	  
compliance	  562, 563.	  	  	  
Peripheral	  arteries	  assume	  a	  muscular,	   less	  compliant	  structure,	  with	  less	  energy	  of	  the	  BP-­‐
PW	  absorbed	  by	  the	  vessel	  wall.	  	  Accordingly	  BP-­‐PW	  amplitude	  increases	  peripherally	  within	  
the	   arterial	   tree	   558, 564.	   	   In	   addition,	   BP-­‐PW	  velocity	   increases	   in	   less	   compliant	   peripheral	  
arteries.	  	  Consequently,	  this	  further	  reduces	  the	  relatively	  small	  temporal	  difference	  between	  
incident	   and	   reflected	   wave	   appearance	   in	   peripheral	   arteries,	   exaggerating	   the	   systolic	  
augmentation	  at	  these	  sites	  558.	  	  	  
Thus,	   in	   peripheral	   arteries,	  with	   reducing	   compliance	   and	   increasing	   proximity	   to	   sites	   of	  
wave	   reflection,	   the	  BP	  pulse	  wave	  systolic	  peak	  becomes	   relatively	  narrowed	  and	  sharper	  
and	  the	  pulse	  pressure	  is	  amplified	  relative	  to	  central	  values.	  	  This	  phenomenon	  is	  referred	  to	  
as	   pulse	   pressure	   amplification	   and	   represents	   a	   function	   of:	   1,	   differential	   compliance	  
between	   central	   and	   peripheral	   arteries;	   2,	   differential	   time	   delay	   between	   incident	   &	  
reflected	  wave	  merger	  between	  central	  and	  peripheral	  arteries	  556, 558, 559.	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6.2.4. The	  blood	  pressure	  pulse	  wave	  in	  aging	  and	  disease:	  arterial	  stiffness	  
“Arterial	  stiffness”	  represents	   loss	  of	  arterial	  compliance	  and	  develops	  as	  a	  consequence	  of	  
modified	   structural	   arterial	   wall	   components	   (e.g.	   loss	   of	   elasticity	   associated	   with	   the	  
cumulative	   effects	   of	   arterial	   pulsatility	   with	   aging)	   560, 561, 565.	   	   Arterial	   compliance	   is	   also	  
determined	   through	   a	   non-­‐structural,	   NO-­‐mediated,	   endothelium	   dependent	   functional	  
component	  562, 563,	  such	  that	  endothelial	  dysfunction	  may	  contribute	  to	  arterial	  stiffness.	  	  The	  
role	   of	   endothelial	   dysfunction	   in	   the	   pathogenesis	   of	   cardiovascular	   disease	   is	   discussed	  
further	  in	  chapter	  6.2.7	  and	  6.2.8.	  
Loss	   of	   arterial	   compliance	   is	   observed	  with	   increasing	   age	   558, 566, 567.	   In	   addition,	   arterial	  
stiffness	  is	  also	  observed	  across	  a	  variety	  of	  CVRF	  states	  including	  smoking,	  hypertension	  568,	  
renal	  failure	  569,	  diabetes	  mellitus,	  hypercholesterolaemia	  570,	  and	  established	  atherosclerotic	  
conditions	  571.	  	  	  
In	  “stiffened”	  arteries,	  the	  BP-­‐PW	  propagates	  through	  the	  arterial	  tree	  at	  accelerated	  velocity	  
and	  with	  relatively	  preserved	  amplitude,	  due	  to	  reduced	  absorption	  of	  the	  pressure	  wave	  558.	  	  
This	   is	   associated	   with	   several	   adverse	   haemodynamic	   consequences:	   	   Firstly,	   end	   organ	  
arterial	  beds	  are	  exposed	  to	  higher	  incident	  wave	  pressures	  due	  to	  reduced	  absorption	  of	  the	  
BP-­‐PW	   by	   compliant	   arteries	   572.	   	   Secondly,	   the	   reflected	   pressure	   wave	   returns	   to	   the	  
proximal	  aorta	  earlier	  within	  the	  pulse	  pressure	  cycle,	  during	  ventricular	  systole.	  	  	  This	  results	  
in	   “augmentation”	   of	   peak	   systolic	   pressure	   within	   the	   proximal	   aorta,	   increased	   cardiac	  
afterload	   and	   predisposition	   to	   left	   ventricular	   hypertrophy	   and	   dysfunction	   558, 559, 573.	  	  
Thirdly,	   earlier	   arrival	   of	   the	   reflected	   pressure	   wave	   results	   in	   loss	   of	   augmentation	   of	  
diastolic	  coronary	  perfusion	  558, 559, 573.	  	  	  
As	   discussed	   above,	   both	  BP-­‐PW	  amplitude	   and	  morphology	   vary	   according	   to	   the	   arterial	  
tree	   site	   556.	   	   Therefore,	   measurement	   of	   peripheral	   (typically	   brachial)	   artery	   systolic	   &	  
diastolic	   BP	   provides	   only	   limited	   &	   indirect	   information	   relating	   to	   the	   burden	   of	   BP-­‐PW	  
effects	   throughout	   the	   arterial	   tree.	   	   Moreover,	   for	   similar	   extremes	   in	   BP	   amplitude	  
measured	   peripherally,	   central	   BP-­‐PW	   waveform	   amplitude	   and	   morphology	   may	   differ	  
significantly	  in	  the	  context	  of	  arterial	  stiffness	  compared	  with	  compliant	  arteries	  574, 575.	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The	   potentially	   greater	   harm	   accrued	   through	   both	   elevated	   central	   and	   end-­‐organ	   BP	  
pressures	   associated	   with	   arterial	   stiffness	   has	   led	   to	   interest	   in	   potentially	   additive	  
information	  that	  determination	  of	  arterial	  stiffness	  and	  central	  BP	  measurement	  might	  hold	  
in	  relation	  to	  the	  risk	  of	  cardiovascular	  disease.	  	  If	  such	  a	  relationship	  exists,	  measurement	  of	  
arterial	  stiffness	  and	  central	  BP,	  rather	  than	  brachial	  artery	  systolic	  BP	  alone,	  might	  represent	  
useful	  tools	  in	  cardiovascular	  risk	  stratification.	  	  Arterial	  stiffness	  and	  central	  BP	  manipulation	  
might	  also	  represent	  a	  therapeutic	  target.	  
	  
6.2.5. Methodological	  approaches	  to	  blood	  pressure	  pulse	  wave	  analysis	  
Characteristic	   features	  of	  the	  peripheral	  BP	  pulse	  waveform	  have	  been	  described	   in	  clinical	  
medicine	   for	   centuries,	   with	   specific	   modifications	   to	   that	   observed	   in	   young	   healthy	  
individuals	   described	   in	   association	   with	   both	   ageing	   and	   pathological	   conditions	   556, 558.	  	  
Graphical	  illustration	  of	  the	  pressure	  pulse	  waveform	  and	  its	  variations,	  were	  first	  described	  
in	  the	  late	  19th	  century	  by	  Mahomed,	  who	  reported	  the	  “sphygmograph”	  obtained	  in	  various	  
patients	   obtained	   through	   equipment	   which	   recorded	   the	   pressure	   waveform	   of	   the	  
peripheral	  pulse	  559.	  	  Such	  graphical	  representation	  of	  the	  pressure	  pulse	  wave	  over	  the	  full	  
cycle	  allows	  calculation	  of	  the	  full	  pressure	  exerted	  by	  the	  pulse	  wave	  on	  the	  arterial	  wall.	  
Techniques	  by	  which	  the	  peripheral	  artery	  sphygmograph	  may	  be	  accurately	  obtained	  have	  
subsequently	   been	   refined,	   with	   contemporary	   methodology	   utilising	   the	   technique	   of	  
“applanation	   tonometry”	   558, 564, 576.	   	   A	   high	   fidelity	   pressure	   transducer	   is	   applied	   to	   a	  
peripheral	   artery	   site	   (typically	   the	   radial	   artery),	   flattening	   the	   vessel	   against	   bone	   (the	  
radius),	  thereby	  eliminating	  tangential	  pressures	  and	  allowing	  the	  pulse	  pressure	  waveform	  
within	  the	  artery	  to	  be	  accurately	  recorded	  558, 564, 576.	  	  Measurement	  of	  the	  BP-­‐PW	  through	  
applanation	  tonometry	  has	  been	  found	  to	  be	  reproducible	  577-­‐579.	  	  	  
Direct	  measurement	  of	  central	  BP	  pulse	  wave	  morphology	  and	  amplitude	  may	  be	  performed	  
through	  aortic	  catheterisation.	  	  However,	  this	  is	  relatively	  impractical	  and	  associated	  with	  a	  
risk	  of	  complication	  that	  exceeds	  justification	  for	  purposes	  of	  either	  CV	  risk	  stratification	  or	  
assessment	   of	   response	   to	   therapeutic	   agents.	   	   However,	   increased	   understanding	   of	   the	  
relationship	  between	  peripheral	  and	  central	  BP	  pulse	  waveform	  morphology	  has	  permitted	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the	   development	   of	   non-­‐invasive	   means	   of	   assessing	   arterial	   stiffness	   and	   central	  
haemodynamics	  through	  peripheral	  BP	  pulse	  waveform	  analysis	  (BP-­‐PWA)	  558, 559.	  
Studies	   have	   been	   conducted	  which	   examined	   both	   peripheral	   artery	   sphygmography	   and	  
invasive	  central	  artery	  pressure	  waveforms,	   facilitating	   the	  calculation	  of	   transfer	   functions	  
which	   mathematically	   relate	   the	   frequency	   components	   of	   the	   peripheral	   waveform	   and	  
those	   of	   central	   waveform.	   	   Consequently,	   together	   with	   measurement	   of	   mean	   arterial	  
pressure	   (which	   varies	   little	   throughout	   the	   arterial	   tree	   despite	   pulse	   pressure	  	  
amplification)	   574,	   the	   application	   of	   a	   “generalised	   transfer	   function”	   may	   be	   used	   to	  
reconstitute	   the	  central	  arterial	  BP-­‐PW	  as	  a	  derivation	  of	   the	   sphygmograph	   recorded	  at	  a	  
peripheral	   artery	   580.	   	   This	   technique	   has	   been	   validated	   in	   several	   populations	   581.	   	   Thus,	  
non-­‐invasively	   derived	   central	   sphygmocardiographs	   provide	   information	   on	   central	  
haemodynamics.	   	   In	   addition	   to	   central	   BP-­‐PW	   amplitude,	   surrogate	   measures	   of	   arterial	  
stiffness,	  including	  augmentation	  index	  may	  be	  derived.	  	  	  
“Augmentation	  index”	  (AI)	  represents	  a	  ratio	  between	  the	  contribution	  made	  to	  peak	  systolic	  
pressure	   from	   the	   reflected	   BP-­‐PW	   and	   the	   absolute	   pulse	   pressure	   within	   the	   ascending	  
aorta:	   it	   is	   a	   measure	   of	   the	   “contribution”	   that	   the	   reflected	   wave	   makes	   to	   central	   BP	  
(figure	  6-­‐2).	  	  The	  greater	  the	  AI,	  the	  greater	  the	  magnitude	  of	  systolic	  pressure	  attributable	  to	  
pulse	  wave	  reflection	  556.	  	  It	  represents	  a	  composite	  measure	  of	  arterial	  stiffness	  throughout	  
the	  arterial	   tree	  as	   it	   is	   influenced	  by	   central	   (e.g.	   aortic)	   stiffness	   (and	   therefore	  BP	  pulse	  
wave	   velocity	   (BP-­‐PWV)	   and	   wave	   absorption)	   and	   peripheral	   impedance	   mismatch	   (e.g.	  
peripheral	  arteriolar	  tone).	  	  Augmentation	  index,	  derived	  through	  PWA	  has	  been	  reported	  as	  
a	  stable	  measurement	  relatively	  resistant	  to	  variation	  in	  BP	  between	  recordings	  577.	  	  Central	  
(i.e.	  ascending	  aortic)	  BP,	  may	  differ	  significantly	  from	  peripheral	  (e.g.	  brachial	  artery)	  BP	  and	  
may	   be	   derived	   through	   application	   of	   the	   generalised	   transfer	   function	   to	   applanation	  
tonometry	  measurements.	  	  	  
“Pulse	  wave	   velocity”	   is	   a	   simple	  measure	   of	   the	   time	   taken	   for	   the	   BP-­‐PW	   to	   propagate	  
through	  a	  given	  distance	  within	  the	  arterial	  tree.	  	  It	  may	  be	  measured	  directly	  by	  timing	  the	  
arrival	   of	   the	   pressure	   pulse	  wave	   at	   two	   separate	   arterial	   sites	   in	   relation	   to	   the	   cardiac	  
cycle.	  Compared	  with	  AI,	  PWV	  is	  a	  more	  focused	  measure	  of	  stiffness	  as	  the	  velocity	  within	  a	  
particular	  arterial	  segment	  (e.g.	  the	  aorta	  or	  the	  brachial	  artery)	  558,	  as	  it	  is	  less	  influenced	  by	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the	   contribution	   of	   impedance	   mismatch	   relative	   to	   other	   surrogate	   markers	   of	   stiffness.	  	  
Carotid	   –	   femoral	   PWV	   relates	   to	   aortic	   (central	   elastic	   arterial)	   stiffness.	   	   Carotid	   –	   radial	  
PWV	  relates	  to	  brachial	  (peripheral	  muscular	  arterial)	  stiffness.	  	  
As	  AI,	  central	  BP	  and	  pulse	  wave	  velocity	  may	  all	  be	  calculated	  through	  assessment	  of	  the	  BP-­‐
PW,	   BP-­‐PWA	   represents	   a	   modality	   by	   which	   arterial	   stiffness	   and	   central	   BP	   may	   be	  
assessed	   556, 558, 559.	   	   These	  measures	   have	   been	   studied	   in	   relation	   to	   subsequent	   risk	   of	  
cardiovascular	  disease	  in	  a	  number	  of	  populations.	  
	   	  
Figure	  6-­‐2:	  	  Illustration	  of	  central	  blood	  pressure	  pulse	  wave	  morphology	  	  
(reproduced	  from	  Williams	  et	  al,	  Circulation	  2006)	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6.2.6. Clinical	  significance	  of	  arterial	  stiffness	  and	  central	  blood	  pressure	  
Arterial	   stiffness,	   determined	   as	   various	   measurements,	   is	   independently	   associated	   with	  
adverse	  cardiovascular	  outcomes	  amongst	  the	  general	  population,	  patients	  with	  CVRF	  states	  
and	   those	   with	   established	   disease	   582.	   	   Augmentation	   index,	   based	   on	   radial	   artery	  
applanation	   tonometry	   recordings,	   is	   independently	   predictive	   of	   all-­‐cause	   mortality	  
amongst	   patients	   with	   established	   cardiovascular	   disease	   583.	   	   In	   addition,	   amongst	   the	  
general	   population,	   AI	   predicts	   development	   of	   incident	   hypertension,	   independent	   of	  
baseline	  BP	  584.	  	  Though	  AI	  was	  found	  to	  lack	  independent	  predictive	  power	  of	  cardiovascular	  
outcomes	   in	   one	   population	   585,	   this	   was	   based	   on	   derivation	   based	   on	   recordings	   at	   the	  
brachial	   artery.	   	   Pulse	   wave	   velocity	   independently	   predicts	   both	   cardiovascular	  	  	  	  	  	  	  
endpoints	   559, 585, 586	   and	   mortality	   559, 586.	   	   Aortic	   BP-­‐PWV	   independently	   predicts	   stroke	  
mortality	   amongst	   hypertensive	   patients	   587	   and	   development	   of	   incident	   hypertension,	  
independent	  of	  baseline	  BP	  584.	  
When	  central	  BP	  measurement	  has	  been	  included	  in	  multivariate	  analysis,	  it	  has	  been	  found	  
to	   hold	   a	   stronger	   association	   with	   risk	   of	   cardiovascular	   events	   than	   peripheral	   BP	  
measurements	  588.	  	  Indeed,	  brachial	  BP	  measurement	  loses	  its	  independent	  predictive	  value	  
when	  central	  BP	  measurement	  is	  considered	  in	  some	  populations	  589.	   	  Central	  arterial	  pulse	  
pressure	   also	   independently	   predicts	   adverse	   outcome	   amongst	   patients	   with	   established	  
vascular	  disease	  590, 591	  in	  the	  general	  population	  589.	  	  	  	  	  
The	  observation	   that	  central	  BP	  may	  be	  more	  relevant	   than	  peripheral	  BP,	   is	   supported	  by	  
evidence	   from	   recent	   large	   RCTs	   of	   antihypertensive	   therapy.	   	   Differential	   effects	   on	  
cardiovascular	   outcomes	   have	   been	   observed	   for	   antihypertensive	   agents	   with	   similar	  
peripheral	   BP	   lowering	   effects,	   raising	   speculation	   as	   to	   the	   mechanisms	   underlying	   the	  
apparent	   superiority	   of	   newer	   antihypertensive	   agents.	   	   Subsequently,	   differential	  
cardiovascular	   outcomes	   for	   equivalent	   reductions	   in	   brachial	   BP	   have	   been	   attributed	   to	  
differing	   central	   BP	   lowering	   properties	   between	   agents	   591.	   	   In	   this	   study,	   central	   BP,	  
determined	   through	  application	   tonometry	   at	   the	   radial	   artery,	  was	  preferentially	   reduced	  
with	   ACE-­‐Is	   and	   CCBs.	   	   Thus	   it	   appears	   plausible	   that	   the	   additive	   benefit	   of	   certain	   BP	  
lowering	   drugs	  may	   be	   achieved	   through	   a	   relatively	   greater	   reduction	   in	   arterial	   stiffness	  
and	  therefore	  reduced	  central	  BP.	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On	   the	   basis	   of	   the	   epidemiological	   risk	   associations	   and	   the	   potential	   central	   BP	   related	  
mechanism	  of	  benefit	  of	  antihypertensive	  therapy,	  arterial	  stiffness	  and	  central	  BP	  have	  been	  
proposed	   as	   adjunctive	  measurements	   in	   the	   assessment	   of	   cardiovascular	   risk	   572	   and	   as	  
potential	  therapeutic	  targets	  in	  the	  prevention	  of	  cardiovascular	  disease	  588.	  	  	  
	  
6.2.7. The	  role	  of	  the	  endothelium	  in	  cardiovascular	  function	  
The	   endothelium	   was	   historically	   considered	   to	   be	   principally	   anatomical	   in	   function,	  
separating	   underling	   collagen	   and	   tissue	   from	   blood	   constituents	   and	   thereby	   preventing	  
spontaneous	  thrombosis.	  	  Recent	  decades	  have	  witnessed	  recognition	  of	  the	  endothelium	  as	  
an	  important	  organ	  system	  with	  a	  role	  in	  several	  homeostatic	  systems.	  
Through	  production	  of	   vasodilator	   and	   vasoconstrictor	   substances,	   the	  endothelium	  exerts	  
extensive	   effects	   in	   modulating	   arterial	   tone,	   compliance	   and	   BP.	   	   In	   addition,	   the	  
endothelium	  is	  involved	  in	  blood	  fluidity	  and	  coagulation,	  being	  responsible	  for	  production	  of	  
factors	   which	   interact	   with	   platelets,	   the	   coagulation	   cascade	   and	   the	   endogenous	  
fibrinolytic	   system.	   	   There	   is	   also	   emerging	   evidence	   that	   the	   endothelium	   interacts	   with	  
several	  homeostatic	  systems,	   including	  glucose	  and	   lipid	  metabolism	  and	  appears	   to	  play	  a	  
role	  in	  mediating	  inflammatory	  processes	  460.	  	  Furthermore,	  endothelial	  dysfunction	  appears	  
to	  be	  centrally	  involved	  in	  the	  pathogenesis	  of	  atherosclerosis	  592.	  
Endothelial	   dysfunction	   is	   a	   component	   of	   increasing	   age,	   risk	   factor	   states	   for	   the	  
development	   of	   cardiovascular	   disease	   and	   established	   cardiovascular	   disease,	   including	  
CHD,	  CHF	  and	  hypertension.	  	  Endothelial	  dysfunction	  has	  been	  demonstrated	  in	  subjects	  with	  
an	   elevated	   lipoprotein	   (a)	   level	   593	   and	   in	   subjects	   with	   hypercholesterolaemia,	   an	   effect	  
that	  appears	  to	  be	  mediated,	  at	  least	  in	  part,	  by	  reduced	  bioavailability	  of	  NO	  594.	  	  Endothelial	  
function	   is	   associated	  with	   obesity	   595,	   models	   of	   insulin	   resistance	   such	   as	   PCOS	   596,	   and	  
elevated	   markers	   of	   systemic	   low	   grade	   inflammation	   597.	   	   Endothelial	   dysfunction	   may	  
represent	  a	  key	  feature	  of	  the	  metabolic	  syndrome.	  
Atherosclerosis	   represents	  an	   inflammatory	  process	   598,	   in	  which	  endothelial	  dysfunction	   is	  
likely	   to	   play	   a	   mediating	   role.	   	   Impaired	   endothelial	   function	   is	   likely	   to	   contribute	   to	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thrombosis	   and	   endothelial	   dysfunction	   appears	   related	   to	   both	   risk	   of	   atherosclerotic	  
plaque	   rupture	   460.	   	   Circulating	   markers	   of	   endothelial	   activation,	   such	   as	   soluble	   ICAM-­‐1	  
levels,	   predict	   the	   development	   of	   type	   2	  DM	   599, 600.	   	   	   In	   addition,	   levels	   are	   increased	   in	  
conditions	  of	  endothelial	  damage,	  including	  following	  acute	  stroke	  601, 602.	  	  Elevated	  ICAM-­‐1	  is	  
associated	   with	   symptomatic	   carotid	   atherosclerotic	   disease	   603	   and	   subcortical	   vascular	  
disease	  604.	  
	  
6.2.8. Clinical	  significance	  of	  endothelial	  dysfunction	  
The	   presence	   of	   endothelial	   dysfunction	   independently	   predicts	   risk	   of	   subsequent	  
cardiovascular	  events	  and	  cardiovascular	  mortality.	  	  	  
Coronary	  endothelial	  dysfunction	  has	  been	  shown	  to	   independently	  predict	   the	  occurrence	  
of	   subsequent	   CV	   events	   605.	   	   In	   addition,	   measurement	   of	   endothelial	   function	   in	   non-­‐
coronary	   &	   cerebral	   arterial	   territories	   holds	   predictive	   value	   for	   clinical	   events	   arising	   in	  
those	   territories.	   	   In	   patients	   with	   CAD,	   FBF	   responses	   to	   ACh	   independently	   predict	   CV	  
events	   456.	   	   Brachial	   artery	   FMD	   also	   predicts	   outcomes	   in	   patients	   with	   CAD	   457.	   	   These	  
findings,	   coupled	   with	   the	   observation	   that	   brachial	   FMD	   is	   highly	   correlated	   with	  
assessment	   of	   endothelial	   function	   by	   coronary	   angiography	   606,	   suggest	   that	   endothelial	  
dysfunction	  appears	   to	  be	  a	   systemic	  disorder.	   	  On	   this	  basis,	  measurement	  of	  endothelial	  
function	   in	   non-­‐coronary	   territories	   has	   been	   proposed	   as	   an	   acceptable	   surrogate	   for	  
function	  in	  the	  arterial	  beds	  in	  which	  clinical	  events	  typically	  arise	  460.	  
The	   independent	   predictive	   value	  of	   endothelium	  dependent	   vasodilatation	  measurement,	  
determined	  as	  either	  FBF	  responses	  or	  FMD,	  extends	  to	  patient	  populations	  with	  risk	  factors	  
but	  without	  established	  cardiovascular	  disease	  458, 459.	  	  	  
Circulating	   levels	  of	   intercellular	  adhesion	  molecule	   (ICAM-­‐1)	  are	  an	   independent	  predictor	  
of	  cardiovascular	  events	  in	  patients	  without	  known	  CVD	  607.	  	  Von	  Willebrand	  factor	  predicts	  
future	  events	  in	  patients	  with	  established	  CV	  disease	  608.	  
Thus,	   measurement	   of	   endothelial	   function	   may	   represent	   a	   potential	   means	   by	   which	  
patients	  at	  increased	  risk	  of	  vascular	  events	  might	  be	  identified.	  	  Measurement	  of	  endothelial	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function	   has	   therefore	   been	   proposed	   as	   a	   tool	   by	   which	   to	   improve	   cardiovascular	   risk	  
stratification	  and	  potentially	  to	  guide	  use	  of	  preventative	  strategies.	  
Most	   strategies	   of	   proven	  benefit	   in	   relation	   to	   reduced	   cardiovascular	   risk	   are	   associated	  
with	   improved	   endothelial	   function.	   	   Notably,	   several	   lifestyle	   modifications	   favourably	  
modify	   endothelial	   function.	   	   Regular	   aerobic	   exercise	   has	   been	   demonstrated	   to	   both	  
prevent	   and	   reverse	   the	   age-­‐associated	   decline	   in	   endothelial-­‐mediated	   vasodilatation	  
amongst	   a	   healthy,	   middle-­‐aged	   population	   609.	   	   These	   findings	   have	   been	   extended	   to	  
include	  patients	  with	  cardiovascular	  disease	  610.	   	  Furthermore,	   it	  appears	   that	  much	  of	   this	  
improvement	   in	   function	   is	   attributable	   to	   increased	   bioavailability	   of	   NO	   from	   the	  
endothelium.	  	  	  	  
Therapeutic	   agents	   which	   reduce	   cardiovascular	   risk	   have	   also	   been	   found	   to	   improve	  
endothelial	   function.	   	  Statin	   therapy	   improves	  endothelial	   function	   461,	  and	  benefit	  may	  be	  
independent	   of	   the	   reduction	   in	   cholesterol	   associated	  with	   treatment	   611.	   	   In	   addition	   to	  
reduction	   in	   LDLc,	   statins	   are	   associated	   with	   reduced	  markers	   of	   systemic	   inflammation,	  
which	  are	  implicated	  in	  endothelial	  dysfunction	  612.	  	  Statin	  therapy	  has	  been	  shown	  to	  reduce	  
ICAM-­‐1	   613.	   	   In	   addition,	   statins	   increase	   expression	   of	   eNOS	   614.	   	   Rather	   than	   plaque	  
regression,	  beneficial	  effects	  on	  endothelial	   function	  and	  plaque	  composition	  are	  proposed	  
as	  likely	  mediators	  of	  the	  benefit	  of	  statin	  therapy	  on	  reduction	  in	  cardiovascular	  risk	  615.	  
The	  observation	  that	  ACE-­‐Is	  appear	  to	  reduce	  CV	  events	  beyond	  that	  expected	  based	  on	  the	  
BP	   lowering	   effect	   has	   been	   hypothesised	   to	   be	   related	   to	   improvement	   in	   endothelial	  
function	   616.	   	   Aside	   from	   BP	   reduction,	   ACE-­‐Is	   reduce	   oxidative	   stress	   through	   decreased	  
Angiotensin	   II	   levels,	  which	   stimulate	  NAD	  oxidase,	   resulting	   in	  ROS	  production	   617	  and	  NO	  
inactivation.	  	  ARBs	  also	  reduce	  endothelial	  markers	  of	  inflammation	  and	  oxidative	  stress	  618.	  
	  
6.2.9. Methodological	  approaches	  to	  endothelial	  function	  assessment	  	  
Endothelial	   function	   may	   be	   measured	   through	   a	   variety	   of	   techniques.	   	   Nitric	   oxide	   is	   a	  
potent	   vasodilatory	   molecule	   produced	   by	   the	   endothelium.	   	   Production	   is	   impaired	   in	  
endothelial	   dysfunction.	   	   Techniques	   which	   stimulate	   NO	   production,	   coupled	   with	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subsequent	   measurement	   of	   the	   vasodilatory	   response,	   provide	   an	   indirect	   means	   of	  	  	  
determination	   of	   endothelial	   function:	   endothelium	   dependent	   vasodilatation.	   	   Several	  
modes	   of	   NO	   production	   stimulation	   are	   available.	   	   These	   form	   the	   basis	   for	   the	   various	  
methods	  of	  measurement	  of	  endothelium	  dependent	  vasodilatation.	  	  
Under	   conditions	   of	   a	   healthy	   endothelium,	   acetylcholine	   stimulates	   endothelial	   NO	  
production,	   resulting	   in	   vasodilatation.	   	   Conversely,	   in	   impaired	   endothelial	   function,	   NO	  
production	  is	  reduced	  and	  either	  an	  impaired	  vasodilatory	  response	  or	  vasoconstriction	  (due	  
to	  direct	  effects	  of	  ACh	  on	  the	  media	  smooth	  muscle)	  is	  observed.	  	  Responses	  to	  infusion	  of	  
vasoactive	  mediators	   permit	   assessment	   of	   dose	   response.	   	   This	  may	   be	   examined	   in	   the	  
coronary	   arteries	   with	   angiography	   (necessitating	   coronary	   catheterisation)	   or	   forearm	  
resistance	  vessels,	  using	  venous	  occlusion	  plethysmography	   (typically	  necessitating	  brachial	  
artery	  catheterisation).	  	  	  
Shear	   stress	   associated	  with	   increased	  blood	   flow	   stimulates	  NO	  production.	   	   This	  may	  be	  
measured	  non-­‐invasively	  using	   vascular	  ultrasound	  of	   the	  brachial	   artery.	   	   Increased	  blood	  
flow	   is	   produced	   as	   part	   of	   a	   reactive	   hyperaemia	   following	   transient	   occlusion	   of	   the	  
brachial	  artery.	   	  Flow-­‐mediated	  dilatation	  (FMD)	  of	  the	  brachial	  artery	  is	  a	  technique	  which	  
allows	   serial	  measurement	  over	   time,	   given	   its	   non-­‐invasive	  nature.	   	   It	   is	   highly	   correlated	  
with	  assessment	  of	  endothelial	   function	  by	   coronary	  angiography	   606.	   	  Brachial	   artery	  FMD	  
and	   FBF	   responses	   to	   infusion	   of	   vasoactive	   substances	   are	   less	   well	   correlated	   in	   some	  
populations	  619.	  	  This	  raises	  the	  possibility	  that	  there	  is	  differential	  regulation	  of	  vascular	  tone	  
in	  conduit	  compared	  with	  resistance	  (microvascular)	  vessels.	  	  	  
Inhibition	   of	  NO	   synthase	   (e.g.	  with	  NMMLA),	   permits	   assessment	   of	   basal	  NO	  production	  
levels,	  as	  an	  alternative	  assessment	  of	  endothelial	  function.	  	  
Brachial	  artery	  FMD	  determined	  through	  US	  and	  FBF	  responses	  to	  ACh	  determined	  through	  
plethysmography	   are	   the	   gold	   standard	  measurements	   for	   endothelial	   function.	  	  However,	  
each	   requires	   specific	   training	   and	   each	   method	   is	   dependent	   on	   operator	   skill	   and	  
experience.	   	   FBF,	   whilst	   correlating	   with	   coronary	   endothelial	   function	   measurement,	   is	  
invasive	  and	  unsuitable	  for	  serial	  measurement.	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Pulse	   amplitude	   tonometry	   reactive	   hyperaemia	   index	   (PAT-­‐RHI),	   represents	   an	   additional	  
means	  of	  non-­‐invasive	  measurement	  of	  endothelium	  dependent	  vasodilatation.	   	  Peripheral	  
arterial	   tone	   measurement	   permits	   assessment	   of	   endothelial	   function	   through	   a	  
standardised	   technique	   without	   need	   for	   extensive	   training	   and	   which	   is	   minimally	  
dependent	   on	   individual	   operator	   skill	   and	   experience.	  	   As	   such	   RHI	  may	   be	  more	   readily	  
applicable	  for	  assessment	  of	  endothelial	  function	  in	  clinical	  trials	  and	  practice	  620.	  	  Peripheral	  
arterial	   tone	   (PAT)	   measurement	   records	   changes	   in	   digital	   (index	   finger)	   pulse	   volume	  
during	   reactive	   hyperaemia,	   as	   a	   surrogate	   marker	   of	   microvascular	   endothelial	  
function.	  	  PAT	  measurements	  are	  performed	  simultaneously	  on	  both	  patient	  arms.	  	  A	  study	  
arm	  is	  subjected	  to	  an	  induced	  reactive	  hyperaemia	  through	  inflation	  of	  a	  brachial	  artery	  BP	  
cuff.	  	  The	  contralateral	  arm	  serves	  as	  a	  control,	  allowing	  correction	  for	  any	  systemic	  artefact	  
(e.g.	  variation	  in	  ambient	  temperature).	  	  RHI	  is	  highly	  correlated	  with	  ultrasound	  determined	  
brachial	   FMD	   621, 622	   and	   coronary	   endothelial	   function	   determined	   through	   ACh	  	  	  	  	  	  	  	  	  	  	  
infusion	  623.	  	  In	  addition,	  it	  is	  independently	  associated	  with	  numerous	  established	  CVRFs	  624.	  	  
	  
6.2.10. The	   relationship	   of	   uric	   acid	  &	   xanthine	   oxidase	   to	   arterial	   stiffness,	  
blood	  pressure	  and	  endothelial	  function	  
As	  discussed	  in	  section	  4.3,	  SUA	  levels	  are	  frequently	  elevated	  in	  the	  setting	  of	  hypertension	  
and	  are	  independently	  predictive	  of	  development	  of	  incident	  hypertension	  358.	  	  A	  mechanistic	  
basis	   for	  a	  direct	  effect	  of	  UA	  underlying	  this	  association	  has	  been	  described	  354, 355, 357	  and	  
reduction	   in	   UA	   through	   XOI	   has	   been	   shown	   to	   reduce	   brachial	   artery	   BP	   in	   certain	  
populations	   359.	   	  There	   is	   little	  data	  available	  relating	  UA	  to	  measures	  of	  central	  BP	  and	  no	  
studies	  have	  examined	  effects	  of	  UA	  reduction	  on	  central	  BP.	  	  	  
The	  relationship	  between	  SUA	  levels	  and	  arterial	  stiffness	  has	  been	  explored	  in	  a	  number	  of	  
studies.	   	   In	   the	   Korean	  Multi-­‐Rural	   Communities	   Cohort	   study	   367,	   Ba-­‐PWV	  was	   increased	  
amongst	   individual	  with	  hyperuricaemia,	  with	   a	  positive	   correlation	  and	   linear	   relationship	  
observed	   in	  both	  male	  and	   female	   individuals.	   	   Serum	  UA	  has	  also	  been	  related	   to	  arterial	  
stiffness	   in	   other	   populations,	   including	   post-­‐menopausal	   women	   360	   and	   Japanese	  
individuals	   361.	   	   In	   patients	   with	   prior	   stroke,	   SUA	   was	   observed	   to	   be	   independently	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associated	   with	   measures	   of	   arterial	   stiffness	   (PWV),	   which	   was	   increased	   in	   those	   with	  
higher	  SUA	  levels	  and	  SUA	  was	  independently	  associated	  with	  PWV	  on	  multivariate	  analysis.	  	  
Moreover,	   in	   this	   population,	   treatment	   with	   Allopurinol	   was	   associated	   with	   short	   term	  
evidence	  of	  reduced	  arterial	  stiffness,	  determined	  as	  AI	  362, 427.	  	  Other	  studies	  have	  failed	  to	  
identify	  an	  association	  between	  SUA	  and	  arterial	  stiffness	  and	  SUA	  363, 364.	  	  	  
As	   discussed	   above,	   arterial	   compliance	   has	   both	   structural	   and	   functional	   components.	  	  
Endothelial	   dysfunction	   is	   implicated	   in	   loss	   of	   arterial	   compliance	   and	   as	   discussed	   in	  
Chapter	  4,	  is	  itself	  associated	  with	  hyperuricaemia	  625.	  	  Conversely,	  UA	  is	  an	  antioxidant	  and	  
administration	   of	   exogenous	   UA	   improves	   endothelial	   function	   385.	   	   Thus,	   UA	   may	   not	  
represent	  the	  mediator	  of	  endothelial	  dysfunction	  but	  could	   instead	  be	  a	  surrogate	  marker	  
for	  alternative	  mechanisms	  of	  impaired	  function.	  
Beyond	  UA	  production,	   XO	   is	   likely	   to	   influence	  endothelial	   function	   in	   a	  number	  of	  ways.	  	  
There	  is	  evidence	  that	  Angiotensin	  II	  and	  XO	  activity	  are	  related	  377, 378	  and	  XO	  may	  represent	  
a	  source	  of	  NAD	  attributable	  oxidative	  stress	  376.	  	  	  	  Oxidative	  stress	  has	  been	  implicated	  as	  a	  
key	  factor	  in	  the	  development	  of	  endothelial	  dysfunction	  456.	  	  Xanthine	  oxidase	  is	  a	  source	  of	  
oxidative	   stress	   and	   consequently	   high	   levels	   of	   XO	   activity	   may	   confer	   endothelial	  
dysfunction,	  with	  elevated	  SUA	  representing	  a	  surrogate	  marker	  for	  this	  mechanism.	  
Oxidative	   stress	   is	   implicated	   in	   the	   pathogenesis	   of	   arterial	   stiffness	   626.	   	   Allopurinol	  
improves	   endothelial	   function,	   potentially	   through	   reduced	  oxidative	   stress	   299, 627	   and	  has	  
been	   shown	   to	   improve	   bioavailability	   of	   NO	   415.	   	   As	   such,	   XOI	   may	   well	   reduce	   arterial	  
stiffness	  through	  affecting	  its	  functional	  determinants.	  
Allopurinol	  has	  also	  been	  shown	  to	  reduce	  circulating	  markers	  of	  endothelial	  activation	  in	  the	  
short	  term.	  	  Allopurinol	  inhibits	  ICAM-­‐1	  expression	  in	  vitro	  628.	  In	  a	  small	  sample	  of	  patients	  
with	  acute	  ischaemic	  stroke,	  6	  weeks	  treatment	  with	  Allopurinol	  300mg	  daily	  was	  associated	  
with	  a	  reduction	  in	  circulating	  ICAM-­‐1	  compared	  with	  placebo	  414.	   	  The	  observed	  difference	  
was	  driven	  by	  a	  rise	  in	  ICAM-­‐1	  in	  the	  placebo	  group	  at	  6	  weeks.	  	  This	  finding,	  rather	  than	  a	  
reduction	  in	  the	  Allopurinol	  group	  and	  static	  placebo	  group	  level,	  may	  reflect	  attenuation	  of	  
an	  inflammatory	  response	  by	  treatment.	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6.3. Chapter	  7	  aims	  &	  hypothesis	  	  
CIMT	  represents	  a	  biomarker	  for	  systemic	  atherosclerotic	  burden	  and	  independently	  predicts	  
risk	  of	  subsequent	  vascular	  events.	  	  In	  some	  populations,	  the	  CIMT	  progression	  over	  time	  is	  
independently	   associated	   with	   modified	   cardiovascular	   risk	   and	   has	   been	   utilised	   as	   a	  
surrogate	   endpoint	   in	   clinical	   trials	   evaluating	   preventative	   strategies	   for	   cardiovascular	  
disease.	   	   Central	   BP,	   arterial	   stiffness	   and	   endothelial	   function	   each	   hold	   independent	  
predictive	   value	   for	   risk	   of	   subsequent	   vascular	   events	   and	   are	   implicated	   in	   the	  
development	  of	  atherosclerotic	  disease.	  	  	  
Although	   there	   are	   conflicting	   epidemiological	   associations,	   SUA	   has	   been	   independently	  
related	   to	   each	   of	   CIMT,	   arterial	   stiffness	   and	   endothelial	   dysfunction.	   	   There	   exists	   a	  
plausible	   mechanistic	   basis	   relating	   both	   UA	   and	   XO	   mediated	   oxidative	   stress	   to	   the	  
development	   of	   atherosclerosis,	   arterial	   stiffness,	   elevated	   central	   BP	   and	   endothelial	  
dysfunction.	  	  	  
As	   detailed	   in	   Chapter	   5,	   studies	   examining	   XO	   inhibition	   have	   typically	   been	   of	   limited	  
duration.	  	  No	  clinical	  data	  have	  been	  published	  regarding	  treatment	  effects	  on	  central	  BP,	  or	  
measures	   of	   atherosclerosis.	   	   There	   is	   a	   relative	   paucity	   of	   data	   for	   the	   stroke	   patient	  
population,	   with	   studies	   limited	   to	   brief	   interventions	   in	   small	   patient	   samples.	   	   The	   only	  
endpoints	   to	   have	   been	   examined	   in	   this	   population	   have	   been	   cerebrovascular	   reactivity	  
and	  AI.	  	  
In	  Chapter	  7,	  the	  details	  of	  a	  study	  which	  sought	  to	  address	  this	  evidence	  gap	  are	  detailed.	  	  A	  
randomised	   double	   blind	   placebo	   controlled	   study,	   concerning	   the	   effect	   of	   one	   years’	  
treatment	  with	  Allopurinol	  300mg	  daily,	  in	  a	  population	  with	  recent	  ischaemic	  stroke	  or	  TIA,	  
was	   performed,	   with	   the	   hypothesis	   that	   treatment	   with	   allopurinol	   would	   reduce	   CIMT	  
progression,	  arterial	  stiffness	  and	  in	  turn	  central	  BP	  and	  would	  improve	  endothelial	  function.	  	  
This	  study	  would	  demonstrate	  feasibility	  of	  CIMT	  measurement	   in	  the	   local	  population	  and	  
provide	  Pilot	  data	  to	  inform	  the	  design	  of	  a	  larger	  future	  study	  examining	  this	  endpoint.	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Chapter	  7 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
The	   effect	   of	   allopurinol	   on	   carotid	   intima-­‐media	  
thickness,	   arterial	   haemodynamics	   and	   endothelial	  
function	   in	  patients	  with	   recent	   ischaemic	  stroke	  and	  
TIA:	  A	  randomised	  controlled	  trial	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7.1. Introduction	  
Despite	   secondary	   preventative	   measures,	   recurrent	   stroke	   events	   remain	   common;	  
approximately	   13%	   of	   participants	   suffered	   recurrent	   stroke	   in	   recent	   secondary	  
preventative	  trials	  115	  and	  40%	  of	  those	  with	  TIA	  experienced	  recurrent	  cardiovascular	  events	  
during	  long-­‐term	  follow	  up	  629.	  	  Novel	  strategies	  are	  needed	  to	  reduce	  this	  burden.	  
Elevated	   SUA	   is	   associated	   with	   increased	   risk	   of	   cardiovascular	   disease	   300	   and	   adverse	  
outcomes	   following	   ischaemic	  stroke	   330, 394.	   	  Allopurinol	   reduces	  SUA	  through	   inhibition	  of	  
the	  xanthine	  oxidoreductase	  (XO)	  enzymatic	  system,	  which	  is	  responsible	  for	  the	  final	  steps	  
in	  purine	  metabolism.	  	  Further,	  XO	  inhibition	  reduces	  the	  ROS	  formed	  through	  action	  of	  the	  
enzyme	   and	   may	   thus	   reduce	   vascular	   oxidative	   stress,	   which	   is	   implicated	   in	  	  	  	  	  
atherogenesis	  376.	  	  Allopurinol	  may	  therefore	  provide	  benefits	  in	  addition	  to	  or	  independent	  
of	  its	  effects	  on	  UA	  299.	  	  
Systematic	   review	   and	  meta-­‐analysis	   of	   studies	   examining	   XO	   inhibition	   has	   demonstrated	  
beneficial	   effects	   on	   endothelial	   function	   and	   other	   surrogate	  measures	   of	   cardiovascular	  
function	  627.	  	  Further,	  following	  stroke,	  allopurinol	  has	  been	  reported	  to	  reduce	  both	  arterial	  
stiffness	  427	  and	  markers	  of	  inflammation	  414	  and	  also	  increases	  NO	  bioavailability	  in	  patients	  
with	  type	  2	  diabetes	  415.	  	  More	  recently,	  treatment	  with	  high	  dose	  allopurinol	  was	  found	  to	  
induce	  regression	  in	  left	  ventricular	  hypertrophy	  630	  and	  improve	  exercise	  capacity	  in	  patients	  
with	   CAD	   439.	   	   However,	   studies	   examining	   XO	   inhibition	   have	   typically	   been	   of	   limited	  
duration	  and	  there	  are	  no	  prolonged	  studies	  in	  the	  stroke	  patient	  population,	  or	  on	  measures	  
of	  atherosclerosis.	  
We	  sought	   to	  address	   this	  evidence	  gap	  by	  performing	  a	   randomised	  double	  blind	  placebo	  
controlled	   study	   with	   a	   one	   year	   treatment	   duration,	   which	   examined	   the	   effect	   of	  
allopurinol	  300mg	  daily	  on	  change	   in	  central	  BP,	  arterial	   stiffness,	  endothelial	   function	  and	  
circulating	  markers	  of	   low	  grade	   inflammation	  and	  also	  provided	  pilot	  data	   concerning	   the	  






This	   study	  was	   a	   randomised	   double	   blind,	   placebo	   controlled	   trial,	   comparing	   allopurinol	  
300mg	  once	  daily	  with	  matched	  placebo	  in	  an	  adult	  population	  with	  recent	  ischaemic	  stroke	  
or	  TIA.	  	  Patients	  were	  followed	  up	  for	  12	  months	  and	  underwent	  repeated	  measurement	  of	  




Patients	  aged	  over	  18	  years,	  both	  males	  and	  females,	  with	  ischaemic	  stroke	  or	  TIA,	  within	  the	  
past	   year,	   were	   eligible	   for	   inclusion.	   	   Ischaemic	   stroke	   and	   TIA	   (ICD	   Classification	   Code	  	  
I63.0-­‐9	  and	  G45.0-­‐1)	  were	  each	  defined	  as	  suggestive	  clinical	  features	  which	  can	  be	  classified	  
according	   to	   the	   Oxfordshire	   Community	   Stroke	   Project	   classification	   and	   which	   had	   a	  
presumed	  vascular	  occlusive	  cause.	   	  Principal	  exclusion	  criteria	  were	  >70%	  extra-­‐cranial	   ICA	  
stenosis,	  significant	  co-­‐morbidity	  likely	  to	  cause	  death	  within	  12	  months	  and	  either	  indication	  
for,	   or	   contra-­‐indication	   to	   (including	   estimated	   glomerular	   filtration	   rate	   <	   50	   ml/min),	  
administration	  of	  allopurinol.	  	  Exclusion	  criteria	  were	  chosen	  to	  minimise	  the	  potential	  risks	  
of	   allopurinol	   treatment	   and	   to	   ensure	   carotid	   IMT	   measurements	   were	   not	   affected	   by	  
intrinsic	  carotid	  disease.	  	  Full	  details	  of	  inclusion	  &	  exclusion	  criteria	  are	  detailed	  in	  table	  7-­‐1.	  	  
Patients	  were	  identified	  during	  admission	  or	  out-­‐patient	  attendance	  at	  the	  Acute	  Stroke	  Unit	  
at	   the	   Western	   Infirmary,	   Glasgow.	   	   All	   participants	   were	   provided	   with	   a	   study	   patient	  
information	   sheet,	   given	   the	   opportunity	   to	   ask	   questions	   and	   provided	  written	   informed	  
consent	   to	   participate.	   	   The	   study	   was	   approved	   by	   the	   West	   Medical	   research	   ethics	  




Table	  7-­‐1:	  	  Principal	  eligibility	  criteria	  
Inclusion	  Criteria	   1.	  Ischaemic	  Stroke	  (including	  TIA,	  where	  symptoms	  last	  less	  
than	  24	  hours).	  
2.	  Brain	  imaging	  not	  suggestive	  of	  an	  alternative	  diagnosis.	  	  
3.	  Randomisation	  within	  one	  year	  of	  ictus.	  
Exclusion	  Criteria	   1.	  >70%	  extra-­‐cranial	  internal	  carotid	  artery	  stenosis.	  
2.	  Significant	  co-­‐morbidity	  or	  frailty	  likely	  to	  cause	  death	  
within	  12	  months	  or	  likely	  to	  make	  adherence	  to	  study	  
protocol	  difficult	  for	  participant.	  
3.	  Contra-­‐indication	  to	  or	  indication	  for	  administration	  of	  
allopurinol	  (as	  detailed	  in	  Summary	  of	  Product	  
Characteristics).	  
4.	  Concurrent	  azathioprine	  or	  6-­‐mercaptopurine	  therapy.	  
5.	  Significant	  hepatic	  impairment	  (defined	  as	  serum	  bilirubin,	  
AST	  or	  ALT	  greater	  than	  three	  times	  upper	  limit	  of	  normal	  
(ULN)).	  
6.	  Estimated	  Glomerular	  Filtration	  Rate	  <	  50	  mls/min	  
7.	  Cognitive	  impairment	  deemed	  sufficient	  to	  compromise	  
capacity	  to	  consent	  or	  to	  comply	  with	  the	  protocol.	  




A	  sample	  size	  of	  40	  participants	  per	  group	  was	  studied.	  	  This	  sample	  provided	  80%	  power	  to	  
detect	   a	   6	   mmHg	   difference	   in	   central	   BP	   427	   (assumed	   SD	   10	   mmHg)	   and	   80%	   and	   90%	  
power	   to	   replicate	   in	   prolonged	   follow	   up,	   respectively,	   previously	   reported	   change	   in	  
augmentation	  index	  (REF	  Khan	  2008)	  and	  circulating	  markers	  of	  vascular	  inflammation	  (Muir	  
2008	   REF)	   following	   Allopurinol	   therapy	   after	   stroke.	   	   The	   primary	   study	   endpoint	   was	  
change	  in	  CIMT	  at	  12	  months.	  	  Based	  on	  a	  mean	  annualised	  CIMT	  progression	  rate	  of	  0.0176	  
mm	  (95%	  CI	  0.0149-­‐0.023,	  SD	  0.05),	  mean	  baseline	  CIMT	  of	  approximately	  1	  mm	  [13,14]	  and	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a	   treatment	   effect	   approximately	   half	   that	   observed	   with	   Statin	   therapy	   [14],	   253	  
participants	   in	   each	   treatment	   group,	   followed	   for	   2	   years,	   would	   provide	   80%	   power	   to	  
detect	  a	  0.03	  mm	  difference	  in	  IMT	  progression	  (alpha	  of	  0.05).	  	  This	  study	  lacked	  power	  to	  
exclude	  a	  potentially	  meaningful	  treatment	  effect	  for	  this	  endpoint	  and	  represented	  a	  pilot	  
study,	  designed	  to	  allow	  us	  to	  confirm	  these	  assumptions	  for	  a	  larger	  CIMT	  trial	  and	  provide	  
preliminary	  data	  whilst	  specifically	  addressing	  important	  pre-­‐specified	  secondary	  endpoints."	  
	  
Randomisation,	  study	  intervention	  &	  masking	  
Enrolled	  participants	  were	  randomised,	  via	  an	  interactive	  voice	  response	  system	  (Robertson	  
Centre	  for	  Biostatistics,	  University	  of	  Glasgow),	  to	  receive	  either	  300mg	  of	  allopurinol	  orally	  
once	  daily	  or	  matched	  placebo,	  on	  a	  1:1	  basis.	   	   Investigators	  and	  patients	  were	  blinded	   to	  
treatment	   allocation.	   	   Allopurinol	   tablets	   were	   manufactured	   and	   over	   encapsulated	   by	  
Bilcare	  Ltd.	  	  Dosing	  began	  on	  the	  day	  following	  baseline	  assessment	  and	  randomisation	  and	  
continued	   for	   one	   year.	   	   Concordance	   with	   therapy	   was	   assessed	   by	   questioning	   and	   pill	  
counts.	  Investigators	  were	  blinded	  to	  SUA	  levels	  to	  avoid	  potential	  inference	  of	  study	  group	  
allocation.	  	  The	  randomisation	  code	  was	  not	  broken	  until	  all	  follow	  up	  was	  complete	  and	  all	  
data	  were	  prepared	  for	  analysis.	  	  
	  
Study	  follow	  up	  visits	  and	  endpoint	  data	  collection	  
All	   study	   procedures	   were	   performed	   in	   the	   Acute	   Stroke	   Unit	   of	   the	  Western	   Infirmary,	  
Glasgow.	   	   Patients	   attended	   study	   visits	   at	   baseline	   (randomisation),	   1,	   3,	   6	  &	  12	  months.	  
Patients	  attended	   following	  an	  overnight	   fast	  and	  were	  asked	   to	  avoid	  caffeine,	   tobacco	  &	  
alcohol	   for	   the	   preceding	   12	   hours.	   	   At	   each	   visit	   a	   clinical	   examination	   including	   brachial	  
artery	  BP	  was	  performed,	  together	  with	  blood	  sampling	  and	  adverse	  event	  review.	  	  Brachial	  
artery	   BP	   measurements	   were	   performed	   [using	   a	   semi-­‐automated	   sphygmomanometer	  
(Critikon	  DINAMAP)].	  Following	  15-­‐minutes	  supine	  rest,	  three	  BP	  measurements	  were	  taken	  
at	  1-­‐minute	   intervals	  and	  the	  mean	  of	   these	  was	  recorded.	   	  Blood	  testing	   included	  routine	  
haematological	  and	  biochemical	  parameters,	  including	  full	  blood	  count,	  urea	  &	  electrolytes,	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liver	   function	  tests	  and	  uric	  acid.	   	  Venepuncture	  was	  performed	  with	  a	  19G	  (green	  needle)	  
vacutainer	   system	   from	   the	   antecubital	   fossa	   (where	   possible).	   	   An	   EDTA	   tube,	   serum	   gel	  
tube	  and	  fluoride/oxalate	  tube	  were	  collected	  (~	  8	  mls	  in	  total)	  at	  each	  study	  visit,	  including	  
the	   safety	   visits.	   Samples	   were	   sent	   directly	   to	   the	   local	   NHS	   laboratory	   for	   analysis.	   	   All	  
blood	  results	  were	  reviewed	  within	  48	  hours	  of	  being	  taken	  by	  an	  investigator	  if	  abnormal.	  
All	  study	  visit	  data	  was	  recorded	  in	  the	  first	  instance	  to	  a	  paper	  based	  CRF,	  which	  was	  stored	  
in	  a	  secure	  fire	  proof	  cabinet	  in	  the	  Western	  Infirmary	  Stroke	  Unit.	  	  During	  the	  course	  of	  the	  
study,	  a	  web	  based	  electronic	  CRF	  was	  developed	  in	  conjunction	  with	  the	  Robertson	  Centre	  
for	   Biostatistics	   (RCB),	   University	   of	   Glasgow.	   	   Data	   from	   the	   paper	   based	   CRFs	   was	  
subsequently	   transcribed	   to	   the	   electronic	   system	   once	   this	   completed	   construction,	   was	  
tested	  and	  subsequently	  became	  live.	  
	  
7.2.1. CIMT	  measurement	  
Carotid	  artery	  intima-­‐media	  thickness	  (CIMT)	  ultrasound	  (US)	  scanning	  protocol	  
A	   7.5MHz	   Zonare	   Z.one	   Smart	   Cart	   annular	   array	   ultrasound	   system	   and	   L8-­‐3	   US	   probe	  
(Zonare	   Medical	   Systems,	   CA	   USA)	   were	   used	   for	   carotid	   US	   CIMT	   image	   acquisition.	  	  	  
Longitudinal	  carotid	  views	  were	  captured	  using	  B	  Mode	  ultrasound.	  	  This	  technique	  permits	  
measurement	  of	  IMT	  across	  an	  AOI,	  for	  example	  the	  distal	  10mm	  of	  the	  CCA.	  	  The	  maximum	  
IMT	  within	  the	  AOI	  and	  the	  mean	  IMT	  for	  the	  length	  of	  the	  AOI	  may	  then	  be	  measured	  during	  
offline	   analysis.	   	   This	   affords	   additional	   information	   and	   greater	   reproducibility	   of	  
measurement	  than	  M	  mode	  US,	  which	  permits	  measurement	  of	  CIMT	  at	  only	  a	  single	  point	  
within	  the	  vessel	  520.	  
The	   scanning	   protocol	   used	   was	   consistent	   with	   that	   recommended	   in	   contemporary	  
guidelines,	   at	   the	   time	   of	   the	   study	   protocol	   approval	   468, 471, 520	   and	   subsequently	   551,	   to	  
permit	   derivation	   of	   both	  mean	   common	  CIMT	   and	  mean	  maximum	  CIMT	  measurements.	  	  
IMT	  measurement	  was	  performed	  according	  to	  the	  same	  protocol	  employed	  in	  the	  PERFORM	  
study,	   which	   included	   CIMT	   as	   a	   surrogate	   measure	   of	   outcome	   631.	   	   All	   IMT	   scans	   were	  
performed	  by	  an	  experienced	  sonographer	  (KS),	  blinded	  to	  study	  treatment	  allocation,	  with	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recent	   accredited	   experience	   in	   CIMT	   measurement	   during	   the	   conduct	   of	   the	   PERFORM	  
study.	  	  	  
Images	   delineating	   CIMT	   were	   recorded	   within	   three	   separate	   AOIs:	   CCA	   (10mm	   length	  
proximal	   to	   carotid	   bulb);	   carotid	   bulb	   (10mm	   length	   proximal	   to	   flow	   divider);	   internal	  
carotid,	   10mm	  distal	   to	   flow	  divider	   468, 471, 520.	   For	   each	   of	   these	  AOIs,	   ultrasound	   images	  
were	   captured	  at	   each	  of	   three	  pre-­‐specified	   angles,	   encompassing	   a	   60	  degree	   arc:	   180⁰,	  
150⁰	  and	  120⁰	  (right	  carotid)	  and	  180⁰,	  210⁰	  and	  240⁰	  (left	  carotid).	  	  A	  Meijer	  carotid	  arc	  was	  
used	  to	  standardise	  the	  acquisition	  of	  images.	  	  Images	  were	  obtained	  to	  include	  both	  the	  far	  
and	  near	  wall	  of	  the	  artery	  for	  each	  angle.	  	  Images	  were	  recorded	  for	  both	  the	  right	  and	  left	  
carotid	  arteries.	  	  Thus,	  CIMT	  was	  imaged	  at	  a	  total	  of	  12	  sites	  within	  the	  right	  and	  left	  carotid	  
arteries	  and	  from	  3	  separate	  angles	  at	  each	  of	   these	  sites,	  allowing	  up	  to	  36	  points	  of	   IMT	  
measurement.	  	  
Several	   seconds	   of	   IMT	   images	   were	   recorded	   with	   the	   Zonare	   system.	   	   A	   still	   image	  
synchronised	  with	   ventricular	   systole	  was	   then	   saved	   in	   digital	   format	   (DICOM)	   by	   the	  US	  
device	  for	  each	  CIMT	  point	  of	  measurement.	  	  The	  study	  image	  was	  identified	  by	  the	  date	  of	  
examination,	   participant	   study	   number	   and	   study	   visit	   month	   number.	   	   Each	   image	   was	  
additionally	   labelled	   according	   to	   the	   arterial	   site	   being	   imaged	   and	   the	   depth	   of	   US	  
measurement.	  
	  
Carotid	  artery	  intima-­‐media	  thickness	  (CIMT)	  ultrasound	  (US)	  off-­‐line	  image	  analysis	  
The	  CIMT	  US	  image	  DICOM	  files	  acquired	  were	  exported	  to	  an	  encrypted	  domain	  on	  a	  secure	  
NHS	   computer	   in	   the	   Acute	   Stroke	  Unit	   at	   the	   Glasgow	  Western	   Infirmary	   Hospital.	   	   Files	  
were	  then	  converted	  to	  TIFF	  format	  to	  permit	  off	   line	   image	  analysis,	  as	  recommended	  for	  
the	  purposes	  of	  deriving	  CIMT	  measurement	  to	  improve	  precision	  and	  reproducibility	  471.	  	  	  
Many	  of	  the	  large	  epidemiological	  studies	  which	  reported	  an	  association	  between	  CIMT	  and	  
CV	  outcomes	  employed	  manual	   reading	  techniques	   for	  CIMT	  measurement.	   	  Subsequently,	  
the	   use	   of	   automated	   and	   semi-­‐automated	   edge	   detection	   software	   has	   facilitated	   wider	  
application	   of	   CIMT	   measurement	   as	   it	   reduces	   the	   time	   required	   to	   analyse	   individual	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scans	   520, 551.	   	   Moreover,	   precision	   and	   reproducibility	   of	   CIMT	   measurement	   are	   both	  
demonstrably	   improved	   with	   this	   approach	   632-­‐634.	   	   Current	   guidelines	   reflect	   this	   and	  
recommend	  the	  use	  of	  semi-­‐automated	  edge	  detection	  system	  that	  permit	  the	  reader	  to	  edit	  
tracked	  borders	   if	   the	  application	  of	   the	   software	  algorithm	  to	  a	  particular	   image	  provides	  
suboptimal	  border	  identification	  520, 551.	  
Image-­‐Pro	  Plus,	  Version	  6.2,	  software	  (Media	  Cybernetics,	  USA)	  was	  used	  for	  CIMT	  US	  image	  
analysis.	   	   This	   software	  has	  previously	  been	  used	   in	   large	  RCTs	  which	   included	  CIMT	  as	  an	  
outcome	  measure	  533.	  
US	   images	   were	   recorded	   at	   a	  measurement	   depth	   of	   either	   4	   cm	   or	   5	   cm	   (according	   to	  
individual	   patient	   arterial	   topography).	   	   The	   Image-­‐Pro	   software	   was	   calibrated	   to	  
accommodate	   either	   TIFF	   file	   resolution,	   with	   the	   separate	   calibrations	   utilized	   for	   CIMT	  
measurement	   according	   to	   the	   depth	   of	   the	   US	   image	   acquired.	   	   The	   level	   of	   pixelar	  
resolution	   (0.0789	   mm	   /	   pixel	   &	   0.0985	   mm	   /	   pixel	   for	   4	   cm	   5cm	   depth	   US	   images,	  
respectively),	   compares	   favourably	   with	   that	   recommended	   in	   guidelines	   and	   reported	   in	  
many	  of	  the	  large	  epidemiological	  studies	  520.	  
Images	   were	   reviewed	   for	   technical	   adequacy	   for	   CIMT	   measurement.	   	   Provided	   the	  
available	  image	  displayed	  the	  vascular	  wall	  as	  a	  regular	  pattern	  that	  correlates	  with	  arterial	  
anatomical	   layers,	   a	  CIMT	  measurement	  was	   recorded.	   	  CIMT	  measurement	  was	  based	  on	  
the	  10	  mm	  AOIs	  as	  defined	  above.	  	  If	  vessel	  tortuosity	  prevented	  a	  full	  10mm	  measurement,	  
CIMT	  was	  measured	  for	  the	  maximum	  available	  length	  of	  the	  particular	  AOI.	  	  
Scans	   were	   analysed	   by	   batch	   reading	   (comprising	   ten	   scans	   per	   batch),	   in	   a	   randomised	  
order.	  	  This	  approach	  was	  adopted	  to	  avoid	  theoretical	  change	  over	  time	  in	  CIMT	  estimates	  
due	  to	  adapted	  reading	  technique	  471.	  	  	  
Blood-­‐intima	   and	   media-­‐adventitia	   boundaries	   were	   marked	   with	   a	   calliper	   and	   semi-­‐
automated	  analysis	  of	  the	  CIMT	  was	  then	  performed	  using	  the	  leading	  edge	  principle.	  	  	  
For	   each	   AOI,	   callipers	  were	   applied	   at	   the	   protocol	   defined	   AOI	   limiting	   boundary	   to	   the	  
leading	  edge	  of	  each	  of	  the	  four	  interfaces	  of	  interest:	  adventitia	  –	  media	  (far	  wall);	  intima	  –	  
lumen	   (far	  wall);	   lumen	  –	   intima	   (near	  wall);	  media	  –	  adventitia	   (near	  wall).	   	  Based	  on	   the	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leading	   edge	   principle,	   the	   auto-­‐edging	   software	   delineated	   (based	   on	   an	   algorithm	  
identifying	   the	   steepest	   point	   of	   inflection	   on	   a	   luminescence	   scale	   applied	   to	   these	  
boundaries),	   the	  boundaries	  between	   the	   tissue	  planes	  of	   interest	   for	   the	  AOI.	   	  The	   image	  
reader	   had	   the	   opportunity	   to	   manually	   edit	   the	   delineated	   boundary	   if	   the	   automated	  
measurement	   deviated	   clearly	   deviated	   from	   the	   interface	   boundary	   (typically	   due	   to	  
artefact	  acoustic	  shadowing	  within	  the	  US	  image).	  	  	  
When	  observed	  within	  the	  AOI,	  carotid	  plaque	  was	   included	  in	  the	  delineated	  boundary,	   in	  
keeping	  with	   current	   recommendations	   520.	   	   This	   afforded	   the	  opportunity	   to	   describe	   the	  
proportion	  of	  patients	  with	  carotid	  plaque	  based	  on	  absolute	  measurements	  and	  to	  perform	  
statistical	   analysis	  both	  with	   inclusion	  of	  plaque	  as	  part	  of	   the	   IMT	  continuous	  variable,	   as	  
recommended	   by	   some	   520	   and	   with	   these	   measurements	   excluded	   based	   on	   absolute	  
measurements,	  as	  suggested	  by	  others	  468.	  
Following	   boundary	   delineation,	   the	   software	   automatically	   calculated	   both	   the	  maximum	  
distance	   between	   interfaces	   and	   the	   mean	   distance	   between	   interfaces	   for	   the	   available	  
length	  of	  the	  AOI	  (up	  to	  10mm).	  	  Accordingly,	  both	  a	  maximum	  CIMT	  and	  a	  mean	  CIMT	  was	  
generated	  for	  each	  AOI	  (up	  to	  36	  measurements	  for	  each	  in	  total).	  	  The	  length	  of	  the	  AOI	  for	  
which	   the	  mean	  CIMT	  was	  calculated	  was	  also	   recorded,	   to	  permit	  calculation	  of	  weighted	  
means	  in	  the	  event	  of	  the	  AOI	  being	  <	  10mm	  for	  any	  points	  of	  measurement.	  
Mean	   and	   maximum	   CIMT	   measurements,	   together	   with	   length	   of	   the	   AOI	   were	  
automatically	  exported	  by	  the	  Image-­‐Pro	  Plus	  software	  to	  a	  Microsoft	  excel	  file,	  labelled	  with	  
the	  patient	   subject	  number	  and	  visit	  month	  number.	   	   These	   files	  were	   then	   transferred	   to	  
the	  Robertson	  Centre	  for	  Biostatistics	  for	  storage	  and	  subsequent	  statistical	  analysis.	  
	  
CIMT	  endpoint	  derivation	  
The	  mean	  maximum	  CIMT	  was	  derived	  as	   the	  arithmetic	  mean	  of	   the	  maximum	  IMT	  value	  
measured	   at	   each	   of	   the	   potential	   36	   points	   of	   CIMT	   measurement.	   	   I.e.	   a	   composite	  
measure	  based	  on	  CIMT	  measurements	  at	  each	  of	  common,	  bulb	  and	   internal	  artery	  sites.	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This	   definition	   is	   consistent	   with	   current	   guidelines	   for	   the	   derivation	   of	   mean	   maximum	  
CIMT	  471, 520, 551.	  
The	  mean	  common	  CIMT	  was	  calculated	  as	  a	  weighted	  mean,	  based	  on	  the	  measurements	  
obtained	   from	  both	   the	   right	   and	   left	   common	   carotid	  AOIs	   at	   each	  of	   the	   three	  different	  
measurement	   angles.	   	   Weighting	   was	   according	   to	   the	   length	   of	   common	   carotid	   IMT	  
segment	   available	   for	   each	   of	   the	   specified	   AOI	   measurements	   (up	   to	   100	   mm	   of	   the	  
common	   segment	   proximal	   to	   the	   carotid	   bulb).	   	   In	   keeping	  with	   recent	   guidelines,	  mean	  
common	  CIMT	  derivation	  was	  based	  on	  measurement	  of	  the	  far	  wall	  only	  520, 550, 551.	   	  Mean	  
maximum	   and	   mean	   common	   CIMT	   derivation	   was	   performed	   by	   statisticians	   at	   RCB,	  
University	  of	  Glasgow	  (HM,	  AM).	  
	  
7.2.2. BP-­‐PWA	  measurement	  	  
Blood	  pressure	  pulse	  wave	  analysis	  scanning	  protocol	  
Patients	  attended	  for	  BP-­‐PWA	  following	  an	  overnight	  fast	  and	  were	  asked	  to	  avoid	  caffeine,	  
tobacco	   &	   alcohol	   for	   the	   preceding	   12	   hours.	   	   Following	   15-­‐minutes	   supine	   rest,	   three	  
brachial	   BP	   measurements	   were	   taken	   at	   1-­‐minute	   intervals,	   using	   a	   semi-­‐automated	  
sphygmomanometer	  (Critikon	  DINAMAP)	  and	  the	  mean	  of	  these	  was	  recorded.	  	  	  
BP-­‐PWA	  was	  performed	  using	  the	  Sphygmocor®	  apparatus	  (PWV	  Medical,	  Sydney	  Australia).	  	  
This	  utilizes	  applanation	  tonometry,	  a	  non-­‐invasive	  technique	  permitting	  high-­‐fidelity	  analysis	  
of	   peripheral	   and	   central	   pulse	  waves	   564, 576.	   	   A	   hand-­‐held	   tonometer	   (Millar	   instruments,	  
Houston	  USA)	  is	  applied	  to	  a	  peripheral	  (radial)	  artery	  site,	  flattening	  the	  wall	  of	  the	  artery.	  	  
This	   eliminates	   tangential	   pressures	   and	   allows	   the	   pressure	   waveform	   within	   the	   radial	  
artery	   to	   be	   recorded	   by	   the	   tonometer	   piezo-­‐resistive	   pressure	   transducer	   (Miller	  
Instruments,	   Houston	  USA)	   564, 576.	   	   Three	   separate	   samples	   of	   right	   radial	   artery	   BP	   pulse	  
waveforms,	  each	  of	  10	   seconds	  duration,	  were	  obtained	  using	   the	  Sphygmocor	   tonometer	  
apparatus.	  	  	  
The	  Sphygmocor	  software	  automatically	  applies	  a	  validated	  generalized	  transfer	  function	  to	  
the	   obtained	   radial	   waveform,	   facilitating	   derivation	   of	   the	   central	   aortic	   BP	   pulse	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waveform	   576.	   	   The	   brachial	   artery	   BP	   was	   utilized	   for	   the	   purpose	   of	   radial	   artery	   BP	  
calibration.	   	   Analysis	   of	   the	   central	   BP	   waveform	   permits	   non-­‐invasive	   determination	   of	  
central	  aortic	  BP	  pulse	  (based	  on	  wave	  amplitude)	  and	  arterial	  stiffness,	  including	  AI	  (based	  
on	   wave	   characteristics	   including	   contour,	   timing	   &	   augmentation	   of	   reflected	   BP	   pulse	  
waves)	  576.	  	  Augmentation	  index	  was	  calculated	  as	  the	  ratio	  of	  difference	  between	  the	  early	  
&	   late	   central	   systolic	   pressure	   peaks	   to	   the	   central	   pulse	   pressure.	   	   This	   method	   of	  
performing	  PWA	  has	  been	  found	  to	  be	  reproducible	  in	  a	  variety	  of	  populations	  579	  and	  is	  an	  
accepted	  technique	  for	  the	  measurement	  of	  arterial	  stiffness	  635.	  
For	   each	   patient	   study	   visit,	   BP-­‐PWA	  measurements	   were	   performed	   in	   triplicate.	   	   These	  
measurement	   data	   were	   entered	   to	   a	   paper	   CRF	   and	   subsequently	   transcribed	   to	   the	  
electronic	   CRF	   and	   stored	   by	   the	   RCB,	   University	   of	   Glasgow	   for	   subsequent	   statistical	  
analysis.	  	  The	  mean	  of	  the	  three	  PWA	  measurements	  was	  used	  in	  analysis.	  	  	  
	  
Blood	  pressure	  pulse	  wave	  velocity	  scanning	  protocol	  
Brachial	  artery	  PWV	  was	  measured	  using	  the	  Sphygmocor®	  apparatus	  (PWV	  Medical,	  Sydney	  
Australia).	   	   Whilst	   an	   electrocardiogram	   (ECG)	   was	   simultaneously	   recorded,	   applanation	  
tonometry,	   using	   a	   hand-­‐held	   piezo-­‐resistive	   pressure	   transducer	   (Miller	   Instruments,	  
Houston	  USA),	  was	  used	  to	  sequentially	  record,	  a	  short	  time	  apart,	  radial	  and	  carotid	  artery	  
waveform	  samples	  of	  10-­‐second	  duration.	   	  The	  tonometer	   is	  applied	  to	  a	  peripheral	  artery	  
site,	   flattening	   the	  wall	   of	   the	   artery.	   	   This	   eliminates	   tangential	   pressures	   and	   allows	   the	  
pressure	  waveform	  within	  the	  artery	  to	  be	  recorded.	  	  The	  transit	  time	  between	  arterial	  sites	  
is	   determined	   by	   gating	   the	   separate	   recordings	   to	   the	   R	  wave	   of	   the	   ECG.	   	   The	   distance	  
between	   the	   two	   arterial	   sites	   was	   estimated	   using	   surface	   measurements.	   	   PWV	   was	  
calculated	  as	  the	  distance	  between	  the	  two	  sites	  divided	  by	  the	  difference	  in	  transit	  time	  for	  
the	   pressure	   pulse	  wave	   to	   reach	   the	   two	   sites.	   	   PWV	   is	   expressed	   in	  metres	   per	   second	  
(m/s).	   	  This	  method	  of	  assessing	  PWV	  has	  been	  found	  to	  be	  reproducible	  579.	   	  The	  mean	  of	  
three	  PWV	  measurements	  recorded	  at	  each	  visit,	  for	  the	  right	  arm,	  was	  used	  in	  the	  analysis.	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7.2.3. Measurement	   of	   peripheral	   arterial	   tonometry	   reactive	   hyperaemia	  
index	  	  
The	   first	   15	   patients	   enrolled	   to	   the	   study	   did	   not	   undergo	   PAT	   measurement	   as	   PAT	  
measurement	   represented	   a	   substantial	   amendment	   to	   the	   study	   protocol	   which	   was	  
implemented	  subsequent	  to	  the	  recruitment	  of	  these	  initial	  15	  patients.	  	  
Patients	  attended	  for	  PAT-­‐RHI	  following	  an	  overnight	  fast	  and	  were	  asked	  to	  avoid	  caffeine,	  
tobacco	   &	   alcohol	   for	   the	   preceding	   12	   hours.	  	   Following	   15-­‐minutes	   supine	   rest,	   three	  
brachial	   BP	   measurements	   were	   taken	   at	   1-­‐minute	   intervals,	   using	   a	   semi-­‐automated	  
sphygmomanometer	  (Critikon	  DINAMAP)	  and	  the	  mean	  of	  these	  was	  recorded.	  	  	  
PAT	  analysis	  was	  performed	  in	  a	  room	  with	  controlled	  temperature	  (23	  degrees	  Celsius),	  to	  
allow	   acclimatisation	   and	   peripheral	   vasodilatation	   /	   constriction	   attributable	   to	   outdoor	  
seasonal	   temperature	   variation	   to	   resolve.	  	   PAT	   recordings	   were	   performed	   using	   the	  
EndoPAT	  2000	  device	   (Itamar	  medical,	  Caesarea,	   Israel).	  	  Pneumatic	  PAT	  probes	  are	  placed	  
on	   the	   index	   finger	  of	  each	  hand.	  	   Following	  probe	   inflation,	   these	  probes	  exert	   a	  uniform	  
pressure	   (70	  mmHg)	   to	   the	   finger	   tip.	  	   This	   pressure	   prevents	   venous	   distension	   of	   finger	  
volume	  but	  permit	  distension	  attributable	  to	  arterial	  pulsation.	  	  	  The	  probes	  are	  attached	  to	  
isolated	  volume	  reservoirs	  which	  buffer	  any	  change	  in	  pressure	  within	  the	  probes,	  as	  occurs	  
on	   a	   cyclic	   basis	   with	   the	   change	   in	   fingertip	   blood	   volume	   associated	   with	   arterial	  
pulsation.	  	  Thus,	  the	  PAT	  device	  permits	  plethysmographic	  recording	  of	  finger	  arterial	  pulse	  
waveform	  and	  amplitude.	  
Baseline	   pulse	   waveform	   and	   amplitude	   recordings	   were	   recorded	   for	   a	   period	   of	   10	  
minutes,	   following	  which	   a	   brachial	   artery	   BP	   cuff	  was	   inflated	   to	   either	   200	  mmHg	  or	   60	  
mmHg	   above	   systolic	   BP	   (whichever	   value	   was	   greater),	   for	   5	   minutes.	  	   Real	   time	  
visualisation	   of	   the	   pulsatile	   wave	   form	   ensured	   that	   vascular	   occlusion	   was	  
achieved.	  	   Following	   BP	   cuff	   deflation,	   waveform	   recording	   continued	   for	   a	   further	   10	  
minutes.	  
The	  magnitude	  of	  flow-­‐mediated	  fingertip	  hyperaemia	  in	  the	  occluded	  arm	  was	  subsequently	  
calculated	  as	  a	  ratio	  of	  mean	  fingertip	  pulse	  amplitude	  during	  the	  second	  minute	  following	  
BP	   cuff	   deflation	   (A)	   to	   the	   mean	   amplitude	   during	   the	   five	   minutes	   prior	   to	   BP	   cuff	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inflation	  (B).	  	  The	  same	  ratio	  was	  calculated	  for	  the	  control	  arm	  (C/D),	  serving	  as	  control	  for	  
variation	  associated	  with	  systemic	  factors.	  	  A	  reactive	  hyperaemia	  index	  (RHI)	  was	  calculated	  
as	  (A/B)	  /	  (C/D).	  	  Calculation	  of	  RHI	  was	  performed	  in	  an	  automated,	  operator-­‐independent	  
fashion,	  using	  EndoPAT	  proprietary	  software.	  	  The	  selection	  of	   timing	  of	   recordings	   for	  RHI	  
calculation	   is	   based	   on	   these	   holding	   the	   strongest	   correlation	   with	   endothelial	   function	  
determined	  at	  coronary	  angiography	  623.	  
	  
7.2.4. Measurement	  of	  circulating	  markers	  of	  endothelial	  function	  
Blood	  was	  sampled	  at	  baseline	  and	  6	  month	  follow	  up	  for	  measurement	  of	  circulating	  levels	  
of	   Von	   Willebrand	   factor	   (vWF),	   soluble	   intercellular	   adhesion	   molecule	   1	   (s-­‐ICAM-­‐1),	   e-­‐
selectin	   &	   s-­‐thrombomodulin.	   	   Highly	   sensitive	   ELISA	   techniques,	   utilising	   the	   quantitative	  
sandwich	  enzyme	  immunoassay	  technique,	  were	  used,	  as	  previously	  described	  414.	  	  s-­‐ICAM-­‐1,	  
e-­‐selectin	   and	   s-­‐thrombomodulin	   assays	  were	   performed	  using	  Quantizing	   ELISA	   kits	   (R&D	  
systems).	  vWF	  assays	  were	  performed	  using	  the	  Technozym	  ELISA	  kit	  (Pathway	  Diagnostics).	  	  
e-­‐Selectin	  and	  s-­‐ICAM-­‐1	  levels	  were	  measured	  from	  serum,	  vWF	  and	  thrombomodulin	  were	  
measured	   from	   citrated	   plasma.	   	   Both	   sample	   types	   were	   stored	   at	   -­‐80	   degrees	   Celsius.	  	  
Laboratory	  analysis	  was	  performed	  by	  DH.	  
	  
7.2.5. Protocol	  amendments	  
Ethical	  approval	  was	  given	  following	  peer	  review	  of	  the	  study	  protocol	  (protocol	  version	  1)	  by	  
the	  West	  Glasgow	  Ethics	  Committee	  2	  on	  25/8/2008.	   	  The	  study	  protocol	  was	  approved	  by	  
local	   NHS	   R&D	  management	   and	   by	   the	  MHRA	   (UK).	   	   Two	   substantial	   amendments	   were	  
made	   to	   the	   original	   study	   protocol,	   dated	   19/1/2010	   (protocol	   version	   2)	   and	   5/8/2010	  
(protocol	   version	   3).	   	   These	   amendments	   were	   approved	   by	   the	   West	   Glasgow	   Ethics	  
Committee	  2,	  local	  NHS	  R&D	  management	  and	  the	  MHRA.	  
In	  brief,	  the	  first	  substantial	  amendment	  made	  provision	  for	  BP-­‐PWA	  endpoint	  data	  to	  also	  
be	  collected	  at	  the	  1	  month	  study	  visit.	  	  The	  amendment	  also	  allowed	  for	  the	  additional	  non-­‐
invasive	  measurement	  of	  endothelial	   function	   in	  study	  patients	  at	  baseline,	  1	  month	  and	  6	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month	   study	   visits.	   	   This	  was	   performed	  with	  measurement	   of	   digital	   reactive	   hyperaemia	  
index	  following	  FMD	  in	  the	  upper	  limb.	  	  This	  amendment	  was	  applicable	  to	  participants	  016	  
through	  080,	  inclusive,	  enrolled	  to	  the	  study.	  
The	  second	  substantial	  amendment	  allowed	  for	  the	  extension	  of	  study	  treatment	  from	  12	  to	  
24	   months,	   in	   patients	   who	   provided	   informed	   consent,	   with	   additional	   measurement	   of	  




A	   statistical	   analysis	   plan	  was	   conceived	   then	   revised	   following	   discussion	  with	   consultant	  
statisticians	  (HM	  &	  AM),	  based	  at	  the	  Robertson	  Centre	  for	  Biostatistics	  at	  the	  University	  of	  
Glasgow.	   	   Dummy	   generated	   data	   was	   used	   to	   populate	   statistics	   reports	   which	   were	  
reviewed	   by	   investigators	   and	   statisticians	   prior	   to	   analysis	   of	   the	   trial	   sample	   data	   with	  
unlocked	   treatment	   allocation	   code,	   which	   was	   performed	   by	   the	   Robertson	   Centre	   for	  
Biostatistics	  (HM	  &	  AM),	  University	  of	  Glasgow.	  
All	  analyses	  were	  performed	  on	  an	  intention	  to	  treat	  basis,	  based	  on	  complete	  data	  available	  
at	   baseline	   and	   final	   follow	   up	   for	   each	   endpoint.	   	   Study	   comparisons	   on	   continuous	  
measurements	  were	  performed	  with	  analysis	  of	  covariance	  (ANCOVA)	  adjusted	  for	  baseline	  
value	  and	  treatment	  allocation	  and	  results	  are	  expressed	  as	  the	  change	  in	  allopurinol	  group	  
value	  minus	   the	   change	   in	  placebo	  group	  value.	   	   Sensitivity	   analysis	  was	  performed	   for	   all	  
efficacy	   endpoints	   to	   assess	   sensitivity	   to	   extreme	   values.	   	   Comparisons	   on	   categorical	  
variables	  were	  performed	  with	  difference	  in	  proportions.	  	  A	  p	  value	  of	  <	  0.05	  was	  considered	  
statistically	  significant.	  	  	  
A	   priori	   primary	   study	   endpoints	   included	   the	   difference	   in	   mean	   maximum	   CIMT	  
progression,	  mean	  common	  CIMT	  progression,	  change	  in	  central	  BP,	  AI,	  AI	  standardised	  for	  
HR	   of	   75	   bpm	   (AI@HR75),	   carotid-­‐radial	   PWV	   and	   brachial	   BP,	   between	   treatment	   groups	  
over	  a	  one	  year	  period.	  	  	  The	  safety	  analysis	  included	  the	  number	  of	  serious	  adverse	  events	  
attributable	  to	  therapy	  and	  the	  number	  of	  all	  serious	  adverse	  events	  and	  all	  adverse	  events.	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Secondary	   endpoints	   included;	   the	   difference	   in	   change	   in	   SUA	   level	   between	   treatment	  
groups,	  at	  1,	  3,	  6	  &	  12	  months;	   the	  difference	   in	  mean	  maximum	  CIMT	  progression,	  mean	  
common	   CIMT	   progression	   and	   change	   in	   circulating	   markers	   of	   endothelial	   activation,	  
between	   treatment	   groups,	   at	   6	   months;	   the	   difference	   in	   change	   in	   central	   BP,	   AI,	   AI	  
(standardised	   for	   HR	   of	   75	   bpm),	   carotid-­‐radial	   PWV,	   brachial	   BP	   and	   PAT-­‐RHI,	   between	  
treatment	  groups,	  at	  1	  &	  6	  months.	  	  
Secondary	  post	  hoc	  analyses	  were	  planned	  to	  correlate	  CIMT	  and	  central	  BP	  measurements	  
at	  baseline	  with	  SUA	  and	  to	  correlate	  change	  in	  CIMT	  and	  central	  BP	  with	  change	  in	  SUA,	  to	  
evaluate	  whether	  these	  parameters	  appeared	  related	  to	  serum	  UA	  level.	  	  
An	  outline	  of	  study	  procedures	  is	  included	  in	  figure	  7-­‐1.	  
	  
Figure	  7-­‐1:	  	  Summary	  of	  Chapter	  7	  study	  design	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7.3. 	  Study	  One	  Results	  
80	   participants	   were	   recruited	   between	   September	   2009	   and	   November	   2010	   (mean	   age	  
(SD)	   67.8	   (9.4)	   years).	   	   12	   month	   follow	   up	   visits	   completed	   on	   8/11/2011.	   	   25	   patients	  
consented	   to	   proceed	   to	   24	   month	   follow	   up.	   	   24	   month	   follow	   up	   visits	   completed	   on	  
13/11/2012.	  	  Statistical	  analysis	  for	  the	  12	  month	  original	  Pilot	  phase	  was	  completed	  in	  June	  
2013.	  
Baseline	  demographic	  characteristics	  and	  study	  endpoint	  parameter	  values	  at	  baseline,	  ,	  are	  
shown,	  respectively,	  in	  tables	  7-­‐2	  and	  7-­‐3.	  	  Endpoint	  parameter	  values	  at	  baseline,	  based	  on	  
the	  full	  randomised	  population	  and	  for	  each	  subgroup	  of	  patients	  for	  whom	  interval	  data	  was	  
available	   for	   comparison,	   are	   shown	   in	   appendix	   C	   (table	   C-­‐1).	   	   Baseline	   values	   for	   those	  
patients	   with	   data	   available	   for	   interval	   analysis	   were	   comparable	   to	   those	   for	   the	  
randomised	   population.	   	   Treatment	   groups	   were	   generally	   well	   balanced	   although	   the	  
placebo	   group	   contained	   a	   greater	   proportion	   of	   participants	   with	   index	   event	   of	   stroke	  
(rather	  than	  TIA)	  and	  diabetes	  whilst	  fewer	  had	  documented	  hypertension,	  AF	  or	  treatment	  
with	  ACE-­‐I	  /	  ARB	  agents.	  	  	  
Table	  7-­‐2:	  	  Allopurinol	  CIMT	  study	  population	  baseline	  characteristics	  







Age	  (years)	   67.9	  (9.50)	   66.9	  (8.72)	   68.8	  (10.25)	   0.38	  
Male	  Sex	   46	  (57.5%)	   60%	   55%	   0.65	  
Smoker	   15	  (18.75%)	   20%	   17.5%	   0.77	  
BMI	   26.9	  (5.48)	   26.1	  (4.52)	   27.7	  (6.24)	   0.21	  
Brachial	  systolic	  	  BP	  (mmHg)	   135.2	  (19.24)	   135.3	  (20.30)	   135.2	  (18.39)	   0.97	  
Brachial	  diastolic	  BP	  (mmHg)	   74.9	  (8.27)	   76.1	  (7.81)	   73.7	  (8.64)	   0.19	  
Serum	  Cholesterol	  (mmol/l)	   4.01	  (0.81)	   4.13	  (0.92)	   3.90	  (0.66)	   0.22	  
Serum	  Glucose	  (mmol/l)	   5.85	  (1.59)	   5.53	  (1.24)	   6.16	  (1.84)	   0.08	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Serum	  Creatinine	  (µmol/l)	   77.59	  (15.08)	   78.8	  (14.95)	   76.4	  (15.31)	   0.48	  
Serum	  Uric	  Acid	  (mmol/l)	   0.32	  (0.09)	   0.32	  (0.09)	   0.31	  (0.08)	   0.56	  





(25.5	  –	  110.0)	  
56.0	  	  (15.5-­‐101.5)	   	  	  0.39	  1	  




























	  2.5%	  57.5%	  27.5%	  10%	  2.5%	  
	  
	  	  0.46	  2	  
IHD	   10.00%	   7.50%	   12.50%	   	  	  0.71	  2	  
Diabetes	   13.75%	   7.50%	   20.00%	   	  	  0.19	  2	  
Previous	  Stroke	  or	  TIA	   17.5%	   15%	   20%	   0.56	  
Hypertension	   42.50%	   50.00%	   35.00%	   0.17	  
AF	   10.00%	   15.00%	   5.00%	   	  	  0.26	  2	  
Anti-­‐platelet	  Therapy	   92.5%	   95%	   90%	   0.39	  	  
ACE	  Inhibitor	  or	  ARB	  Therapy	  	   48.75%	   60%	   37.5%	   	  	  	  0.044	  
Diuretic	  Therapy	   31.25%	   22.5%	   40%	   0.09	  
CCB	   16.5%	   20.0%	   12.5%	   	  	  	  0.55	  2	  
Beta-­‐Blocker	  Therapy	   28.75%	   12.5%	   45%	   0.003	  2	  
Lipid	  Lowering	  Therapy	   92.5%	   95%	   90%	   	  	  	  	  0.39	  
Data	  are	  expressed	  as	  mean	  (SD)	  for	  continuous	  variables	  and	  %	  for	  categorical	  variables,	  with	  the	  exception	  of	  
time	   from	   ictus	   to	   randomisation	   &	   the	   circulating	   endothelial	   function	   parameters,	   where	   median	  
(interquartile	   range	   is	   given).	   	   For	   continuous	   variables,	   p-­‐values	   are	   from	   two-­‐sample	   t-­‐test,	   except	  when	  a	  
variable	   did	   not	   approximate	   to	   the	   Normal	   distribution	   when	   the	   Mann-­‐Whitney	   test	   1	   was	   used.	   	   For	  
categorical	  variables	  p-­‐values	  are	  from	  Chi-­‐squared	  test,	  except	  for	  this	  denoted	  by	  2	  which	  are	  from	  Fisher’s	  
exact	   text.	   	  A	  p	  value	  of	  <	  0.05	  was	  considered	  statistically	   significant.	   	  BMI,	  body	  mass	   index;	  TIA,	   transient	  
ischemic	  attack;	  	  OCSP,	  Oxford	  Clinical	  Stroke	  Project;	  AF,	  atrial	  fibrillation;	  IHD,	  ischaemic	  heart	  disease;	  TACS,	  
total	  anterior	  circulation	  stroke;	  PACS,	  partial	  anterior	  circulation	  stroke;	  LACS,	  lacunar	  stroke;	  POCS,	  posterior	  
circulation	  stroke;	  mRS,	  modified	  Rankin	  scale;	  ACE,	  angiotensin	  converting	  enzyme;	  ARB,	  angiotensin	  receptor	  
blocker;	  CCB,	  calcium	  channel	  blocker.	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Table	  7-­‐3:	  	  Allopurinol	  study	  population	  endpoint	  parameter	  baseline	  values	  
Study	  sample	  	  
(n,	  Allopurinol	  /	  Placebo)	  
	  
All	  Participants	   Allopurinol	   Placebo	   P-­‐value	  
Uric	  acid,	  mmol	  /	  litre	  
(37/40)	  
0.32	  (0.09)	   0.32	  (0.09)	   0.31	  (0.08)	   0.56	  
Mean	  maximum	  CIMT,	  mm	  
(39/40)	  
1.18	  (0.31)	   1.20	  (0.32)	   1.17	  (0.30)	   0.70	  
Mean	  common	  (far	  wall	  
CIMT),	  mm	  	  
(39/40)	  
0.83	  (0.15)	   0.83	  (0.16)	   0.82	  (0.15)	   0.83	  
Mean	  aortic	  SBP,	  mmHg	  
(40/39)	  
111.7	  (14.9)	   112.3	  (15.8)	   111.0	  (14.0)	   0.71	  
Mean	  aortic	  DBP,	  mmHg	  
(40/39)	  
90.0	  (10.1)	   91.0	  (10.6)	   88.9	  (9.6)	   0.37	  
Mean	  aortic	  Tr,	  ms	  
(40/38)	  
135.8	  (10.00)	   136.4	  (9.43)	   135.2	  (10.67)	   0.62	  
Mean	  augmentation,	  mmHg	  
(40/39)	  
17.9	  (7.9)	   17.3	  (7.5)	   18.5	  (8.3)	   0.50	  
AI	  (P2/P1),	  %	  
(40/39)	  
	  
153.7	  (17.8)	   152.0	  (15.03)	   155.4	  (20.3)	   0.40	  
AI	  (AG/PP),	  %	  	  
(40/39)	  
34.2	  (7.7)	   33.9	  (7.0)	   34.6	  (8.5)	   0.69	  
AI@HR75,	  %	  	  
(40/39)	  
28.8	  (7.9)	   28.4	  (8.1)	   29.3	  (7.9)	   0.60	  
Mean	  end	  systolic	  pressure,	  
mmHg	  	  
(40/39)	  
114.4	  (15.4)	   114.5	  (16.0)	   114.3	  (14.9)	   0.96	  
PWV	  (brachial),	  m/s	  	  
(33/35)	  
8.48	  (0.98)	   8.55	  (1.01)	   8.41	  (0.96)	   0.57	  
Brachial	  SBP,	  mmHg	  	  
(40/40)	  
135.2	  (19.2)	   135.3	  (20.3)	   135.2	  (18.4)	   0.97	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Brachial	  DBP,	  mmHg	  	  
(40/40)	  
74.9	  (8.3)	   76.1	  (7.8)	   73.7	  (8.6)	   0.19	  
PAT-­‐RHI	  	  
(32/30)	  
2.4	  (0.79)	   2.5	  (0.91)	   2.2	  (0.61)	   0.15	  
ICAM-­‐1	  	  
(37/35)	  
263.8	  (89.0)	   238.4	  (71.3)	   290.7	  (98.5)	   0.012	  
e-­‐Selectin	  	  
(37/35)	  
36.2	  (15.1)	   32.6	  (13.8)	   40.0	  (15.8)	   0.038	  
vWF	  	  
(37/35)	  
1.29	  (0.42)	   1.35	  (0.39)	   1.23	  (0.44)	   0.26	  
Thrombomodulin	  	  
(37/35)	  
3299	  (838)	   3283	  (860)	   3315	  (826)	   0.87	  
Data	  are	  expressed	  as	  mean	  (standard	  deviation).	  	  P-­‐values	  are	  from	  two-­‐sample	  t-­‐	  test.	  	  CIMT,	  carotid	  intima	  
media	  thickness;	  SBP,	  systolic	  blood	  pressure;	  DBP,	  diastolic	  blood	  pressure;	  Tr,	  time	  to	  reflected	  wave;	  AI,	  
augmentation	  index;	  AI@HR75,	  augmentation	  index	  corrected	  for	  heart	  rate	  of	  75	  bpm;	  PWV,	  pulse	  wave	  
velocity;	  PAT-­‐RHI,	  peripheral	  artery	  tonometry	  reactive	  hyperaemia	  index;	  ICAM-­‐1,	  intercellular	  adhesion	  




In	  total,	  72	  participants	  completed	  6	  month	  follow	  up	  and	  69	  completed	  12	  month	  follow	  up.	  	  
Vital	  status	  was	  ascertained	  for	  all	  participants	  except	  one,	  who	  left	  the	  country	  and	  was	  lost	  
to	  follow	  up.	  	  Of	  the	  remaining	  10	  patients	  with	  incomplete	  12	  month	  follow	  up,	  3	  withdrew	  
following	  adverse	  events	  respectively	  of	  brain	  tumour,	  pancreatic	  carcinoma	  and	  depressive	  
psychosis;	   5	   chose	   to	   withdraw	   and	   2	   did	   not	   attend	   for	   the	   final	   visit	   despite	   repeated	  
attempts	   to	   schedule	   appointments.	   	   A	   CONSORT	   diagram	   detailing	   recruitment	   and	  
withdrawals	  is	  shown	  in	  figure	  7-­‐2.	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Figure	  7-­‐2:	  	  Patient	  follow	  up	  at	  6	  &	  12	  months	  -­‐	  CONSORT	  2010	  Flow	  Diagram	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Study	  treatment	  concordance	  
91%	   of	   patients	   took	   at	   least	   80%	   of	   their	   prescribed	   study	   medication	   doses	   based	   on	  
returned	   pill	   counts	   and	   withdrawals	   as	   detailed	   above.	   	   One	   patient	   (who	   subsequently	  
withdrew)	  received	  no	  study	  medication,	  as	   renal	   function	  had	  deteriorated	  subsequent	   to	  




2	  patients	  had	  developed	  neutropenia	  at	  1	  month	  follow	  up	  (one	  attributed	  to	  intercurrent	  
viral	  infection,	  the	  other	  potentially	  to	  study	  medication).	  	  1	  patient	  developed	  an	  urticarial	  
rash	   within	   one	   week	   (likely	   due	   to	   concomitant	   nicotine	   replacement	   patches).	   	   Study	  
medication	  was	  immediately	  discontinued	  without	  rechallenge	  in	  all	  3	  patients.	  	  All	  3	  patients	  
were	   in	   the	  placebo	  group	  on	  unblinding	  of	   treatment	  allocation	  on	  study	  completion.	   	  No	  
other	  study	  treatment	  related	  serious	  adverse	  events	  or	  adverse	  reactions	  were	  reported.	  	  	  
	  
Serum	  Uric	  Acid	  
Serum	   UA	   values	   at	   baseline	   are	   detailed	   in	   table	   7-­‐3.	   	   Between	   September	   2009	   and	  
November	  2011,	  the	  local	  NHS	  laboratory	  uric	  acid	  assay	  showed	  an	  average	  bias	  of	  +3.3%	  to	  
the	   target	   values	   assigned	   by	   UKNEQAS	   (based	   on	   the	  mean	   results	   for	   all	   labs	   using	   the	  
endpoint	  uricase	  method).	  	  This	  bias	  was	  largely	  due	  to	  the	  local	  method,	  which	  used	  Abbott	  
reagents.	  
Change	  in	  SUA	  at	  1,	  3,	  6	  &	  12	  months,	  together	  with	  intergroup	  comparisons	  of	  change	  from	  
baseline,	  are	  detailed	  in	  table	  7-­‐4.	  	  Serum	  UA	  level	  fell	  significantly	  with	  allopurinol	  compared	  
with	  placebo	  at	  each	  follow	  up	  time	  point.	  	  Repeated	  statistical	  analysis,	  with	  adjustment	  for	  
baseline	  treatment	  with	  ACE-­‐I	  /	  ARB	  (which	  differed	  significantly	  between	  treatment	  groups),	  
did	   not	   affect	   the	   observed	   results	   (table	   7-­‐5).	   	   Figure	   7-­‐3	   illustrates	   change	   in	   SUA	   from	  
baseline	  during	  follow	  up	  in	  each	  group.	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Table	  7-­‐4:	  	  Change	  in	  serum	  uric	  acid	  at	  1,	  3,	  6	  &	  12	  month	  follow	  up	  
Follow	  up	  month	  
(n,	  Allopurinol	  /	  
Placebo)	  
Allopurinol	   Placebo	   Mean	  intergroup	  
difference	  (95%	  CI)	  
P	  value	  
1	  month	  (33	  /	  36)	   -­‐0.11	  (0.06)	   -­‐0.01	  (0.05)	   -­‐0.100	  (-­‐0.122	  ,	  -­‐0.077)	  	   <	  0.0001	  
3	  months	  (34	  /	  37)	   -­‐0.10	  (0.07)	   -­‐0.01	  (0.04)	   -­‐0.086	  (-­‐0.111	  ,	  -­‐0.061)	  	   <	  0.0001	  
6	  months	  (34	  /	  35)	   -­‐0.09	  (0.08)	   -­‐0.01	  (0.04)	   -­‐0.070	  (-­‐0.096,	  -­‐0.044)	   <	  0.0001	  
12	  months	  (34	  /	  34)	   -­‐0.09	  (0.07)	   -­‐0.01	  (0.05)	   -­‐0.076	  (-­‐0.104,	  -­‐0.048)	   <	  0.0001	  




Table	  7-­‐5:	  	  Change	  in	  serum	  uric	  acid	  at	  6	  &	  12	  month	  follow	  up	  
(adjusted	  for	  baseline	  treatment	  with	  ACE-­‐I	  /	  ARB)	  
Parameter	  
(n,	  Allopurinol	  /	  
Placebo)	  
Mean	  intergroup	  difference	   Adjusted	  for	  treatment	  
with	  	  ACE-­‐I	  /	  ARB	  
Adjusted	  
P	  value	  
1	  month	  (33	  /	  36)	  
	  
-­‐0.100	  (-­‐0.122	  ,	  -­‐0.077)	  	   -­‐0.101	  (-­‐0.124	  ,	  -­‐0.077)	  	   <	  0.0001	  
3	  months	  (34	  /	  37)	  
	  
-­‐0.086	  (-­‐0.111	  ,	  -­‐0.061)	  	   -­‐0.086	  (-­‐0.111	  ,	  -­‐0.061)	  	   <	  0.0001	  
6	  months	  (34	  /	  35)	  
	  
-­‐0.070	  (-­‐0.096,	  -­‐0.044)	  
	  
-­‐0.070	  (-­‐0.097,	  -­‐0.043)	  	   <	  0.0001	  
12	  months	  (34	  /	  34)	  
	  
-­‐0.076	  (-­‐0.104,	  -­‐0.048)	  
	  
-­‐0.077	  (-­‐0.106,	  -­‐0.048)	   <	  0.0001	  
Data	  are	  mmol/litre,	  presented	  as	  mean	  (95%	  confidence	  interval).	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7.3.1. CIMT	  analysis	  
Baseline	  mean	  maximum	  CIMT	  and	  mean	  common	  CIMT	  values	  appeared	  balanced	  between	  
treatment	   groups	   and	   are	  detailed	   in	   table	   7-­‐3.	   	   Carotid	  CIMT	  measurements	  meeting	   the	  
dimension	  based	  criteria	  for	  presence	  of	  carotid	  plaque,	  of	  at	  least	  one	  angle	  measurement	  
at	  any	  of	  the	  three	  carotid	  segments,	  indicated	  that	  carotid	  plaque	  was	  present	  in	  56	  patients	  
(70.9%).	  	  No	  difference	  was	  observed	  in	  the	  proportion	  of	  patients	  with	  presence	  of	  carotid	  
plaque	  between	  treatment	  groups	  at	  baseline:	  allopurinol,	  n	  =	  30	  (76.92%);	  placebo,	  n	  =	  26	  
(65.00%),	   p	   =	   0.33	   (for	   difference	   in	   2	   proportions).	   	   Figures	   C-­‐1	   and	   C-­‐2	   (appendix	   C)	  
illustrate,	   respectively,	   the	   spread	   of	   mean	  maximum	   and	  mean	   common	   (far	   wall)	   CIMT	  
measurements	  at	  baseline.	  
67	  patients	  had	  CIMT	  data	  recorded	  at	  both	  baseline	  and	  6	  month	  visits	  for	  comparison.	  	  	  No	  
significant	   difference	   was	   observed	   between	   the	   treatment	   groups,	   for	   either	   mean	  
maximum	  or	  mean	  common	  CIMT	  progression,	  at	  6	  month	  follow	  up.	  	  A	  sensitivity	  analysis,	  
with	   censoring	  of	  observed	  extreme	  values,	  was	  performed	   for	  mean	  maximum	  CIMT	  at	  6	  
months.	  	  Similar	  results	  were	  obtained	  in	  this	  analysis.	  	  Change	  in	  mean	  maximum	  and	  mean	  
common	  CIMT	  values	  between	  baseline	  and	  6	  months	  within	  each	  treatment	  group,	  together	  
with	  comparison	  of	  intergroup	  changes	  from	  baseline,	  are	  detailed	  in	  table	  7-­‐6.	  	  
Table	  7-­‐6:	  	  CIMT	  parameter	  progression	  at	  6	  month	  follow	  up	  
Parameter	  
(n,	  Allopurinol	  /	  Placebo)	  
Allopurinol	   Placebo	   Mean	  intergroup	  
difference	  (95%	  CI)	  
P	  value	  
Mean	  maximum	  	  
(35	  /	  32)	  
0.04	  (0.20)	   0.05	  (0.21)	   -­‐0.005	  	  (-­‐0.101,	  0.091)	   0.91	  
Mean	  maximum	  
(sensitivity	  analysis)	  
(34	  /	  31)	  
0.02	  (0.16)	   0.02	  (0.14)	   0.002	  (-­‐0.070,	  0.074)	   0.96	  
Mean	  common	  (far	  
wall)	  	  (35	  /	  32)	  
-­‐0.00	  (0.07)	   0.00	  	  (0.12)	   -­‐0.006	  (-­‐0.050,	  0.038)	   0.79	  
Data	  are	  mm,	  presented	  as	  mean	  (SD),	  unless	  otherwise	  stated.	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65	  patients	  had	  IMT	  data	  recorded	  at	  both	  baseline	  and	  12	  month	  visits	  for	  comparison.	  	  	  A	  
CONSORT	  diagram,	  detailing	  explanations	  for	  patient	  unavailability	  for	  this	  analysis	  is	  shown	  
in	  appendix	  C	  (figure	  C-­‐3).	  	  	  	  	  
Change	  in	  mean	  maximum	  and	  mean	  common	  CIMT	  values	  between	  baseline	  and	  12	  months	  
within	  each	  treatment	  group,	  together	  with	  comparison	  of	  intergroup	  changes	  from	  baseline,	  
are	  detailed	  in	  table	  7-­‐7.	  	  No	  significant	  difference	  was	  observed	  between	  treatment	  groups	  
in	  mean	  maximum	  CIMT	  progression	  at	  12	  months	  (-­‐0.060mm;	  95%	  CI,	  -­‐0.146,	  0.027mm,	  p	  =	  
0.17).	   	  Mean	  common	  CIMT	  progression	  was	   significantly	   reduced	   in	   the	  Allopurinol	  group	  
compared	   with	   the	   Placebo	   group	   at	   12	   month	   follow	   up	   (-­‐0.097mm,	   95%	   CI;	   -­‐0.175,	   -­‐
0.019mm,	  p=0.015).	  	  	  
A	  sensitivity	  analysis,	  with	  censoring	  of	  observed	  extreme	  values,	  was	  performed	  for	  mean	  
common	  CIMT	  at	  12	  months.	  	  The	  treatment	  effect	  was	  preserved	  in	  this	  analysis	  (-­‐0.057mm,	  
95%	  CI;	   -­‐0.0108,	   -­‐0.006mm,	  p	   =	   0.029).	   	   Change	   in	   CIMT	  parameters	   from	  baseline	   during	  
follow	  up	  in	  each	  group	  are	  shown	  in	  figures	  7-­‐4,	  7-­‐5	  &	  7-­‐6.	  	  
	  
Table	  7-­‐7:	  	  CIMT	  parameter	  progression	  at	  12	  month	  follow	  up	  
Parameter	  
(n,	  Allopurinol	  /	  Placebo)	  
Allopurinol	   Placebo	   Mean	  intergroup	  
difference	  (95%	  CI)	  
P	  value	  
Mean	  maximum	  
(31	  /	  34)	  
0.01	  (0.15)	   0.07	  (0.19)	   -­‐0.060	  (-­‐0.146,	  0.027)	   0.17	  
Mean	  common	  (far	  
wall)	  (31	  /	  34)	  
-­‐0.02	  (0.09)	   0.08	  (0.20)	   -­‐0.097	  (-­‐0.175,	  -­‐0.019)	   0.015	  
Mean	  common	  (far	  
wall),	  (sensitivity	  
analysis)	  (31	  /	  32)	  
-­‐0.02	  (0.09)	   0.04	  (0.11)	   -­‐0.057	  (-­‐0.108,	  -­‐0.006)	   0.029	  
Data	  are	  mm,	  presented	  as	  mean	  (SD),	  unless	  otherwise	  stated.	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Figure	  7-­‐5:	  	  Change	  in	  mean	  common	  (far	  wall)	  CIMT	  (mm)	  between	  baseline	  and	  
subsequent	  follow-­‐up	  



















































Figure	  7-­‐6:	  	  Change	  in	  mean	  common	  (far	  wall)	  CIMT	  (mm)	  between	  baseline	  and	  
subsequent	  follow-­‐up	  (sensitivity	  analysis)	  
	  































































There	   was	   satisfactory	   intra-­‐observer	   agreement	   for	   CIMT	   image	   analysis	   for	   both	   mean	  
maximum	   and	  mean	   common	   CIMT.	   	   The	   within	   observer	   intra-­‐class	   correlation	   (ICC)	   for	  
mean	   maximum	   CIMT	   was	   0.91	   (95%	   CI;	   0.79,	   0.96),	   based	   on	   repeated	   analysis	   of	   20	  
participants	  mean	  maximum	  CIMT	  at	  baseline.	  	  A	  Bland-­‐Altman	  plot	  (figure	  7-­‐7)	  for	  the	  intra-­‐
observer	   variability	   did	   not	   demonstrate	   any	   trend	   for	   variability	   to	   be	   dependent	   on	   the	  
underlying	  mean	  value	  for	  mean	  maximum	  carotid	   IMT.	   	  The	  within	  observer	   ICC	  for	  mean	  
common	   (far	   wall)	   CIMT	   was	   0.87	   (95%	   CI;	   0.77,	   0.93),	   based	   on	   repeated	   analysis	   of	   40	  
participants	  mean	  common	  CIMT	  at	  baseline.	  	  A	  Bland-­‐Altman	  plot	  (figure	  7-­‐8)	  for	  the	  intra-­‐
observer	   variability	   did	   not	   demonstrate	   any	   trend	   for	   variability	   to	   be	   dependent	   on	   the	  
underlying	  mean	  value	  for	  mean	  common	  (far	  wall)	  carotid	  IMT.	  	  	  
	  
Figure	  7-­‐7:	  	  Intra	  –observer	  agreement	  for	  mean	  maximum	  CIMT	  analysis	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Figure	  7-­‐8:	  	  Intra	  –observer	  agreement	  for	  mean	  common	  (far	  wall)	  CIMT	  analysis	  
	  
Post	  hoc	  analyses	  
The	  difference	   in	   the	  proportion	  of	  patients	   treated	  with	  ACE-­‐I	  or	  ARB	  between	   treatment	  
groups	  at	  baseline	  was	  significant.	  	  This	  potentially	  favoured	  the	  observation	  of	  a	  treatment	  
effect	  in	  favour	  of	  Allopurinol.	  	  We	  therefore	  repeated	  statistical	  analysis	  with	  adjustment	  for	  
baseline	  ACE-­‐I	   or	   ARB	  use.	   	   The	   adjusted	   intergroup	   differences	   for	  mean	  maximum	  CIMT	  
and	  mean	   common	   CIMT	   progression	   at	   6	   and	   12	  months	   are	   detailed	   in	   table	   7-­‐8.	   	   The	  
results	  appeared	  unaffected	  by	  this	  adjustment.	  
On	   identifying	   a	   statistically	   significant	   difference	   in	   12	   month	   mean	   common	   CIMT	  
progression	  between	  treatment	  groups,	  we	  performed	  correlation	  between	  baseline	  serum	  
UA	  and	  baseline	  mean	  common	  CIMT	  and	  between	  change	  in	  serum	  UA	  at	  6	  and	  12	  months	  
and	   change	   in	   mean	   common	   CIMT	   at	   6	   &	   12	   months.	   	   The	   correlation	   coefficient	   and	  
accompanying	  p	  value	  for	  each	  correlation	  are	  detailed	  in	  table	  7-­‐9.	  	  A	  non-­‐significant	  trend	  
toward	  a	   linear	   correlation	  between	  baseline	  mean	  maximum	  CIMT	  and	  baseline	   SUA	  was	  
observed.	   	   No	   correlation	   between	   the	   observed	   change	   in	   SUA	   and	   change	   in	   mean	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common	   CIMT	   at	   either	   6	   or	   12	   months	   was	   apparent.	   	   Repeated	   statistical	   analysis,	  
including	   adjustment	   for	   the	   observed	   change	   in	   SUA	   at	   12	   months,	   did	   not	   affect	   the	  
difference	   in	   mean	   common	   CIMT	   progression	   observed	   between	   treatment	   groups	   (-­‐
0.102mm,	  95%	  CI;	  -­‐0.195,	  -­‐0.008mm,	  p=0.033).	  
	  
Table	  7-­‐8:	  	  CIMT	  parameter	  progression	  at	  12	  month	  follow	  up,	  adjusted	  for	  
baseline	  treatment	  with	  ACE-­‐I	  /	  ARB	  at	  baseline	  	  
Parameter	  
(n,	  Allopurinol	  /	  Placebo)	  
Mean	  intergroup	  
difference	  
Adjusted	  for	  treatment	  
with	  	  ACE-­‐I	  /	  ARB	  
Adjusted	  
P	  value	  
Mean	  maximum	  CIMT	  
(31	  /	  34)	  
-­‐0.060	  (-­‐0.146,	  0.027)	   -­‐0.061	  (-­‐0.149,	  0.028)	  
	  
0.18	  
Mean	  common	  CIMT	  	  
(31	  /	  34)	  
-­‐0.097	  (-­‐0.175,	  -­‐0.019)	  
	  
-­‐0.097	  (-­‐0.176,	  -­‐0.017)	  
	  
0.019	  
Mean	  common	  CIMT	  
(sensitivity	  analysis)	  
(31	  /	  32)	  
-­‐0.057	  (-­‐0.108,	  -­‐0.006)	   -­‐0.062	  (-­‐0.113,	  -­‐0.011)	  
	  
0.018	  
Data	  are	  mm,	  presented	  as	  mean	  (95%	  confidence	  interval).	  
	  
	  
Table	  7-­‐9:	  	  CIMT	  correlations	  with	  Uric	  Acid	  
	   Allopurinol	   Placebo	   All	  
Baseline	   0.161	  (0.34)	   0.245	  (0.127)	   0.181	  (0.11)	  
Change	  at	  6	  months	   0.094	  (0.60)	   0.197	  (0.28)	   0.169	  (0.18)	  
Change	  at	  12	  months	   0.051	  (0.79)	   0.020	  (0.91)	   0.150	  (0.24)	  
Data	  are	  presented	  as	  correlation	  coefficient	  (p	  value)	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7.3.2. BP-­‐PWA	  analysis	  	  
Baseline	   BP-­‐PWA	   values	   are	   detailed	   in	   table	   7-­‐3.	   	   60	   patients	   had	   PWA	  data	   recorded	   at	  
both	  baseline	  and	  1	  month	  visits	  for	  comparison.	   	   	   Incomplete	  BP-­‐PWA	  data,	  due	  to	  partial	  
technical	  inadequacy	  of	  PWA	  signal	  acquisition,	  meant	  determination	  of	  mean	  peripheral	  T2,	  
mean	  peripheral	  AI	  was	  based	  on	  57	  patients.	  	  Similarly,	  determination	  of	  mean	  aortic	  Tr	  was	  
based	  on	  58	  patients.	  	  
Change	  in	  BP-­‐PWA	  parameter	  values	  between	  baseline	  and	  1	  month	  within	  each	  treatment	  
group,	   together	   with	   comparison	   of	   intergroup	   differences	   from	   baseline,	   are	   detailed	   in	  
table	  7-­‐10.	  	  Adjustment	  for	  baseline	  treatment	  with	  ACE-­‐I	  /	  ARB	  did	  not	  affect	  the	  observed	  
results	  (table	  7-­‐11).	  	  	  
	  
Table	  7-­‐10:	  	  BP-­‐PWA	  parameter	  change	  at	  1	  month	  follow	  up	  
Parameter	  






difference,	  (95%	  CI)	  
P	  value	  
Mean	  aortic	  SBP	  (32/28)	   -­‐3.8	  (10.1)	   -­‐3.1	  (9.8)	   -­‐0.3	  (-­‐5.1	  ,	  4.6)	  	   0.91	  
Mean	  aortic	  DBP	  (32/28)	   -­‐3.3	  (8.1)	   -­‐3.1	  (8.5)	   0.443	  (-­‐3.6	  ,	  4.5)	  	   0.83	  
Mean	  aortic	  Tr,	  ms	  	  
(32/26)	  
0.39	  (6.17)	   -­‐0.96	  (13.73)	   2.52	  (-­‐1.670	  ,	  6.73)	  	   0.24	  
Mean	  augmentation	  
(32/28)	  
-­‐2.0	  (4.8)	   -­‐0.1	  (6.9)	   -­‐2.2	  (-­‐5.0	  ,	  0.6)	  	   0.13	  
AI	  (P2/P1),	  %	  (32/28)	   -­‐6.3	  (10.9)	   0.5	  (16.5)	   -­‐7.3	  (-­‐14.2	  ,	  -­‐0.5)	  	   0.036	  
AI	  (AG/PP),	  %	  (32/28)	   -­‐3.0	  (5.6)	   0.1	  (6.6)	   -­‐3.1	  (-­‐6.2	  ,	  -­‐0.0)	  	   0.048	  
AI@HR75,	  %	  (32/28)	   -­‐2.1	  (5.8)	   -­‐0.1	  (5.6)	   -­‐2.3	  (-­‐5.1	  ,	  0.6)	  	   0.12	  
Mean	  ESP,	  mmHg	  (32/28)	   -­‐4.9	  (11.4)	   -­‐3.5	  (10.2)	   -­‐1.4	  (-­‐6.6,	  3.9)	   0.60	  
Data	  are	  expressed	  as	  mean	  (standard	  deviation),	  unless	  otherwise	  stated.	  	  	  SBP,	  systolic	  blood	  pressure	  
(mmHg);	  DBP,	  diastolic	  blood	  pressure	  (mmHg);	  Tr,	  time	  to	  reflected	  wave;	  AI,	  augmentation	  index;	  
AI@HR75,	  augmentation	  index	  corrected	  for	  heart	  rate	  of	  75	  bpm;	  ESP,	  end	  systolic	  pressure	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Table	  7-­‐11:	  	  BP-­‐PWA	  parameter	  change	  at	  1	  month	  follow	  up,	  
adjusted	  for	  treatment	  with	  ACE-­‐I	  /	  ARB	  at	  baseline	  
Parameter	  
(n,	  Allopurinol	  /	  Placebo)	  
Mean	  intergroup	  
difference	  
Adjusted	  for	  treatment	  
with	  	  ACE-­‐I	  /	  ARB	  
Adjusted	  
P	  value	  
Mean	  aortic	  SBP,	  mmHg	   -­‐0.3	  (-­‐5.1	  ,	  4.6)	  	   0.2	  (-­‐4.7	  ,	  5.2)	  	   0.93	  
Mean	  aortic	  DBP,	  mmHg	   0.443	  (-­‐3.6	  ,	  4.5)	  	   0.6	  (-­‐3.5	  ,	  4.7)	  	   0.78	  
Mean	  aortic	  Tr,	  ms	   2.52	  (-­‐1.670	  ,	  6.73)	  	   1.90	  (-­‐2.43	  ,	  6.23)	  	   0.38	  
Mean	  augmentation	   -­‐2.2	  (-­‐5.0	  ,	  0.6)	  	   -­‐1.5	  (-­‐4.3	  ,	  1.2)	  	   0.27	  
AI	  (P2/P1),	  %	   -­‐7.3	  (-­‐14.2	  ,	  -­‐0.5)	  	   -­‐6.3	  (-­‐13.2	  ,	  0.6)	  	   0.07	  
AI	  (AG/PP),	  %	   -­‐3.1	  (-­‐6.2	  ,	  -­‐0.0)	  	   -­‐2.7	  (-­‐5.8	  ,	  0.5)	  	   0.09	  
AI@HR75,	  %	   -­‐2.3	  (-­‐5.1	  ,	  0.6)	  	   -­‐1.9	  (-­‐4.8	  ,	  1.0)	  	   0.20	  
Mean	  ESP,	  mmHg	   -­‐1.4	  (-­‐6.6,	  3.9)	   -­‐0.7	  (-­‐6.1	  ,	  4.6)	  	   0.78	  
Data	  are	  expressed	  as	  mean	  (95%	  confidence	  interval).	  	  SBP,	  systolic	  blood	  pressure;	  DBP,	  diastolic	  blood	  
pressure;	  Tr,	  time	  to	  reflected	  wave;	  AI,	  augmentation	  index;	  AI@HR75,	  augmentation	  index	  corrected	  for	  
heart	  rate	  of	  75	  bpm:	  ESP,	  end	  systolic	  pressure	  
	  
	  
68	  patients	  had	  PWA	  data	  recorded	  at	  both	  baseline	  and	  6	  month	  visits	  for	  comparison.	  	  	  One	  
patient	  in	  the	  placebo	  group	  had	  incomplete	  BP-­‐PWA	  data,	  such	  that	  determination	  of	  mean	  
peripheral	  T2,	  mean	  peripheral	  AI	  and	  mean	  aortic	  Tr	  was	  based	  on	  67	  patients.	  
Change	  in	  BP-­‐PWA	  parameter	  values	  between	  baseline	  and	  6	  months	  within	  each	  treatment	  
group,	   together	   with	   comparison	   of	   intergroup	   differences	   from	   baseline,	   are	   detailed	   in	  
table	  7-­‐12.	  	  Adjustment	  for	  baseline	  treatment	  with	  ACE-­‐I	  /	  ARB	  did	  not	  affect	  the	  observed	  
results	  (table	  7-­‐13).	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Table	  7-­‐12:	  	  BP-­‐PWA	  parameter	  change	  at	  6	  month	  follow	  up	  
Parameter	  
(n,	  Allopurinol	  /	  Placebo)	  
Allopurinol	   Placebo	   Mean	  intergroup	  
difference,	  (95%	  CI)	  
P	  value	  
Mean	  aortic	  SBP,	  (35	  /	  33)	   -­‐2.6	  (13.5)	   0.3	  (12.8)	   -­‐2.2	  (-­‐8.5,	  4.2)	  	   0.50	  
Mean	  aortic	  DBP	  (35	  /	  33)	   -­‐2.4	  (10.0)	   -­‐0.6	  (10.3)	   -­‐1.1	  (-­‐5.9,	  3.8)	   0.67	  
Mean	  aortic	  Tr,	  ms	  (35	  /	  32)	   0.60	  (8.22)	   -­‐0.27	  (11.32)	   1.27	  (-­‐2.28,	  4.83)	  	   0.48	  
Mean	  augmentation	  (35	  /	  33)	   -­‐1.4	  (6.5)	   0.6	  (6.7)	   -­‐1.9	  (-­‐4.8,	  1.0)	  	   0.20	  
AI	  (P2/P1),	  %	  (35	  /	  33)	   -­‐3.3	  (14.4)	   -­‐2.8	  (26.3)	   -­‐0.9	  (-­‐11.0,	  9.1)	  	   0.85	  
AI	  (AG/PP),	  %	  (35/33)	   -­‐2.02	  (6.5)	   3.4	  (21.2)	   -­‐5.4	  (-­‐12.3,	  1.5)	  	   0.13	  
AI@HR75,	  %	  (35	  /	  33)	   -­‐1.2	  (5.8)	   -­‐0.2	  (6.6)	   -­‐1.1	  (-­‐4.0	  ,	  1.8)	  	   0.45	  
Mean	  ESP,	  mmHg	  (35	  /	  33)	   -­‐2.8	  (13.9)	   -­‐0.8	  (14.1)	   -­‐1.4	  (-­‐8.0,	  5.2)	  	   0.68	  
Data	  are	  expressed	  as	  mean	  (standard	  deviation),	  unless	  otherwise	  stated.	  	  SBP,	  systolic	  blood	  pressure	  
(mmHg);	  DBP,	  diastolic	  blood	  pressure	  (mmHg);	  Tr,	  time	  to	  reflected	  wave;	  AI,	  augmentation	  index;	  
AI@HR75,	  augmentation	  index	  corrected	  for	  heart	  rate	  of	  75	  bpm:	  ESP,	  end	  systolic	  pressure	  
	  
Table	  7-­‐13:	  	  BP-­‐PWA	  parameter	  change	  at	  6	  month	  follow	  up,	  
adjusted	  for	  treatment	  with	  ACE-­‐I	  /	  ARB	  at	  baseline	  
Parameter	  
(n,	  Allopurinol	  /	  Placebo)	  
Mean	  intergroup	  
difference	  
Adjusted	  for	  treatment	  
with	  	  ACE-­‐I	  /	  ARB	  
Adjusted	  
P	  value	  
Mean	  aortic	  SBP,	  mmHg	   -­‐2.2	  (-­‐8.5,	  4.2)	  	   -­‐2.2	  (-­‐8.5,	  4.2)	   0.50	  
Mean	  aortic	  DBP,	  mmHg	   -­‐1.1	  (-­‐5.9,	  3.8)	   -­‐1.0	  (-­‐6.0,	  4.0)	   0.68	  
Mean	  aortic	  Tr,	  ms	   1.27	  (-­‐2.28,	  4.83)	  	   0.78	  (-­‐2.82,	  4.38)	   0.67	  
Mean	  augmentation	   -­‐1.9	  (-­‐4.8,	  1.0)	  	   -­‐1.8	  (-­‐4.8,1.2)	   0.23	  
AI	  (P2/P1),	  %	   -­‐0.9	  (-­‐11.0,	  9.1)	  	   0.7	  (-­‐9.3,	  10.7)	   0.89	  
AI	  (AG/PP),	  %	   -­‐5.4	  (-­‐12.3,	  1.5)	  	   -­‐5.4	  (-­‐12.6,	  1.7)	   0.13	  
AI@HR75,	  %	   -­‐1.1	  (-­‐4.0	  ,	  1.8)	  	   -­‐0.8	  (-­‐3.7,	  2.2)	   0.61	  
Mean	  ESP,	  mmHg	   -­‐1.4	  (-­‐8.0,	  5.2)	  	   -­‐1.3	  (-­‐8.1,	  5.4)	   0.69	  
Data	  are	  expressed	  as	  mean	  (95%	  confidence	  interval).	  	  SBP,	  systolic	  blood	  pressure;	  DBP,	  diastolic	  blood	  
pressure;	  Tr,	  time	  to	  reflected	  wave;	  AI,	  augmentation	  index;	  AI@HR75,	  augmentation	  index	  corrected	  for	  
heart	  rate	  of	  75	  bpm;	  ESP,	  end	  systolic	  pressure	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57	  patients	  had	  PWA	  data	  recorded	  at	  both	  baseline	  and	  12	  month	  visits	  for	  comparison.	  	  	  A	  
CONSORT	  diagram,	  detailing	  explanations	  for	  patient	  unavailability	  for	  this	  analysis	  is	  shown	  
in	  appendix	  C	  (figure	  C-­‐4).	   	  One	  patient	  in	  the	  placebo	  group	  had	  incomplete	  BP-­‐PWA	  data,	  
such	  that	  determination	  of	  mean	  peripheral	  T2,	  mean	  peripheral	  AI,	  mean	  aortic	  AI@HR75	  
and	  mean	  aortic	  Tr	  was	  based	  on	  56	  patients.	  
Change	  in	  BP-­‐PWA	  parameter	  values	  between	  baseline	  and	  12	  months	  within	  each	  treatment	  
group,	   together	   with	   comparison	   of	   intergroup	   differences	   from	   baseline,	   are	   detailed	   in	  
table	  7-­‐14.	  	  Mean	  aortic	  SBP	  and	  augmentation	  index	  were	  each	  significantly	  reduced	  in	  the	  
Allopurinol	  group	  compared	  with	  the	  Placebo	  group,	  at	  12	  month	  follow	  up.	  	  AI,	  corrected	  for	  
heart	  rate	  of	  75	  bpm,	  was	  non-­‐significantly	  reduced	  in	  the	  Allopurinol	  group.	  	  Adjustment	  for	  
baseline	  treatment	  with	  ACE-­‐I	  /	  ARB	  did	  not	  affect	  the	  observed	  results	  (table	  7-­‐15).	  	  Changes	  
in	   aortic	   mean	   systolic	   BP	   and	   in	   AI,	   from	   baseline	   during	   follow	   up,	   for	   each	   treatment	  
group,	  are	  illustrated	  in	  figures	  7-­‐9	  and	  7-­‐10.	  	  
	  
Table	  7-­‐14:	  	  BP-­‐PWA	  parameter	  change	  at	  12	  month	  follow	  up	  
Parameter	  






difference,	  (95%	  CI)	  
P	  value	  
Mean	  aortic	  SBP	  (30	  /	  27)	   -­‐4.2	  (13.3)	   3.2	  (11.0)	   -­‐6.6	  (-­‐13.0	  ,	  -­‐0.3)	   0.042	  
Mean	  aortic	  DBP	  (30	  /	  27)	   -­‐3.5	  (10.0)	   0.4	  (8.1)	   -­‐2.8	  (-­‐7.4	  ,	  1.8)	   0.23	  
Mean	  aortic	  Tr,	  ms	  (30	  /	  26)	   0.42	  (7.33)	   -­‐0.33	  (5.56)	   1.43	  (-­‐1.92	  ,	  4.77)	   0.40	  
Mean	  augmentation	  (30	  /	  27)	   -­‐1.6	  (7.7)	   2.1	  (5.8)	   -­‐3.9	  (-­‐7.1,	  -­‐0.70)	   0.018	  
AI	  (P2/P1),	  %	  (30	  /	  27)	   -­‐2.5	  (15.4)	   5.0	  (19.3)	   -­‐9.4	  (-­‐17.3,	  -­‐1.5)	   0.02	  
AI	  (AG/PP),	  %	  (30	  /	  27)	   -­‐1.6	  (7.2)	   2.4	  (8.9)	   -­‐4.4	  (-­‐7.9	  ,	  -­‐1.0)	   0.013	  
AI@HR75,	  %	  (30	  /	  26)	   -­‐0.6	  (6.5)	   1.8	  (9.1)	   -­‐3.0	  (-­‐6.6	  ,	  0.6)	  	   0.10	  
Mean	  ESP,	  mmHg	  (30	  /	  27)	   -­‐4.5	  (13.8)	   2.0	  (10.7)	   -­‐6.0	  (-­‐12.4,	  0.4)	  	   0.07	  
Data	  are	  expressed	  as	  mean	  (standard	  deviation),	  unless	  otherwise	  stated.	  	  SBP,	  systolic	  blood	  pressure	  
(mmHg);	  DBP,	  diastolic	  blood	  pressure	  (mmHg);	  Tr,	  time	  to	  reflected	  wave;	  AI,	  augmentation	  index;	  
AI@HR75,	  augmentation	  index	  corrected	  for	  heart	  rate	  of	  75	  bpm;	  ESP,	  end	  systolic	  pressure	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Table	  7-­‐15:	  	  BP-­‐PWA	  parameter	  change	  at	  12	  month	  follow	  up,	  
adjusted	  for	  treatment	  with	  ACE-­‐I	  /	  ARB	  at	  baseline	  
Parameter	  
(n,	  Allopurinol	  /	  Placebo)	  
Mean	  intergroup	  
difference	  
Adjusted	  for	  treatment	  
with	  	  ACE-­‐I	  /	  ARB	  
Adjusted	  
P	  value	  
Mean	  aortic	  SBP,	  mmHg	   -­‐6.6	  (-­‐13.0	  ,	  -­‐0.3)	   -­‐7.1	  (-­‐13.4,	  -­‐0.7)	   0.031	  
Mean	  aortic	  DBP,	  mmHg	   -­‐2.8	  (-­‐7.4	  ,	  1.8)	   -­‐3.0	  (-­‐7.6,	  1.6)	  	   0.20	  
Mean	  aortic	  Tr,	  ms	   1.43	  (-­‐1.92	  ,	  4.77)	   1.42	  (-­‐1.99,	  4.82)	  	   0.41	  
Mean	  augmentation	   -­‐3.9	  (-­‐7.1,	  -­‐0.70)	   -­‐4.1	  (-­‐7.4,	  -­‐0.9)	  	   0.014	  
AI	  (P2/P1),	  %	   -­‐9.4	  (-­‐17.3,	  -­‐1.5)	   -­‐9.6	  (-­‐17.6,	  -­‐1.7)	   0.019	  
AI	  (AG/PP),	  %	   -­‐4.4	  (-­‐7.9	  ,	  -­‐1.0)	   -­‐4.4	  (-­‐8.0,	  -­‐0.9)	  	   0.014	  
AI@HR75,	  %	   -­‐3.0	  (-­‐6.6	  ,	  0.6)	  	   -­‐3.0	  (-­‐6.7,	  0.6)	  	   0.10	  
Mean	  ESP,	  mmHg	   -­‐6.0	  (-­‐12.4,	  0.4)	  	   -­‐6.3	  (-­‐12.7,	  0.2)	   0.06	  
Data	  are	  expressed	  as	  mean	  (95%	  confidence	  interval).	  	  SBP,	  systolic	  blood	  pressure;	  DBP,	  diastolic	  blood	  
pressure;	  Tr,	  time	  to	  reflected	  wave;	  AI,	  augmentation	  index;	  AI@HR75,	  augmentation	  index	  corrected	  for	  
heart	  rate	  of	  75	  bpm;	  ESP,	  end	  systolic	  pressure	  
	  
Post	  hoc	  analyses	  
Repeated	  statistical	  analysis,	   including	  adjustment	   for	   the	  observed	  change	   in	  SUA,	  did	  not	  
affect	   the	   difference	   in	   change	   in	   mean	   central	   aortic	   systolic	   BP	   observed	   between	  
treatment	   groups	   at	   either	   6	   (-­‐2.3mmHg,	   95%	  CI;	   -­‐9.9,	   5.3mmHg,	   p=0.55)	   or	   12	  months	   (-­‐
8.0mmHg,	  95%	  CI;	  -­‐15.5,	  -­‐0.4mmHg,	  p=0.039).	  
On	  identifying	  a	  statistically	  significant	  difference	  in	  12	  month	  change	  in	  mean	  central	  aortic	  
systolic	  BP	  between	  treatment	  groups,	  we	  performed	  correlation	  between	  baseline	  SUA	  and	  
baseline	  mean	  central	  aortic	  systolic	  BP	  and	  between	  change	  in	  SUA	  at	  6	  and	  12	  months	  and	  
change	  in	  mean	  central	  aortic	  systolic	  BP	  at	  6	  &	  12	  months.	  	  The	  correlation	  coefficient	  and	  
accompanying	  p	  value	  for	  each	  correlation	  are	  detailed	  in	  table	  7-­‐16.	   	  We	  identified	  a	  non-­‐
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significant	  trend	  toward	  a	  linear	  correlation	  between	  baseline	  mean	  central	  aortic	  systolic	  BP	  
and	  baseline	  SUA.	   	  We	   identified	  no	  correlation	  between	   the	  observed	  change	   in	  SUA	  and	  
change	  in	  mean	  common	  CIMT	  at	  either	  6	  or	  12	  months.	  
	  
Table	  7-­‐16:	  	  Central	  systolic	  BP	  correlations	  with	  Uric	  Acid	  
	   Allopurinol	   Placebo	   All	  
Baseline	   0.136	  (0.42)	   0.287	  (0.077)	   0.204	  (0.08)	  
Change	  at	  6	  months	   -­‐0.083	  (0.64)	   0.235	  (0.19)	   0.102	  (0.42)	  
Change	  at	  12	  months	   0.075	  (0.69)	   -­‐0.183	  (0.37)	   0.186	  (0.17)	  
Data	  are	  presented	  as	  correlation	  coefficient	  (p	  value)	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Figure	   7-­‐10:	   	   Change	   in	   Augmentation	   Index	   (AG/PP,	   %)	   between	   baseline	   and	  
subsequent	  follow-­‐up	  
	  


















































Baseline	   BP-­‐PWV	   values	   are	   detailed	   in	   table	   7-­‐3.	   	   45,	   54	   and	   51	   patients	   had	   PWV	   data	  
recorded	  at	  both	  baseline	  and	  each	  of	  1,	  6	  and	  12	  month	  visits,	  respectively,	  for	  comparison.	  	  
Change	   in	  BP-­‐PWV	  parameter	   values	  between	  baseline	   and	  1,	   6	  &	  12	  months	  within	   each	  
treatment	   group,	   together	   with	   comparison	   of	   intergroup	   changes	   from	   baseline,	   are	  
detailed	   in	   table	  7-­‐17.	   	  No	   significant	   intergroup	  difference	  was	  observed	   in	   change	   in	  BP-­‐
PWV	  from	  baseline	  at	  any	  follow	  up	  time	  point.	  	  Adjustment	  for	  treatment	  with	  ACE-­‐I	  /	  ARB	  
at	  baseline	  did	  not	  affect	  the	  observed	  results	  (table	  7-­‐18).	  	  
Table	  7-­‐17:	  	  Change	  in	  BP-­‐PWV	  at	  1,	  6	  &	  12	  month	  follow	  up	  
Time	  point	  






difference,	  (95%	  CI)	  
P	  value	  
1	  month	  (27/19)	   -­‐0.03	  (0.72)	   -­‐0.00	  (1.17)	   0.00	  (-­‐0.06	  ,	  0.06)*	   	  	  0.91	  1	  
6	  months	  (31	  /	  23)	   -­‐0.11	  (0.81)	   -­‐0.18	  (1.23)	   0.15	  (-­‐0.33,	  0.64)	   0.53	  
12	  months	  (23	  /	  18)	   -­‐0.08	  (0.97)	   -­‐0.07	  (1.15)	   0.08	  (-­‐0.51	  ,	  0.68)	   0.78	  
Data	  are	  metres	  /	  second,	  expressed	  as	  mean	  (standard	  deviation),	  unless	  otherwise	  stated.	  	  BP-­‐PWV,	  
blood	  pressure	  pulse	  wave	  velocity.	  	  ANCOVA	  natural	  log	  transformation	  1.	  
	  
Table	  7-­‐18:	  	  Change	  in	  BP-­‐PWV,	  adjusted	  for	  baseline	  treatment	  with	  ACE-­‐I	  /	  ARB	  
Time	  point	  
(n,	  Allopurinol	  /	  Placebo)	  
Mean	  intergroup	  
difference	  
Adjusted	  for	  treatment	  
with	  	  ACE-­‐I	  /	  ARB)	  
Adjusted	  
P	  value	  
1	  month	  	   0.00	  (-­‐0.06	  ,	  0.06)*	   -­‐0.01	  (-­‐0.07	  ,	  0.06)	  	   0.84	  1	  
6	  months	  	   0.15	  (-­‐0.33,	  0.64)	   0.02	  (-­‐0.04	  ,	  0.08)	  	   0.56	  1	  
12	  months	  	   0.08	  (-­‐0.51	  ,	  0.68)	   0.01	  (-­‐0.06	  ,	  0.08)	  	   0.75	  1	  
Data	  are	  expressed	  as	  mean	  (95%	  confidence	  interval).	  	  BP-­‐PWV,	  blood	  pressure	  pulse	  wave	  velocity.	  	  




Baseline	  brachial	  BP	  values	  are	  detailed	  in	  table	  7-­‐3.	  	  74,	  71,	  72	  and	  60	  patients	  had	  brachial	  
BP	  data	  recorded	  at	  both	  baseline	  and	  each	  of	  1,	  3,	  6	  and	  12	  month	  visits,	  respectively,	  for	  
comparison.	  	  	  
Change	  in	  brachial	  artery	  systolic	  and	  diastolic	  BP	  values,	  between	  baseline	  and	  1,	  3,	  6	  &	  12	  
month	   follow	   up	   within	   each	   treatment	   group,	   together	   with	   comparison	   of	   intergroup	  
changes	  from	  baseline,	  are	  detailed	  in	  tables	  7-­‐19	  and	  7-­‐20,	  respectively.	  	  Absolute	  brachial	  
artery	  systolic	  and	  diastolic	  values	  at	  baseline,	  1,	  3,	  6	  &	  12	  months	  are	  detailed,	  respectively,	  
in	  tables	  C-­‐2	  and	  C-­‐3	  (appendix	  C).	  	  Adjustment	  for	  baseline	  treatment	  with	  ACE-­‐I	  /	  ARB	  did	  
not	   affect	   the	   observed	   results	   for	   either	   systolic	   (table	   7-­‐21)	   or	   diastolic	   (table	   7-­‐22)	  
comparisons.	   	   Change	   in	   brachial	   artery	   systolic	   BP	   (mmHg)	   between	   baseline	   and	  
subsequent	  follow-­‐up	  is	  illustrated	  in	  figure	  7-­‐11.	  	  	  
	  
Table	  7-­‐19:	  	  Brachial	  artery	  systolic	  BP	  parameter	  change	  at	  1,	  3,	  6	  &	  12	  month	  follow	  up	  
Time	  point	  	  






difference,	  (95%	  CI)	  
P	  value	  
1	  month	  (38/36)	   -­‐5.9	  (15.2)	   -­‐3.3	  (11.8)	   -­‐1.9	  (-­‐7.9	  ,	  4.2)	   0.54	  
3	  months	  (35/36)	   -­‐1.5	  (18.1)	   3.7	  (16.8)	   -­‐4.9	  (-­‐12.0	  ,	  2.2)	   0.17	  
6	  months	  (37/35)	   -­‐4.5	  (17.6)	   1.5	  (15.2)	   -­‐5.4	  (-­‐13.1	  ,	  2.2)	   0.16	  
12	  months	  (30/30)	   -­‐5.1	  (15.8)	   5.0	  (12.7)	   -­‐9.9	  (-­‐17.3	  ,	  -­‐2.4)	   0.01	  
Data	  are	  mmHg,	  expressed	  as	  mean	  (standard	  deviation),	  unless	  otherwise	  stated.	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Table	  7-­‐20:	  	  Brachial	  artery	  diastolic	  BP	  parameter	  change	  at	  1,	  3,	  6	  &	  12	  month	  follow	  up	  
Time	  point	  	  
(n,	  Allopurinol	  /	  Placebo)	  
Allopurinol	   Placebo	   Mean	  intergroup	  
difference,	  (95%	  CI)	  
P	  value	  
1	  month	  (38/36)	   -­‐1.8	  (6.3)	   -­‐2.4	  (9.2)	   1.9	  (-­‐1.5	  ,	  5.3)	   0.28	  
3	  months	  (35/36)	   3.4	  (8.7)	   5.4	  (11.1)	   -­‐0.4	  (-­‐4.7	  ,	  3.9)	   0.85	  
6	  months	  (37/35)	   -­‐2.1	  (7.7)	   -­‐0.2	  (8.9)	   -­‐0.9	  (-­‐4.7	  ,	  2.9)	   0.65	  
12	  months	  (30/30)	   -­‐1.9	  (7.8)	   0.5	  (8.0)	   -­‐1.4	  (-­‐5.4	  ,	  2.5)	   0.47	  





Table	  7-­‐21:	  	  Brachial	  artery	  systolic	  BP	  parameter	  change,	  adjusted	  for	  baseline	  treatment	  with	  ACE-­‐I	  &	  ARB	  
Time	  point	  	  
(n,	  Allopurinol	  /	  Placebo)	  
Mean	  intergroup	  
difference	  
Adjusted	  for	  treatment	  
with	  	  ACE-­‐I	  /	  ARB	  
Adjusted	  
P	  value	  
1	  month	  (38/36)	   -­‐1.9	  (-­‐7.9	  ,	  4.2)	   -­‐1.7	  (-­‐7.9	  ,	  4.5)	  	   0.59	  
3	  months	  (35/36)	   -­‐4.9	  (-­‐12.0	  ,	  2.2)	   -­‐6.0	  (-­‐13.2	  ,	  1.2)	  	   0.10	  
6	  months	  (37/35)	   -­‐5.4	  (-­‐13.1	  ,	  2.2)	   -­‐6.1	  (-­‐13.9	  ,	  1.7)	  	   0.12	  
12	  months	  (30/30)	   -­‐9.9	  (-­‐17.3	  ,	  -­‐2.4)	   -­‐10.2	  (-­‐17.7	  ,	  -­‐2.7)	  	   0.09	  
Data	  are	  mmHg,	  expressed	  as	  mean	  (95%	  confidence	  interval).	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Table	  7-­‐22:	  	  Brachial	  artery	  diastolic	  BP	  parameter	  change,	  adjusted	  for	  baseline	  treatment	  with	  ACE-­‐	  /	  ARB	  
Time	  point	  
(n,	  Allopurinol	  /	  Placebo)	  
Mean	  intergroup	  
difference	  
Adjusted	  for	  treatment	  
with	  	  ACE-­‐I	  /	  ARB	  
Adjusted	  
P	  value	  
1	  month	  (38/36)	   1.9	  (-­‐1.5	  ,	  5.3)	   1.7	  (-­‐1.8	  ,	  5.1)	  	   0.34	  
3	  months	  (35/36)	   -­‐0.4	  (-­‐4.7	  ,	  3.9)	   -­‐1.1	  (-­‐5.4	  ,	  3.2)	  	   0.60	  
6	  months	  (37/35)	   -­‐0.9	  (-­‐4.7	  ,	  2.9)	   -­‐0.9	  (-­‐4.8	  ,	  3.0)	  	   0.64	  
12	  month	  (30/30)	   -­‐1.4	  (-­‐5.4	  ,	  2.5)	   -­‐1.6	  (-­‐5.5	  ,	  2.3)	  	   0.42	  
Data	  are	  mmHg,	  expressed	  as	  mean	  (95%	  confidence	  interval).	  	  	  
	  
	  
7.3.3. Peripheral	  arterial	  tone	  reactive	  hyperaemia	  index	  analysis	  	  
PAT-­‐RHI	  values	  at	  baseline	  are	  detailed	  in	  table	  7-­‐3.	  	  58	  patients	  had	  peripheral	  arterial	  tone	  
data	   recorded	   at	   both	   baseline	   and	   1	   month	   visits	   for	   comparison.	   	   	   54	   patients	   had	  
peripheral	  arterial	   tone	  data	   recorded	  at	  both	  baseline	  and	  6	  month	  visits	   for	   comparison.	  	  
Due	   to	   partial	   technical	   inadequacy	   of	   peripheral	   arterial	   tone	   signal	   acquisition,	  
determination	  of	  RHI	  was	  based	  on	  52	  patients.	  	  	  
Change	  in	  PAT-­‐RHI	  values	  at	  1	  and	  6	  months,	  together	  with	  intergroup	  comparison	  of	  change	  
from	  baseline,	   are	  detailed	   in	   table	  7-­‐23.	   	  A	  non-­‐	   significant	   trend	   to	   reduction	   in	  PAT-­‐RHI	  
was	  observed	  with	   allopurinol	   treatment	   compared	  with	  placebo,	   at	   1	  month	  but	  was	  not	  
evident	  after	  6	  months.	   	  Adjustment	  for	  baseline	  treatment	  with	  ACE-­‐I	  /	  ARB	  did	  not	  affect	  
the	  observed	  results	  (table	  7-­‐24).	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7.3.4. Circulating	  markers	  of	  vascular	  biology	  analysis	  
Baseline	  vascular	  biology	  values	  are	  detailed	  in	  table	  7-­‐3.	  	  The	  coefficient	  of	  variation	  for	  the	  
ICAM-­‐1,	  e-­‐selectin,	  vWF	  &	  thrombomodulin	  assays	  were,	  respectively,	  33.7%,	  41.7%,	  32.6%	  
&	   25.4%.	   	   72	   patients	   had	   circulating	   markers	   of	   vascular	   biology	   data	   recorded	   at	   both	  
baseline	  and	  6	  month	  visits	  for	  comparison.	   	   	  Explanations	  for	  patient	  unavailability	  for	  this	  
analysis	  are	  detailed	  in	  the	  CONSORT	  diagram	  in	  figure	  7-­‐2.	  	  	  
The	  distribution	  of	  s-­‐ICAM-­‐1	  and	  s-­‐thrombomodulin	  were	  positively	  skewed	  and	  therefore	  a	  
natural	   logarithmic	   transformation	   was	   used	   before	   performing	   comparative	   analysis.	  	  
Change	   in	   circulating	   markers	   of	   vascular	   biology	   at	   6	   months,	   together	   with	   intergroup	  
comparison	   of	   change	   from	   baseline,	   are	   detailed	   in	   table	   7-­‐23.	   	   No	   significant	   difference	  
between	  groups	  was	  observed	  for	  change	  in	  any	  circulating	  markers	  of	  endothelial	  function	  
at	  6	  months,	  including	  after	  adjustment	  for	  baseline	  treatment	  with	  ACE-­‐I	  /	  ARB	  (table	  7-­‐24).	  
	  
Table	  7-­‐23:	  	  Endothelial	  function	  parameter	  change	  at	  1	  &	  6	  month	  follow	  up	  
Parameter	  
(n,	  Allopurinol	  /	  Placebo)	  
Allopurinol	   Placebo	   Mean	  intergroup	  
difference,	  (95%	  CI)	  
P	  value	  
PAT-­‐RHI	  
-­‐	  1	  month	  (31/27)	  








-­‐0.37	  (-­‐0.77,	  0.04)	  




ICAM-­‐1,ng/ml	  (37/35)	   6.4	  (33.3)	   6.1	  (40.8)	   	  	  -­‐0.00	  (-­‐0.07,	  0.07)	  1	   	  	  0.97	  1	  
e-­‐Selectin,	  ng/ml	  (37/35)	   1.36	  (5.95)	   -­‐1.77	  (6.44)	   2.41	  (-­‐0.53,	  5.35)	   0.11	  
vWF,	  units/ml	  (37/35)	   0.00	  (0.29)	   -­‐0.01	  (0.33)	   -­‐0.03	  (-­‐0.11,	  0.18)	   0.63	  
Thrombomodulin,	  ng/ml	  
(37/35)	  
95	  (398)	   3	  (291)	   	  	  0.03	  (-­‐0.02,	  0.07)	  1	   	  	  0.23	  1	  
Data	  are	  expressed	  as	  mean	  (standard	  deviation),	  unless	  otherwise	  stated.	  	  PAT-­‐AI,	  peripheral	  arterial	  
tonometry	  augmentation	  index;	  PAT-­‐RHI,	  peripheral	  artery	  tonometry	  reactive	  hyperaemia	  index;	  ICAM-­‐1,	  
inter	  cellular	  adhesion	  molecule-­‐1;	  vWF,	  von	  Willebrand	  Factor.	  	  ANCOVA	  natural	  log	  transformation	  1.	  
	  
	  228	  
Table	  7-­‐24:	  	  Endothelial	  function	  parameter	  change	  at	  1	  &	  6	  months,	  
adjusted	  for	  treatment	  with	  ACE-­‐I	  /	  ARB	  at	  baseline	  
Parameter	  
(n,	  Allopurinol	  /	  Placebo)	  
Mean	  intergroup	  
difference	  
Adjusted	  for	  treatment	  




-­‐	  1	  month	  	  
-­‐	  6	  month	  
	  
-­‐0.37	  (-­‐0.77,	  0.04)	  
-­‐0.21	  (0.58,	  0.17)	  
	  
-­‐0.37	  (-­‐0.79,	  0.05)	  




ICAM-­‐1,	  ng/ml	   	  	  -­‐0.00	  (-­‐0.07,	  0.07)	  1	  	   	  	  -­‐0.00	  (-­‐0.08,	  0.07)	  1	  	   	  	  0.93	  1	  
e-­‐Selectin,	  ng/ml	   2.41	  (-­‐0.53,	  5.35)	   2.17	  (-­‐0.81,	  5.15)	   0.15	  
vWF,	  units/ml	   -­‐0.03	  (-­‐0.11,	  0.18)	   0.03	  (-­‐0.12,	  0.17)	  	   0.69	  
Thrombomodulin,	  
ng/ml	  
	  	  0.03	  (-­‐0.02,	  0.07)	  1	   	  	  0.03	  (-­‐0.02,	  0.07)	  1	   	  	  0.25	  1	  
Data	  are	  expressed	  as	  mean	  (95%	  confidence	  interval).	  	  PAT-­‐AI,	  peripheral	  arterial	  tonometry	  augmentation	  
index;	  PAT-­‐RHI,	  peripheral	  artery	  tonometry	  reactive	  hyperaemia	  index;	  ICAM-­‐1,	  inter	  cellular	  adhesion	  




There	  was	   no	   difference	   between	   Allopurinol	   and	   Placebo	   treatment	   groups	   for	   recurrent	  
stroke,	  TIA,	  MI	  or	  any	  combination	  of	  these	  clinical	  endpoints	  (table	  7-­‐25).	  
Table	  7-­‐25:	  	  Cardiovascular	  events	  at	  12	  month	  follow-­‐up	  






%,	  (95%	  CI)	  
P	  value	  
Combined	  recurrent	  TIA	  /	  
stroke	  /	  MI	  
3	  (7.5%)	   4	  (10.0%)	   -­‐2.5%	  (-­‐14.9,	  9.9%)	   0.69	  




This	   double	   blind	   randomised	   controlled	   trial	   found	   that	   one	   year	   of	   treatment	   with	  
allopurinol	   reduced	   mean	   common	   CIMT	   progression,	   central	   systolic	   BP	   and	   arterial	  
stiffness,	   in	   patients	   with	   recent	   ischaemic	   stroke	   or	   TIA.	   	   No	   differences	   in	   either	   mean	  
maximum	   CIMT	   progression	   or	   measures	   of	   endothelial	   function	   were	   observed.	   	   These	  
results	   represent	   the	   first	   observation	   that	   allopurinol	   can	   favourably	   modify	   CIMT	  
progression	   and	   central	   BP	   and	   extends	   the	   evidence	   in	   the	   stroke	   population	   to	   include	  
sustained	  treatment	  effects	   in	  relation	  to	  arterial	  stiffness.	   	  These	  data	  provide	  evidence	   in	  
support	  of	  the	  hypothesis	  that	  XOI	  may	  reduce	  the	  risk	  of	  cardiovascular	  events.	  
	  
CIMT	  progression	  
As	   discussed	   in	   chapters	   4	   and	   5,	   there	   is	   a	   mechanistic	   basis	   for	   XOI	   having	   favourable	  
effects	  on	  CIMT.	  	  UA	  holds	  numerous	  molecular	  and	  cellular	  properties	  which	  may	  contribute	  
to	   atherogenesis,	   including	   SMC	   proliferation	   353	   and	   LDL	   oxidation	   345.	   	   In	   addition,	   XO	  
activity,	   through	   elevated	   oxidative	   stress	   and	   in	   turn	   endothelial	   dysfunction,	   holds	  
atherogenic	   properties	   376.	   	   As	   detailed	   in	   Chapter	   5,	   in	   addition	   to	   reducing	   SUA,	   XOI	   has	  
been	  shown	  to	  favourably	  modify	  both	  oxidative	  stress	  and	  endothelial	  dysfunction.	  	  XOI	  has	  
also	  been	   shown	   to	   reduce	  BP	   in	   adolescent	  hypertensives	   359	   and	  as	   shown	   in	   this	   study,	  
appears	  to	  confer	  favourable	  central	  haemodynamic	  effects	  in	  the	  stroke	  population.	  
The	   CIMT	   progression	   findings	   in	   the	   current	   study	   necessitate	   a	   degree	   of	   caution	   in	  
interpretation.	  	  Firstly,	  this	  was	  a	  small	  study	  with	  insufficient	  power	  to	  exclude	  a	  potentially	  
important	  treatment	  effect.	  	  Despite	  this,	  a	  statistically	  significant	  treatment	  effect	  in	  favour	  
of	   Allopurinol	  was	   observed.	   	  Whilst	   the	   annualised	   CIMT	   progression	   rate	   in	   the	   placebo	  
group	   exceeded	   that	   included	   in	   the	   power	   calculation,	   it	   was	   within	   95%	   confidence	  
intervals	   based	   on	   other	   population	   statistics.	   	   Nevertheless,	   reproduction	   of	   the	   current	  
finding	   in	  a	   separate	  population	   is	  needed	   to	  provide	  assurance	   that	   these	   findings	  do	  not	  
represent	  a	  type	  1	  statistical	  error.	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Secondly,	   benefit	  was	   observed	   only	   on	  mean	   common	  CIMT	   and	   not	   on	  mean	  maximum	  
CIMT	  progression.	  	  This	  may	  be	  accounted	  for	  by	  the	  observation	  that	  mean	  maximum	  CIMT	  
incorporates	   CIMT	   measurements	   at	   multiple	   carotid	   segment	   levels	   and	   represents	   an	  
inherently	   more	   variable	   measurement	   parameter	   (coefficient	   of	   variation	   in	   the	   study	  
population	  was	  26%	  for	  mean	  maximum	  CIMT	  compared	  with	  18%	  for	  mean	  common	  CIMT),	  
making	  it	  a	  less	  powerful	  outcome	  measure	  520.	  	  It	  is	  now	  accepted	  that	  mean	  common	  CIMT	  
is	   the	   recommended	   standard	   for	   reporting	   in	   both	   clinical	   practice	   and	   research	  	  	  	  	  	  	  	  	  	  	  
studies	   520, 551.	   	   The	   within	   observer	   intra-­‐class	   correlation	   coefficient	   for	   mean	   common	  
CIMT	  was	  0.87	  (95%	  CI,	  0.77	  –	  0.93)	  and	  for	  mean	  maximum	  CIMT	  was	  0.91	  (95%	  CI,	  0.79	  to	  
0.96),	   both	   of	   which	   appeared	   satisfactory.	   	   The	   study	   demonstrated	   feasibility	   of	   CIMT	  
measurement	   in	   the	   local	   population,	   provides	   data	   regarding	   CIMT	   and	   annual	   CIMT	  
progression	   in	   the	   local	   ischaemic	  stroke	  and	  TIA	  population	   to	   inform	  a	  power	  calculation	  
for	  future	  study	  and	  the	  data	  may	  be	  included	  in	  any	  future	  meta-­‐analysis.	  	  
Evidence	  which	  has	  emerged	   following	   the	   inception	  of	   this	   study	  now	  suggests	   that	  CIMT	  
progression	  may	  have	  limitations	  as	  a	  surrogate	  marker	  for	  modified	  CV	  risk	  in	  clinical	  trials.	  	  
Both	   CIMT	   and	   CIMT	   progression	   have	   been	   shown	   to	   independently	   predict	   risk	   of	  
subsequent	  cardiovascular	  events,	  including	  stroke	  526, 527.	  	  In	  the	  case	  of	  the	  latter,	  there	  is	  
now	  debate	  as	  to	  whether	  progression	  independently	  predicts	  risk	  or	  whether	  retardation	  in	  
CIMT	  progression	  by	  therapeutic	  means	  modifies	  cardiovascular	  risk,	  independently	  of	  other	  
mechanisms	   547, 548.	   	   This	   may	   reflect	   lack	   of	   sensitivity	   rather	   than	   change	   in	   CIMT	   not	  
reflecting	   CV	   risk.	   	   Nonetheless,	   the	   observation	   in	   this	   study	   that	   CIMT	   progression	   was	  
retarded	  with	  active	  treatment	  is	  encouraging	  when	  considering	  its	  potential	  in	  prevention	  of	  
atherosclerotic	  cardiovascular	  disease.	  
	  
Central	  blood	  pressure,	  arterial	  stiffness	  and	  endothelial	  function	  
Epidemiological	   studies	   have	   demonstrated	   an	   independent	   association	   between	   UA	   and	  
incident	   hypertension	   358.	   	   Both	   UA	   and	   the	   ROS	   produced	   through	   XO	   activity	   hold	  
properties	  which	   are	   implicated	   in	   the	  pathogenesis	   and	  pathophysiology	  of	   hypertension.	  	  
Uric	   acid	   exerts	   effects	   within	   the	   macula	   densa	   354,	   appears	   to	   influence	   renal	   salt	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handling	  356	  and	  exerts	  effects	  on	  the	  Renin	  angiotensin	  system	  357.	  	  Xanthine	  oxidase	  is	  likely	  
to	   represent	   a	   significant	   source	   of	   vascular	   oxidative	   stress,	   particularly	   under	  
pathophysiological	   conditions	   377.	   	   This	   is	   associated	   with	   impaired	   endothelial	   function	  
which	   is	   in	   turn	   associated	   with	   impaired	   balance	   of	   production	   of	   vasodilatory	   and	  
vasoconstrictive	  agents	  including	  NO	  and	  endothelin	  346, 376.	  	  In	  addition,	  XO	  activity	  appears	  
to	  be	   inter-­‐related	  with	  angiotensin	  II	  377, 378,	  which	   is	  part	  of	  the	  final	  common	  pathway	  in	  
initiating	   hypertensive	   change	   with	   the	   vasculature	   636.	   	   In	   recent	   years,	   evidence	   has	  
emerged	   that	   Allopurinol	   can	   reduce	   systemic	   BP.	   	   In	   an	   adolescent	   population	   with	  
hypertension	  naive	  to	  other	  antihypertensive	  therapy,	  1	  month	  of	  treatment	  with	  Allopurinol	  
resulted	  in	  a	  reduced	  BP	  of	  6.9	  /2.0	  mmHg	  359.	  	  Subsequently,	  the	  same	  group	  demonstrated	  
that	   in	   a	   similar	   population,	   uric	   acid	   reduction	   per	   se,	   achieved	   through	   treatment	   with	  
either	   Allopurinol	   or	   Probenecid,	   was	   effective	   in	   reducing	   blood	   pressure	   637.	   Studies	  
examining	  BP	  lowering	  effects	  in	  other	  hypertensive	  populations	  have	  not	  been	  forthcoming.	  
More	   recently,	   several	   studies	   have	   been	   reported	   which	   included	   indirect	   measures	   of	  
haemodynamic	   effects	   of	   allopurinol.	   	   In	   populations	   with	   CRF	   638,	   CHD	   630	   and	   DM	   224,	  
Allopurinol	  has	  been	  found	  to	  reduce	   left	  ventricular	  mass	   in	  patients	  with	  evidence	  of	   left	  
ventricular	   hypertrophy.	   	   Although	   LVH	   is	   considered	   to	   reflect	   cardiac	   after	   load	   and	  
systemic	  BP,	  the	  authors	  of	  these	  studies	  observed	  that	  the	  reduction	  in	  LV	  mass	  appeared	  to	  
occur	   independently	   of	   any	   treatment	   effect	   on	   BP	   (though	   the	   studies	   may	   have	   lacked	  
power	   to	   demonstrate	   a	   BP	   lowering	   effect	   per	   se).	   	   This	   has	   raised	   the	   question	   as	   to	  
whether	  Allopurinol	  has	  the	  potential	  to	  reduce	  BP	  in	  these	  populations	  but	  also	  as	  to	  how	  
Allopurinol	  confers	  favourable	  effects	  on	  LV	  mass	  if	  this	  is	  not	  through	  reduction	  in	  systemic	  
BP.	  
Several	   potential	   mechanisms	   of	   BP	   independent	   improvement	   in	   LV	   mass	   have	   been	  
proposed.	   	   Firstly,	   reduced	   arterial	   stiffness	  may	   reduce	   cardiac	   afterload,	   even	   if	   brachial	  
artery	   BP	   is	   unchanged	   638.	   	   Secondly,	   Allopurinol	   has	   been	   shown	   to	   reduce	   oxygen	  
consumption	  by	   the	  myocardium	  639	  and	   reduces	  oxidative	   stress	  which	  may	  play	  a	   role	   in	  
left	   ventricular	   hypertrophy	   640.	   	   In	   addition,	   Allopurinol	   appears	   to	   confer	   anti-­‐ischaemia	  
effects.	   	   In	  patients	  with	  angina,	  treatment	  was	  associated	  with	   improved	  exercise	  capacity	  
and	  time	  to	  ST	  depression	  on	  ECG	  monitoring	  439.	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The	  data	  in	  the	  current	  study	  may	  provide	  an	  additional	  mechanism	  which	  could	  account	  for	  
findings	   in	   respect	  of	  LV	  mass.	   	  A	  significant	   reduction	   in	  central	  mean	  systolic	  BP,	  derived	  
through	   BP-­‐PWA,	   was	   observed	   with	   12	   months	   of	   Allopurinol	   therapy.	   	   Central	   BP	  
measurement	   may	   represent	   a	   better	   predictive	   tool	   than	   brachial	   BP	   for	   risk	   of	  
cardiovascular	  events	  588, 589,	  which	  may	  reflect	  central	  BP	  more	  accurately	  reflecting	  cardiac	  
afterload	  and	  the	  pressure	  to	  which	  coronary	  and	  cerebral	  arteries	  are	  exposed.	  
Pleiotropic	  effects	  of	  BP	  agents	  with	  apparent	  superiority	  have	  been	  proposed	  as	  underlying	  
these	   findings.	   	   Clinical	   trials	  which	   have	   demonstrated	   differential	   reduction	   in	   risk	   of	   CV	  
events	  between	  antihypertensive	  agents,	  despite	  similar	   reductions	   in	  brachial	  BP	   591,	  have	  
also	  observed	  differential	  effects	  on	  central	  BP	  between	  agents,	  proposing	  this	  as	  a	  potential	  
mechanism	  which	  might	  account	  for	  differential	  effects	  on	  risk.	  	  Thus,	  the	  current	  findings	  of	  
central	  BP	  reduction	  offer	  a	  potential	  mechanism	  by	  which	  LV	  mass	  might	  be	  reduced	  with	  
Allopurinol.	   	   In	  addition,	   a	   significant	   reduction	   in	  brachial	   systolic	  BP	  was	  observed	   in	   the	  
current	   study	   following	   12	   months	   treatment.	   	   A	   non-­‐significant	   trend	   to	   reduction	   in	  
brachial	   SBP	   was	   observed	   at	   1,	   3	   and	   6	   months.	   	   At	   12	   months	   the	   magnitude	   of	   this	  
difference	  was	  estimated	  at	  nearly	  10	  mmHg,	   though	  95%	  confidence	   intervals	  were	  wide.	  
The	  observed	  statistically	  significant	  difference	  at	  12	  months	  was	  partly	  attributable	  to	  a	  rise	  
BP	  in	  the	  placebo	  group	  that	  exceeded	  that	  which	  would	  usually	  be	  expected	  in	  a	  clinical	  trial	  
population.	   	  A	  clinical	   trial	  of	   the	  effect	  of	  Allopurinol	  on	  24-­‐hour	  ambulatory	  BP	  measures	  
should	  be	  performed	  to	  confirm	  the	  effect	  on	  blood	  pressure.	  
Augmentation	  index	  was	  significantly	  reduced	  with	  allopurinol	  therapy.	  	  AI,	  standardised	  for	  
a	   heart	   rate	   of	   75	   bpm	   was	   non-­‐significantly	   reduced.	   	   It	   has	   been	   suggested	   that	   this	  
parameter	  may	  represent	  a	  better	  measure	  for	  AI	  reporting	  641,	  though	  the	  epidemiological	  
association	  with	  risk	  of	  cardiovascular	  events	  is	  established	  for	  uncorrected	  AI	  642.	  	  In	  a	  small	  
study	  with	   three	  month	   follow	  up,	   allopurinol	   treatment	  was	   previously	   associated	  with	   a	  
reduction	   in	   AI	   427.	   	   The	   current	   study	   results	   confirm	   this	   finding	   in	   a	   larger	   sample	   and	  
provide	  evidence	  of	  a	  sustained	  treatment	  effect.	  	  	  
The	  reduction	  in	  central	  BP	  may	  be	  attributable	  to	  this	  accompanying	  observed	  reduction	  in	  
arterial	  stiffness,	  which	  represents	  a	  key	  determinant	  of	  central	  BP	  580.	   	   In	  turn,	  endothelial	  
function	   is	   a	   determinant	   of	   arterial	   stiffness	   563.	   	   In	   patients	   with	   cardiovascular	   disease,	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large	  artery	  endothelial	  function	  is	  improved	  with	  allopurinol	  therapy	  627	  which	  also	  improves	  
endothelial	   NO	   bioavailability	   415,	   offering	   a	   potential	   mechanism	   for	   reduced	   arterial	  
stiffness	  following	  allopurinol	  treatment.	  	  Of	  note,	  carotid	  -­‐	  radial	  PWV	  was	  not	  affected	  by	  
Allopurinol	  therapy	  in	  the	  current	  study.	  	  Considered	  together	  with	  the	  AI	  findings,	  effects	  on	  
arterial	  stiffness	  may	  be	  conferred	  through	  greater	  effects	  on	  larger	  artery	  function	  relative	  
to	  resistance	  vessels.	  
No	   significant	   benefit	   on	   endothelial	   function,	   determined	   either	   as	   PAT-­‐RHI	   or	   circulating	  
markers	  of	   endothelial	   activation,	  was	  observed	   in	   the	   current	   study.	   	   This	  was	   somewhat	  
unexpected	  and	  at	  odds	  with	  the	  otherwise	  beneficial	  effects	  observed.	  	  The	  study	  may	  have	  
lacked	   statistical	   power	   for	   this	   outcome,	   as	   the	   PAT	   RHI	   outcome	   measurement	   was	  
included	  only	  after	   the	  study	  commenced,	   limiting	  the	  number	  of	  participants	  available	   for	  
analysis	  of	  this	  endpoint.	  	  In	  addition,	  PAT	  RHI	  represents	  a	  composite	  of	  both	  large	  and	  small	  
arterial	   function.	   	  Although	  both	   large	  artery	  and	  resistance	  vessel	  endothelial	   function	  are	  
each	   correlated	  with	   coronary	   endothelial	   function,	   the	   two	  measures	   are	   themselves	   less	  
well	   correlated	   619.	   	   Reported	   as	   an	   index	   of	   pulse	  wave	   amplitude,	   lack	   of	   benefit	   in	   the	  
EndoPAT	   measurement	   could	   potentially	   reflect	   reduced	   vascular	   tone	   in	   the	   context	   of	  
improved	  endothelial	  function	  overall.	  	  However,	  the	  current	  study	  lacked	  control	  measures	  
to	  further	  evaluate	  this	  hypothesis.	  	  	  
Circulating	  markers	  of	  vascular	  inflammation	  and	  endothelial	  function	  were	  also	  unchanged	  
following	   6	   months	   of	   treatment.	   	   In	   a	   previous	   study	   of	   Allopurinol	   effects	   in	   a	   stroke	  
population,	   2	   months	   of	   treatment	   was	   associated	   with	   a	   reduction	   in	   ICAM-­‐1	   compared	  
with	  Placebo	  therapy	  414.	  	  This	  result	  appeared	  to	  be	  driven	  by	  an	  attenuation	  of	  rise	  in	  ICAM-­‐
1	   in	   the	   Allopurinol	   group	   following	   stroke.	   	   It	   may	   be	   that	   Allopurinol	   confers	   beneficial	  
effects	   with	   respect	   to	   the	   initial	   propensity	   to	   endothelial	   activation	   in	   the	   period	  
immediately	   following	   an	   ischaemic	   event	   but	   that	   after	   a	   6	   month	   interval,	   endothelial	  





Relative	  importance	  of	  UA	  reduction	  in	  mediating	  beneficial	  effects	  of	  XOI	  	  
Previous	   studies	   in	   patients	   with	   heart	   failure	   suggest	   the	   beneficial	   effects	   of	   allopurinol	  
may	   be	   independent	   of	   any	   reduction	   in	   SUA	   299.	   	   The	   current	   study	   utilised	   only	   one	  UA	  
lowering	   therapeutic	   strategy	   and	   no	   measure	   of	   oxidative	   stress.	   	   It	   was	   therefore	   not	  
designed	  to	  further	  differentiate	  the	  mechanism	  of	  benefit	  of	  Allopurinol.	  	  However,	  in	  post-­‐
hoc	  analysis,	  no	  correlation	  between	  the	  observed	  change	  in	  UA	  and	  change	  in	  either	  mean	  
common	   CIMT	   or	   central	   BP	   was	   identified,	   potentially	   indicating	   a	   UA	   independent	  
treatment	  effect.	  	  Statistical	  analysis	  with	  adjustment	  for	  the	  observed	  change	  in	  UA	  did	  not	  
affect	  the	  observed	  results	  for	  either	  CIMT	  or	  central	  BP	  outcomes.	  	  
Study	   participants	   were	   enrolled	   irrespective	   of	   their	   baseline	   UA	   level.	   	   Consequently,	  
although	  highly	  statistically	  significant,	  the	  observed	  therapeutic	  reduction	  in	  UA	  level	  (0.08	  
mmol/l)	  was	  relatively	  modest,	  and	  from	  a	  lower	  baseline	  level	  (0.31	  mmol/l),	  compared	  with	  
studies	  which	  selected	  patients	  based	  on	  elevated	  serum	  UA.	  	  Baseline	  uric	  acid	  did	  not	  differ	  
significantly	  between	  patients	  treated	  with	  known	  uricosuric	  agents	  and	  those	  who	  were	  not	  
(SUA	   0.33mmol/l	   vs.	   0.30mmol/l,	   p	   =	   0.10).	   	   Post	   hoc	   analysis	   of	   the	   largest	   trial	   of	   XO	  
inhibition	  to	  date,	  the	  OPT-­‐CHF	  study,	  suggested	  benefit	  of	  XO	  inhibition	  may	  be	  limited	  to	  
those	   with	   baseline	   hyperuricaemia	   398,	   with	   no	   difference	   observed	   between	   active	  
treatment	   and	   placebo	   groups	   in	   the	   trial	   as	   a	   whole.	   	   Conversely,	   improved	   endothelial	  
function	  has	  been	  reported	  with	  XO	  inhibition	  in	  patients	  with	  increased	  cardiovascular	  risk	  
despite	   apparently	  normal	   levels	  of	  UA	   434.	   	   It	   is	   feasible	   that	  patient	   subgroups	  exist	  who	  
might	  experience	  differential	  benefit	  of	  XOI,	  according	   to	   their	  baseline	  UA	   level.	   	  Through	  
inclusion	   of	   patients	   irrespective	   of	   baseline	   UA	   level,	   the	   results	   of	   this	   study	   provide	  
evidence	  of	  treatment	  benefit	  in	  a	  general	  population	  with	  normal	  range	  uricaemia.	  	  	  	  	  	  
	  
Safety	  profile	  
The	  study	  provides	  reassurance	  regarding	  the	  safety	  profile	  of	  allopurinol	  in	  this	  population:	  
treatment	   dose	   was	   well	   tolerated	   during	   the	   study,	   with	   high	   concordance	   documented	  
through	   pill	   counts	   and	   confirmed	  with	   the	   observed	   reduction	   in	   serum	  UA.	   	   No	   serious	  
adverse	  reactions	  attributable	  to	  active	  study	  medication	  were	  observed.	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Limitations	  
Although	  the	  study	  was	  a	  double	  blind	  RCT,	  thereby	  minimising	  likelihood	  of	  bias,	  there	  were	  
several	   limitations	  which	  must	  be	  considered.	   	  Firstly,	  as	  discussed	  above,	  the	  study	   lacked	  
power	   to	  detect	   a	  CIMT	  progression	   treatment	  effect	  between	  groups.	   	   Progression	   in	   the	  
placebo	  group	  was	  higher	  than	  anticipated	  and	  the	  CIMT	  findings	  require	  reproduction	  in	  a	  
separate	  population.	  
Secondly,	  the	  study	  utilised	  only	  one	  UA	  lowering	  strategy	  and	  was	  therefore	  not	  designed	  to	  
further	   differentiate	   the	   mechanism	   of	   benefit	   in	   terms	   of	   UA	   lowering	   versus	   reduced	  
vascular	  oxidative	  stress.	  	  	  
Thirdly,	   despite	   randomisation,	   there	   were	   minor	   imbalances	   between	   treatment	   groups.	  	  
These	  included	  a	  greater	  proportion	  of	  participants	  in	  the	  placebo	  group	  with	  index	  event	  of	  
stroke	  (rather	  than	  TIA),	  diabetes	  and	  beta-­‐blocker	  treatment,	  whilst	  fewer	  had	  documented	  
hypertension,	  AF	  or	  treatment	  with	  ACE-­‐I	  /	  ARB	  agents.	  	  The	  difference	  in	  the	  proportion	  of	  
patients	  treated	  with	  ACE-­‐I	  or	  ARB	  between	  treatment	  groups	  was	  significant	  and	  potentially	  
favoured	  the	  observation	  of	  a	  treatment	  effect	  in	  favour	  of	  allopurinol.	  	  Therefore,	  statistical	  
analysis	  with	  adjustment	  for	  this	   imbalance	  was	  performed	  and	  found	  the	  treatment	  effect	  
on	  CIMT	  progression,	  central	  mean	  systolic	  pressure,	  brachial	  systolic	  BP	  and	  AI,	  were	  each	  
unchanged.	   	   There	   was	   no	   significant	   difference	   between	   the	   treatment	   groups	   in	  
modification	  of	  any	  therapy	  associated	  with	  reduced	  risk	  of	  cardiovascular	  events	  during	  the	  
12	  months	  of	  follow	  up.	  	  It	  is	  feasible	  that	  other	  unidentified	  confounding	  factors	  could	  have	  
influenced	  the	  observed	  results.	  
Fourthly,	  there	  was	  incomplete	  data	  available	  for	  all	  study	  outcomes	  at	  final	  follow	  up	  visits.	  	  
This	   predominantly	   reflected	   patient	   withdrawals	   but	   in	   a	   proportion	   of	   cases	   this	   was	  
attributable	   to	   technical	   inadequacy	   of	  measurements,	   particularly	   in	   the	   case	   of	   BP-­‐PWA	  
and	   BP-­‐PWV	   outcomes.	   	   Consequently,	   some	   degree	   of	   attrition	   bias	   may	   have	   been	  
introduced.	   	   	   	  However,	  patient	  withdrawals	  were	  unrelated	   to	   the	   study	   intervention	  and	  
incomplete	   availability	   of	   final	   follow	   up	   endpoint	   data	   was	   balanced	   between	   the	   two	  
treatment	  groups.	  	  Baseline	  endpoint	  parameter	  values	  in	  the	  randomised	  population	  did	  not	  
differ	   significantly	   from	   those	   in	   the	  population	  with	  data	   available	   for	   12	  month	   analysis.	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Final	  endpoint	  follow	  up	  data	  was	  available	  in	  94%,	  83%,	  87%	  and	  88%	  of	  patients	  for	  CIMT,	  
BP-­‐PWA,	  brachial	  BP	  and	  endothelial	  function,	  respectively.	  	  	  
Fifthly,	  this	  study	  did	  not	  explore	  whether	  a	  dose	  dependent	  response	  exists	  with	  treatment.	  	  
It	  is	  feasible	  that	  greater	  magnitude	  of	  benefit	  than	  that	  observed	  in	  the	  current	  study	  could	  
be	  achieved	  with	  allopurinol	  therapy;	  a	  dose-­‐dependent	  improvement	  in	  endothelial	  function	  
has	  been	  reported	  299	  and	  regression	  in	  LVH	  was	  achieved	  with	  higher	  doses	  than	  were	  used	  
in	  this	  trial	  630.	  	  	  
Finally,	  the	  study	  population	  represented	  a	  group	  of	  patients	  with	  either	  predominantly	  mild	  
severity	  ischaemic	  stroke	  or	  TIA,	  who	  were	  able	  to	  participate	  in	  repeated	  study	  visits	  over	  a	  
12	  months	  period.	   	  The	  population	  was	  neither	  restricted	  nor	  enriched	  according	  to	  stroke	  
aetiological	   criteria.	   	  As	   such,	   the	   results	  may	  not	  be	  generalisable	   to	   the	  entire	   ischaemic	  
stroke	  population.	  	  	  
	  
Conclusion	  
In	  conclusion,	  this	  randomised,	  placebo-­‐controlled	  double	  blind	  study	  extends	  the	  evidence	  
of	   sustained	   beneficial	   effects	   of	   allopurinol	   treatment	   on	   the	   vasculature	   to	   include	   the	  
stroke	  patient	  population,	  with	  effects	   including	  reductions	   in	  CIMT	  progression,	  central	  BP	  
and	  arterial	  stiffness.	   	  No	  treatment	  effect	  was	  observed	  in	  relation	  to	  studied	  measures	  of	  
endothelial	   function.	   	   These	   data	   support	   the	   hypothesis	   that	   XOI	   holds	   the	   potential	   to	  
reduce	   the	   risk	   of	   cardiovascular	   events	   and	   provide	   evidence	   supportive	   of	   further	  
evaluation	  of	  this	  therapeutic	  strategy	  in	  definitive	  clinical	  endpoint	  studies.	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Chapter	  8 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Final	  conclusions	  &	  future	  directions	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Despite	   the	   emergence	   of	   effective	   treatments	   for	   acute	   stroke,	   incomplete	   effectiveness	  
and	  applicability	  together	  with	  high	  incidence,	  mean	  that	  cerebrovascular	  disease	  remains	  a	  
leading	  cause	  of	  both	  mortality	  and	  adult	  disability.	  	  The	  burden	  of	  cerebrovascular	  disease	  is	  
set	   to	   rise	   with	   the	   effects	   of	   globalisation	   and	   expansion	   of	   the	   elderly	   population.	  	  
Preventative	  strategies	  are	  crucial	  in	  limiting	  this	  burden.	  
The	   studies	   included	   in	   this	   thesis	   address	   two	   aspects	   of	   secondary	   prevention	   following	  
ischaemic	  stroke	  and	  TIA;	  firstly,	  the	  potential	  for	  optimised	  detection	  of	  paroxysmal	  AF	  and	  
in	   turn,	   appropriate	   use	   of	   anticoagulant	   based	   secondary	   prevention;	   secondly;	   the	  
potential	   for	   a	   novel	   therapeutic	   strategy	   in	   the	   prevention	   of	   cardiovascular	   and	  
cerebrovascular	  disease;	  xanthine	  oxidase	  inhibition.	  
In	  a	  randomised	  controlled	  trial,	  including	  unselected	  patients	  with	  acute	  ischaemic	  stroke	  or	  
TIA,	  the	  routine	  addition	  of	  7	  days	  non-­‐invasive	  cardiac	  event	  monitoring	  to	  current	  guideline	  
based	   clinical	   practice,	   was	   found	   to	   significantly	   enhance	   detection	   of	   episodes	   of	  
paroxysmal	   AF	   which	   would	   justify	   initiation	   of	   anticoagulant	   therapy.	   	   Treatment	   with	  
anticoagulation	   was	   also	   significantly	   enhanced.	   	   In	   addition,	   cardiac	   event	   monitoring	  
detected	  a	  high	  proportion	  of	  patients	  in	  this	  population	  with	  evidence	  of	  briefer	  episodes	  of	  
PAF,	   the	   significance	   of	   which	   is	   uncertain,	   as	   is	   the	   appropriateness	   of	   more	   aggressive	  
treatment	  with	  anticoagulation.	  	  This	  study	  provides	  the	  first	  randomised	  evidence,	  to	  guide	  
clinicians	   in	   the	   approach	   to	   investigation	   for	   initially	   occult	   paroxysmal	   AF	   in	   unselected	  
patients	  with	  ischaemic	  stroke	  and	  TIA.	  	  	  Clinical	  practice	  based	  on	  existing	  clinical	  guidelines	  
appears	   inadequate	   and	   this	   study	   should	   allow	   the	   level	   of	   evidence	   and	   strength	   of	  
recommendations	  of	  future	  guidelines	  to	  be	  improved.	  
In	   a	   related	   observational	   study,	   the	   PPV	   of	   AF	   detection	   in	   the	   immediate	   aftermath	   of	  
ischaemic	  stroke	  and	  TIA,	  for	  AF	  subsequently	  evident	  after	  a	  90	  day	  interval,	  was	  found	  to	  
be	  high.	   	  This	  suggests	  that	  AF	  detected	  through	  early	  monitoring	   is	  unlikely	  to	  represent	  a	  
transient	   phenomenon,	   attributable	   to	   transient	   physiological	   conditions	   associated	   with	  
acute	   ischaemia.	   	  Accordingly,	  treatment	  decisions	  based	  on	  AF	   identification	   in	  this	  period	  
appear	  justified.	  	  Negative	  predictive	  value	  of	  early	  monitoring	  for	  subsequent	  AF	  detection	  
was	  only	  moderate,	  raising	  the	  question	  as	  to	  whether	  repeated	  interval	  monitoring	  might	  be	  
justified	   in	   selected	  patients.	   	   This	  question,	   together	  with	   clarification	  of	   the	   relevance	  of	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brief	  episodes	  of	  AF	  detectable	  early	  after	  stroke,	  should	  form	  the	  basis	  for	  future	  research	  in	  
this	  area.	  
A	  systematic	   review	  and	  meta-­‐analysis	   confirmed	   that	  XOI	  confers	  beneficial	  effects	  within	  
the	  vasculature,	  including	  improved	  endothelial	  function	  and	  reduced	  circulating	  markers	  of	  
oxidative	  stress.	  	  Whilst	  evidence	  is	  available	  which	  supports	  the	  hypothesis	  that	  XOI	  has	  the	  
potential	  to	  reduce	  the	  risk	  of	  cardiovascular	  events,	  clinical	  endpoint	  studies	  are	  lacking	  and	  
studies	  demonstrating	  beneficial	  effects	  on	  surrogate	  markers	  of	  outcome	  have	  tended	  to	  be	  
of	   limited	   duration.	   	   The	   optimal	   dose	   and	   target	   population	   for	   treatment	   remains	  
uncertain,	  as	  does	  the	  mechanism	  of	  benefit.	  
In	  a	  double	  blind,	  randomised,	  placebo	  controlled	  trial,	  which	  included	  patients	  with	  recent	  
ischaemic	  stroke	  or	  TIA,	  one	  years’	  treatment	  with	  the	  XO	  inhibitor	  Allopurinol	  was	  found	  to	  
reduce	  mean	  common	  CIMT	  progression,	  central	  systolic	  BP	  and	  arterial	  stiffness.	  	  Treatment	  
was	  well	  tolerated,	  with	  no	  treatment	  related	  serious	  adverse	  reactions.	  	  Observed	  beneficial	  
treatment	  effects	  may	  have	  been	  unrelated	  to	  the	  observed	  reduction	  in	  UA,	  though	  further	  
study	   is	   required	   to	   fully	   differentiate	   underlying	   mechanisms.	   	   No	   treatment	   effect	   was	  
observed	   in	   relation	   to	   studied	  measures	  of	  endothelial	   function.	   	   The	   study	  extended	   the	  
evidence	  of	  XOI	  treatment	  effects	  to	  sustained	  effects	  on	  arterial	  stiffness	  within	  the	  stroke	  
patient	   population	   and	   to	   surrogate	   measurements	   of	   CIMT	   progression	   and	   central	   BP.	  	  
These	   data	   support	   the	   hypothesis	   that	   XOI	   holds	   the	   potential	   to	   reduce	   cardiovascular	  
events	  and	  provide	  evidence	  supportive	  of	  further	  evaluation	  of	  this	  therapeutic	  strategy	  in	  
definitive	  clinical	  endpoint	  studies.	  
In	   this	   regard,	   a	   randomised	   double	   blind	   placebo	   controlled	   trial	   is	   planned	   which	   will	  
evaluate	   Allopurinol	   in	   patients	  with	   ischaemic	   stroke	   or	   TIA	   in	   relation	   to	   each	   of;	   white	  
matter	   hyperintensities	   and	   silent	   brain	   infarction	   (on	   MRI);	   LVH	   regression;	   peripheral	  
arterial	   BP	   and	   clinical	   outcomes,	   including	   both	   measures	   of	   cognition	   and	   rates	   of	  
cardiovascular	   events.	   	   The	   study	   aims	   to	   definitively	   establish	   whether	   allopurinol	   has	  
beneficial	  effects	  on	  three	  powerful	  surrogate	  endpoints	  for	  adverse	  outcomes	  after	  stroke	  
and	   thereby	  allow	  a	  pivotal	   large	   scale	   clinical	   endpoint	   study	   to	  be	  designed,	   funded	  and	  
implemented.	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Table	  A-­‐1:	  Sensitivity,	  specificity,	  PPV	  &	  NPV	  for	  SP	  investigation	  detected	  AF	  at	  90	  days,	  in	  
the	  SP,	  SP-­‐AM	  and	  combined	  study	  groups,	  for	  corresponding	  duration	  AF	  episodes	  after	  90	  
days	  	  
	   Sensitivity	   Specificity	   PPV	   NPV	  
SP	  group	  90	  “Sustained”	  PAF	   29	  (4	  -­‐	  71)	   95	  (74	  -­‐	  100)	   67	  (9	  -­‐	  99)	   78	  (56	  -­‐	  93)	  
SP	  group	  90	  “any	  duration”	  
PAF	  
19	  (4	  -­‐	  46)	   100	  (74	  -­‐	  100)	   100	  (37	  -­‐	  100)	   44	  (23	  -­‐	  66)	  
SP-­‐AM	  group	  90	  “Sustained”	  
PAF	  
57	  (18	  –	  90)	   88	  (70	  –	  100)	   80	  (28	  –	  100)	   83	  (59	  –	  96)	  
SP-­‐AM	  group	  90	  “any	  
duration”	  PAF	  
43	  (18	  –	  71)	   89	  (52	  –	  100)	   86	  (42	  –	  100)	   50	  (25	  –	  75)	  
	  
Combined	  group	  90	  
“Sustained”	  PAF	  
43	  (18	  -­‐	  71)	   94	  (81	  -­‐	  99)	   75	  (35	  -­‐	  97)	   81	  (65	  -­‐	  91)	  
Combined	  group	  90	  “any	  
duration”	  PAF	  
30	  (15	  -­‐	  49)	   95	  (74	  -­‐	  100)	   90	  (56	  -­‐	  100)	   46	  (30	  -­‐	  63)	  
Data	  are	  presented	  as	  %	  (95%	  CI).	  	  SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  
monitoring;	  PAF,	  paroxysmal	  atrial	  fibrillation;	  PPV,	  positive	  predictive	  value;	  NPV,	  negative	  predictive	  value	  
	  
Table	  A-­‐2:	  Sensitivity,	  specificity,	  PPV	  &	  NPV	  for	  all	  combined	  Study	  1	  investigations	  at	  90	  
days,	   in	   the	   SP-­‐AM	  and	   combined	   study	   groups,	   for	   corresponding	  duration	  AF	   episodes	  
after	  90	  days	  
	   Sensitivity	   Specificity	   PPV	   NPV	  
SP-­‐AM	  Group	  90	  “Sustained”	  
PAF	  
81	  (29	  -­‐	  96)	   94	  (70	  -­‐	  100)	   83	  (36	  -­‐	  100)	   88	  (64	  -­‐	  99)	  
SP-­‐AM	  Group	  90	  “any	  
duration”	  PAF	  
79	  (29	  -­‐	  96)	   89	  (52	  -­‐	  100)	   92	  (62	  -­‐	  100)	   73	  (39	  -­‐	  94)	  
Combined	  Group	  90	  
“Sustained”	  PAF	  
50	  (23	  –	  77)	   94	  (81	  –	  99)	   78	  (40	  –	  97)	   83	  (67	  –	  93)	  
	  
Combined	  Group	  90	  “any	  
duration”	  PAF	  
47	  (28	  –	  66)	   95	  (74	  –	  100)	   93	  (68	  –	  100)	   53	  (35	  –	  70)	  
	  
Data	  are	  presented	  as	  %	  (95%	  CI).	  	  SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  
monitoring;	  PAF,	  paroxysmal	  atrial	  fibrillation;	  PPV,	  positive	  predictive	  value;	  NPV,	  negative	  predictive	  value	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Table	  A-­‐3:	  Sensitivity,	  specificity,	  PPV	  &	  NPV	  of	  “any	  duration”	  PAF,	  on	  SP	  investigations	  at	  
90	   days,	   in	   the	   SP,	   SP-­‐AM	   and	   combined	   study	   groups,	   for	   “sustained”	   duration	   PAF	   on	  
interval	  R-­‐test	  investigation	  after	  90	  days	  
	   Sensitivity	   Spec	   PPV	   NPV	  
SP-­‐AM	  Group	  SP	  90	   71	  (29	  –	  96)	   88	  (62	  –	  98)	   71	  (29	  –	  96)	   88	  (62	  –	  98)	  
SP	  Group	  SP	  90	   29	  (4	  –	  71)	   95	  (74	  –	  100)	   67	  (9	  –	  99)	   78	  (56	  –	  93)	  
Combined	  Group	  SP	  90	   50	  (23	  –	  77)	   91	  (77	  –	  98)	   70	  (35	  –	  93)	   82	  (67	  –	  93)	  
Data	  are	  presented	  as	  %	  (95%	  CI).	  	  SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  
monitoring;	  PAF,	  paroxysmal	  atrial	  fibrillation;	  PPV,	  positive	  predictive	  value;	  NPV,	  negative	  predictive	  value	  
	  
	  
Table	  A-­‐4:	  Sensitivity,	  specificity,	  PPV	  &	  NPV	  of	  “any	  duration”	  PAF,	  on	  all	  combined	  Study	  
1	   investigations	   at	   90	   days,	   in	   the	   SP-­‐AM	   and	   combined	   study	   groups,	   for	   “sustained”	  
duration	  PAF	  on	  interval	  R-­‐test	  investigation	  
	   Sensitivity	   Spec	   PPV	   NPV	  
SP-­‐AM	  Group	  initial	  R	  &	  SP	  
90	  
100	  (65	  –	  100)	   69	  (41	  –	  89)	   58	  (28	  –	  85)	   100	  (76	  –	  100)	  
Combined	  Group	  R	  &	  SP	  90	   64	  (35	  –	  87)	   83	  (66	  –	  93)	   60	  (32	  –	  84)	   85	  (69	  –	  95)	  
Data	  are	  presented	  as	  %	  (95%	  CI).	  	  SP,	  standard	  practice;	  SP-­‐AM,	  standard	  practice	  plus	  additional	  
monitoring;	  PAF,	  paroxysmal	  atrial	  fibrillation;	  PPV,	  positive	  predictive	  value;	  NPV,	  negative	  predictive	  value	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Table	  B-­‐1:	  Sensitivity	  analysis	  for	  brachial	  artery	  FMD	  studies	  
Study	  removed	   I2	   Mean	  Difference	  (95%	  CI)	   P	  value	  
Doehner	  2002	   82%	   2.22	  (-­‐0.42,	  4.86)	   0.10	  
Guthikonda	  2004	   81%	   2.07	  (-­‐0.42,	  4.55)	   0.10	  
El	  Solh	  2006	   82%	   2.43	  (-­‐0.46,	  5.31)	   0.10	  
Eskurza	  2006	   0%	   3.36	  (2.00,	  4.71)	   <0.00001	  
Yiginer	  2008	   81%	   2.43	  (-­‐0.51,	  5.37)	   0.11	  
FMD	  data	  are	  expressed	  as	  a	  %	  change	  in	  vessel	  diameter	  
	  
Table	  B-­‐2:	  Sensitivity	  analysis	  for	  venous	  occlusion	  plethysmography	  FBF	  studies	  
Study	  removed	   I2	   Mean	  Difference	  (95%	  CI)	   P	  value	  
O’Driscoll	  1999	   6%	   84.80	  (54.55,	  115.05)	   <0.00001	  
Butler	  2000	   64%	   55.83	  (-­‐5.78,	  117.43)	   0.08	  
Farquharson	  2002	   71%	   72.13	  (2.14,	  142,11)	   0.04	  
Guthikonda	  2003	   64%	   60.66	  (11.33,	  109.98)	   0.02	  
George	  2006	   71%	   67.11	  (-­‐9.27,	  143.50)	   0.09	  
FBF	  data	  are	  expressed	  as	  %	  change	  in	  flow	  relative	  to	  non-­‐infused	  control	  arm	  
	  
Table	  B-­‐3:	  Sensitivity	  analysis	  for	  MDA	  studies	  
Study	  removed	   I2	   Mean	  Difference	  (95%	  CI)	   P	  value	  
Heunks	  1999	   92%	   -­‐0.53	  (-­‐0.85,	  -­‐0.20)	   0.001	  
Butler	  2000	   93%	   -­‐0.75	  (-­‐1.21,	  -­‐0.30)	   0.001	  
Farquharson	  2002	   92%	   -­‐0.48	  (-­‐0.79,	  -­‐0.17)	   0.002	  
Desco	  2002	   93%	   -­‐0.75	  (1.24,	  -­‐0.26)	   0.003	  
El	  Solh	  2006	   94%	   -­‐0.64	  (-­‐1.01,	  -­‐0.27)	   0.0006	  
Yiginer	  2008	   86%	   -­‐0.34	  (-­‐0.57,	  -­‐0.12)	   0.003	  
MDA	  data	  are	  expressed	  as	  nmol/ml	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Figure	  B-­‐1:	  	  Forrest	  plot	  detailing	  end	  of	  treatment	  phase	  brachial	  artery	  FMD	  (%	  change	  in	  




Figure	  B-­‐2:	  	  Forrest	  plot	  detailing	  end	  of	  treatment	  phase	  FBF	  response	  to	  ACh	  (%	  change	  in	  




Figure	  B-­‐3:	  	  Forrest	  plot	  detailing	  end	  of	  treatment	  phase	  circulating	  MDA	  (nmol/ml);	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Table	  C-­‐1:	  Baseline	  outcome	  parameter	  values	  for	  subgroups	  with	  complete	  data	  available	  
for	  interval	  comparison	  	  
	  
Study	  sample,	  n	  
	  
Allopurinol	   Placebo	   All	  
Uric	  acid,	  mmol/l	  
Randomised,	  37	  /	  40	   0.32	  (0.09)	   0.31	  (0.08)	   0.32	  (0.09)	  
1	  month	  analysis,	  33	  /	  36	   0.32	  (0.10)	   0.30	  (0.08)	   0.31	  (0.09)	  
3	  month	  analysis,	  34	  /37	   0.32	  (0.10)	   0.30	  (0.08)	   0.31	  (0.09)	  
6	  month	  analysis,	  34	  /	  35	   0.31	  (0.09)	   0.30	  (0.08)	   0.31	  (0.09)	  
12	  month	  analysis,	  34	  /	  34	   0.32	  (0.09)	   0.30	  (0.08)	   0.31	  (0.09)	  
Mean	  maximum	  CIMT,	  mm	  
Randomised,	  39	  /	  40	   1.20	  (0.32)	   1.17	  (0.30)	   1.18	  (0.31)	  (95%	  CI,	  
1.111,	  1.249)	  
6	  month	  analysis,	  35	  /	  32	   1.21	  (0.33)	   1.20	  (0.30)	   1.20	  (0.32)	  (95%	  CI,	  
1.122,	  1.278)	  
12	  month	  analysis,	  31	  /	  34	   1.18	  (0.25)	   1.16	  (0.32)	   1.17	  (0.29)	  (95%	  CI,	  
1.098,	  1.241)	  
6	  months	  sensitivity	  analysis,	  34/31	   1.22	  (0.33)	   1.20	  (0.31)	   1.21	  (0.32)	  (95%	  CI,	  
1.131,	  1.289)	  
Mean	  common	  CIMT	  (far	  wall),	  mm	  
Randomised,	  39	  /	  40	   0.83	  (0.16)	   0.82	  (0.15)	   0.83	  (0.15)	  (95%	  CI,	  
0.796,	  0.864)	  
6	  month	  analysis,	  35	  /	  32	   0.84	  (0.16)	   0.84	  (0.15)	   0.84	  (0.16)	  (95%	  CI,	  
0.801,	  0.879)	  
12	  month	  analysis,	  31	  /	  34	   0.85	  (0.17)	   0.82	  (0.16)	   0.83	  (0.16)	  (95%	  CI,	  
0.790,	  0.870)	  
12	  months	  sensitivity	  analysis,	  
31	  /	  32	  
0.85	  (0.17)	   0.82	  (0.16)	   0.84	  (0.16)	  (95%	  CI,	  
0.780,	  0.880)	  
Mean	  aortic	  SBP,	  mmHg	  
-­‐	  Randomised	  (40	  /	  39)	  
-­‐	  1	  month	  CG	  (32/28)	  
-­‐	  6	  month	  CG	  (35	  /	  33)	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Mean	  aortic	  DBP,	  mmHg	  
-­‐	  Randomised	  (40	  /	  39)	  
-­‐	  1	  month	  CG	  (32/28)	  
-­‐	  6	  month	  CG	  (35/33)	  













Mean	  aortic	  Tr,	  ms	  
-­‐	  Randomised	  (40	  /	  38)	  
-­‐	  1	  month	  CG	  (32/26)	  
-­‐	  6	  month	  CG	  (35	  /	  32)	  













Mean	  augmentation,	  mmHg	  
-­‐	  Randomised	  (40/39)	  
-­‐	  1	  month	  CG	  (32/28)	  
-­‐	  6	  month	  CG	  (35/33)	  













AI	  (P2/P1),	  %	  
-­‐	  Randomised	  (40/39)	  
-­‐	  1	  month	  CG	  (32/28)	  
-­‐	  6	  month	  CG	  (35/33)	  













AI	  (AG/PP),	  %	  
-­‐	  Randomised	  (40/39)	  
-­‐	  1	  month	  CG	  (32/28)	  
-­‐	  6	  month	  CG	  (35/33)	  














-­‐	  Randomised	  (40/39)	  
-­‐	  1	  month	  CG	  (32/28)	  
-­‐	  6	  month	  CG	  (35/33)	  













Mean	  end	  systolic	  pressure,	  mmHg	  
-­‐	  Randomised	  (40/39)	  
-­‐	  1	  month	  CG	  (32/28)	  
-­‐	  6	  month	  CG	  (35/33)	  













PWV	  (brachial),	  m/s	  
-­‐	  Randomised	  (35/33)	  
-­‐	  1	  month	  CG	  (27/19)	  
-­‐	  6	  month	  CG	  (31/23)	  














Brachial	  SBP,	  mmHg	  
-­‐	  Randomised	  
-­‐	  1	  month	  CG	  
-­‐	  3month	  CG	  
-­‐	  6	  month	  CG	  
















Brachial	  DBP,	  mmHg	  
-­‐	  Randomised	  
-­‐	  1	  month	  CG	  
-­‐	  3	  month	  CG	  
-­‐	  6	  month	  CG	  

















-­‐	  Randomised	  (32/30)	  
-­‐	  1	  month	  CG	  (31/27)	  











-­‐	  Randomised	  (32/30)	  
-­‐	  1	  month	  CG	  (31/27)	  










Data	  are	  expressed	  as	  mean	  (standard	  deviation).	  	  CIMT,	  carotid	  intima	  media	  thickness;	  SBP,	  systolic	  blood	  
pressure;	  DBP,	  diastolic	  blood	  pressure;	  Tr,	  time	  to	  reflected	  wave;	  AI,	  augmentation	  index;	  AI@HR75,	  
augmentation	  index	  corrected	  for	  heart	  rate	  of	  75	  bpm;	  PWV,	  pulse	  wave	  velocity;	  PAT-­‐RHI,	  peripheral	  artery	  
tonometry	  reactive	  hyperaemia	  index.	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Table	  C-­‐2:	  Brachial	  artery	  SBP	  values	  at	  follow	  up	  visits	  according	  to	  treatment	  group	  
	  
Time	  point	  	  






Baseline	  (40/40)	   135.3	  (20.3)	   135.2	  (18.4)	   N/A	  
1	  month	  (38/36)	   128.7	  (21.0)	   128.4	  (16.0)	   0.54	  
3	  months	  (35/36)	   133.0	  (19.8)	   137.6	  (15.6)	   0.17	  
6	  months	  (37/35)	   130.2	  (23.6)	   133.3	  (19.5)	   0.16	  
12	  months	  (30/30)	   128.7	  (22.4)	   136.9	  (21.0)	   0.01	  
Data	  are	  mmHg,	  expressed	  as	  mean	  (standard	  deviation).	  	  P	  value	  refers	  to	  difference	  in	  change	  in	  brachial	  
systolic	  BP	  from	  baseline	  (ANCOVA,	  adjusted	  for	  baseline	  brachial	  systolic	  BP) 
	  
	  
Table	  C-­‐3:	  Brachial	  artery	  DBP	  values	  at	  follow	  up	  visits	  according	  to	  treatment	  group	  
	  
Time	  point	  	  






Baseline	  (40/40)	   76.1	  (7.8)	   73.7	  (8.6)	   N/A	  
1	  month	  (38/36)	   74.0	  (7.5)	   70.1	  (9.7)	   0.28	  
3	  months	  (35/36)	   79.1	  (9.0)	   	  78.1	  (10.3)	   0.85	  
6	  months	  (37/35)	   73.9	  (10.0)	   72.5	  (9.4)	   0.65	  
12	  months	  (30/30)	   73.0	  (9.0)	   72.4	  (9.3)	   0.47	  
Data	  are	  mmHg,	  expressed	  as	  mean	  (standard	  deviation).	  	  P	  value	  refers	  to	  difference	  in	  change	  in	  brachial	  
diastolic	  BP	  from	  baseline	  (ANCOVA,	  adjusted	  for	  baseline	  brachial	  diastolic	  BP)	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